OA20877A

OA20877A - Fungicidal compositions.

Info

Publication number: OA20877A
Application number: OA1202200356
Authority: OA
Inventors: Thomas James HOFFMAN; Ulrich Johannes Haas; David Beattie
Original assignee: Syngenta Crop Protection Ag
Priority date: 2020-03-05
Filing date: 2021-03-04
Publication date: 2023-05-29

Abstract

A fungicidal composition comprising a mixture of components (A) and (B), wherein components (A) and (B) are as defined in claim 1, and use of the compositions in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.

Description

Fungicidal Compositions

The present invention relates to noveî fungicidal compositions, to their use in agriculture or horticulture for controlling diseases caused by phytopathogens, especially phytopathogenic fungi, and to methods of controlling diseases on useful plants.

Whilst many fungicidal compounds and compositions, belonging to various different Chemical classes, hâve been/are being developed for use asfungicides in crops of useful plants, crop tolérance and activity against particular phytopathogenic fungi do not always satisfy the needs of agricultural practice in many respects. Therefore, there is a continuing need to find new compounds and compositions having superior biological properties for use in controlling or preventing infestation of plants by phytopathogenic fungi. For exampie, compounds possessing a greater biological activity, an advantageous spectrum of activity, an increased safety profile, improved physico-chemical properties, increased biodegradability. Or else, compositions possessing a broader spectrum of activity, improved crop tolérance, synergistic interactions or potentiating properties, or compositions which display a more rapid onset of action or which hâve longer lasting residual activity or which enable a réduction in the number of applications and/or a réduction in the application rate of the compounds and compositions required for effective control of a phytopathogen, thereby enabling bénéficiai résistance-management practices, reduced environmental impact and reduced operator exposure.

The use of compositions comprising mixtures of different fungicidal compounds possessing different modes of action can address some of these needs (eg, by combining fungicides with differing spectrums of activity).

According to the present invention, there is provided a fungicidal composition comprising a mixture of components (A) and (B) as active ingrédients, wherein component (A) is a compound of formula (I)

wherein

X îs CH or N;

R¹ is methyl;

R² is hydrogen;

R³ is hydrogen;

R⁴ is selected from the group consisting of hydrogen, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, π-butyl, iso-butyl, sec-butyl, trifluoromethyl, trifluoroethyl, /so-propyloxy, n-propyloxy, cyclopropyl and cyclobutyl;

R⁵ îs selected from the group consisting of hydrogen, hafogen, methyl and trifluoromethyl;

and wherein R⁴ and R⁵ are not both hydrogen;

or an agronomically acceptable sait thereof;

or an N-oxide thereof and component (B) is a compound selected from the group consisting of:

bixafen, sulfur, copper hydroxide, triclopyricarb, acibenzolar-S-methyl, copper oxy chloride, cyproconazole, difenoconazoie, epoxicon-azole, flutriafol, hexaconazole, ipconazole, metconazole, 20 paclobutrazole, prothioconazole, prochloraz, propiconazole, pyrisoxazole, tebucon-azole, fenpropidin, fenpropimorph, spiroxamîne, cyprodinil, fludioxonil, metalaxyi, metalaxyl-M (mefenoxam), carbendazim, penthiopyrad, azoxystrobin, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, mancozeb, folpet, chlorothalonil, fluazinam, fluxapyroxad, fenhexamid, fos-etyl25 aluminium, pyribencarb, tricyclazole, mandipropamid, flubeneteram, isopyrazam, sedaxane, benzovindiflupyr, pydiflumetofen, isoflucypram, isotianil, dipymetitrone, fluindapyr, coumethoxystrobin (jiaxiangjunzhî), Ivbenmixianan, mandestrobin, oxathiapiprolin, pyraziflumid, inpyrfluxam, mefentrifluconazole, ipfentrifluconazole, aminopyrifen, (Z,2E)-5-[1-(4-chloropheny1)pyrazol-3-yl]oxy-2methoxyimino-N,3-dimethyl-pent-3-enamide, florylpicoxamid, fenpicoxamid, ipflufenoquin, 30 quinofumelin, benzothiostrobin, fluopyram, pyrapropoyne, 2-(difluoromethyl)-N-(3-ethyl-1,1-dimethylindan-4-yl)pyridine-3-carboxamide, 4-[[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1,2,4-triazol1-yl)propyl]-3-pyridyl]oxy]benzonitrile, metyltetraprole, fluoxapiprolin, enoxastrobin, 4-[[6-[2-(2,4difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-thioxo-4H-1_l2_l4-triazol-1-yl)propyl]-3pyridyl]oxy]benzonitrile, trinexapac, trinexapac-ethyl, coumoxystrobin, N'-[5-bromo-2-methyl-6-[(1S)-135 methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidine, N'-[5-bromo-2-methyl-6-[(1 R)-1 methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidine, N'-[5-bromo-2-methyl-6-(1-methyl2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl-fofTnamidine, N'-[5-chloro-2-methyl-6-(1-methyi-2propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl-fomnamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2propoxy-ethoxy)-3-pyridyl]-N-isopropyl-N-methyl-formamidine, N’-[5-bromo-2-meth y 1-6-(220877 propoxypropoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidine, N-isopropyl-N’-[5-methoxy-2-methyl-4-

(2,2,2-trifluoro-1-hydroxy-1-phenyl-ethyl)phenyi]-N-methyl-formamidine, N -|4-(1-cyclopropyl-2,2,2trifluoro-1-hydroxy-ethyl)-5-methoxy-2-methyf-phenyl]-N-isopropyl-N-methyl-formamidine, N-ethyl-N'(5-methoxy-2-methyl-4-[2-trifluoromethyÎ)oxetan-2-yl]phenyl]-N-methyl-formamidine, N-ethyl-N'-[5methoxy-2-methyl-4-[2-trifuoromethyl)tetrahydrofuran-2-yl]phenyl]-N-methyl-formamidine, N-(2fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yi]benzamide, N-methoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5(trifluoromethyl)-l ,2,4-oxadiazol-3-y]]phenyl]methyl]propanamide, [(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4-methoxy-3-propanoyloxy-pyridine-2-carbonyl)amino]propanoate, 1-methoxy-3-methyl-1-[[4[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyt]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyi)-1,2,4-oxadiazo[-3-yl]phenyl]methyl]propanamide, 4,4dimethyl-2-[[4-[5-(trifluoromethyl)-1,2_I4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, 5,5-dimethyl2-[[4-[5-(trifluoromethyi)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazoiidin-3-one, ethyl 1-[[4-[5(trifluoromethyl)-l ,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5(trifluoromethyl)-l ,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, 2-{6-(4-chlorophenoxy)-2(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 2-I6-(4-bromophenoxy)-2-(trifluoromethyl)3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 3-[2-(1-chîorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxypropyl]imidazo!e-4-carbonttrile, 3-[2-(1-chlorocyclopropyl)-3-(3-chloro-2-fluoro-phenyl)-2-hydroxypropyl]imidazole-4-carbonitrile, (4-phenoxyphenyl)methyi 2-amino-6-methyi-pyridine-3-carboxylate, Nmethyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzenecarbothioamide; N-methyl-4-[5(trifluoromethyl)-l ,2,4-oxadiazol-3-yl]benzamide; (Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yt]oxy-2methoxyimino-N,3-dimethyi-pent-3-enamide, (5-methyl-2-pyridyl)-[4-[5-(trifluoro methyi)-1,2,4oxadiazol-3-yl]phenyl]methanone, (3-methylisoxazol-5-yl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazot-3yljphenyljmethanone, ethyl 1-[[5-[5-(trifliJoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4carboxylate, 2,2-diflijoro-N-methyl-2-l4-[5-(trifiuoromethyJ)-1,2,4-oxadiazol-3-yl]phenyl]acetamide, N[(Z)-methoxyîminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-[N-methoxy-Cmethyl-carbonimidoyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-[3-(4-chtorophenyl)-4,5dihydroisoxazol-5-yl]-5-methyl-1,2,4-oxadiazole-3-carboxamide, 2-(difluoromethyl)-N-(1,1-dimethyl-3propyl-indan-4-yl)pyridtne-3-carboxamide, ((1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyi] (2S)-2-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino] propanoate, [(1S,2S)-2-(4-fluoro-2-methylphenyl)-1,3-dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4-methoxy-pyridine-2carfoonyl]amino]propanoate, cis-jasmone, potassium phosphonate, calcium phosphonate, glyphosate (including the diammonium, isopropylammonium and potassium salts thereof), 2,4-D (including the choline sait and 2-ethylhexyl ester thereof), dicamba (including the aluminium, aminopropyl, bisamînopropylmethyl, choline, dichloroprop, diglyco lamine, dimethyiamine, dimethylammonium, potassium and sodium salts thereof), glufosinate (including the ammonium sait thereof), thiamethoxam, cyclobuirifluram, isocycloseram, spiropidion, abamectin, emamectin, cyantraniliprole, chlorantraniliprole, diafenthiuron, broflanilide, 2-chloro-N-cyc!opropyi-5-(1-(2,6-dlchloro-4-[1,2,2,2tetrafiuoro-1-(trifIuoromethyl)ethyl]phenyl}-1H-pyrazol-4-yl)-N-methylnicotinamide and fluxametamide.

In general, the weight ratio of component (A) to component (B) may preferably be from 100:1 to 1:100, from 50:1 to 1:50, from 20:1 to 1:50, from 15:1 to 1:50, from 15:1 to 1:30, from 12:1 to 1:25, from 10:1 to 1:20, from 5:1 and 1:15, from 3:1 to 1:10 or from 2:1 to 1:5.

Further according to the invention, there is provided a method of controlling or preventing phytopathogenic diseases, especîally phytopathogenicfungi, on useful plants or on propagation material thereof, which comprises applying to the useful plants, the locus thereof or propagation material thereof a fungicidal composition according to the invention.

The benefits provided by certain fungicidal mixture compositions according to the invention may also include, inter alia, advantageous Ievels of biological activity for protecting plants against diseases that are caused by fungi or superior properties for use as agrochemical active ingrédients (for example, greater biological activity, an advantageous spectrum of activity, an increased safety profile, improved physico-chemical properties, or increased biodegradability).

The presence of one or more possible asymmetric carbon atoms in a compound of formula (I) means that the compounds may occur in optically isomenc forms. Le., enantiomeric or diastereomeric forms. Also atropisomers may occur as a resuit of restricted rotation about a single bond. The present invention includes ail those possible isomeric forms (e.g. géométrie isomers) and mixtures thereof for a compound of formula (I). The present invention includes ail possible tautomeric forms for a compound of formula (I), and also a racemic compound, i.e., a mixture of at least two enantiomers in a ratio of substantially 50:50.

In each case, the compounds of formula (I) according to the invention are in free form, in oxidized form as a N-oxide or in sait form, e.g. an agronomically usable sait form. N-oxides are oxidized forms of tertiary amines or oxidized forms of nitrogen containing heteroaromatic compounds. They are described for instance in the book “Heterocyclic N-oxides by A. Albini and S. Pietra, CRC Press, Boca Raton 1991.

Preferred groups and values for the substituents X, R¹, R², R³, R⁴ and R⁵ in the compounds of formula (I) are, in any combination thereof, as set out below.

X is CH or N. Preferably, X is CH.

R¹ is methyl.

R² is hydrogen.

R³ is hydrogen.

R⁴ is selected from the group consistîng of hydrogen, chloro, bromo, iodo, methyl, ethyl, n-propyl, iso5 propyl, n-butyl, iso-butyl, sec-butyl, trifluoromethyl, trifluoroethyl, /so-propyloxy, n-propyloxy, cyclopropyl and cyclobutyl. Preferably, R⁴ îs selected from the group consistîng of hydrogen, methyl, ethyl, n-propyl, /so-propyl, n-butyl, /so-butyl, sec-butyl, trifluoromethyl, trifluoroethyl, iso-propyloxy, n-propyloxy, cyclopropyl and cyclobutyl. More preferably, R⁴ is selected from the group consistîng of hydrogen, npropyl, /so-propyl, n-butyl, /so-butyl, sec-butyl, trifluoromethyl, /so-propyloxy, n-propyloxy, cyclopropyl 10 and cyclobutyl. Even more preferably, R⁴ is selected from the group consistîng of hydrogen, n-propyl, /so-propyl, /so-butyl, sec-butyl, trifluoromethyl, /so-propyloxy, cyclopropyl and cyclobutyl.

In a preferred embodiment, R⁴ is selected from the group consistîng of n-propyl, /so-propyl, /so-butyl, sec-butyl, trifluoromethyl, /so-propyloxy, cyclopropyl and cyclobutyl (Preferably, n-propyl, /so-propyl, 15 trifluoromethyl).

R^s is selected from the group consistîng of hydrogen, halogen, methyl and trifluoromethyl. Preferably, R⁵ is selected from the group consistîng of hydrogen, methyl and trifluoromethyl. More preferably, R^s is selected from the group consistîng of hydrogen and trifluoromethyl, Most preferably, R^s is hydrogen.

Provided that R⁴ and R⁵ are not both hydrogen.

Preferably, component (A) is a compound selected from, methyl (Z)-3-methoxy-2-[2-methyi-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate (compound X.01), methyl (Z)-3-methoxy-2-[2-methyl-5-(3-sec-butylpyrazol-1-yl)phenoxy]prop-2-enoate (compound X.02), methyl (Z)-2-[5-(3-îSopropoxypyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.03), methyl (ZJ-Z-lS-fS-cyclobutylpyrazol-l-yO-Z-methyl-phenoxyl-S-methoxy-prop-S-enoate (compound X.04), methyl (Z)-2-[5-(3-isobutylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.05), methyl (Z)-2-[5-(3-isopropytpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.06), methyl (Z)-2-[5-(3-cyclopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.07), methyi (Z)-3-methoxy-2-[2-methyi-5-[3-(trifluoromethyl)pyrazol-1-yl)phenoxy]prop-2-enoate (compound X.Û8), methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazo)-2-yl)phenoxy]prop-2-enoate (compound X.09), methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)lriazol-2-yl]phenoxy]prop-2-enoate (compound X.10), methyl (Z)-2-[5-(4-cyclopropyltriazol-2-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.11), or methyl (Z)-2-[5-(4-isopropyltriazol·2-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.12), as defined in Table X below.

More preferably, component (A) is a compound selected from, methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate (compound X.01), methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)-2-methyt-phenoxy]-3-methoxy-prop-2-enoate (compound X.06), methyl (23-3-methoxÿ-2-[2-methyl·5-[3-(trif^uoΓomethyl)ρyrazo!-1-yl]phenoxy]prop“2-enoate (compound X.08), methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate (compound X.09), methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl)phenoxy]prop-2-enoate (compound X.10), or methyl (Z)-2-[5-(4-isopropyltriazol-2-yl)-2-methyl~phenoxy]-3-methoxy-prop-2-enoate (compound X.12), as defined in Table X below.

Even more preferably, component (A) is a compound selected from, methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate (compound X.01), methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.06), methyl (Z>3-methoxy-2-[2-methyi-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate (compound X.08), methyl (ZFS-methoxy^-p-methyl-S-fA-propyltriazol^-ylJphenoxyJprop^enoate (compound X.09), or methyl (Z)-3-methoxy-2-[2-methyi-5-[4-(trîfluoromethyl)tnazol-2-yl]phenoxy]prop-2-enoate (compound X.10), as defined in Table X below.

Even more preferably still, component (A) is a compound selected from, methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate (compound X.01), methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)-2-rneîhyl·phenoxyk3-methoxy-prûp-2-enoate (compound X.06), methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate (compound X.08), or methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazo!-2-yl)phenoxy]prop-2-enoate (compound X.09), as defined in Table X below.

Yet even more preferably still, component (A) is a compound selected from, methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate (compound X.01), methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate (compound X.08), or methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyftriazol-2-yl)phenoxy]prop-2-enoate (compound X.09), as defined in Table X below.

Most preferably, component (A) îs a compound selected from, methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol·1-yl)phenoxy]prop-2-efΊoate (compound X.01), or methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate (compound X.08), as defined in Table X below.

In one embodiment component (A) is methyl (Zj-S-methoxy^-^-methyl-S-ÎS-propylpyrazol-lyl)phenoxy]prop-2-enoate (compound X.01),

In another embodiment component (A) is methyl (Z)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyi)pyrazol-1-yl]phenoxy]prop-2-enoate (compound X.08).

Table X

Compound number	Compound structure	IUPAC name
X.01	/ y O O	methyl (Z)-3-methoxy-2-[2-methyl-5-(3propylpyrazol-1-yl)phenoxy]prop-2enoate

Compound number	Compound structure	IUP AC name
X.02		methyl (Z)-3-methoxy-2-[2-methy1-5-(3sec-butylpyrazol'1-yl)phenoxy]prop-2enoate
X.03	O—/ 1	methyl (Z)-2-[5-(3-isopropoxypyrazol-1 yl)-2-methyl-phenoxy]-3-methoxy-prop-2enoate
X.04	1 o p -0 '—O x	methyl (Z)-2-[5-(3-cyclobutylpyrazol-1-yl)2-methyt-phenoxy]-3-methoxy-prop-2- enoate
X.05	'AC-Qo p -Q^-0 x	methyl (Z)-2-[5-(3-isobutylpyrazol-1-yl)-2methyl-phenoxy]-3-methoxy-prop-2enoate

Compound number	Compound structure	IUPAC name
X.06	O VÂ	methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)2-methyl-phenoxy]-3-methoxy-prop-2- enoate
	r °'r
X.07	Q i ?	methyl (Z)-2-[5-(3-cyclopropylpyrazol-1yl)-2-methyl-phenoxy]-3-methoxy-prop-2enoate
X.08	“jQfSrT	methyl (Z)-3-methoxy-2-[2-methyl-5-[3- (trifluoromethyl)pyrazol-l- yl]phenoxy]prop-2-enoate
X.09	G 1 f A	methyl (Z)-3-methoxy-2-[2-methyl·5-(4- propyltriazol-2-yl)phenoxy]prop-2-enoate

Compound number	Compound structure	IUPAC name
X.10	F	methyl (Z}-3-methoxy~2-[2-methyl-5-[4(trifluoromethyl)triazol-2-yl]phenoxy]prop2-enoate
X.11	^xo	methyl (Z)-2-[5-(4-cyclopropyltriazol-2-yl)2-methyl-phenoxy]-3-methoxy-prop-2- enoate
X.12	I	methyl (Z)-2-[5-(4-isopropyttriazol-2-yl)-2methyl-phenoxy]-3-methoxy-prop-2enoate

Component (B) is a compound selected from the group consisting of:

bixafen, sulfur, copper hydroxide, triclopyricarb, acibenzolar-S-methyl, copper oxychloride, 5 cyproconazoie, difenoconazole, epoxicon-azole, flutriafol, hexaconazole, ipconazole, metconazole, paclobutrazole, prothioconazole, prochloraz, propiconazole, pyrisoxazole, tebucon-azole, fenpropidin, fenpropimorph, spiroxamine, cyprodinil, fludioxonil, metalaxyl, metalaxyl-M (mefenoxam), carbendazim, penthiopyrad, azoxystrobin, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobîn, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, 10 pyraoxystrobin, mancozeb, folpet, chlorothalonil, fluazinam, fluxapyroxad, fenhexamid, fos-etylaluminium, pyribencarb, tricyclazole, mandipropamid, fiubeneteram, tsopyrazam, sedaxane, benzovindiflupyr, pydiflumetofen, isoflucypram, isotianil, dipymetitrone, fluindapyr, coumethoxystrobin (jiaxiangjunzhi), Ivbenmixianan, mandestrobin, oxathiapiprolin, pyraziflumid, inpyrfluxam, mefentrifluconazole, ipfentrifluconazole, aminopyrifen, (Z,2E)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-220877

methoxyimino-N,3-dimethyl-pent-3-enamide, florylpicoxamid, fenpicoxamid, ipflufenoquin, quinofumelin, benzothiostrobin, fluopyram, pyrapropoyne, 2-(dif]uoromethyl)-N-(3-ethyl-1,1-dimethylindan-4-yl)pyridine-3-carboxamide, 4-[[6-[2-(2,4-dîfluorophenyl)-1,1-difluoro-2-hydroxy-3-(1,2,4-triazof1-yl)propyl]-3-pyridyi]oxy]benzonitrile, metyltetraprole, fluoxapiprolin, enoxastrobin, 4-[[6-[2-(2,4d ifluorophe ny I)-1,1 -d ifl uoro-2-hydroxy-3-(5-thioxo-4 H-1,2,4-triazol-1 -yt)propyi]-3pyridyl]oxy]benzonitrile, trinexapac, trinexapac-ethyl, coumoxystrobin, N'-[5-bromo-2-methyl-6-[(1S)-1methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidine, N'-[5-bromo-2-methyl-6-[(1 R)-1methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidine, N'-[5-bromo-2-methyl-6-(1-methyl2-propoxy-ethoxy)-3-pyridyi]-N-ethyl-N-methyl-formamidine, N’-[5-chloro-2-methy!-6-(1-methyl-2propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl-forma midine, N'-[5-bromo-2-methyl-6-(1-methyl-2propoxy-ethoxy)-3-pyridylj-N-isopropyl-N-methyl-forma midine, N’-[5-bromo-2-methyl-6-(2propoxypropoxy)-3-pyridyl]-N-ethyl-N-methyi-formamidine, N-isopropyi-N’-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1-phenyl-ethyl)phenyi]-N-methyl-formamidine, N’-[4-(1-cyclopropyl-2,2,2trifluoro-1-hydroxy-ethyl)-5-methoxy-2-methyi-phenyl]-N-isopropyl-N-methyl-formamidine, N-ethyl-N’[5-methoxy-2-methyl-4-[2-tfifluoromethyl)oxetan-2-yl]phenyl]-N-methyl-fomna midine, N-ethyl-N'-[5methoxy-2-methyl-4-[2-trifuoromethyl)tetrahydrofuran-2-yl]phenyt]-N-meth y l-forma midine, N-(2fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-methoxy-N-[[4-[5(trifluoromethyl)-l ,2,4-oxadiazol-3-yl]phenyl]methyllcyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5(trifluoromethyl)-l ^A-oxadiazol-S-yllphenyOmethyllpiOpanamide, N-ethyl-2-methyl-N-[[4-[5(trifluoromethyl)-l ,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, [(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4-methoxy-3-propa noyloxy-pyrid in e-2-carbon y l)amino] propa noate, 1-methoxy-3-methy!-1-[[4[5-(trifluoromethyl)-1_t2,4-oxadiazol-3-yl]pheny]]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-([4-[5-(trifluoromethyl)-1,2,4-oxadrazol-3yl]phenyl]methyl]urea, N-[[4-[5-(trifiuoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 4,4dimethyl-2-[(4-[5-(trifluoromethyl)-1,2,4~oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, 5,5-dimethyl2-[[4-[5-(trifIuoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyi]isoxazolidin-3-one, ethyl 1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazo!-3-yl]phenyl]methyl]pyrazoie-4-carboxylate, N,N-dimethyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, 2-[6-(4-chlorophenoxy)-2(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 2-[6-(4-bromophenoxy)-2-(trifiuoromethyl)3-pyridyl]-1-(1,2,4-triazoi-1-yl)propan-2-ol, 3-[2-(1-chlorocyclopropy 1)-3-(2-fluorophen y i)-2-hydroxypropyl]imidazole-4-carbonitrile, 3-[2-(1-chiorocyclopropyl)-3-(3-chJoro-2-fluoro-phenyl)-2-hydroxypropyl]imidazole-4-carbonitrile, (4-phenoxyphenyl)methyl 2-amino-6-methyl-pyridine-3-carboxylate, Nmethyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzenecarbothioamide; N-methyl-4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide; (Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy-2methoxyimino-N,3-dimethyl-pent-3-enamide, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methanone, (3-methylisoxazol-5-yl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methanone, ethyl 1-[E5-[5-(trifluoromethyl)-1,2,4-oxadiazol·3-yl]-2-thienyl]methyl]pyrazole-4carboxylate, 2,2-difluoro-N-methyf-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide, N[(Z)-methoxyimrnomethyl]-4-[5-(trifluoromethyl)-1,2₁4-oxadiazol-3-yl]benzamide, N-[N-methoxy-Cmethyl-carbonimidoyli-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-[3-(4-chlorophenyl)-4,5 dihydroisoxazol-5-yl]-5-methyl-1,2,4-oxadiazole-3-carboxamide, 2-(difluoromethyl)-N-(1,1-dimethyl-3propyl-indan-4-yl)pyridine-3-carboxamide, [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl] (2S)-2-[(3-acetoxy-4-methoxy-pyndine-2-carbonyl)amino]propanoate, [(1S,2S)-2-(4-fluoro-2-methylphenyl)-1,3-dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4-methoxy-pyridine-2carbonyl]amino]propanoate, cis-jasmone, potassium phosphonate, calcium phosphonate, glyphosate (inciuding the diammonium, isopropylammonium and potassium salts thereof), 2,4-D (inciuding the choline sait and 2-ethylhexyl ester thereof), dicamba (inciuding the aluminium, aminopropyl, bisaminopropylmethyl, choline, dichloroprop, diglycolamine, dimethylamine, dimethylammonium, potassium and sodium salts thereof), glufosinate (inciuding the ammonium sait thereof), thiamethoxam, cyclobutrifluram, isocycloseram, spiropidion, abamectin, emamectin, cyantraniliprole, chlorantraniliprole, diafenthiuron, broflanilide, 2-chloro-N-cyclopropyl-5-(1-{2,6-dichloro-4-[1,2,2,2tetrafiuoro-1-(trifluoromethyl)ethyl]phenyl}-1H-pyrazol-4-yt)-N-methylnicotinamide and fluxametamide.

Preferably, component (B) is a compound selected from the group consisting of, bixafen, sulfur, copper hydroxide, triclopyricarb, acibenzolar-S-methyl, copper oxychloride, cyproconazole, difenoconazole, epoxicon-azole, flutriafol, hexaconazole, ipconazole, metconazole, paclobutrazole, prothioconazole, prochloraz, propiconazole, pyrisoxazole, tebucon-azole, fenpropidin, fenpropimorph, spiroxamine, cyprodinil, fludioxonil, metalaxyl, metalaxyl-M (mefenoxam), carbendazim, penthiopyrad, azoxystrobin, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, mancozeb, folpet, chlorothalonil, fluazinam, fluxapyroxad, fenhexamid, fos-etyl-aluminium, pyribencarb, tricyclazole, mandipropamid, flubeneteram, isopyrazam, sedaxane, benzovindiflupyr, pydiflumetofen, isoflucypram, isotianil, dipymetitrone, fluindapyr, coumethoxystrobin (jiaxiangjunzhi), Ivbenmixianan, mandestrobin, oxathiapiprolin, pyraziflumid, inpyrfluxam, mefentrifluconazole, ipfentrifluconazote, aminopyrifen, (Z_Ί2E)-5-[1-(4-chlOΓophenyl)pyΓazol-3-yl]oxy-2-methoxyimino-N,3-dίmethyl·peπt-3-enamide, florylpicoxamid, fenpicoxamid, ipfiufenoquin, quinofumelin, benzothiostrobin, fluopyram, pyrapropoyne, 2-(difluoromethyl)-N-(3-ethyl-1,1-dimethyl-indan-4-yl)pyridine-3-carboxamide, 4-[[6-[2-(2,4difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy]benzonitrile, metyltetraprole, fluoxapiprolin, enoxastrobin, 4-[[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5thioxo-4H-1,2,4-tri azol-1 -yl)propyl]-3-pyridyl]oxy]benzonitrile, trinexapac, trinexapac-ethyl, coumoxystrobin, N'-[5-bromo-2-methyl-6-[(1S)-1-methyl-2-propoxy-ethoxy]-3-pyridyi]-N-ethyl-N-methylformamidine, N'-[5-bromo-2-methyl-6-[(1 R)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methylformamidine, N'-I5-bromo-2-methyl·6-(1-methyl·2-pΓOpoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-chloro-2-methy 1-6-(1 -methy l-2-propoxy-ethoxy )-3-pyridy l]-N-ethy l-N-methylformamidine, N’-i5-bromo-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyî]-N-isopropy!-N-methylforma midine, N'-[5-bromo-2-methy!-6-(2-propoxypropoxy)-3-pyridyl]-N-ethyl-N-methyl-forma midine, Nisopropyl-N’45-methoxy-2-methy 1-4-(2,2,2-trifluoro-1-hydroxy-1-phenyl-ethyl)phenyl]-N-methy Iforma midine, N’-[4-(1-cyclopropyl-2,2,2-trifluoro-1-hydroxy-ethyl)-5-methoxy-2-methyl-phenyl]-Nisopropyl-N-meth y l-forma midine, N-ethyl-N’-[5-methoxy-2-methyl-4-[2-tnfluoromethyl)oxetan-2yl]phenyl]-N-methyl-formamidine, N-ethy l-N’-[5-methoxy-2-methyl-4-[2-trifuora methy l)tetrahydrofuran

2-yl]phenyl]-N-methyl-formamidine,

N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl(cyclûpropanecarboxamide, N,2-dimethoxy-N-[[4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyt]methy(]propanamide, [(1S,2S)-1-methyl-2-(o-toiyl)propyl] (2S)-2-[(4-methoxy-3-propanoyloxypyridine-2-carbonyl)amino]propanoate, 1-methoxy-3-methyi-1-[[4-[5-(tnfluoromethyl)-1,2,4-oxadiazol-3yl]phenyi]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-mettioxy-1-[[4-[5-(trîfluoromethyl)-1,2,4-oxadiazol-3-yl]pheny1]methyl]urea, N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 4,4-dimethyl-2-[[4-[5(trifluoromethyl)-l ,2,4-oxadiazol-3-yl]phenyl]methyljisoxazolidin-3-one, 5,5-dimethyl-2-[[4-[5(trifluoromethyl)-l ,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3One, ethyl 1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yi]phenyl]methyl]-1,2,4-triazol-3-amine, 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3pyndyl]-1-(1,2,4-triazoi-1-yl)propan-2-oJ, 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyndyl]-1-(1,2,4triazol-1-yl)propan-2-ol, 3-(2-(1-chlorocycloprOpyl)-3-(2-fluorophenyl)-2-hydroxy-propyl]imidazole-4carbon itrile, 3-(2-(1-chlorocyclopropyl)-3-(3-chioro-2-fluoro-phenyl)-2-hydroxy-propyl]imidazole-4carbonitrile, (4-phenoxyphenyt) methyl 2-amino-6-methyl-pyridine-3-carboxylate, N-methyl-4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzenecarbothioamide; N-methyl-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide; (Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3dimethyl-pent-3-enamide, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methanone, (3-methylisoxazol-5-yl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]pheny1]methanone, ethyl 1 -((5-(5-(trifluoromethyl)-l ,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4carboxylate, 2,2-difluoro-N-methyl-2-(4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide, N[(Z)-methoxyiminomethy[]-4-[5-(tπfluoromethyl)-1,2,4-oxadiazol·3-y^]benzamide, N-[N-methoxy-Cmethyl-carbonimidoyJ]-4-[5-(trifluoromethyl)-1,2₁4-oxadiazol-3-yl]benzamide, N-[3-(4-chloropheny 1)-4,5dihydroisoxazol-5-yl]-5-methyl-1,2,4-oxadiazole-3-carboxamide, 2-(difluoromethyi)-N-(1,1-dimethyl-3propyl-rndan-4-yl)pyridine-3-carboxamide, [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl] (2S)-2-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]propanoate, [(1S,2S)-2-(4-fluoro-2-methylphenyl)-1,3-dimethyl-butyl( (2S)~2-[[3-(acetoxymethoxy)-4-methoxy-pyridine-2carbonyl]amino]propanoate, c/s-jasmone, potassium phosphonate, calcium phosphonate, glyphosate (including the diammonium, isopropylammonium and potassium salts thereof), 2,4-D (including the choline sait and 2-ethylhexyl ester thereof), dicamba (including the aluminium, aminopropyl, bisaminopropylmethyl, choline, dichloroprop, diglycolamine, dimethylamine, dimethylammonium, potassium and sodium salts thereof), glufosinate (including the ammonium sait thereof), thiamethoxam, cyclobutrifluram, isocycloseram, spiropidion, abamectin, emamectin, cyantraniliprole, chlorantraniliprole, diafenthiuron, broflanilide, 2-chloro-N-cyclopropyl-5-(1-{2,6-dichloro-4-[1,2,2,2tetrafluoro-ITtrifluoromethyOethylJphenylJ-IH-pyrazol^-ylhN-methylnicotinamide and fluxametamide.

More preferably, component (8) is a compound selected from the group consisting of, bixafen, triclopyricarb, cyproconazole, difenoconazole, epoxîcon-azole, flutriafol, hexaconazole, ipconazole, metconazole, prothioconazole, propiconazole, tebucon-azole, azoxystrobin, dimoxystrobin.

fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, mancozeb, chlorothalonil, fluxapyroxad, pyribencarb, benzovindiflupyr, isoflucypram, coumethoxystrobin (jiaxiangjunzhi), mandestrobin, mefentrifluconazole, ipfentrifluconazole, benzothiostrobin, metyttetraprole, enoxastrobin, coumoxystrobin, [(1S,2S)-1-methyl-2-(o4olyl)propyl] (2S)-2-[(4-methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate, 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1yl)propan-2-ol, 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1 -(1,2,4-triazol-1-yl)propan-2-ol, 3[2-(1-chlorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile and 3-[2-(1ch lo rocyclopropy1)-3-(3-ch loro-2-fluoro-phe ny l)-2-h y d roxy-propyl] imidazole-4~carbonitrile.

Even more preferabiy, component (B) is a compound selected from the group consisting of, bixafen, triclopyricarb, cyproconazole, difenoconazole, epoxicon-azole, flutriafol, hexaconazole, rpconazole, metconazole, prothioconazole, propiconazole, tebucon-azole, azoxystrobin, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, mancozeb, chlorothalonil, fluxapyroxad, pyribencarb, benzovindiflupyr, isoflucypram, coumethoxystrobin (jiaxiangjunzhi), mandestrobin, mefentrifluconazole, rpfentrifluconazole, benzothiostrobin, metyltetra proie, enoxastrobin, coumoxystrobin, 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 3-[2-(1 chlorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxy-propy1]imidazole-4-carbonitrile and 3-[2-(1chlorocyclopropyl)-3-(3-chloro-2-fluoro-phenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile.

Even more preferabiy still, component (B) is a compound selected from the group consisting of, cyproconazole, difenoconazole, hexaconazole, prothioconazole, propiconazole, azoxystrobin, trifloxystrobin, picoxystrobin, pyraclostrobin, mancozeb, chlorothalonil, fluxapyroxad, benzovindiflupyr, isoflucypram and metyltetraprole.

Yet even more preferabiy still, component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, hexaconazole, prothioconazole, propiconazole, azoxystrobin, trifloxystrobin, picoxystrobin, pyraclostrobin, mancozeb, chlorothalonil and metyltetraproie.

Further more preferabiy still, component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, prothioconazole, azoxystrobin, trifloxystrobin, pyraclostrobin and metyltetraprole.

Yet further more preferabiy still, component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, pyraclostrobin and metyltetraprole.

In one embodiment, component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, prothioconazole, fenpropidîn, fludioxonil, azoxystrobin, trifloxystrobin, pyraclostrobin, mancozeb, mefentrifluconazole, florylpicoxamid, metyltetraprole, trinexapac-ethyl, glyphosate, a biostimulant comprising organic carbon, nutrients and amino acids (Quantis™), N-(2-fluorophenyl)-4-[5(trifluoromethyl)-l ,2,4-oxadiazol-3-yl]benzamide and [(1 S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyioxy-pyridine-2-carbonyf)amino]propanoate. Preferably in this embodiment, component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, prothioconazole, fenpropidîn, fludioxonil, azoxystrobin, trifloxystrobin, pyraclostrobin, mancozeb, mefentrifluconazole, florylpicoxamid, metyltetraprole, trinexapac-ethyl, glyphosate, N-(2-fluorophenyi)4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide and ((1S,2S)-1-methyl-2-(o-tolyi)propyl] (2S)-2[(4-methoxy-3-propanoyîoxy-pyridine-2-carbonyl)amino]propanoate, More preferably in this embodiment, component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, prothioconazole, fenpropidîn, fludioxonil, azoxystrobin, trifloxystrobin, pyraclostrobin, mancozeb, mefentrifluconazole, metyltetraprole, trinexapac-ethyl and glyphosate.

The component (B) compounds are referred to herein and above by a so-called ISO common name or another common name being used in individual cases or a trademark name. The component (B) compounds are known and are commercially available and/or can be prepared using procedures known in the art and/or procedures reported in the fiterature.

In a preferred composition according to the invention component (A) is compound no. X.01 methyl (Z)3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of bixafen, triclopyricarb, cyproconazole, difenoconazole, epoxicon-azole, flutriafol, hexaconazole, ipconazole, metconazole, prothioconazole, propiconazole, tebucon-azole, azoxystrobin, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, mancozeb, chlorothalonil, fluxapyroxad, pyribencarb, benzovindiflupyr, isoflucypram, coumethoxystrobin (jiaxiangjunzhî), mandestrobin, mefentrifluconazole, ipfentrifluconazole, benzothiostrobin, metyltetraprole, enoxastrobin, coumoxystrobin, 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 2-[6-(4-bromophe noxy)-2- (triflu o romethy l)-3- py rid y I]-1 -(1,2,4-tri azol-1 -y I) pro pan-2-ol, 3-(2-(1 chlorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxy-propyl]imidazole-4-carbonitriie and 3-(2-(1chlorocyclopropyl)-3-(3-ch!oro-2-fiuoro-phenyl)-2-hydroxy-propyl}imidazole-4-carbonitrile, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:50.

In another preferred composition according to the invention, component (A) is compound no. X.06 methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of bixafen, triclopyricarb, cyproconazole, difenoconazole, epoxicon-azole, flutriafol, hexaconazole, ipconazole, metconazole, prothioconazole, propiconazole, tebucon-azole, azoxystrobin, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, mancozeb, chlorothalonil, fluxapyroxad, pyribencarb, benzovindiflupyr, isoflucypram, coumethoxystrobin (jiaxiangjunzhi), mandestrobin, mefentrifluconazole, ipfentrifluconazole, benzothîostrobin, metyltetraprole, enoxastrobin, coumoxystrobin, 2-[6-(4-chlorophenoxy)-2-(trifiuoromethyl)-3-pyridy 1)-1-(1,2,4-triazo 1-1-y l)propan-2-ol, 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyrîdy 1)-1-(1,2,4-triazol-1-yl)propan-2-ol, 3-(2-(1chlorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile and 3-(2-(1chlorocyc!opropyi)-3-(3-chloro-2-fluoro-phenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:50.

In another preferred composition according to the invention, component (A) is compound no. X.08 methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of bixafen, triclopyricarb, cyproconazole, difenoconazole, epoxicon-azoie, flutriafol, hexaconazole, ipconazole, metconazole, prothioconazole, propiconazole, tebucon-azole, azoxystrobin, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrôbin, mancozeb, chlorothalonil, fluxapyroxad, pyribencarb, benzovindiflupyr, isoflucypram, coumethoxystrobin (jiaxiangjunzhi), mandestrobin, mefentrifluconazole, ipfentrifluconazole, benzothîostrobin, metyltetraprole, enoxastrobin, coumoxystrobin, 2-[6-(4-chlorophenoxy)-2-(trffluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 2-[6~(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 3-(2-(1chlorocyclopropyj)-3-(2-fiuorophenyl)-2-hydroxy-propy!]imidazoie-4-carbonitrile and 3-(2-(1chlorocyclopropyl)-3-(3-chloro-2-fluoro-phenyl)-2-hydroxy-propyl]imidazole-4-carbonîtrile, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:50.

In another preferred composition according to the invention, component (A) îs compound no. X.09 methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of bixafen, triclopyricarb, cyproconazole, difenoconazole, epoxicon-azole, flutriafol, hexaconazole, ipconazole, metconazole, prothioconazole, propiconazole, tebucon-azole, azoxystrobin, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, mancozeb, chlorothalonil, fluxapyroxad, pyribencarb, benzovindiflupyr, isoflucypram, coumethoxystrobin (jiaxiangjunzhi), mandestrobin, mefentrifluconazole, ipfentrifluconazole, benzothîostrobin, metyltetraprole, enoxastrobin, coumoxystrobin, 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl)-1-(1,2,4-triazol-1-yl)propan-2-ol, 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 3-(2-(1chlorocyclopropyl)-3-(2-fluoropheny])-2-hydroxy-propyl]imidazole-4-carbonîtrîle and 3-(2-(1chlorocyclopropyl)-3-(3-chloro-2-fiuoro-phenyl)-2-hydroxy-propyl]imidazoie-4-carbonitrile, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:50.

In another preferred composition according to the invention, component (A) is compound no. X.10 methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)tiiazol-2-yl]phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consistîng of bixafen, triclopyricarb, cyproconazole, difenoconazole, epoxicon-azole, flutrîafol, 5 hexaconazoie, ipconazole, metconazole, prothioconazoie, propiconazoie, tebucon-azole, azoxystrobin, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, maneozeb, chlorothalonil, fluxapyroxad, pyribencarb, benzovindiflupyr, isoflucypram, coumethoxystrobin (jiaxiangjunzhi), mandestrobin, mefentrifluconazole, ipfentrifluconazole, benzothiostrobin, metyltetraprole, enoxastrobin, 10 coumoxystrobin, 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyrîdyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 3-(2-(1chiorocyclopropyl)-3-(2-fluorophenyi)-2-hydroxy-propyl]imidazole-4-carbonitri!e and 3-(2-(1 chiorocyclopropyl)-3-(3-ch!oro-2-fluoro-phenyl)-2-hydroxy-propyl)imidazole-4-cafbonîtrile, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:50.

In another preferred composition according to the invention, component (A) is compound no. X.12 methyl (Z)-2-[5-(4-isopropyltriazol-2-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consistîng of bixafen, triclopyricarb, cyproconazole, difenoconazole, epoxicon-azole, flutrîafol, 20 hexaconazoie, ipconazole, metconazole, prothioconazoie, propiconazoie, tebucon-azole, azoxystrobin, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, maneozeb, chlorothalonil, fluxapyroxad, pyribencarb, benzovindiflupyr, isoflucypram, coumethoxystrobin (jiaxiangjunzhi), mandestrobin, mefentrifluconazole, ipfentrifluconazole, benzothiostrobin, metyltetraprole, enoxastrobin, 25 coumoxystrobin, 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyi]-1-(1,2,4-triazol-1-yl)propan-2-ol, 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 3-(2-(1chlorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile and 3-(2-(1chlorocyclopropyl)-3-(3-chloro-2-fluoro-phenyl)-2-hydroxy-propyi]imidazole-4-carbonitrile, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:50, 30

In a more preferred composition according to the invention component (A) is compound no. X.01 methyl (Z)-3-methoxy-2-[2-meîhyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consistîng of cyproconazole, difenoconazole, hexaconazoie, prothioconazoie, propiconazoie, azoxystrobin, 35 trifloxystrobin, picoxystrobin, pyraclostrobin, maneozeb, chlorothalonil, fluxapyroxad, benzovindiflupyr, isoflucypram and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:50.

In a more preferred composition according to the invention component (A) is compound no, X.06 methyl 40 (Z)-2-[5-(3-isopropyipyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, hexaconazole, prothioconazole, propiconazole, azoxystrobm, trifloxystrobin, picoxystrobin, pyraclostrobîn, mancozeb, chlorothaionil, fluxapyroxad, benzovindiflupyr, isoflucypram and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:50.

In a more preferred composition according to the invention component (A) is compound no. X.08 methyl (Z)-3-methoxy-2-[2-methyl-5-{3-(trifluoromethyl)pyrazot-1-yl]phenoxyjprop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, hexaconazole, prothioconazole, propiconazole, azoxystrobïn, trifloxystrobin, picoxystrobin, pyraclostrobîn, mancozeb, chlorothaionil, fluxapyroxad, benzovindiflupyr, isoflucypram and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:50.

In a more preferred composition according to the invention component (A) is compound no. X.09 methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, hexaconazole, prothioconazole, propiconazole, azoxystrobïn, trifloxystrobin, picoxystrobin, pyraclostrobîn, mancozeb, chlorothaionil, fluxapyroxad, benzovindiflupyr, isoflucypram and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:50.

In a more preferred composition according to the invention component (A) is compound no. X.10 methyl (Z)-3-methoxy-2-[2-methyl-5-(4-(trifluoromethyl)triazoi-2-yl]phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, hexaconazole, prothioconazole, propiconazole, azoxystrobïn, trifloxystrobin, picoxystrobin, pyraclostrobîn, mancozeb, chlorothaionil, fluxapyroxad, benzovindiflupyr, isoflucypram and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:50.

In a more prefenred composition according to the invention component (A) is compound no. X.12 methyl (Z)-2-[5-(4-isopropyltriazol-2-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, hexaconazole, prothioconazole, propiconazole, azoxystrobïn, trifloxystrobin, picoxystrobin, pyraclostrobîn, mancozeb, chlorothaionil, fluxapyroxad, benzovindiflupyr, isoflucypram and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:50.

In a preferred composition according to the invention component (A) is compound no. X.01 methyl (Z)3-methoxy-2-[2-methyl-5-(3-propylpyrazol·1-yl)phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and comportent (B) is a compound selected from the group consisting of bixafen, triclopyricarb, cyproconazoie, difenoconazole, epoxicon-azole, flutriafol, hexaconazole, ipconazole, metconazole, prothioconazole, propiconazole, tebucon-azole, azoxystrobin, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobîn, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, mancozeb, chlorothalonil, fluxapyroxad, pyrîbencarb, benzovindiflupyr, isoflucypram, coumethoxystrobin (jiaxiangjunzhi), mandestrobîn, mefentrifluconazole, îpfentrifluconazole, benzothiostrobin, metyltetraprole, enoxastrobin, coumoxystrobin, 2-[6-(4-chlorophenaxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-oi, 3-(2-(1chlorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile and 3-(2-(1chlorocyclopropyl)-3-(3-chloro-2-fluoro-phenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

In another preferred composition according to the invention, component (A) is compound no. X.06 methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of bixafen, triclopyricarb, cyproconazoie, difenoconazole, epoxicon-azole, flutriafol, hexaconazole, ipconazole, metconazole, prothioconazole, propiconazole, tebucon-azole, azoxystrobin, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobîn, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, mancozeb, chlorothalonil, fluxapyroxad, pyrîbencarb, benzovindiflupyr, isoflucypram, coumethoxystrobin (jiaxiangjunzhi), mandestrobîn, mefentrifluconazole, îpfentrifluconazole, benzothiostrobin, metyltetraprole, enoxastrobin, coumoxystrobin, 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 2-[6-(4-bromophenoxy)-2-(irifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 3-(2-(1chlorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile and 3-(2-(1chtorocyclopropyi)-3-(3-chloro-2-fluoro-phenyl)-2-hydroxy-propyl]imrdazole-4-carbonitrile, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

In another preferred composition according to the invention, component (A) is compound no. X.08 methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of bixafen, triclopyricarb, cyproconazoie, difenoconazole, epoxicon-azole, flutriafol, hexaconazole, ipconazole, metconazole, prothioconazole, propiconazole, tebucon-azole, azoxystrobin, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobîn, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, mancozeb, chlorothalonil, fluxapyroxad, pyrîbencarb, benzovindiflupyr, isoflucypram, coumethoxystrobin (jiaxiangjunzhi), mandestrobîn, mefentrifluconazole, îpfentrifluconazole, benzothiostrobin, metyltetraprole, enoxastrobin, coumoxystrobin, 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-oi,

2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yi)propan-2-ol_T

3-(2-(1chiorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxy-propyl]îmidazote-4-carbonitrile and 3-(2-(1chlorocyciopropyl)-3-(3-chloro-2-fluoiO-phenyl)-2-hydroxy-propyl]imidazole-4-cafbonitrile, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

In another preferred composition according to the invention, component (A) is compound no. X.09 methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of bixafen, triclopyricarb, cyproconazole, difenoconazole, epoxicon-azole, flutriafol, hexaconazole, ipconazole, metconazole, prothioconazole, propiconazole, tebucon-azole, azoxystrobin, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, mancozeb, chlorothalonil, fluxapyroxad, pyrtbencarb, benzovindiflupyr, isoflucypram, coumethoxystrobin (jraxiangjunzhi), mandestrobin, mefentrifluconazole, ipfentrifluconazûle, benzothiostrobin, metyltetraprole, enoxastrobîn, coumoxystrobin, 2-[6-(4-chloΓophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol·1-y!)propan-2-ol, 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyf]-1-(1,2,4-triazol-1-yl)propan-2-ol_t 3-(2-(1 ch lorocyciopropy l)-3-(2-fluorophenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile and 3-(2-(1chlorocyclopropyl)-3-(3-chloro-2-fluoro-phenyl)-2-hydroxy-propyl]imîdazole-4-carbonitrile, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

In another preferred composition according to the invention, component (A) is compound no. X.10 methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trifiuoromethyl)triazol-2-yl]phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of bixafen, triclopyricarb, cyproconazole, difenoconazole, epoxicon-azole, flutriafol, hexaconazole, ipconazole, metconazole, prothioconazole, propiconazole, tebucon-azole, azoxystrobin, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, mancozeb, chlorothalonil, fluxapyroxad, pyribencarb, benzovindiflupyr, isoflucypram, coumethoxystrobin (jiaxiangjunzhi), mandestrobin, mefentrifluconazole, ipfentrifluconazole, benzothiostrobin, metyltetraprole, enoxastrobîn, coumoxystrobin, 2-[6-(4-chlorophenoxy)-2-(trifluoro methy l)-3-pyridy 1(-1-(1,2,4-triazol-1-y l)propan-2-ol, 2-[6-(4-bromoptienoxy)-2-(trifluoromethyl)-3-pyridy 1(-1-(1,2,4-triazol-1-yl)propan-2-ol, 3-(2-(1chlorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile and 3-(2-(1ch lorocyciopropy l)-3-(3-chloro-2-fl uoro-phenyl)-2-h y droxy-propylJimidazole-4-carbonitrile, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

In another preferred composition according to the invention, component (A) is compound no. X.12 methyl (Z)-2-[5-(4-isûpΓopyltΓiazol·2-yl)-2-metlΊyl-pheπoxy]-3-methoxy-prop-2-erΊoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of bixafen, triclopyheart», cyproconazoie, difenoconazole, epoxicon-azole, flutriafol, hexaconazole, ipconazole, metconazole, prothioconazole, propiconazole, tebucon-azole, azoxystrobin, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobin, 5 orysastrobin, picoxystrobin, pyraciostrobin, pyrametostrobin, pyraoxystrobin, mancozeb, chlorothalonil, fluxapyroxad, pyribencarb, benzovindiflupyr, isoflucypram, coumethoxystrobin (jiaxiangjunzhi), mandestrobin, mefentrifluconazole, ipfentrifluconazole, benzothiostrobin, metyitetraproie, enoxastrobin, coumoxystrobin, 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyll-1-(1,2,4-triazol-1-yl)propan-2-ol, 3-[2-(1 10 chlorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile and 3-[2-(1chlorocyclopropyl)-3-(3-chioro-2-fluoro-phenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

In a preferred composition according to the invention component (A) is compound no. X.01 methyl (Z)3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxrde thereof, and component (B) is a compound selected from the group consisting of cyproconazoie, difenoconazole, hexaconazole, prothioconazole, propiconazole, azoxystrobin, trifloxystrobin, picoxystrobin, pyraclostrobin, mancozeb, chlorothalonil, fluxapyroxad, benzovindiflupyr, 20 isoflucypram and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

In another preferred composition according to the invention, component (A) is compound no. X.06 methyl (Z)-2-[5-(3-rsopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate or a sait, 25 enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of cyproconazoie, difenoconazole, hexaconazole, prothioconazole, propiconazole, azoxystrobin, trifloxystrobin, picoxystrobin, pyraclostrobin, mancozeb, chlorothalonil, fluxapyroxad, benzovindiflupyr, isoflucypram and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

In another preferred composition according to the invention, component (A) is compound no. X.08 methyl (Z)-3-methoxy-2-[2-methyl-5-I3-(trifluoromethyl)pyrazol-1-yllphenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of cyproconazoie, difenoconazole, hexaconazole, prothioconazole, propiconazole, 35 azoxystrobin, trifloxystrobin, picoxystrobin, pyraclostrobin, mancozeb, chlorothalonil, fluxapyroxad, benzovindiflupyr, isoflucypram and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

In another preferred composition according to the invention, component (A) is compound no. X.09 40 methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, hexaconazole, prothioconazole, propiconazole, azoxystrobin, trifloxystrobin, picoxystrobin, pyraclostrobin, mancozeb, chlorothalonil, fluxapyroxad, benzovindiflupyr, isoflucypram and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from

10:1 to 1:10 (or even more preferably, 7,5:1 to 1:7.5),

In another preferred composition according to the invention, component (A) is compound no. X.10 methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyi)triazol-2-yl]phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group 10 consisting of cyproconazole, difenoconazole, hexaconazole, prothioconazole, propiconazole, azoxystrobin, trifloxystrobin, picoxystrobin, pyraclostrobin, mancozeb, chlorothalonil, fluxapyroxad, benzovindiflupyr, isoflucypram and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

In another preferred composition according to the invention, component (A) is compound no. X.12 methyl (2^-2-[5-(4-isopropyltrfazol·2-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, hexaconazole, prothioconazole, propiconazole, azoxystrobin, trifloxystrobin, picoxystrobin, pyraclostrobin, mancozeb, chlorothalonil, fluxapyroxad, 20 benzovindiflupyr, isoflucypram and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

in a preferred composition according to the invention component (A) is compound no. X.01 methyl (Z)3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, prothioconazole, azoxystrobin, trifloxystrobin, pyraclostrobin and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

In another preferred composition according to the invention, component (A) is compound no. X.06 methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, prothioconazole, azoxystrobin, trifloxystrobin, pyraclostrobin and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from

10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

In another preferred composition according to the invention, component (A) is compound no. X.08 methyl (Σ)-3-methoxy-2-[2-methyl·5-[3-(trifluoromethyf)pyrazol·1-yl]phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group 40 consisting of cyproconazole, difenoconazole, prothioconazole, azoxystrobin, trifloxystrobin, pyraclostrobîn and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from

10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

In another preferred composition according to the invention, component (A) is compound no. X.09 methyl (Z)-3-methoxy-2-[2-methyi-5-(4-propy!triazol-2-yl)phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, prothioconazole, azoxystrobïn, trifloxystrobin, pyraclostrobîn and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

In another preferred composition according to the invention, component (A) is compound no. X.10 methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trîfluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, prothioconazole, azoxystrobïn, trifloxystrobin, pyraclostrobîn and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7,5).

In another preferred composition according to the invention, component (A) is compound no. X.12 methyl (Z)-2-[5-(4-isopropyttriazol-2-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate or a sait, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, prothioconazole, azoxystrobïn, trifloxystrobin, pyraclostrobîn and metyltetraprole, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

In one embodiment of the invention there is provided a synergistic fungicidal composition comprising a mixture of components (A) and (B) as active ingrédients, wherein component (A) is:

methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate (compound X.01), methyl (Z)-2-|5-(3-isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.06), methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyi)pyrazol-1-yl]phenoxy]prop-2-enoate (compound X.08), methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol·2-yl)phenoxy]prop-2-enoate (compound X.09), or methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yt]phenoxy]prop-2-enoate (compound X.10);

or an agronomically acceptable sait thereof;

cyproconazole, difenoconazole, prothioconazole, azoxystrobin, trifloxystrobin, pyraclostrobin and metyltetraprole.

Preferably, in an embodiment of the invention there is provided a synergistic fungicidal composition 5 comprising a mixture of components (A) and (B) as active ingrédients, wherein component (A) is:

methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate (compound X.01), methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.06), methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate (compound X.08), methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate (compound X.09), or methyl (Z)-3-methoxy“2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy)prop-2-enoate (compound X.10);

or an agronomically acceptable sait thereof;

cyproconazole, difenoconazole, prothioconazole, azoxystrobin, trifloxystrobin, pyraclostrobin and 20 metyltetraprole, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 7.5:1 to 1:7.5).

In anotherembodiment ofthe invention there is provided a synergistic fungicidal composition comprising a mixture of components (A) and (B) as active ingrédients, wherein component (A) is:

methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate (compound X.01), methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.06), methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate (compound X.08), methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yi)phenoxy]prop-2-enoate (compound X.09), or methyl (Z)-3-methoxy-2-[2-methyl·5-[4-(triΐluoFomethyl)triazol-2-yl]phenoxy]ρroρ-2-enoate (compound X.10);

or an agronomically acceptable sait thereof;

cyproconazole, difenoconazole, prothioconazole, fenpropidin, fludioxonil, azoxystrobin, trifloxystrobin, pyraclostrobin, mancozeb, mefentrifluconazole, florylpicoxamid, metyltetraprole, trinexapac-ethyl, glyphosate, N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1 g^-oxadiazol-S-yllbenzamide and [(1 S,2S)-1 methyl-2-(o-tolyl)propyi] (2S)-2-[(4-methoxy-3-propanoyloxy-pyridine-2-carbonyl)amino]propanoate (preferabiy, wherein the weight ratio of component (A) to component (B) is from 100:1 to 1:100).

The term “fungicide as used herein means a compound that Controls, modifies, or prevents the growth offungi. The temn “fungicidally effective amount” means the quantity ofsuch a compound or combination of such compounds that is capable of producing an effect on the growth offungi. Controlling or modifying effects include al) déviation from natural development, such as killing, retardation and the like, and prévention includes barrier or other défensive formation in or on a plant to prevent fungal infection.

The term “plants refers to ail physical parts of a plant, including seeds, seedlings, saplings, roots, tu bers, stems, stalks, foliage, and fruits.

The term plant propagation materiar dénotés ail generative parts of a plant, for example seeds or végétative parts of plants such as cuttings and tubers. It includes seeds in the strict sense, as well as roots, fruits, tubers, bulbs, rhizomes, and parts of plants.

The terni locus as used herein means fields in or on which plants are growing, or where seeds of cultivated plants are sown, or where seed will be placed into the soil. It includes soil, seeds, and seedlings, as well as established végétation.

Throughout this document the expression “composition stands for the various mixtures or combinations of components (A) and (B) (including the above-defined embodiments), for exampie in a single “readymix form, in a combined spray mixture composed from separate formulations of the single active ingrédient components, such as a “tank-mix, and in a combined use of the single active ingrédients when applied in a sequential manner, i.e. one after the other with a reasonably short period, such as a few hours or days. The order of applying the components (A) and (B) is not essentiel for working the présent invention.

The composition according to the invention is effective against harmful microorganisms, such as microorganisms, that cause phytopathogenicdiseases, in particular against phytopathogenic fungi and bacteria.

The composition ofthe invention may be used to control plant diseases caused by a broad spectrum of fungal plant pathogens in the Basidiomycete, Ascomycete, Oomycete and/or Deuteromycete, Blasocladiomycete, Chrytidiomycete, Gfomeromycete and/or Mucoromycete classes.

The composition is effective in controlling a broad spectrum of plant diseases, such as foliar pathogens of omamental, turf, vegetable, field, cereal, and fruit crops.

These pathogens may include:

Oomycetes, including Phytophthora diseases such as those caused by Phytophthora capsici, Phytophthora infestans, Phytophthora sojae, Phytophthora fragariae, Phytophthora nîcotianae, Phytophthora cinnamomi, Phytophthora citricola, Phytophthora citrophthora and Phytophthora erythroseptica; Pythium diseases such as those caused by Pythium aphanidermatum, Pythium arrhenomanes, Pythium graminicoia, Pythium irregutare and Pythium ultimum; diseases caused by 10 Peronosporales such as Peronospora destructor, Peronospora parasitica, Plasmopara viticola,

Plasmopara haistedii, Pseudoperonospora cubensis, Albugo candida, Sclerophthora macrospora and Bremia lactucae; and others such as Aphanomyces cochlioides, Labyrinthuia zosterae, Peronosclerospora sorghi and Sclerospora graminicoia;

Ascomycètes, including blotch, spot, blast or blight diseases and/or rots for example those caused by Pleosporales such as Stemphylium solani, Stagonospora tainanensis, Spilocaea oleaginea, Setosphaeria turcica, Pyrenochaeta iycopehsici, Pteospora herbarum, Phoma destructive, Phaeosphaeria herpotrichoides, Phaeocryptocus gaeumannii, Ophiosphaerella graminicoia, Ophioboius graminis, Leptosphaeria maculans, Hendersonia creberrima, Helmînthosporium 20 triticirepentis, Setosphaeria turcica, Drechslera glycines, Didymeila bryoniae, Cycioconium oleagineum, Corynespora cassiicola, Coch/iobolus sativus, Bipolaris cactivora, Venturia inaequafis, Pyrenophora teres, Pyrenophora tritici-repentis, Altemaria alternata, Altemaria brassicicoia, Altemaria sofani and ASternaria tomatophila, Capnodiales such as Septoria tritici, Septoria nodorum, Septoria glycines, Cercospora arachidicola, Cercospora sojina, Cercospora zeae-maydis, Cercosporeila capseliae and

Cercosporeila herpotrichoides, Cladosporium carpophilum, Cladosporium effusum, Passalora futva, Ciadosporium oxysporum, Dothistroma septosporum, Isariopsis clavispora, Mycosphaereila fijiensis, Mycosphaerella graminicoia, Mycovellosielia koepkeii, Phaeoisahopsis bataticoia, Pseudocercospora vitis, Pseudocercosporella herpotrichoides, Ramularia beticola, Ramutaria colio-cygni, Magnaporthales such as Gaeumannomyces graminis, Magnaporthe grisea, Pyricularia oryzae, Diaporthales such as

Anisogramma anomale, Apiognomonia errabunda, Cytospora platani, Diaporthe phaseolorum, Discuta destructive, Gnomonia fructicoia, Greeneria uvicola, Meianconium juglandinum, Phomopsts viticola, Sirococcus clavigignenti-juglandacearum, Tubakia dryina, Dicarpella spp., Valsa ceratosperma, and others such as Actinothyrium graminis, Ascochyta pisi, Aspergillus flavus, Aspergilfus fumigatus, Aspergiilus nidulans, Asperisporium caricae, Biumeriella jaapii, Candida spp., Capnodium ramosum,

Cephaloascus spp., Cephalosporium gramineum, Ceratocystis paradoxa, Chaetomium spp., Hymenoscyphus pseudoalbidus, Coccidioides spp., Cylindrosporium padi, Diplocarpon maiae, Drepanopeziza campestris, Elsinoe ampeiina, Epicoccum nigrum, Epidermophyton spp., Eutypa lata, Geotrichum candidum, Gibellina cerealis, Gloeocercospora sorghi, Gloeodes pomigena, Gloeosporium perennans; Gloeotinia femulenta, Griphospaeria corticola, Kabatiella Uni, Leptographium microsporum,

Leptosphaeruiînia crassiasca, Lophodermium seditiosum, Marssonina graminicoia, Microdochium nivale, Monilinia fructicola, Monographeila albescens, Monosporascus cannonballus, Naemacycius spp., Ophiostoma novo-ulmi, Paracoccidioides brasi/iensis, Pénicillium expansum, Pestalotia rhododendri, Petriellidium spp., Pezicula spp., Phîalophora gregata, Phyllachora pomigena, Phymatotrichum omnivora, Physalospora abdita, Pfectosporium tabacinum, Poiyscytalum pustulans, Pseudopeziza medicaginis, Pyrenopeziza brassicae, Ramulispora sorghi, Rhabdocline pseudotsugae, Rhynchosporium secalis, Sacrocladium oryzae, Scedosporium spp., Schizothyrium pomi, Sclerotinia scierotiorum, Sdemtinia miner, Scierotium spp., Typhula ishikariensis, Seimatosporium mariae, Lepteutypa cupressi, Septocyta ruborum, Sphaceloma perseae, Sporonema phacidioides, Stigmina palmivora, Tapesia yaliundae, Taphrina builata, Thielviopsls basicola, Trichoseptoria fructigena, Zygophlala jamaicensis; powdery mildew diseases for exampie those caused by Erysiphales such as Blumeria graminis, Erysiphe polygoni, Uncinuia necator, Sphaerotheca fuligena, Podosphaera leucotricha, Podospaera macularis Golovinomyces cichoracearum, Leveiliula taurica, Microsphaera diffusa, Oidiopsis gossypii, Phyllactinia guttata and Oidium arachidis; molds for example those caused by Botryosphaeriales such as Dothioreila aromatica, Dipiodia seriata, Guignardia bidwellii, Botrytis cinerea, Botryotinia allii, Botryotinia fabae, Fusicoccum amygdali, Lasiodiplodia theobromae, Macrophoma theicofa, Macrophomina phaseoiina, Phyilosticta cucurbitacearum; anthracnoses for example those caused by Glommerelales such as Colietotrichum gloeosporioides, Colietotrichum lagenarium, Colietotrichum gossypii, Glomerella cingulata, and Colietotrichum graminicola; and wilts or blights for example those caused by Hypocreales such as Acremonium strictum, Ctaviceps purpurea, Fusarium culmorum, Fusarium graminearum, Fusarium virguliforme, Fusarium oxysporum, Fusarium subglutinans, Fusarium oxysporum f.sp. cubense, Geriachia nivale, Gibberella fujikuroi, Gibberella zeae, Gliocladium spp., Myrothecium verrucaria, Nectria ramulariae, Trichoderma viride, Trichothecium roseum, and Verticillium theobromae;

Basidiomycetes, including smuts for example those caused by Ustilaginaîes such as Ustiiaginoidea virens, Ustilago nuda, Ustilago tritici, Ustilago zeae, rusts for example those caused by Puccinlaies such as Cerotelium fiel, Chrysomyxa arctostaphyli, Coleosporium ipomoeae, Hemileia vastatrix, Puccinia arachidis, Puccinia cacabata, Puccinia graminis, Puccinia recondita, Puccinia sorghi, Puccinia hordei, Puccinia striiformis f.sp. Hordei, Puccinia striiformis f.sp. Secalis, Pucciniastrum coryli, or Uredinales such as Cronartium ribicola, Gymnosporangium juniperi-viginianae, Melampsora medusae, Phakopsora pachyrhizi, Phragmidium mucronatum, Physopella ampeiosidis, Tranzschelia discolor and Uromyces viciae-fabae; and other rots and diseases such as those caused by Cryptococcus spp., Exobasidium vexans, Marasmieilus inoderma, Mycena spp., Sphacelotheca reiliana, Typhula ishikariensis, Urocystis agropyri, itersonilia perplexans, Corticium invisum, Laetisaria fuciformis, Waitea circinata, Rhizoctonia solani, Thanetephorus cucurmeris, Entyloma dahiiae, Entylomella microspora, Neovossia moliniae and Tiiletia caries;

Blastocladiomycetes, such as Physoderma maydis;

Mucoromycetes, such as Choanephora cucurbitarum.; Mucor spp.; Rhizopus arrhizus;

as well as diseases caused by other species and généra closely related to those hsted above.

In addition to their fungicidal activity, the compositions may also hâve activity against bacteria such as

Erwinia amylovora, Erwinia caratovora, Xanthomonas campestris, Pseudomonas syringae,

Strptomyces scabies and other related species as well as certain protozoa.

The composition according to the invention is particularly effective against phytopathogenic fungi belonging to the following classes: Ascomycètes (e.g. Venturia, Podosphaera, Erysiphe, Monilinia, Mycosphae relia, Uncinuia); Basidiomycetes (e.g. the genus Hemileia, Rhizoctonia, Phakopsora, Puccinia, Ustilago, Tilletia); Fungi împerfecti (also known as Deuteromycetes; e.g. Botrytis, Helminthosponum, Rhynchosporium, Fusarium, Septoria, Cercospora, Atternaria, Pyricularia and Pseudocercosporella); Oomycetes (e.g. Phytophthora, Peronospora, Pseudoperonospora, Albugo, Bremia, Pythîum, Pseudosclerospora, Plasmopara).

Crops of useful plants in which the composition according to the invention can be used include perennial and annual crops, such as berry plants for example blackberries, blueberries, cranberrîes, raspberries and strawbemes; cereals for example barley, maize (corn), millet, oats, rice, rye, sorghum triticale and wheat; fibre plants for example cotton, flax, hemp, jute and sisal; field crops for example sugar and fodder beet, coffee, hops, mustard, oilseed râpe (canola), poppy, sugar cane, sunflower, tea and tobacco; fruit trees for example apple, apricot, avocado, banana, cherry, citrus, nectarine, peach, pear and plum; grasses for example Bermuda grass, bluegrass, bentgrass, centipede grass, fescue, ryegrass, St. Augustine grass and Zoysia grass; herbs such as basil, borage, chives, coriander, lavender, lovage, mint, oregano, parsley, rosemary, sage and thyme; legumes for example beans, lentils, peas and soya beans; nuts for example almond, cashew, ground nut, hazelnut, peanut, pecan, pistachio and walnut; palms for example oil palm; ornamentals for exampte flowers, shrubs and trees; other trees, for example cacao, coconut, olive and rubber; vegetables for example asparagus, aubergine, broccoli, cabbage, carrot, cucumber, garlic, lettuce, marrow, melon, okra, onion, pepper, potato, pumpkin, rhubarb, spinach and tomato; and vines for example grapes.

Crops are to be understood as being those which are naturally occurrïng, obtained by conventional methods of breeding, or obtained by genetic engineering. They include crops which contain so-called output traits (e.g. improved storage stability, higher nutritional value and improved flavour).

Crops are to be understood as also încluding those crops which hâve been rendered tolérant to herbicides like bromoxynit or classes of herbicides such as ALS-, EPSPS-, GS-, HPPD- and PPOinhibitors. An example of a crop that has been rendered tolérant to imidazolinones, e.g. imazamox, by conventional methods of breeding is Cîearfield® summer canola. Examples of crops that hâve been rendered tolérant to herbicides by genetic engineering methods include e.g. glyphosate- and glufosinate-resistant maize varieties commerclally available under the trade names RoundupReady®, Herculex I® and LibertyLink®.

Crops are also to be understood as being those which naturally are or hâve been rendered résistant to harmful insects, This includes plants transformed by the use of recombinant DNA techniques, for example, to be capable of synthesising one or more selectiveiy acting toxins, such as are known, for example, from toxin-producing bacteria. Examples of toxins which can be expressed include 5endotoxins, végétative insecticidal proteins (Vip), insecticidal proteins of bacteria colonising nematodes, and toxins produced by scorpions, arachnids, wasps and fungi.

An example of a crop that has been modified to express the Bacillus thuringiensis toxin is the Bt maize KnockOut® (Syngenta Seeds). An example of a crop comprising more than one gene that codes for insecticidal résistance and thus expresses more than one toxin is VipCot® (Syngenta Seeds). Crops or seed material thereof can also be résistant to multiple types of pests (so-called stacked transgenic events when created by genetic modification). For example, a plant can hâve the ability to express an insecticidal protein while at the same time being herbicide tolérant, for example Herculex I® (Dow AgroSciences, Pioneer Hi-Bred International).

The compounds of Formula (I) (including anyone ofcompounds X.01 toX.12) orfungicidal compositions according to the présent invention comprising a compound of Formula (I) may be used in controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi (such as Phakopsora pachyrhizi) on soy bean plants.

In particular, transgenic soybean plants expressing toxins, for example insecticidal proteins such as delta-endotoxins, e.g. CrylAc (CrylAc Bt protein). Accordingly, this may include transgenic soybean plants comprising event MON87701 (see U.S. Patent No. 8,049,071 and related applications and patents, as well as WO 2014/170327 A1 (eg, see paragraph [008] reference to Intacta RR2 PRO™ soybean)), event MON87751 (US. Patent Application Publication No. 2014/0373191) or event DAS81419 (U.S. Patent No. 8632978 and related applications and patents).

Other transgenic soybean plants may comprise event SYHT0H2 - HPPD tolérance (U.S. Patent Application Publication No. 2014/0201860 and related applications and patents), event MON89788 glyphosate tolérance (U.S. Pat. No. 7,632,985 and related applications and patents), event MON87708 -dicamba tolérance (U.S. Patent Application Publication No. US 2011/0067134 and related applications and patents), event DP-356043-5 - glyphosate and ALS tolerance (U.S. Patent Application Publication No. US 2010/0184079 and related applications and patents), event A2704-12 - glufosinate tolerance (U.S. Patent Application Publication No. US 2008/0320616 and related applications and patents), event DP-305423-1 - ALS tolerance (U.S. Patent Application Publication No. US 2008/0312082 and related applications and patents), event A5547-127 - glufosinate tolerance (U.S. Patent Application Publication No. US 2008/0196127 and related applications and patents), event DAS-40278-9 - tolerance to 2,4drchlorophenoxyacetic acid and aryloxyphenoxypropionate (see WO 2011/022469, WO 2011/022470, WO 2011/022471, and related applications and patents), event 127 - ALS tolerance (WO 2010/080829 and related applications and patents), event GTS 40-3-2 - glyphosate tolérance, event DAS-68416-42,4-dichlorophenoxyacetic acid and glufosinate tolérance, event FG72 - glyphosate and isoxaflutole tolérance, event BPQ-CV127-9 - ALS tolérance and GU262 - glufosinate tolérance or event SYHT04R - HPPD tolérance.

The compounds of Formula (!) (including any one of compounds X.01 to X.12) orfungicidal compositions according to the présent invention comprising a compound of Formula (I) may be used in controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi (such as Phakopsora pachyrhizî) on soy bean plants. In particular, there are known in the scientific literature certain Elite soybean plant varieties where R-gene stacks, conferring a degree of immunity or résistance to spécifie Phakopsora pachyrhizî, hâve been been introgressed in the plant genome, see for example: “Fighting Asian Soybean Rust, Langenbach C, et al, Front Plant Science 7(797) 2016).

An elite plant is any plant from an elite line, such that an elite plant is a représentative plant from an elite variety. Non-limiting examples of elite soybean varieties that are commercially available to farmers or soybean breeders include: AG00802, A0868, AG0902, A1923, AG2403, A2824, A3704, A4324, A5404, AG5903, AG6202 AG0934; AG1435; AG2031 ; AG2035; AG2433; AG2733; AG2933; AG3334; AG3832; AG4135; AG4632; AG4934; AG5831 ; AG6534; and AG7231 (Asgrow Seeds, Des Moines, lowa, USA); BPR0144RR, BPR 4077NRR and BPR 4390NRR (Bio Plant Research, Camp Point, III., USA); DKB1751 and DKB37-51 (DeKalb Genetics, DeKaib, IH., USA); DP 4546 RR, and DP 7870 RR (Delta & Fine Land Company, Lubbock, Tex., USA); JG 03R501, JG 32R606C ADD and JG 55R503C (JGL Inc., Greencastle, Ind,, USA); NKS 13-K2 (NK Division of Syngenta Seeds, Golden Valley, Minnesota, USA); 90M01,91M30, 92M33, 93M11,94M30, 95M30, 97B52, P008T22R2; P16T17R2; P22T69R; P25T51R; P34T07R2; P35T58R; P39T67R; P47T36R; P46T21 R; and P56T03R2 (Pioneer Hi-Bred International, Johnston, lowa, USA); SG4771NRR and SG5161NRR/STS (Soygenetics, LLC, Lafayette, Ind., USA); S00-K5, S11-L2, S28-Y2, S43-B1, S53-A1, S76-L9, S78-G6, S0009-M2; S007-Y4; S04-D3; S14-A6; S20-T6; S21-M7; S26-P3; S28-N6; S30-V6; S35-C3; S36-Y6; S39-C4; S47-K5; S48-D9; S52-Y2; S58Z4; S67-R6; S73-S8; and S78-G6 (Syngenta Seeds, Henderson, Ky., USA); Richer (Northstar Seed Ltd. Alberta, CA); 14RD62 (Stine Seed Co. la., USA); or Armor 4744 (Amnor Seed, LLC, Ar., USA).

Thus, in a further preferred embodiment, the compounds of Formula (I) (including any one of compounds X.01 to X.12), or fungicidal compositions according to the présent invention comprising a compound of Formula (I), are used to control Phakopsora pachyrhizî, (including fungicidally-resistant strains thereof, as outlined below) on Elite soybean plant varieties where R-gene stacks, conferring a degree of immunity or résistance to spécifie Phakopsora pachyrhizî, hâve been been introgressed in the plant genome. Numerous benefits may be expected to ensue from said use, e.g, improved biological activity, an advantageous or broader spectrum of activity (inc. sensitive and résistant strains of Phakopsora pachyrhizî), an increased safety profile, improved crop tolérance, synergistic interactions or potentiating properties, improved onset of action or a longer lasting residual activity, a réduction in the number of applications and/or a réduction in the application rate ofthe compounds and compositions required for effective control ofthe phytopathogen (Phakopsora pachyrhizi), thereby enabling bénéficiai résistancemanagement practices, reduced environmental impact and reduced operator exposure.

Under certain circumstances, fungicidal compositions according to the présent invention comprising a compound of Formula (I) when used in controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi (such as Phakopsora pachyrhizi) on soy bean plants (in particular any of the transgenic soybean plants as described above), may display a synergistic interaction between the active ingrédients.

The compounds of Formula (I) (including any one of compounds X.01 toX.12) orfungicidal compositions according to the présent invention comprising a compound of Formula (I) may be used in controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi (in particular, Phakopsora pachyrhizi) on soybean plants.

Additionalty, to date, no cross-résistance has been observed between the compounds of Formula (I) (including any one of compounds X.01 to X.12) and the current fungicidal solutions used to control Phakopsora pachyrhizi.

Indeed, fungicidal-resistant strains of Phakopsora pachyrhizi hâve been reported in the scientific 20 literature, with strains résistant to one or more fongicides from at least each of the following fungicidal mode of action classes being observed: sterol demethylation-inhibitors (DMI), quinone-outside-inhibitors (Qol) and succinate dehydrogenase inhibitors (SDHl). See for example: “Sensitivity of Phakopsora pachyrhizi towards quinone-outside-inhibitors and demethylation-inhibitors, and corresponding résistance mechanisms.” Schmitz H K et al, Pest Manag Soi (2014) 70: 378-388; First détection of a 25 SDH variant with reduced SDHl sensitivity in Phakopsora pachyrhizi” Simôes K et al, J Plant Dis Prof (2018) 125: 21-2; “CompeMve fitness of Phakopsora pachyrhizi isolâtes with mutations in the CYP51 and CYTB genes.” Klosowski AC et ai, Phytopathology (2016) 106: 1278-1284; “Détection ofthe F129L mutation in the cytochrome b gene in Phakopsora pachyrhizi. Klosowski AC et ai, Pest Manag Sci (2016) 72: 1211-1215.

Thus, in a preferred embodiment, the compounds of Formula (I) (including any one of compounds ΧΌ1 to X.12), or fungicidal compositions according to the présent invention comprising a compound of Formula (I), are used to control Phakopsora pachyrhizi which are résistant to one or more fungicides from any ofthe following fungicidal MoA classes: sterol demethylation-inhibitors (DMI), quinone-outside35 inhibitors (Qol) and succinate dehydrogenase inhibitors (SDHl).

The compounds ofthe présent invention, wherein X, R¹, R², R³, R⁴, R^s and R⁶ are as defined for formula (I), can be made as shown in the following schemes.

The compounds offormula (l) according tothe invention, wherein X, R¹, R², R³, R⁴ and R⁵ are as defined for formula (I), can be obtained by transformation of a compound of formula (II), wherein R¹, R² and R³are as defined for compounds of formula (I) and R¹¹ is halogen (preferably chloro, bromo or iodo) or 5 pseudohalogen (e.g -OSOîCHs, -OSO2CF3 or-OSOziCFzJaCFa) and compounds of formula (III) wherein

X, R⁴ and R⁵ are as defined for compounds of formula (I), in the presence of a base such as K2CO3, a palladium compound such as tris(dibenzylideneacetone)dipalladium(O) and a supporting phosphine ligand such as 2-Di-tert-butylphosphino-3,4,5,6-tetramethyl-2',4’,6'-triisopropyi-1 J’-biphenyl in an organic solvent such as toluene at températures between 20°C - 110°C. Such transformations are 10 described in Angew. Chem. Int. Ed. 2011, p. 8944 and are shown in scheme 1.

Scheme 1

Alternativeîy, compounds of formula (I) can be obtained from compounds of formula (IV) wherein R¹, R²and R³ are as defined for compounds of formula (I) and R¹² is as defined in scheme 2, and compounds of formula (III) wherein X, R⁴ and R⁵ are as defined for compounds of formula (I), in the presence of a base such as pyridine and a copper sait such as Cu(OAc)2 in an inert organic solvent such as 20 dichloromethane. This is shown in scheme 2.

Scheme 2

Compounds of formula (IV), wherein R¹, R² and R³ are as defined for compounds of formula (I) and R¹²is as defined in scheme 2, can be obtained from compounds of formula (II), wherein R¹, R², R³ and R¹' are as defined above, by treatment with a base such as potassium acetate, a diborane species R¹²-R¹²5 wherein R¹² is as defined in scheme 3, a palladium compound such as tris(dibenzylideneacetone)dipailadlum(0) and a supporting phosphine ligand such as 2-Dicyclohexylphosphino-2’,4',6'-triisopropyl-1 ,Τ-biphenyl in an organic solvent such as tetrahydrofuran or éthanol, optionally followed by borane group hydrolysis or transestérification. This îs shown in scheme 3.

Scheme 3

Compounds of formula (II), wherein R¹, R² and R³ are as defined for compounds of formula (I) and R¹¹is as defined above, can be obtained from compounds of formula (V) wherein R¹, R² and R³ are as defined for compounds of formula (I), R¹¹ is as defined above and R¹³ is H or C1-C4 alkyl, by treatment with a base such as sodium methoxide and a formylating agent such as methyl formate to generate compounds of formula (Va), wherein R¹, R² and R³ are as defined for compounds of formula (I), R¹¹ is as defined above and R¹⁴ is H or methyl, followed by méthylation with a reagent such dimethyl sulfate in the presence of a base such as K2CO3. This is shown in scheme 4.

Scheme 4

Compounds of formula (V), wherein R¹, R² and R³ are as defined for compounds of formula (f), R¹¹ is as defined above and R¹³ is H or C1-C4 alkyl, can be obtained from compounds of formula (VI) wherein R', R² and R³ are as defined for compounds of formula (I) and R¹¹ is as defined above, by treatment with a base such as K2CO3 and an alkylation agent of formula (VII) in an organic solvent such as N-methyl pyrrolidone. This is shown in scheme 5.

Scheme 5

(V)

Compounds of formula (VI) wherein R¹, R² and R³ are as defined for compounds of formula (I) and R¹¹is as defined above are commercîally available or readily prepared from commercially avatlable

compounds by standard functional group transformations well known to a person skilled in the art and described in March’s Advanced Organic Chemistry, Smith and March, δ' édition, Wiley, 2007.

Alternative ly, compounds of formula (1), wherein X, R¹, R², R^s, R⁴ and R⁵ are as defined for compounds 5 of formula (i), can be obtained from compounds of formula (VIII) wherein X, R', R², R³, R⁴ and R⁵ are as defined for compounds of formula (I) and R¹³ is H or C1-C4 alkyl, by treatment with a base such as sodium methoxide and a formylating agent such as methyl formate to generate compounds of formula (IX), wherein X, R¹, R², R³, R⁴ and R⁵ are as defined for compounds of formula (I) and R¹⁴ is H or methyl, followed by méthylation with a reagent such dimethyl sulfate in the presence of a base such as K2CO3.

This is shown in scheme 6.

Scheme 6

Compounds of formula (VIII), wherein X, R¹, R², R³, R⁴ and R⁵ are as defined for compounds of formula (I) and R¹³ is H or C1-C4 alkyl, can be obtained from compounds of formula (V) wherein R¹, R² and R³are as defined for compounds of formula (I), R¹³ is H or C1-C4 alkyl and R¹¹ is halogen (preferably, chloro, bromo, iodo) orpseudohalogen (e.g OSO2CH3, OSO2CF3 or-OSC^CFahCFa) and compounds of formula (III) wherein X, R⁴ and R⁶ are as defined for compounds of formula (I), m the presence of a base such as K2CO3, a palladium compound such as tris(dibenzylideneacetone)dipalladium(0) and a supporting phosphine ligand such as 2-Di-tert-butylphosphino-3₁4,5,6-tetramethyl-2',4',6'-triisopropyl1,1 '-biphenyl in an organic solvent such as toluene at températures between 20’C - 110°C. This is shown in scheme 7.

Scheme 7

The préparation of compounds of formula (III) wherein X, R⁴ and R⁵ are as defined for compounds of formula (I) is well known to a person skilied in the art and has ample precedence in the scientific lite rature.

Alternatively, certain compounds of formula (I) can be prepared from compounds of formula (l-a), wherein X, R', R², R³ and R^s are as defined for compounds of formula (I) and R¹⁴ is halogen (preferably chloro, bromo or iodo) or pseudohalogen (e.g -OSO2CH3, -OSO2CF3 or -OSO2(CF2)3CF3), in the presence of a coupling reagent and a transition metal-based catalyst. There are no particular limitations on the coupling agent, catalyst and solvent provided it is used in ordinary coupling reactions, such as those described in “Cross-Coupling Réactions: A Practical Guide (Topics in Current Chemistry), edited by Norio Miyaura und S.L. Buchwald (éditions Springer), or “Metal-Catalyzed Cross-Coupling Réactions, edited by Armin de Meijere and François Diederich (éditions WILEY-VCH). This is shown in Scheme 8.

Scheme 8

Furthermore, compounds of formula (I), wherein R¹, R², R³, R⁴ and R⁵ are as defined above and X is CH, can be prepared from a compound of formula (Ha), wherein R¹, R² and R³ are as defined for 5 compounds of formula (I), via one-pot reaction sequence comprising a diazotîzation and réduction to the résultant hydrazine sait of formula (X) wherein R¹, R² and R³ are as defined for compounds of formula (I), followed by cyclization with a compound of formula (XI), wherein R^z is hydrogen or Ci-C^alkyl and R⁴ and R⁵ are as defined for compounds of formula (I), For related examples, see WO2018/104214. This is shown in Scheme 9.

Scheme 9

Altematîvely, compounds of formula (XII) can be prepared from compounds of formula (XIII), via nitro group réduction reaction using a métal (e.g, Pd/C, iron, or Raney Nickel) in a suitable solvent (e.g. MeOH or éthanol) in the presence of a reducing agent (e.g. hydrogen gas, ammonium chloride, formic acid, or hydrazine) at a température between 25°C and 65°C. In some cases, an improved reaction performance is gained when an increase in pressure is applied. For related examples, see: Yoshii, Y. et ai Chem. Commun. (2015), 51,1070; Takeshiba, H. et a/Eur. Pat. Appl., (1997) 807631. The nitro group réduction reaction can be followed by via radical-nucleophilic aromatrc substitution reaction (Sandmeyer) in the presence of a nitrite source (eg, NaNOz oriso-amylnitrite), and a copper source (eg, CuCN) in an acceptable solvent System, such as aqueous acetonitrile, at suitable températures (e.g. 0°C to 1OO“C). This reaction is shown in Scheme 10.

Scheme 10

The compounds of formula (XIII) according to the invention, wherein X, R¹, R², R³, R⁴ and R⁵ are as defined for formula (I), can be obtained by transformation of a compound of formula (XIV), wherein R¹, R² and R³ are as defined for compounds of formula (I) and R¹¹ is halogen (prefereably chloro, bromo or 5 iodo), or psuedohalogen (e.g., -OSO2CH3, -OSO2CF3 or -OSChtCFzJaCFa) and compounds of formula (III) wherein X, R⁴ and R⁵ are as defined for compounds of formula (I), in the presence ofa base such as K2CO3, a métal compound such as tris(dibenzylideneacetone)dipalladrum(O) and optionally with a supporting phosphine ligand such as 2-di-tert-butylphosphino-3,4,5,6-tetramethy 1-2^41,6-10isopropyl1 ,T-biphenyl in an organic solvent such as toluene at températures between 20’0 - 110’C, Such 10 transformations are described in Angew. Chem. Int. Ed. (2011), 8944 and are shown in scheme 11.

Furthemnore, compounds of formula (XIII) can be obtained from compounds of formula (XIV) wherein R¹, R² and R³ are as defined for compounds of formula (I) and R¹¹ is halogen, and compounds offormula (III) wherein R⁴ and R⁶ are as defined for compounds offormula (I), optionally in the presence ofa base 15 such as pyridine or K2CO3 and optionally in the presence copper sait such as Cu(OAc)2 in a suitable inert organic solvent such as dichloromethane. This is shown in scheme 11.

Scheme 11

O

(XIV)

Altematively, compounds of formula (XII) can be prepared from compounds of formula (VI), wherein R¹,

R^z and R³ are as defined for compounds of formula (I) and R¹¹ is halogen (prefereably chloro, bromo or iodo), or psudohatogen (e.g., -OSO2CH3, -OSO2CF3or-OSC^fCFajaCFa) and compounds of formula (III) wherein X, R⁴ and R⁵ are as defined for compounds of formula (I), in the presence of a base (eg, K2CO3), a copper compound (eg. Cul) and optionally a co-reagent (eg, N,N'-dimethyl-1,2-ethanediamine or N,N’dimethyl-1,2-cyclohexanedlamine) in a suitable organic solvent (eg, toluene ordioxane) attempératures between 2O’C-15O°C. Such transformations are described in ACS Oméga 2018, 3, 1955 or WO 2013083604 and are shown in the scheme 12.

Alternatively, compounds of formula (Xlla) can be prepared from compounds of formula (Via), wherein R¹, R² and R³ are as defined for compounds of formula (J) and R¹¹ is halogen (prefereably chloro, bromo or iodo), or psuedohalogen (e.g., -OSO2CH3, -OSO2CF3 or -OSOziCFz^CFj) and R¹⁵ is a suitable protecting group for a phénol function (eg, silyl group, ether group, benzyl) and compounds of formula (III) wherein X, R⁴ and R⁵ are as defined for compounds of formula (I), in the presence of a base (eg, K2CO3), a copper compound (eg, Cul) and optionally a co-reagent (eg, N,N’-dimethyl-1,2-ethanediamine or N,N^!-dimethyl·1,2-cyclohexanedîamine) in a suitable organic solvent (eg, toluene or dioxane) at températures between 20°C-150°C. Such transformations are described in A CS Oméga 2018, 3, 19551969 or WO 2013083604 and are shown in the scheme 13.

Scheme 13

(XI la)

Alternatively, compounds of formula (XVII) can be prepared from compounds of formula (XV), wherein R¹, R² and R³ are as defined for compounds of formula (I) and R¹³ is H or C1-C4 alkyl and R¹⁶ is as 5 defined in Scheme 14 via nucleophilic aromatic substitution reactions with compound (XVI) in the presence of a nitrite source (eg, NaNOa or /so-amylnitrite) in acidic conditions (eg, H2SO4 0r HBF4) and a copper source (eg, CuSÛ4 or CuCN) in an acceptable solvent System at suitable températures (e.g. 0°C to 100“C). Such transformations are described in CN 101580477 or Journal oflowa Academy of Science 2010, 116, 27-35 and are shown in the scheme 14.

Scheme 14

Alternatively, compounds of formula (XVII) can be prepared from compounds offormula (XVIII), wherein X, R¹, R², R³, R⁴ and R^s are as defined for compounds of formula (I) and R¹³ is H or C1-C4 alkyl and R^,B is as defined in Scheme 15 via nucleophilic aromatic substitution réactions with compound (XVI) in the presence of a base (eg, CsaCOs), a catalyst (copper source; eg, Cul or CuO), optionally in the presence of a co-reagent (eg, 1,10-phenanthroline) in an acceptable solvent system (eg, toluene) at suitable températures (e.g. 0°C to 110°C). Such transformations are described in WO 2007010082 or WO200837626 and are shown in Scheme 15.

Alternatively, compounds of formula (XVilc), wherein R¹, R² and R³ are as defined for compounds of formula (I) and R’³ is H or C1-C4 alkyl, can be obtained from compounds of formula (XIX) wherein R¹, R² and R³ are as defined for compounds of formula (I) by treatment with a base (eg, CS2CO3 or K2CO3) and an alkylation agent of formula (VII), optionally in an organic solvent such as N-methyl pyrrolidone.

Compounds of formula (XX), wherein R¹, R² R³ and R¹³ are as defined above, can be obtained from compounds of formula (XVilc) via nitro group réduction reaction using a métal (e.g. Pd/C, iron, or Raney Nickel) in a suitable solvent (e.g. MeOH or éthanol) in the presence of a reducing agent (e.g. hydrogen gas, ammonium chloride, formic acid, or hydrazine) at a température between 25°C and 65°C. In some cases, an improved reaction performance is gained when an increase in pressure is applied.

This is shown in scheme 16.

Scheme 16

(»9

Altematively, compounds of formula (XVIIc), wherein R¹, R² and R³ are as defined for compounds of formula (I) and R¹³ is H or C1-C4 alkyl, can be obtained from compounds of formula (XXI) wherein R', 5 R² R³ are as defined above and R¹⁷ is halogen by treatment with compounds of formula (XVI) in the presence of a base (eg, CS2COs), a catalyst (copper source; eg, Cul) in an acceptable solvent System, such as aqueous DMSO, at suitable températures (e.g. 0°C to 120°C). Such transformations are describedby Xiao, Yan et al. in J. Org. Chem. 2013, 78, 5804-5809 and are shown in the scheme 17.

Scheme 17

(XXI)

R¹⁷ = halogen

Alternatively, compounds of formula (XXIV) wherein R¹, R^s and R³ are as defined for compounds of formula (I) and R¹⁸ is OH, OR¹⁵, OR^1S, NO2, NH2, R¹², wherein R¹⁵ is a surtable protecting group for a 5 phénol function, R¹⁹ is an optionally substituted C1-C4 alkyl (eg, acetate function) and R¹² is a diborane species defined in scheme 18, can be obtained from compounds of formula (XXII) wherein R¹, R², R³and R¹³ are defined above via a sequence comprising a sélective réduction of the nitro function to give compounds (XXIII), wherein R’, R², R³ and R^1B are defined as above followed by a one-pot reaction sequence comprising a diazotization and a substitution of the corresponding diazonium sait with 10 compounds of formula (III), wherein R⁴, R^s, and X are defined for compounds of formula (I). This sequence is shown in scheme 18.

The nitro group réduction reaction can be performed using a métal (e.g. Pd/C, iron, or Raney Nickel) in a suitable solvent (e.g. MeOH or éthanol) in the presence of a reducîng agent (e.g, hydrogen gas, 15 ammonium chloride, formic acid, or hydrazine) at a température between 25°C and 65°C. In some cases, an improved reaction performance is gained when an increase in pressure is applied. For related examples, see: J. Org. Chem. 1980, 45, 4992; Bull. Chem. Soc. Jpn. 1983, 56, 3159. The réduction reaction can be followed by a one-pot reaction diazotation-substitution reaction in the presence of a nitrite source (eg, NaNO2 or rso-amylnitrite) in acidic conditions (eg, AcOH or H2SO4), and a copper 20 source (eg, Cu(OAc)a) in an acceptable solvent System, such as methanol, at suitable températures (e.g. 0°C to 100°C) For related examples, see: Chem. Eur. J. 2014, 20,14619. This sequence is shown in Scheme 18.

Scheme 18

R¹⁶ = OH, OR¹⁵, OR^1S NO₂, NH₂, R¹²

R¹⁵ = phénol protecting group; R^1S = optionally substituted C^-C^alkyl

In particular, compounds (XIII), wherein R¹, R², R³· R⁴, R^s and X are as defined for compounds of formula 5 (I), can be obtained from compounds of formula (XXIla) wherein R¹, R², R³· R⁴, R^s and X are as defined for compounds of formula (I) via a sequence comprising a sélective réduction of the nitro function to give compounds (XXIIIa) wherein R¹, R² and R³ are as defined for compounds of formula (I) followed by a one-pot reaction sequence comprising a diazotization and a substitution ofthe corresponding diazonium sait with compounds of formula (III), wherein R⁴, R⁶, and X are as defined for compounds of formula (I), 10 as described in scheme 19.

The nitro group réduction reaction can be performed using a métal (e.g. Pd/C, iron, or Raney Nickel) in a suitable solvent (e.g. MeOH or éthanol) in the presence of a reducîng agent (e.g. hydrogen gas, ammonium chloride, formic acid, or hydrazine) at a température between 25°C and 65°C. In some 15 cases, an improved reaction performance is gaîned when an increase in pressure is applied. For related examples, see: J. Org. Chem. 1980, 45, 4992; Bull Chem. Soc. Jpn. 1983, 56, 3159. The réduction reaction can be followed by a one-pot reaction diazotation-substitution reaction in the presence of a nitrite source (eg, NaNOa or /so-amylnitrite) in acidic conditions (eg, AcOH or H2SCU), and a copper source (eg, CufOAcR) in an acceptable solvent system, such as methanol, at suitable températures 20 (e.g. 0°C to 100°C)to give compounds (XIII); for related examples, see: Chem. Eur. J. 2014, 20,14619.

Compounds of formula (XXV), wherein R¹, R², R³ R⁴, R⁵ and X are as defined for compounds of formula (I), can be obtained via réduction of the nitro function of compounds of formula (XIII), wherein R¹, R², R³· R⁴, R⁵ and X are as defined for compounds of formula (I). The nitro group réduction reaction can be performed using a métal (e.g. Pd/C, iron, or Raney Nickel) in a suitable solvent (e.g. MeOH or éthanol) in the presence of a reducing agent (e.g. hydrogen gas, ammonium chloride, formic acid, or hydrazine) at a température between 25°C and 65°C. in some cases, an improved reaction performance is gained when an increase in pressure is applied. For related examples, see: J. Org. Chem. 1980, 45, 4992; Bull.

Chem. Soc. Jpn. 1983, 56, 3159. This sequence is shown in Scheme 19.

Scheme 19

(XXIIa)

Altematively, compounds of formula (XIII), wherein R¹, R², R³· R⁴, R⁵ and X are as defined for compounds of formula (I), can be obtained from compounds of formula (XXIlia) wherein R¹, R² and R³are as defined for compounds of formula (I) via a sequence comprising a Sandmeyer reaction, in the presence of a nitrite source (eg, NaNOï or iso-amylnitrite), and a copper source (eg, CuBr) in an acceptable solvent system, such as aqueous acetonitrile, at suitable températures (e.g. 0°C to 100°C), to give compounds of formula (XXI) wherein R¹, R², R³are as defined for compounds of formula (I) and R¹⁷ is a haiogen followed by a substitution with compounds of formula (I11), wherein R⁴, R⁵, and X are as defined for compounds of formula (I), in the presence of a copper source (eg, CuO or Cul) as a catalyst and ligands (eg, oxime derived, bi-, tri-, tetra-dentate derived ligands) in an acceptable solvent System, such as acetonitrile, at suitable températures (e.g. 0°C to 82’C) as reported by Taillefer, M. et al. in Eur. J. Org. Chem. 2004, 4, 695-709. This sequence is shown in Scheme 20.

Scheme 20

R¹⁷ = halogen

Alternatively, compounds of formula (XXVII) wherein R¹, R² and R³ are as defined for compounds of 5 formula (I) can be obtained from compounds of formula (XXVI) wherein R’, R² and R³are as defined for compounds of formula (I) and R¹² is as defined in scheme 21, in the presence of an oxidant (eg, H2O2, O2) in aqueous media at suitable températures (e.g. 20°C to 1ÛO°C). For related exampies, see: Luo, D.P. et al. in Adv. Synth. Cat. 2019, 361, 961-964. This reaction is shown in Scheme 21.

Scheme 21

Alternatively, compounds of formula (XXIX), wherein R¹, R² and R³ are as defined for compounds of formula (I) and R¹⁶ is defined as in scheme 22, can be prepared from compounds of formula (XXVIII), wherein R¹, R² and R³ are as defined for compounds of formula (I) and R¹⁰ is defined as in scheme 22, via nitro group réduction reaction using a métal (e.g. Pd/C, iron, or Raney Nickel) in a suitable solvent (e.g. MeOH or éthanol) in the presence of a reducing agent (e.g. hydrogen gas, ammonium chloride, formic acid, or hydrazine) at a température between 25°C and 65’C, In some cases, an improved reaction performance îs gained when an increase in pressure is applied. For related examples, see: Yoshii, Y. et al Chem. Commun. 2015, 51, 1070; Takeshiba, H. et al Eur. Pat. Appl., (1997) 807631. The réduction reaction can be followed by a Sandmeyer reaction in the presence of a nitrite source (eg, NaNO₂ or /so-amylnitrite), and a copper source (eg, CuCN) in an acceptable solvent System, such as aqueous acetonitrile, at suitable températures (e.g. 0°C to 100°C). This reaction is shown in Scheme 22.

Scheme 22

Alternatively, compounds of formula (I) wherein X, R¹, R², R^J, R⁴ and R⁵ are as defined above, can be obtained by transformation of another, closely related, compound of formula I (or an analogue thereof) using standard synthesis techniques known to the person skilied in the art. Non-exhaustive examples include oxidation réactions, réduction reactions, hydrogénation reactions, hydrolysis reactions, coupling reactions, aromatic nucteophilic or electrophîlic substitution reactions, nucleophllic substitution reactions, alkylation reactions, nucleophllic addition reactions and halogénation reactions.

Functional group interconversions as described in the previous schemes are known to the persons skilied in the art. Extensive lists of reaction conditions can be found in: Comprehensive Organic Functional Group Transformations, Edited by A. R. Katritzky, O. Meth-Cohn and C. W. Rees. Pergamon Press (Elsevier Science Ltd.), Tarrytown, NY. 1995; or in: Comprehensive Organic Transformations: A Guide to Functional Group Préparations, Edited by Richard C. La rock, Wiley-VCH, New York 1999.

If the synthesis yields mixtures of isomers, a séparation is generally not necessarïly required because in some cases the individual isomers can be interconverted during work-up for use or during application (e. g. under the action of light, acids or bases). Such conversions may also take place after use, e. g. in the treatment of plants in the treated plant, or in the harmful fungus to be controlled.

Compositions of this invention, including ail of the above disclosed embodiments and preferred examples thereof, can be mixed with one or more further pesticides including further fungicides, insecticides, nematocides, bactéricides, acaricides, growth regulators, chemosterilants, semiochemicals, repellents, attractants, pheromones, feeding stimulants or other bioiogically active compounds to form a multi-component pesticide giving an even broader spectrum of agricultural protection.

Exemples of such agricultural protectants with which the composition ofthis invention can be formulated are:

Fungicides such as etridiazole, fluazinam, benalaxyl, benalaxyl-M (kiralaxyl), furalaxyl, metalaxyl, metalaxyl-M (mefenoxam), dodicin, N’42,5-dimethyl-4-phenoxy-phenyi)-N-ethyl-N-methyl· formamtdine, N’-f4-(4,5'dichloro-thiazol-2-yloxy)-2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidine₁N'-[4-[[3-[(4-chlorophenyl)methyl]-1,2_]4-thiadiazol-5yl]oxy]-2,5dimethyl-phenyl]-N-ethyl-N-methylformamidine, ethirimol, 3'-chloro-2-methoxy-N-[(3RS)-tetrahydro-2-oxofuran-3-yl]acet-2',6'-xylidide (clozylacon), cyprodinil, mepanipyrim, pyrimethanil, dithianon, aureofungin, biasticidin-S, biphenyl, chloroneb, dicloran, benzovindiflupyr, pydiflumetofen, hexachlorobenzene, quintozene, tecnazene, (TCNB), toiclofos-methyl, metrafenone, 2,6-dichloro-N-(4-trifluoromethy!benzyl)-benzamide, fluopicolide (flupicolide), tioxymid, flusulfamide, benomyl, carbendazim, carbendazim chlorhydrate, chlorfenazole, fuberidazole, thiabendazole, thiophanate-methyl, benthiavalicarb, chlobenthiazone, probenazole, acibenzolar, bethoxazin, pyriofenone (IKF-309), acibenzolar-S-methyl, pyribencarb (KIF-7767), butylamine, 3-iodo-2-propinyl n-butylcarbamate (IPBC), iodocarb (isopropanyl butylcarbamate), isopropanyl butylcarbamate (iodocarb), picarbutrazox, polycarbamate, propamocarb, tolprocarb, 3-(difluoromethyl)-N-(7-fluoro-1,1,3,3-tetramethyl-indan-4-y1)-1 -methylpyrazole-4-carboxamide diclocymet, N-[(5-chloro-2-îsopropy^-phenyt)methyl]-N-cyclopropyl·3(difluoΓOmethy^)-5“fluoro-1-methyl·pyΓazole-4-carboxamide N-cyclopropyl-3-(difiuoromethyl)-5-fiuorO’N[(2-isopropylphenyl)methyl]-1 -methyl-pyrazole-4-carboxamide carpropamid, chlorothalonil, flumorph, oxine-copper, cymoxanil, phenamacril, cyazofamid, flutianil, thicyofen, chlozolinate, iprodione, procymidone, vinclozolin, bupirimate, dinocton, dinopenton, dinobuton, dinocap, meptyldinocap, diphenylamine, phosdiphen, 2,6-dimethyl-[1,4]dithÎino[2,3-c:5,6-c']dipyrrote-1,3,5,7(2H,6H)4etraone, azithîram, etem, ferbam, mancozeb, maneb, metam, metiram (polyram), metiram-zinc, nabam, propineb, thiram, vapam (metam sodium), zineb, ziram, dithioether, isoprothiolane, ethaboxam, fosetyl, phosetyl-AI (fosetyl-al), methyl bromide, methyl iodide, methyl isothiocyanate, cyclafuramid, fenfuram, validamycin, streptomycin, (2RS)-2-bromo-2-(bromomethyl)glutaronitrile (bromolhalonil), dodine, doguadine, guazatine, iminoctadine, iminoctadine triacetate, 2,4-D, 2,4-DB, kasugamycin, dimethirimol, fenhexamid, hymexazole, hydroxyisoxazole imazalil, imazalil sulphate, oxpoconazole, pefurazoate, prochloraz, triflumizole, fenamidone, Bordeaux mixture, calcium polysulfîde, copper acetate, copper carbonate, copper hydroxide, copper naphthenate, copper oleate, copper oxychloride, copper oxyquinolate, copper silicate, copper sulphate, copper tallate, cuprous oxide, sulphur, carbaryl, phthalide (fthalide), dingjunezuo (Jun Si Qi), oxathiapiprolin, fluoroimide, mandipropamid, KSF-1002, benzamorf, dimethomorph, fenpropimorph, tridemorph, dodemorph, diethofencarb, fentin acetate, fentin hydroxide, carboxin, oxycarboxin, drazoxolon, famoxadone, mphenylphenol, p-phenylphenol, tribromophenol (TBP), 2-[2-[(7,8-difluoro-2-methyl-3-quinolyl)oxy]-6fluoro-phenyl]propan-2-ol 2-[2-fiuoro-6-[(8-fluoro-2-methyl-3-quinolyl)oxy]phenyl]propan-2-ol cyflufenamid, ofurace, oxadixyl, fîutolanil, mepronil, isofetamid, fenpiclonii, fludioxonil, pencycuron, 5 edifenphos, iprobenfos, pyrazophos, phosphorus acids, tecloftalam, captafol, captan, ditalimfos, triforine, fenpropidin, ptperalin, osthol, 1-methylcyclopropene, 4-CPA, chlormequat, clofencet, dichlorprop, dimethipin, endothal, ethephon, flumetralin, forctilorfenuron, gibberellic acid, gibberellins, hymexazol, maleic hydrazide, mepiquat, naphthalene acetamide, paclobutrazol, prohexadione, prohexadione-calcium, thidiazuron, tribufos (tributyl phosphorotrithioate), trinexapac, 10 uniconazole, α-naphthalene acetic acid, polyoxin D (polyoxrim), BLAD, chitosan, fenoxanil, folpet, 3-(difluoromethy!)-N-methoxy-1-methyl-N-[1-methyl-2-(2,4,6-trichlorophenyl)ethyl]pyrazole-4carboxamide, bixafen, fluxapyroxad, furametpyr, isopyrazam, penflufen, penthiopyrad, sedaxane, fenpyrazamine, diclomezine, pyrifenox, boscalid, fluopyram, diflumetorim, fenarimol, 5-fluoro-2-(ptolylmethoxy)pyrimidin-4-amine ferimzone, dimetachlone (dîmethaclone), pyroquilon, proquinazid, 15 ethoxyquin, quinoxyfen, 4,4,5-trifluoro-3,3-dimethyl-1-(3-quinolyl)isoqutnoline, 4,4-difluoro-3,3dimethyl-1-(3-quinolyl)isoquinoline 5-fluoro-3,3,4,4-tetramethyl-1-(3-quinolyl)isoquinoline 9-fluoro-2,2dimethyl-5-(3-quinolyl)-3H-1,4-benzoxazepîne, tebufloquin, oxolinic acid, chinomethionate (oxythioquinox, quinoxymethionate), spiroxamine, (E)-N-methyl-2- [2- (2, 5-dimethylphenoxymethyl) phenyl]-2-methoxy-iminoacetamide, (mandestrobin), azoxystrobin, coumoxystrobin, dimoxystrobin, 20 enestroburin, enoxastrobin, fenamistrobin, flufenoxystrobin, fluoxastrobin, kresoxim-methyl, mandestrobin, metaminostrobin, metominostrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, triclopyricarb, trifloxystrobin, amisulbrom, dichlofluanid, tolylfluanid, but-3-ynyl N-[6-[[(Z)-[(1-methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate, dazomet, isotianîl, tiadinil, thifluzamide, benthiazole (TCMTB), silthiofam, zoxamide, anilazine, 25 tricyclazole, (.+-,)-cis-1-(4-chlorophenyi)-2-(1H-1,2,4-triazol-1-yl)-cycloheptanol (huanjunzuo), 1-(5brorno-2-pyrrdyl)-2-(2₁4-difluorophenyi)-1,1-difiuoro-3-(1,2,4-triazol-1-yl)propan-2-ol 2-(1 -tert-butyl)-1 (2-chloropheny 1)-3-(1,2,4-triazol-1-yl)-propan-2-ol (TCDP), azaconazole, bitertanol (biloxazol), bromuconazole, climbazole, cyproconazole, difenoconazole, dimetconazoie, diniconazole, diniconazole-M, epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutrîafol, 30 hexaconazoie, imibenconazole, ipconazole, ipfentrifluconazole, metconazole, myclobutanil, penconazole, propiconazoie, prothioconazoie, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triazoxide, triticonazole, mefentrifluconazole, 2-[[(1R,5S)-5-[(4fluorophenyl)methyi]-1-hydroxy-2_l2-dimethyl-cyclopentyl]methyl]-4H-1,2,4-triazole-3-thione, 2-[[3-(2chlorophenyi)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl]-4H-1,2,4-triazole-3-thione, ametoctradin 35 (imidium), ipravalicarb, valifenalate, 2-benzyl-4-chlorophenol (Chlorophene), allyl alcohol, azafenidin, benzalkonium chloride, chloropicrin, cresol, daracide, dichlorophen (dichlorophene), difenzoquat, dipyrithione, N-(2-p-chlorobenzoylethyl)-hexaminium chloride, NNF-0721, octhilinone, oxasulfuron, propamidine and propionic acid.

Insecticides such as abamectin, acephate, acetamiprid, amidoflumet (S-1955), avermectin, azadirachtin, azinphos-methyl, bifenthrin, bifenazate, buprofezin, carbofuran, cartap, chlorantraniliprole (DPX-E2Y45), chlorfenapyr, chlorfiuazuron, chlorpyrifos, chlorpyrifos-methyl, chromafenozide, cloth ianidin, cyflumetofen, cyfluthrin, beta-cyfluthrin, cyhaiothrin, iambda-cyhalothrin, cypemnethrin, 5 cyromazine, deltamethrin, diafenthiuron, diazinon, dieldrin, diflubenzuron, dîmefluthrin, dimethoate, dinotefuran, diofenolan, emamectin, endosulfan, esfenvalerate, ethiprole, fenothiocarb, fenoxycarb, fenpropathrin, fenvalerate, fipronil, flonicamid, flubendiamide, flucythrinate, tau-fluvalinate, flufe nerim (UR-50701), flufenoxuron, fonophos, halofenozide, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, isofenphos, lufenuron, malathion, metaflumizone, metaldehyde, methamîdophos, 10 methidathion, methomyl, methoprene, methoxychlor, metofluthrin, monocrotophos, methoxyfenozide, nitenpyram, nithiazine, novaluron, noviflumuron (XDE-007), oxamyl, parathion, parathion-methyl, pennethrin, phorate, phosalone, phosmet, phosphamidon, pirimicarb, profenofos, profluthrin, pymetrozine, pyrafiu proie, pyrethrin, pyridalyl, pyrifluquinazon, pyriprole, pyriproxyfen, rotenone, ryanodine, spinetoram, spinosad, spirodiclofen, spîromesifen (BSN 2060), spirotetramat, suîprofos, 15 iebufenozide, teflubenzuron, tefluthrin, terbufos, tetrachlorvinphos, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tralomethrin, triazamate, trichlorfon and triflumuron;

Bactéricides such as streptomycin;

Acaricides such as amitraz, chinomethionat, chlorobenzilate, cyenopyrafen, cyhexatin, dicofol, dienochlor, etoxazote, fenazaqurn, fenbutatin oxide, fenpropathrin, fenpyroximate, hexythiazox, propargite, pyridaben and tebufenpyrad; and

Biological agents such as Baciilus thuringiensis, Bacilius thuringiensis delta endotoxin, baculovirus, and 25 entomopathogenîc bacteria, virus and fungi.

Other examples of “reference” mixture compositions are as follows (wherein the term “TX” represents a compound (according to the définition of component (A) ofthe compositions of the présent invention) selected from compound no. X.01, X.02, X.03, X.04, X.05, X.06, X.07, X.08, X.09, X.10, X.11 or X.12 30 as defined in the Table X above): a compound selected from the group of substances consisting of

Petroleum oils + TX, 1,1-bis(4-chloro-phenyl)-2-ethoxy éthanol + TX, 2,4-dichlorophenyl benzenesulfonate + TX, 2-fluoro-N-methyl-N-l-naphthylacetamide + TX, 4-chlorophenyl phenyl sulfone + TX, acetoprole + TX, aldoxycarb + TX, amidithion + TX, amidothioate + TX, amiton + TX, amiton hydrogen oxalate + TX, amitraz + TX, ara mite + TX, arsenous oxide + TX, azobenzene + TX, azothoate 35 + TX, benomyl + TX, benoxa-fos + TX, benzyi benzoate + TX, bixafen + TX, brofenvalerate + TX, broflanilide + TX, bromo-cyclen + TX, bromophos + TX, bromopropylate + TX, buprofezin + TX, butocarboxim + TX, butoxycarboxim + TX, butylpyridaben + TX, calcium polysulfide + TX, camphechlor + TX, carbanolate + TX, carbophenothion + TX, cymiazole + TX, chino-methionat + TX, chforbenside + TX, chlordimeform + TX, chlordimeform hydrochloride + TX, chlorfenethol + TX, chlorfenson + TX, 40 chlorfensulfide + TX, chlorobenzilate + TX, chloromebuform + TX, chloromethiuron + TX,

chloropropylate + TX, chlorthiophos + TX, cinerin I + TX, cinerin II + TX, cinerins + TX, closantel + TX, coumaphos + TX, crotamiton + TX, crotoxyphos + TX, cufraneb + TX, cyanthoate + TX, DCPM + TX, DDT + TX, demephion + TX, demephion-O + TX, demephion-S + TX, demeton-methyl + TX, demetonO + TX, demeton-O-methyl + TX, demeton-S + TX, demeton-S-methyl + TX, demeton-S-methylsulfon 5 + TX, dichlofluanid + TX, dichlorvos + TX, dicliphos + TX, dienochlor + TX, dimefox + TX, dinex + TX, dinex-diclexine + TX, dinocap-4 + TX, dinocap-6 + TX, dinocton + TX, dino-penton + TX, dinosulfon + TX, dinoterbon + TX, dioxathion + TX, diphenyl sulfone + TX, disulfiram + TX, DNOC + TX, dofenapyn + TX, doramectin + TX, endothion + TX, eprinomectin + TX, ethoate-methyl + TX, etrimfos + TX, fenazaflor + TX, fenbutatin oxide + TX, fenothiocarb + TX, fenpyrad + TX, fen-pyroximate + TX, 10 fenpyrazamine + TX, fenson + TX, fentrifanil + TX, flubenzimine + TX, flucycloxuron + TX, fluenetil +

TX, fiuorbenside + TX, FMC 1137 + TX, formetanate + TX, formetanate hydrochlonde + TX, formparanate + TX, gamma-HCH + TX, glyodîn + TX, halfenprox + TX, hexadecyl cyclopropane carboxylate + TX, isocarbophos + TX, jasmolin I + TX, jasmolin Il + TX, jodfenphos + TX, lindane + TX, malonoben + TX, mecarbam + TX, mephosfolan + TX, mesulfen + TX, methacrifos + TX, 15 methyl bromide + TX, metolcarb + TX, mexacarbate + TX, milbemycin oxime + TX, mipafox + TX, monocrotophos + TX, morphothion + TX, moxîdectin + TX, naled + TX, 4-chioro-2-(2-chloro-2methylpropyl)-5-[(6-iodo-3-pyridyl)methoxy]pyridazin-3-one + TX, nifluridtde + TX, nikkomycins + TX, nitrilacarb + TX, nitrilacarb 1:1 zinc chloride complex + TX, omethoate + TX, oxydeprofos + TX, oxydisulfoton + TX, pp'-DDT + TX, parathion + TX, permethrin + TX, phenkapton + TX, phosalone + TX, 20 phosfolan + TX, phosphamidon + TX, polychloroterpenes + TX, polynactins + TX, proclonol + TX, promacyl + TX, propoxur + TX, prothidathion + TX, prothoate + TX, pyrethrin I + TX, pyrethrin II + TX, pyrethrins + TX, pyridaphenthion + TX, pyrimitate + TX, quinalphos + TX, quintiofos + TX, R-1492 + TX, phosglycin + TX, rotenone + TX, schradan + TX, sebufos + TX, selamectin + TX, sophamide + TX, SSI121 + TX, sulfiram + TX, sulfluramid + TX, sulfotep + TX, sulfur + TX, diflovidazin + TX, tau-fluvalinate 25 + TX, TEPP + TX, terbam + TX, tetradifon + TX, tetrasul + TX, thiafenox + TX, thiocarboxime + TX, thiofanox + TX, thiometon + TX, thioquinox + TX, thuringiensîn + TX, triamiphos + TX, triarathene + TX, triazophos + TX, triazuron + TX, trifenofos + TX, trinactin + TX, vamidothion + TX, vaniliprole + TX, bethoxazin + TX, copper dioctanoate + TX, copper sulfate + TX, cybutryne + TX, dichlone + TX, dichlorophen + TX, endothal + TX, fentin + TX, hydrated lime + TX, nabam + TX, quinoclamine + TX, 30 quinonamid + TX, simazine + TX, triphenyltin acetate + TX, triphenyltin hydroxide + TX, crufomate + TX, piperazine + TX, thiophanate + TX, chloralose + TX, fenthion + TX, pyridin-4-amine + TX, strychnine + TX, 1-hydroxy-1 H-pyridine-2-thione + TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide + TX, 8hydroxyquinoline sulfate + TX, bronopol + TX, copper hydroxide + TX, cresol + TX, dipyrithione + TX, dodicin + TX, fenaminosulf + TX, formaldéhyde + TX, hydrargaphen + TX, kasugamycin + TX, 35 kasugamycin hydrochloride hydrate + TX, nickel bis(dimethyldithiocarbamate) + TX, nitrapyrin + TX, octhilinone + TX, oxolinic acid + TX, oxytetracycline + TX, potassium hydroxyquinoline sulfate + TX, probenazole + TX, streptomycin + TX, streptomycin sesquisulfate + TX, tecloftaîam + TX, thiomersal + TX, Adoxophyes orana GV + TX, Agrobacterium radiobacter + TX, Ambtyseius spp. + TX, Anagrapha falcifera NPV + TX, Anagrus atomes + TX, Aphelinus abdominaiis + TX, Aphidius colemani + TX,

Aphidoletes aphidimyza + TX, Autographe californica NPV + TX, Bacillus sphaericus Neide + TX,

Beauveria brongniartii + TX, Chrysoperla carnea + TX, Cryptotaemus montrouzieri + TX, Cydia pomoneüa GV + TX, Dacnusa sibirica + TX, Diglyphus isaea + TX, Encarsia formosa + TX, Eretmocerus eremicus + TX, Heterortiabditis bacteriophora and H. megidis + TX, Hippodamia convergeas + TX, Leptomastix dactylopii + TX, Macrolophus caliginosus + TX, Mamestra brassicae NPV + TX, 5 Metaphycus helvolus + TX, Metarhizium anisopliae var. acridum + TX, Metarhizium anisopliae var.

anisopliae + TX, Neodiprion sertifer NPV and N. leconteî NPV + TX, Orius spp, + TX, Paecilomyces fumosoroseus + TX, Phytoseiulus persimilis + TX, Steinernema bibionis + TX, Steinernema carpocapsae + TX, Steinernema feltiae + TX, Steinernema glaseri + TX, Steinernema riobrave + TX, Steinernema riobravis + TX, Steinernema scapterisci + TX, Steinernema spp. + TX, Trichogramma spp.

+ TX, Typhlodromus occidentalis + TX , Verticillium lecanii + TX, apholate + TX, bisazir+ TX, busulfan + TX, dimatif + TX, hemel + TX, hempa + TX, metepa + TX, methiotepa + TX, methyl apholate + TX, morzid + TX, penfluron + TX, tepa + TX, thiohempa + TX, thiotepa + TX, tretamine + TX, uredepa + TX, (E)-dec-5-en-1-yl acetate with (E)-dec-5-en-1-ol + TX, (E)-trideo4-en-1-yl acetate + TX, (E)-6methylhept-2-en-4-ol + TX, (E,Z)-tetradeca-4,10-dien-1-yl acetate + TX, (Z)-dodec-7-en-1-yl acetate +

TX, (Z)-hexadec-11-enal + TX, (Z)-hexadec-11-en-1-yi acetate + TX, (Z)-hexadec-13-en-11-yn-1-yl acetate + TX, (Z)-icos-13-en-10-one + TX, (Z)4etradec-7-en-1-al + TX, (Z)-tetradec-9-en-1-ol + TX, (Z)tetradec-9-en-1-yl acetate + TX, (7E,9Z)-dodeca-7,9-dien-1-yl acetate + TX, (9Z, 11E)-tetradeca-9,11dien-1-yl acetate + TX, (9Z,12E)-tetradeca-9,12-dien-1-yi acetate + TX, 14-methyloctadec-1-ene + TX, 4-methylnonan-5-ol with 4-methylnonan-5-one + TX, alpha-multistriatin + TX, brevicomin + TX, codlelure + TX, codlemone + TX, cuelure + TX, disparlure + TX, dodec-8-en-1-yl acetate + TX, dodec-9-en-1-yl acetate + TX, dodeca-8 + TX, 10-dien-1-yl acetate + TX, dominicalure + TX, ethyl 4-methyloctanoate + TX, eugenol + TX, frontafin + TX, grandlure + TX, grandîure 1 + TX, grandlure 11 + TX, grandlure III + TX, grandlure IV + TX, hexalure + TX, ipsdienol + TX, ipsenol + TX, japonilure + TX, lineatin + TX, litlure + TX, looplure + TX, medlure + TX, megatomoic acid + TX, methyl eugenol + TX, muscalure + TX, octadeca-2,13-dien-1-yl acetate + TX, octadeca-3,13-dien-1-yl acetate + TX, orfralure + TX, oryctalure + TX, ostramone + TX, siglure + TX, sordidin + TX, sulcatol + TX, tetradec-11-en-1-yl acetate + TX, trimedlure + TX, trimedlure A + TX, trimedlure Bi + TX, trimedlure B2 + TX, trimedlure C + TX, trunc-call + TX, 2-(octylthio)-ethanol + TX, butopyronoxyl + TX, butoxy(pofypropylene glycol) + TX, dibutyl adipate + TX, dibutyl phthalate + TX, dibutyl succinate + TX, diethyltoluamide + TX, dimethyl carbate + TX, dimethyl phthalate + TX, ethyl hexanediol + TX, hexamide + TX, methoquin-butyl + TX, methylneodecanamide + TX, oxamate + TX, picaridin + TX, 1-dichloro-1-nitroethane + TX, 1,1-dichloro2,2-bis(4-ethylphenyl)-ethane + TX, 1,2-dichloropropane with 1,3-dichloropropene + TX, 1-bromo-2chloroethane + TX, 2,2,2-trichloro-1-(3,4-dichioro-phenyl)ethyl acetate + TX, 2,2-dichlorovinyl 2ethylsulfinylethyl methyl phosphate + TX, 2-(1,3-dithiolan-2-yl)phenyl dimethylcarbamate + TX, 2-(235 butoxyethoxy)ethyl thiocyanate + TX, 2-(4,5-dimethyl-1,3-dioxolan-2-yl)phenyl methylcarbamate + TX, 2-(4-chloro-3,5-xylyloxy)ethanol + TX, 2-chlorovinyl diethyl phosphate + TX, 2-imidazolidone + TX, 2isovalerylindan-1,3-dîone + TX, 2-methyl(prop-2-ynyl)aminophenyl methylcarbamate + TX, 2thiocyanatoethyl laurate + TX, 3-bromo-1-chloroprop-1-ene + TX, S-methyl-l-phenylpyrazoî-S-yl dimethyl-carbamate + TX, 4’methyl(prop-2-ynyl)amino-3,5-xylyl methylcarbamate + TX, 5,5-dimethyl-340 oxocyclohex-1-enyl dimethylcarbamate + TX, acethion + TX, acrylonitrile + TX, aldrin + TX, allosamidin

+ TX, allyxycarb + TX, alpha-ecdysone + TX, aluminium phosphide + TX, aminocarb + TX, anabasine + TX, athidathion + TX, azamethiphos + TX, Bacillus thuringiensis delta endotoxins + TX, barium hexafluorosilicate + TX, barium polysulfide + TX, barthrin + TX, Bayer 22/190 + TX, Bayer 22408 + TX, beta-cyfluthrin + TX, beta-cypermethrin + TX, bioethanomethrin + TX, biopermethrîn + TX, bis(25 chloroethyl) ether * TX, borax + TX, bromfenvinfos + TX, bromo-DDT + TX, bufencarb + TX, butacarb + TX, butathiofos + TX, butonate + TX, calcium arsenate + TX, calcium cyanide + TX, carbon disulfide + TX, carbon tetrachloride + TX, cartap hydrochloride + TX, cevadîne + TX, chlorbicycien + TX, chlordane + TX, chlordecone + TX, chloroform + TX, chloropicrin + TX, chlorphoxim + TX, chlorprazophos + TX, cis-resmethrin + TX, cismethrin + TX, clocythrin + TX, copper acetoarsenite + TX, 10 copper arsenate + TX, copper oleate + TX, coumithoate + TX, cryolite + TX, CS 708 + TX, cyanofenphos + TX, cyanophos + TX, cyciethrin + TX, cythioate + TX, d-tetramethrin + TX, DAEP + TX, dazomet + TX, decarbofuran + TX, diamidafos + TX, dicapthon + TX, dichlofenthion + TX, dicresyl + TX, dicyclanil + TX, dieldrin + TX, diethyl 5-methylpyrazol-3-yl phosphate + TX, dilor + TX, dimefiuthrin + TX, dimetan + TX, dimethrin + TX, dimethylvinphos + TX, dimetilan + TX, dinoprop + TX, dinosam + TX, dinoseb + 15 TX, diofenolan + TX, dioxabenzofos + TX, dithicrofos + TX, DSP + TX, ecdysterone + TX, El 1642 + TX,

EMPC + TX, EPBP + TX, etaphos + TX, ethiofencarb + TX, ethyl formate + TX, ethylene dibromide + TX, ethylene dichloride + TX, ethylene oxide + TX, EXD + TX, fenchlorphos + TX, fenethacarb + TX, fenitrothion + TX, fenoxacrim + TX, fenpirithrin + TX, fensulfothîon + TX, fenthion-ethyl + TX, flucofuron + TX, fosmethilan + TX, fospirate + TX, fosthietan + TX, furathîocarb + TX, furethrin + TX, guazatine + 20 TX, guazatine acétates + TX, sodium tetrathiocarbonate + TX, halfenprox + TX, HCH + TX, HEOD +

TX, heptachlor + TX, heterophos + TX, HHDN + TX, hydrogen cyanide + TX, hyquincarb + TX, IPSP + TX, isazofos + TX, isobenzan + TX, isodrin + TX, isofenphos + TX, isolane + TX, isoprothiolane + TX, isoxathion + TX, juvénile hormone I + TX, juvénile hormone II + TX, juvénile hormone III + TX, kelevan + TX, kinoprene + TX, lead arsenate + TX, leptophos + TX, lirimfos + TX, lythidathion + TX, m-cumenyl 25 methylcarbamate + TX, magnésium phosphide + TX, mazidox + TX, mecarphon + TX, menazon + TX, mercurous chloride + TX, mesulfenfos + TX, metam + TX, metam-potassium + TX, metam-sodium + TX, methanesulfonyi fluoride + TX, methocrotophos + TX, methoprene + TX, methothrin + TX, methoxychlor + TX, methyl isothiocyanate + TX, methylchloroform + TX, methylene chloride + TX, metoxadiazone + TX, mirex + TX, naftalofos + TX, naphthalene + TX, NC-170 + TX, nicotine + TX, 30 nicotine sulfate + TX, nithiazine + TX, nomicotine + TX, 0-5-dichloro-4-iodophenyl O-ethyl ethylphosphonothîoate + TX, Ο,Ο-diethyl 0-4-methyl-2-oxo-2H-chromen-7-yl phosphorothioate + TX, 0,0-dîethyl O-6-methyl-2-propylpyrimidin-4-yl phosphorothioate + TX, Ο,Ο,Ο',Ο’-tetrapropyl dithiopyrophosphate + TX, oleic acid + TX, para-dichlorobenzene + TX, parathion-methyl + TX, pentachlorophenol + TX, pentachlorophenyl laurate + TX, PH 60-38 + TX, phenkapton + TX, phosnichlor 35 + TX, phosphine + TX, phoxim-methyl + TX, pirrmetaphos + TX, polychlorodicyclopentadiene isomers +

TX, potassium arsenite + TX, potassium thiocyanate + TX, precocene I + TX, precocene II + TX, precocene III + TX, primidophos + TX, profluthrin + TX, promecarb + TX, prothiofos + TX, pyrazophos + TX, pyresmethrin + TX, quassia + TX, quinalphos-methyl + TX, quinothion + TX, rafoxanide + TX, resmethrin + TX, rotenone + TX, kadethrin + TX, ryania + TX, ryanodine + TX, sabadiila) + TX, schradan 40 + TX, sebufos + TX, SI-0009 + TX, thiapronil + TX, sodium arsenite + TX, sodium cyanide + TX, sodium

fluoride + TX, sodium hexafluorosilicate + TX, sodium pentachlorophenoxîde + TX, sodium selenate + TX, sodium thiocyanate + TX, sulcofuron + TX, sulcofuron-sodium + TX, sulfuryl fluoride + TX, sulprofos + TX, tar oils + TX, tazimcarb + TX, TDE + TX, tebupirimfos + TX, temephos + TX, terallethrin + TX, tetrachloroethane + TX, thicrofos + TX, thiocyclam + TX, thiocyclam hydrogen oxalate + TX, thionazin 5 + TX, thiosultap + TX, thiosultap-sodium + TX, tralomethrin + TX, transpermethrin + TX, triazamate +

TX, trichtormetaphos-3 + TX, trichloronat + TX, trimethacarb + TX, tolprocarb + TX, triclopyricarb + TX, triprene + TX, veratridine + TX, veratrine + TX, XMC + TX, zetamethrin + TX, zinc phosphide + TX, zoiaprofos + TX, and meperfluthrin + TX, tetra methylfluthrin + TX, bis(tributyltin) oxide + TX, bromoacetamide + TX, ferrie phosphate + TX, niclosamide-olamine + TX, tributyltin oxide + TX, 10 pyrimorph + TX, trifenmorph + TX, 1,2-dibromo-3-chloropropane + TX, 1,3-dichloropropene +TX, 3,4dichlorotetrahydrothio-phene 1,1-dioxide + TX, 3-(4-chlorophenyl)-5-methylrhodanine + TX, 5-methyl-6thioxo-1,3,5-thiadiazinan-3-ylacetic acid + TX, 6-isopentenylaminopurine + TX, 2-fluoro-N-(3methoxyphenyl)-9H-purin-6-amine + TX, benclothiaz + TX, cytokinins + TX, DCIP + TX, furfural + TX, isamidofos + TX, kinetin + TX, Myrothecium verrucaria composition + TX, tetrachlorothiophene + TX, 15 xyienols + TX, zeatin + TX, potassium ethylxanthate + TX .acibenzolar + TX, acibenzolar-S-methyl +

TX, Reynoutria sachalinensis extract + TX, alpha-chlorahydrin + TX, antu + TX, barium carbonate + TX, bisthiosemi + TX, brodifacoum + TX, bromadiolone + TX, bromethalin + TX, chlorophacinone + TX, cholecalciferol + TX, coumachlor + TX, coumafuryl + TX, coumatetralyl + TX, crimidine + TX, difenacoum + TX, difethiaione + TX, diphacinone + TX, ergocalciferol + TX, flocoumafen + TX, fluoroacetamide + 20 TX, flupropadine + TX, flupropadine hydrochloride + TX, norbormide + TX, phosacetim + TX, phosphorus + TX, pindone + TX, pyrinuron + TX, scilliroside + TX, -sodium fiuoroacetate + TX, thallium sulfate + TX, warfarin + TX, -2-(2-butoxyethoxy)ethyl piperonylate + TX, 5-(1,3-benzodioxol-5-yl)-3hexylcyclohex-2-enone + TX, farnesol with nerolidol + TX, verbutin + TX, MGK 264 + TX, piperonyl butoxide + TX, piprotal + TX, propyl isomer+ TX, S421 + TX, sesamex+ TX, sesasmolin +TX, sulfoxide 25 + TX, anthraquinone + TX, copper naphthenate + TX, copper oxychloride + TX, dicyclopentadiene +

TX, thiram + TX, zinc naphthenate + TX, ziram + TX, imanin + TX, ribavirin + TX, chloroinconazide + TX, mercuric oxide + TX, thiophanate-methyl + TX, azaconazole + TX, bitertanol + TX, bromuconazole + TX, cyproconazoie + TX, difenoconazole + TX, dîniconazole -+ TX, epoxiconazole + TX, fenbuconazole + TX, fluquinconazole + TX, flusilazole + TX, flutriafol + TX, furametpyr + TX, 30 hexaconazole + TX, imazalil- + TX, imiben-conazole + TX, ipconazole + TX, metconazole + TX, myclobutanil + TX, paclobutrazole + TX, pefurazoate + TX, penconazole + TX, prothioconazole + TX, pyrifenox + TX, prochloraz + TX, propiconazole + TX, pyrisoxazole + TX, -simeconazole + TX, tebucon-azole + TX, tetraconazole + TX, triadimefon + TX, triadimenol + TX, triflumizole + TX, tritîconazole + TX, ancymidol + TX, fenarimol + TX, nuarimol + TX, bupirimate + TX, dimethirimol + TX, 35 ethirimol + TX, dodemorph + TX, fenpropidin + TX, fenpropimorph + TX, spiroxamine + TX, tridemorph + TX, cyprodinil + TX, mepanipyrim +TX, pyrimethanil + TX, fenpiclonil + TX, fludioxonil + TX, benalaxyl + TX, furalaxyl + TX, -metalaxyl -+ TX, Rmetalaxyl + TX, ofurace + TX, oxadixyl + TX, carbendazim + TX, debacarb + TX, fuberidazole -+ TX, thiabendazole + TX, chlozolinate + TX, dtchlozoline + TX, myclozoline- + TX, procymidone + TX, vinclozoline + TX, boscalid + TX, carboxin + TX, fenfuram + TX, 40 flutolanii + TX, meproniI + TX, oxycarboxin + TX, penthiopyrad + TX, thifluzamide + TX, dodine + TX, iminoctadine + TX, azoxystrobïn + TX, dimoxystrobin + TX, enestroburin + TX, fenaminstrobin + TX, flufenoxystrobin + TX, fluoxastrobin + TX, kresoxim-methyl + TX, metominostrobin + TX, trifloxystrobin + TX, orysastrobin + TX, picoxystrobin + TX, pyraclostrobîn + TX, pyrametostrobîn + TX, pyraoxystrobin + TX, ferbam + TX, mancozeb + TX, maneb + TX, metiram + TX, propineb + TX, zineb + TX, captafol + TX, captan + TX, fiuoroimide + TX, folpet + TX, tolylfluanid + TX, bordeaux mixture + TX, copper oxide + TX, mancopper + TX, oxine-copper + TX, nitrothai-isopropyl + TX, edifenphos + TX, iprobenphos + TX, phosdiphen + TX, toiclofos-methyl + TX, anîlazine + TX, benthiavalicarb + TX, blasticidin-S + TX, chloroneb -+ TX, chloro-tha-ΙοηίΙ + TX, cyflufenamid + TX, cymoxanil + TX, cyclobutrifluram + TX, dicîocymet + TX, diclomezine -+ TX, didoran + TX, diethofencarb + TX, dimethomorph -+ TX, flumorph + TX, dithianon + TX, ethaboxam + TX, etridiazole + TX, famoxadone + TX, fenamidone + TX, fenoxanil + TX, ferimzone + TX, fluazinam + TX, fluopicolide + TX, flusulfamide + TX, fluxapyroxad + TX, -fenhexamid + TX, fosetyl-aluminium -+ TX, hymexazol + TX, iprovaîicarb + TX, cyazofamid + TX, methasulfocarb + TX, metrafenone + TX, pencycuron + TX, phthalide + TX, pofyoxins + TX, propamocarb + TX, pyribencarb + TX, proquinazid + TX, pyroquilon + TX, pyriofenone + TX, quinoxyfen + TX, quintozene + TX, tiadinit + TX, triazoxîde + TX, tricyclazole + TX, triforine + TX, validamycin + TX, valifenalate + TX, zoxamîde + TX, mandîpropamîd + TX, fîubeneteram + TX, isopyrazam + TX, sedaxane + TX, benzovindiflupyr + TX, pydiflumetofen + TX, 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (3',4',5'-trifluoro-biphenyl-2-yl)-amide + TX, isoflucypram + TX, îsotianil + TX, dipymetitrone + TX, 6-ethyl-5,7-dioxO'pyrrolol4,5][1,4]dithiino(1,2-c]isothiazole-3-carbonitnle + TX, 2-(difiuoromethyl)-N-[3ethyl-1,1-dimethyl-indan-4-yl]pyridine-3-carboxamide + TX, 4-(2,6-difluorophenyf)-6-methyl-5-piienylpyridazine-3-carbonitrile + TX, (R)-3-(difluoromethyl)-1-methyl-N-[1,1,3-trimethylindan-4-yl]pyrazote-4carboxamide + TX, 4-(2-bromo-4-fluoro-phenyl)-N-(2-chloro-6-fluoro-phenyl)-2,5-dimethyl-pyrazol-3amine + TX, 4- (2- bromo- 4- fluorophenyl) - N- (2- chloro- 6- fluorophenyl) -1,3- dimethyl-1 H- pyrazol5- amine + TX, fluindapyr + TX, coumethoxystrobin (jiaxiangjunzhi) + TX, Ivbenmixianan + TX, dichlobentiazox + TX, mandestrobin + TX, 3-(4,4-difluoro-3,4-dihydro-3,3-dimethylîsoquinolin-1yl)quinolone + TX, 2-[2-fiuoro-6-[(8-fluoro-2-methyl-3-quinolyi)oxy]phenyl]propan-2-ol + TX, oxathiapiprolin + TX, tert-butyl N-[6-[([(1-methyîtetrazol-5-yt)-phenyl-methylene]amino]oxymethyl]-2pyridyi]carbamate + TX, pyraziflumid + TX, inpyrfluxam + TX, trolprocarb + TX, mefentrifluconazole + TX, îpfentrifluconazoie+ TX, 2-(difluoromethyl)-N-[(3R)-3-ethyl-1_t1-dimethyl-îndan-4-yl]pyridine-3carboxamide + TX, N'-(2,5-dimethy^-4-phenoxy-phenyl)-N-ethyl-N-methyl·formamidine + TX, N -(4-(4,5dichiorothiazo!-2-yl)oxy-2,5-dimethyi-phenylJ-N-ethyl-N-methyl-formamidine + TX, [2-(3-(2-(1-(2-(3,5bîs(difluoromethy I) py razol-1 -y IJacety I J-4-piperidy l]th iazol-4-y l]-4,5-d ihydroisoxazol-5-y l]-3-ch lorophenyl] methanesulfonate + TX, but-3-ynyl N-[6-[((Z)-[(1-methyltetrazol-5-yl)-phenyl· methylene]amino]oxymethyi]-2-pyridyl]carbamate + TX, methyl N-[[5-[4-(2,4-dimethy!phenyi)triazol-2yi]-2-methyl-phenyl]methyl]carbamate + TX, 3-chloro-6-methyl-5-phenyl-4-(2,4,6trifiuorophenyl)pyridazine + TX, pyridachlometyl + TX, 3-(difluoromethyl)-1-methyl-N-(1,1,3trimethylindan-4-yl]pyrazole-4-carboxamide + TX, 1 -(2-((1 -(4-chlorophenyt)pyrazol-3-yl]oxymethyl]-3methyl-phenyl]-4-methyl-tetrazol-5-one + TX, 1-methyl-4-[3-methy l-2-[[2-methy 1-4-(3,4,5trimethylpyΓazol·1-yl)phenoxy]methyl|phenyl]tetrazol-5-one + TX, aminopyrifen + TX, ametodradin + TX, amisulbrom + TX, penflufen + TX, (Z,2E)-5-[1-(4-chioropheny!)pyrazol-3-yl]oxy-2-methoxyimino

N,3-dimethyl-pent-3-enamide + TX, florylpicoxamid + TX, fenpicoxamid + TX, tebufloquin + TX, ipflufenoquin + TX, quinofumelin + TX, isofetamid + TX, N-[2-[2,4-dichloro-phenoxy]phenyl]-3(difluoromethyl)-1-methyl-pyrazoie-4-carboxamide + TX, N-[2-[2-chloro-4(trifluoromethyl)phenoxy]phenyl]-3-(difluoromethyl)-1-methyl-pyrazole-4-carboxamide + TX, benzothiostrobin + TX, phenamacril + TX, 5-amino-1,3,4-thiadiazole-2-thioI zinc sait (2:1) + TX, fluopyram + TX, flutianil + TX, fiuopîmomide + TX, pyrapropoyne + TX, picarbutrazox + TX, 2(difluoromethyl)-N-(3-ethyl-1,1-dimethyl-indan-4-yl)pyridine-3-carboxamide + TX, 2- (difluoromethyi) N- ((3R) -1,1,3- trimethyiindan- 4- yl) pyridine- 3- carboxamide + TX, 4-[[6-[2-(2,4-difluorophenyl)-1,1difluoro-2-hydroxy-3-(1,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy]benzonitrile + TX, metyltetraprole + TX, 2(difluoromethyl) - N- ((3R) - 1, 1, 3- trimethyiindan- 4- yl) pyridine- 3- carboxamide + TX, a- (1, 1dimethylethyl) - a- [4'- (trifluoromethoxy) [1, T- biphenyl] - 4- yl] -5- pyrimidinemethanol + TX, fluoxapiprolrn + TX, enoxastrobîn + TX, 4-[[6-[2-(2,4-difluorophenyl)-1,1-dîfluoro-2-hydroxy-3-(1,2,4triazol-1-yl)propyl]-3-pyridyl]oxy] benzonitrile + TX, 4-[[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxyS-ÎS-sulfanyl-LZ^-triazol-l-yljpropyll-S-pyridyOoxy] benzonitrile + TX, 4-[[6-[2-(2,4-difluorophenyl)-1,1dîfluoro-2-hydroxy-3-(5-thioxo-4H-1,2,4-trίazol·1-yl)propyl]-3-pyridyl]oxy]benzonitrile + TX, trinexapac + TX, coumoxystrobin + TX, zhongshengmycîn + TX, thiodiazole copper + TX, zinc thiazole + TX, amectotractin + TX, iprodione + TX, N-octyl-N'-[2-(octylamino)ethy[]ethane-1.2-diamine + TX; N'-[5bromo-2-methyl-6-[(1S)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methy1-formamidine + TX, N'[5-bromo-2-methyl-6-[(1R)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyî-N-methyl-formamidine + TX, N'-[5-bromo-2-methyl·6-(1-mettlyl·2-propoxy-ethoxy)-3-pyridyί]-N-ethyl-N-methyl·formamidine + TX, N’[5-chloro-2-methy!-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidine + TX, N'-[5bromo-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-isopropyl-N-methyl-formamidine + TX (these compounds may be prepared from the methods described in WO2015/155075); N'-[5-bromo-2methyt-6-(2-propoxypropoxy)-3-pyrîdyl]-N-ethyl-N-methyl-formamidine + TX (this compound may be prepared from the methods described in iPCOM000249876D); N-isopropyl-N’-(5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1-phenyl-ethyl)phenyl]-N-methyl-formamidine+ TX, N’-[4-(1-cycfopropyl2,2,2-trifluoro-1-hydroxy-etl^yl)-5-methoxy-2-mett1yl-phenyl]-N-isoρroρyl·N-methyl·formamidine + TX (these compounds may be prepared from the methods described in WO2018/228896); N-ethyl-N'-[5methoxy-2-methyl-4-[2-trifluoromethyl)oxetan-2-yl]phenyl]-N-methyl-formamidine + TX, N-ethyl-N’-[5methoxy-2-methyl-4-[2-trifuoromethyl)tetrahydrofuran-2-yl]phenyl]-N-methyl-formamidine + TX (these compounds may be prepared from the methods described in WO2019/110427); N-[(1R)-1-benzyl-3chloro-1-methyl-but-3-enyi]-8-fluoro-quînoline-3-carboxamide + TX, N-[(1S)-1-benzyl-3-chloro-1methyl-but-3-enyt]-8-fluoro-quinoline-3-carboxamide + TX, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methylpropyl]-8-fluoro-quînoline-3-carboxamide + TX, N-((1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8fluoro-qutnoline-3-carboxamide + TX, N-[(1 R)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3carboxamide + TX, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamîde + TX, 8fluoro-N-[(1 R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoiine-3-carboxamide + TX, 8-fluoro-N[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinolîne-3-carboxamide + TX, N-[(1R)-1-benzyl1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide + TX, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-8fluoro-quinoline-3-carboxamide + TX, N-^IRl-l-benzyl-S-chloro-l-methyl-but-S-enyO-S-fluoro quinoline-3-carboxamide + TX, N-((1S)-1-benzyl-3-chIoro-1-methyl-but-3-enyi)-8-fluoro-quinoline-3carboxamide + TX (these compounds may be prepared from the methods described in

WO2017/1 53380),

1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethyl-isoquinoline + TX, 1-(6,7dimethylpyrazûlo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3_r3-dimethyl-isoquinolîne + TX, 4,4-difluoro-3,3dimethyl-1-(6-methylpyrazolo[1,5-a]pyridir)-3-yl)isoquinoline + TX, 4,4-difluoro-3,3-dimethyl-1-(7methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline + TX, 1-(6-chloro-7-methyl-pyrazoto[1,5-a]pyridin-3-yl)4,4-difluoro-3,3-dimethyl-isoquinoline + TX (these compounds may be prepared from the methods described in WO2017/025510); 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline + TX, 1-(4,5-dimethyIbenzimidazoi-1-yl)-4,4-difluoro-3,3-dimethyl-isoquinoline + TX, 6chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline + TX, 4,4-difluoro-1-(5fluoro-4-methyl-benzimidazol-1-yl)-3,3-dimethyl-isoquinoline + TX, 3-(4,4-difluoro-3,3-dimethyl-1isoquinolyl)-7,8-dihydro-6H-cyclopenta(e]benzimidazole + TX (these compounds may be prepared from the methods described in WO2016/156085); [(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(3-hydroxy-4methoxy-pyridine-2-carbonyl)amino]propanoate + TX, [(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(3acetoxy-4-methoxy-pyridîne-2-carbonyl)amîno]propanoate + TX, [(1 S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4-methoxy-3-propanoyloxy-pyridine-2-carbonyl)amino]propanoate + TX, [(1 S,2S)-2-(4-fluoro2-methyl-phenyl)-1,3-dimethyl-butyl] (2S)-2-[(3-hydroxy-4-methoxy-pyridine-2carbonyl)amino]propanoate + TX, [(1S,2S)-2-(4-fluoro-2-methyl-pheny1)-1,3-dimethyl-butyl] (2S)-2-[(3acetoxy-4-methoxy-pyndine-2-carbonyl)amino]propanoate + TX, [(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)1,3-dimethyl-butyl] (2S)-2-[(4-methoxy-3-propanoyloxy-pyridine-2-carbonyl)aminojpropanoate + TX, Nmethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide + TX, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazoî-3-yl]phenyl]methyl]propanamide + TX, N-ethyl2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazof-3-yl]phenyl]methyl]propanamide + TX, 1-methoxy-3methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]pheny1]methyl]urea + TX, 1,3-dîmethoxy-1-[[4-[5(trifluoromethyl)-l ,2,4-oxadiazol-3-yl]phenyl]methyl]urea + TX, 3-ethyl-1-methoxy-1-[[4-[5(trifluoromethyl)-l ,2,4-oxadiazol-3-yl]phenyl]methyl]urea + TX, N-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]propanamide + TX, 4,4-dimethyl-2-[[4-[5-(trifluoromethyi)-1,2,4-oxadiazol3-yl]phenyllmethyl]isoxazolidin-3-one + TX, S.S-dimethyi^-f^qS-ttrifluoromethyl)-! ,2,4-oxadiazol-3yljphenyl]methyl]îsoxazolidin-3-one +· TX, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate + TX, N,N-dimethy]-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine + TX. The compounds in this paragraph may be prepared from the methods described in WO 2017/055473, WO 2017/055469, WO 2017/093348 and WO 2017/118689; 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol + TX (this compound may be prepared from the methods described in WO 2017/029179); 2-[6-(4bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazo1-1-yl)propan-2-ol + TX (this compound may be prepared from the methods described in WO 2017/029179); 3-[2-(1-chlorocyclopropyl)-3-(2fluorophenyt)-2-hydrûxy-propyl]imidazole-4-carbonitrile + TX (this compound may be prepared from the methods described in WO 2016/156290); 3-[2-(1-chlorocyclopropyl)-3-(3-chloro-2-fluoro-phenyl)-2hydroxy-propyî]imidazole-4-carbonitrile + TX (this compound may be prepared from the methods described in WO 2016/156290); (4-phenoxyphenyl)methy1 2-amino-6-methyl-pyridine-3-carboxylate + TX (this compound may be prepared from the methods described in WO 2014/006945); 2,6-Dimethyl1H,5H-[1,4]dithiîno[2,3-c:5,6-c']dipyrrole-1,3,5,7(2H,6H)-tetrone + TX (this compound may be prepared from the methods described in WO 2011/138281); N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol·3yl]benzenecarbothioamide + TX; N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide + TX; (Z,2E)-5-[1-(2,4-dichlOΓOphenyl)pyrazol·3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide + TX (this compound may be prepared from the methods described in WO 2018/153707); N'-(2-chloro-5methyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidine + TX; N'-[2-chloro-4-(2-fluorophenoxy)-5methyl-phenyl]-N-ethyl-N-mEthyl-formamidine + TX (this compound may be prepared from the methods described in WO 2016/202742); 2-(difluoromethyl)-N-[(3S)-3-ethyl-1,1-dimethyl-indan-4-yl]pyridine-3carboxamide + TX (this compound may be prepared from the methods described in WO 2014/095675); (5-methyl-2-pyridyl)-[4-[5-(trifIuoromethyl)-1,2,4-oxadiazoi-3-yl]phenyl]methanone + TX, (3methylisoxazol-5-yl)-[4-[5-(trifluoromethyi)-1,2,4-oxadiazol-3-yl]phenyl]methanone + TX (these compounds may be prepared from the methods described in WO 2017/220485); 2-oxo-N-propyl-2-[4[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide + TX (this compound may be prepared from the methods described in WO 2018/065414); ethyl 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2thienyl]methyl]pyrazole-4-carboxylaie + TX (this compound may be prepared from the methods described in WO 2018/158365) ; 2,2-difluoro-N-methyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]acetamide + TX, N-[(E)-methoxyiminomethyl]-4-[5-(trifluoromethyt)-1,2,4-oxadiazol-3yl]benzamide + TX, N-[(Z)-methoxyimînomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide + TX, N-[N-methoxy-C-methyl-carbonimidoyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide + TX (these compounds may be prepared from the methods described in WO 2018/202428), a biostimulant comprising organic carbon, nutrients and amino acids (Quantis™) + TX.

The references in brackets behind the active ingrédients, e.g. [3878-19-1] refer to the Chemical Abstracts Registry number. The above described mixing partners are known. Where the active ingrédients are included in The Pesticide Manual [The Pesticide Manual - A World Compendium; Thirteenth Edition; Editor: C. D. S. TomLin; The British Crop Protection Council], they are described therein under the entry number given in round brackets hereinabove for the particular compound; for example, the compound abamectin is described under entry number (1). Where [CCN] is added hereinabove to the particular compound, the compound in question is included in the Compendium of Pesticide Common Names, which is accessible on the internet [A. Wood; Compendium of Pesticide Common Names. Copyright © 1995-2004]; for example, the compound acetoprole is described under the internet address http://www. a la n wood. net/pesticid es/a cetoprole.html

Most of the active ingrédients described above are referred to hereinabove by a so-called common name, the relevant ISO common name or another common name being used in individual cases. If the désignation is not a common name, the nature of the désignation used instead is given in round brackets for the particular compound; in that case, the IUPAC name, the lUPAC/Chemical Abstracts name, a Chemical name, a traditionai name, a compound name or a develoment code is used or, if neither one of those désignations nor a common name is used, an alternative name îs employed. “CAS Reg. No means the Chemical Abstracts Registry Number,

In the “reference mixture compositions the mixtures of compounds of formula (I) (selected from Table X (above)) with active ingrédients described above comprise a compound selected from Table X (above) and an active ingrédient as described above preferably in a mixing ratio of from 100:1 to 1:100, especially from 50:1 to 1:50, more especially in a ratio of from 20:1 to 1:20, even more especially from 10:1 to 1:10, very especially from 5:1 and 1:5, spécial preference being given to a ratio of from 2:1 to 1:2, and a ratio of from 4:1 to 2:1 being likewise preferred, above ali in a ratio of 1:1, or 5:1, or 5:2, or 5:3, or 5:4, or 4:1, or 4:2, or 4:3, or 3:1, or 3:2, or 2:1, or 1:5, or 2:5, or 3:5, or 4:5, or 1:4, or 2:4, or 3:4, or 1:3, or 2:3, or 1:2, or 1 ;600, or 1:300, or 1:150, or 1:35, or 2:35, or 4:35, or 1:75, or 2:75, or 4:75, or 1:6000, or 1:3000, or 1:1500, or 1:350, or 2:350, or 4:350, or 1:750, or 2:750, or 4:750. Those mixing ratios are by weight.

The mixture compositions as described above (both according to the ivnetion and the “reference” mixture compositions) can be used in a method for controtling pests, which comprises applying a composition comprising a mixture as described above to the pests or their environment.

The mixtures comprising a compound of formula (I) selected from Table X (above) and one or more active ingrédients as described above can be applied, for example, in a single “ready-mix” form, in a combined spray mixture composed from separate formulations of the single active ingrédient components, such as a “tank-mix, and in a combined use of the single active ingrédients when applied in a sequential manner, i.e. one after the other with a reasonably short period, such as a few hours or days. The order of applying the compounds of formula (I) selected from Table X (above) and the active ingrédients as described above is not essential for working the présent invention.

The compositions of the présent invention may also be used in crop enhancement. According to the présent invention, 'crop enhancement’ means an improvement in plant vigour, an improvement in plant quality, improved tolérance to stress factors, and/or improved input use efficiency.

According to the présent invention, an ‘improvement in plant vigour’ means that certain traits are improved qualitatively or quantitatively when compared with the same trait in a control plant which has been grown under the same conditions in the absence of the method of the invention. Such traits include, but are not limited to, early and/or improved germination, improved emergence, the abilrty to use less seeds, increased root growth, a more developed root system, increased root nodulation, increased shoot growth, increased tillering, stronger tillers, more productive tillers, increased or improved plant stand, less plant verse (lodging), an increase and/or improvement in plant height, an increase in plant weight (fresh or dry), bigger leaf blades, greener leaf colour, increased pigment content, increased photosynthetic activity, earlier tlowering, longer panicles, early grain maturity, increased seed, fruit or pod size, increased pod or ear number, increased seed number per pod or ear, increased seed mass, enhanced seed filling, less dead basal leaves, delay ofsenescence, improved vitality ofthe plant, increased levels of amino acids in storage tissues and/or less inputs needed (e.g. less fertiliser, water and/orlabourneeded). A plantwith improved vigour may hâve an increase in any ofthe aforementioned traits or any combination or two or more of the aforementioned traits.

According to the présent invention, an ‘improvement in plant quality’ means that certain traits are improved qualitatively orquantitatively when compared with the same trait in a control plant which has been grown under the same conditions in the absence of the method of the invention. Such traits include, but are not limited to, improved Visual appearance of the plant, reduced ethylene (reduced production and/or inhibition of réception), improved quality of harvested material, e.g. seeds, fruits, leaves, vegstables (such improved quality may manifest as improved visual appearance of the harvested material), improved carbohydrate content (e.g. increased quantifies of sugar and/or starch, improved sugar acid ratio, réduction of reducing sugars, increased rate of development of sugar), improved proteln content, improved oil content and composition, improved nutritional value, réduction in anti-nutritional compounds, improved organoleptic properties (e.g. improved taste) and/or improved consumer health benefits (e.g. increased levels of vitamins and anti-oxidants)), improved post-harvest characteristics (e.g. enhanced shelf-iife and/or storage stabilîty, easier processa brlity, easier extraction of compounds), more homogenous crop development (e.g. synchronised germination, flowering and/or fruiting of plants), and/or improved seed quality (e.g. for use in following seasons). A plant with improved quality may hâve an increase in any of the aforementioned traits or any combination or two or more ofthe aforementioned traits.

According to the présent invention, an ‘improved tolérance to stress factors’ means that certain traits are improved qualitatively or quantitatively when compared with the same trait in a control plant which has been grown underthe same conditions in the absence of the method ofthe invention. Such traits include, but are not limited to, an increased tolérance and/or résistance to abiotic stress factors which cause sub-optimal growing conditions such as drought (e.g. any stress which leads to a lack of water content in plants, a lack of water uptake potential or a réduction in the water supply to plants), cold exposure, heat exposure, osmotic stress, UV stress, flooding, increased salinity (e.g. in the soil), increased minerai exposure, ozone exposure, high light exposure and/or limited availability of nutrients (e.g. nitrogen and/or phosphorus nutrients). A plant with improved tolérance to stress factors may hâve an increase in any ofthe aforementioned traits or any combination or two or more ofthe aforementioned traits. In the case of drought and nutrient stress, such improved tolérances may be due to, for example, more efficient uptake, use or rétention of water and nutrients,

According to the présent invention, an 'improved input use efficiency’ means that the plants are able to grow more effectively using given levels of inputs compared to the grown of control plants which are grown underthe same conditions in the absence ofthe method ofthe invention. In particular, the inputs include, but are not limited to fertiliser (such as nitrogen, phosphorous, potassium, micronutrients), light and water. A plant with improved input use efficiency may hâve an improved use of any of the aforementioned inputs or any combination of two or more of the aforementioned inputs.

Other crop enhancements of the présent invention include a decrease in plant height, or réduction in tillering, which are bénéficiai features in crops or conditions where it is désirable to hâve less biomass and fewertilfers.

Any or all of the above crop enhancements may lead to an improved yield by improving e.g. plant physiology, plant growth and development and/or plant architecture. In the context of the présent invention ‘yield’ includes, but is not limited to, (i) an increase in bromass production, grain yield, starch content, oil content and/or protein content, which may resuit from (a) an increase in the amount produced by the plant per se or (b) an improved abitity to harvest plant matter, (ii) an improvement in the composition of the harvested material (e.g. improved sugar acid ratios, improved oil composition, increased nutritional value, réduction of anti-nutritional compounds, increased consumer health benefits) and/or (iii) an increased/facilitated ability to harvest the crop, improved processability of the crop and/or better storage stability/shelf life. Increased yield of an agricultural plant means that, where it is possible to take a quantitative measurement, the yield of a product of the respective plant is increased by a measurable amount over the yield of the same product of the plant produced under the same conditions, but without application ofthe présent invention. According to the present invention, it is preferred that the yield be increased by at least 0.5%, more preferred at least 1%, even more preferred at least 2%, still more preferred at least 4% , preferably 5% or even more.

Any or all ofthe above crop enhancements may also lead to an improved utilisation of land, i.e. land which was previously unavailable or sub-optimal for cultivation may become available. For example, plants which show an increased ability to survive in drought conditions, may be able to be cultivated in areas of sub-optimal rainfaII, e.g. perhaps on the fringe of a desert or even the desert itself.

In one aspect of the present invention, crop enhancements are made in the substantial absence of pressure from pests and/or diseases and/or a biotic stress. In a further aspect of the present invention, improvements în plant vigour, stress tolerance, quality and/or yield are made in the substantial absence of pressure from pests and/or diseases. For example pests and/or diseases may be contre lied by a pesticidal treatment that is applied prior to, or at the same time as, the method of the present invention. In a still further aspect ofthe present invention, improvements in plant vigour, stress tolerance, quality and/or yield are made in the absence of pest and/or disease pressure. In a further embodiment, improvements in plant vigour, quality and/or yield are made in the absence, or substantial absence, of abiofic stress.

The compositions of the present invention may also be used în the field of protecting storage goods against attack of fungi. According to the present invention, the term “storage goods” is understood to dénoté natural substances of vegetable and/or animal origin and their processed forms, which hâve been taken from the natural life cycle and for which long-term protection is desired. Storage goods of vegetable origin, such as plants or parts thereof, for example stalks, leafs, tubers, seeds, fruits or grains, can be protected în the freshly harvested state or in processed form, such as pre-dried, moistened, comminuted, ground, pressed or roasted. Also falling under the définition of storage goods is timber, whether in the form of crude timber, such as construction timber, eiectricity pylons and barrîers, or in the form of finished articles, such as fumiture or objects made from wood. Storage goods of animal origin are hides, leather, furs, hairs and the like. The composition according the present invention can prevent disadvantageous effects such as decay, discoloration or mold. Preferably “storage goods is understood to dénoté natural substances of vegetable origin and/or their processed forms, more preferably fruits and their processed forms, such as pomes, stone fruits, soft fruits and citrus fruits and their processed forms. In another preferred embodiment of the invention “storage goods” is understood to dénoté wood.

Therefore a further aspect of the present invention is a method of protecting storage goods, which comprises applying to the storage goods a composition according to the invention.

The composition of the present invention may also be used in the field of protecting technical material against attack of fungi. According to the present invention, the term “technical material includes paper; carpets; constructions; cooling and heating Systems; walkboards; ventilation and air conditioning Systems and the like; preferably “technical material” is understood to dénoté wall-boards. The composition according the present invention can prevent disadvantageous effects such as decay, discoloration or mold.

The composition according to the invention is generally formulated in various ways using formulation adjuvants, such as carriers, solvents and surface-active substances. The formulations can be in various physical forms, e.g. in the form of dusting powders, gels, wettable powders, water-dispersible granules, water-dispersible ta blets, effervescent pellets, emulsifiable concentrâtes, microemulsifiable concentrâtes, oîl-in-water émulsions, oil-fiowables, aqueous dispersions, oily dispersions, suspoemulsions, capsule suspensions, emulsifiable granules, soluble liquids, water-soluble concentrâtes (with water or a water-miscible organic solvent as carrier), impregnated polymer films or in other forms known e.g. from the Manual on Development and Use of FAO and WHO Spécifications for Pesticides, United Nations, First Edition, Second Révision (2010). Such formulations can either be used directly or diluted prior to use. The dilutions can be made, for example, with water, liquid fertilisers, micronutrients, biological organisms, oil or solvents.

The formulations can be prepared e.g. by mixing the active ingrédient with the formulation adjuvants in order to obtain compositions tn the form of finely divided solids, granules, solutions, dispersions or émulsions. The active ingrédients can also be fomnulated with other adjuvants, such as finely divided solids, minerai oils, oils of vegetable or animal origin, modified oils of vegetable or animal origin, organic solvents, water, surface-active substances or combinations thereof.

The active ingrédients can also be contained in microcapsules. Microcapsules contain the active ingrédients in a porous carrier. This enables the active ingrédients to be released into the environment 10 in controlled amounts (e.g. slow-release). Microcapsules usually hâve a diameter of from 0.1 to 500 microns. They contain active ingrédients in an amount of about from 25 to 95 % by weight ofthe capsule weight. The active ingrédients can be in the form of a monolithic solid, in the form of fine particles in solid or liquid dispersion or in the form of a suitable solution. The encapsulating membranes can comprise, for example, natural or synthetic rubbers, cellulose, styrene/butadiene copolymers, 15 polyacrylonitrile, polyacrylate, polyesters, polyamides, polyureas, polyuréthane or chemically moditïed polymers and starch xanthates or other polymers that are known to the person skilled in the art. Alternatively, very fine microcapsules can be formed in which the active ingrédient is contained in the form of finely divided particles in a solid matrix of base substance, but the microcapsules are not themselves encapsulated.

The formulation adjuvants thaï are suitable for the préparation of the formulations according to the invention are known per se. As liquid carriers there may be used: water, toluene, xylene, petroleum ether, vegetable oils, acetone, methyl ethyl ketone, cyclohexanone, acid anhydrides, acetonitrile, acetophenone, amyl acetate, 2-butanone, butylène carbonate, chlorobenzene, cyclohexane, 25 cyclohexanol, alkyl esters of acetic acid, diacetone alcohol, 1,2-dichloropropane, diethanolamine, pdiethylbenzene, diethylene glycol, diethylene glycol abietate, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, /V,/V-dimethylformamide, dimethyl sulfoxide, 1,4dioxane, ciipropylene glycol, dipropylene glycol methyl ether, dipropyîene glycol dibenzoate, diproxitol, alkylpyrrolidone, ethyl acetate, 2-ethylhexanol, ethylene carbonate, 1,1,1-trichloroethane, 2-heptanone, 30 alpha-pînene, d-limonene, ethyl lactate, ethylene glycol, ethylene glycol butyl ether, ethylene glycol methyl ether, gamma-butyrolactone, glycerol, glycerol acetate, glycerol diacetate, glycerol triacetate, hexadecane, hexylene glycol, isoamyl acetate, isobornyl acetate, isooctane, isophorone, isopropylbenzene, isopropyl myristate, lactic acid, laurylamine, mesityl oxide, methoxypropanol, methyl isoamyl ketone, methyl îsobutyl ketone, methyl laurate, methyl octanoate, methyl oleate, methylene 35 chloride, m-xylene, n-hexane, n-octylamine, octadecanoic acid, octylamine acetate, oleic acid, oleylamine, o-xylene, phénol, polyethylene glycol, propionic acid, propyl lactate, propylene carbonate, propylene glycol, propylene glycol methyl ether, p-xylene, toluene, triethyl phosphate, triethylene glycol, xylenesulfonic acid, paraffin, minerai oil, trichloroethylene, perchloroethylene, ethyl acetate, amyl acetate, butyl acetate, propylene glycol methyl ether, diethylene glycol methyl ether, methanol, éthanol, isopropanol, and alcohols of higher molecutar weight, such as amyl alcohol, tetrahydrofurfuryl alcohol, hexanol, octanol, ethylene glycol, propylene glycol, glycerol, /V-methyl-2-pyrrolidone and the like.

Surtable solid carriers are, for exampfe, talc, titanium dioxide, pyrophyllite clay, silica, attapulgite clay, kieselguhr, limestone, calcium carbonate, bentonite, calcium montmorillonite, cottonseed husks, wheat flour, soybean flour, pumice, wood flour, ground walnut sheIls, lignin and similar substances.

A large number of surface-active substances can advantageously be used in both solid and liquid formulations, especially in those formulations which can be diluted with a carrier prior to use. Surfaceactive substances may be anîonic, cationic, non-ionic or polymeric and they can be used as emulsifiers, wetting agents or suspending agents or for other purposes, Typical surface-active substances include, for example, salts of alkyl sulfates, such as drethanolammonium lauryl sulfate; salts of alkylarylsulfonates, such as calcium dodecylbenzenesulfonate; aîkylphenol/alkylene oxide addition Products, such as nonylphenol ethoxylate; alcohol/alkylene oxide addition products, such as tridecylalcohol ethoxylate; soaps, such as sodium stéarate; salts of alkylnaphthalenesulfonates, such as sodium dibutylnaphthalenesulfonate; dialkyl esters of sulfosuccinate salts, such as sodium di(2ethylhexyl)sulfosuccinate; sorbitol esters, such as sorbitol oleate; quaternary amines, such as lauryltrimethylammonium chloride, polyethylene glycol esters of fatty acids, such as polyethylene glycol stéarate; block copolymers of ethylene oxide and propylene oxide; and salts of mono- and dialkylphosphate esters; and also further substances described e.g. in McCutcheon's Détergents and Emulsifïers Annual, MC Publishing Corp., Ridgewood New Jersey (1981),

Further adjuvants that can be used in pesticidal formulations include crystallisation inhîbitors, viscosity modifiers, suspending agents, dyes, anti-oxidants, foaming agents, light absorbers, mixing auxiliaries, antifoams, complexing agents, neutralising or pH-modifying substances and buffers, corrosion inhîbitors, fragrances, wetting agents, take-up enhancers, micronutrients, plasticisers, glidants, lubricants, dispersants, thickeners, antifreezes, microbicides, and liquid and solid fertilisers.

The formulations according to the invention can include an additive comprising an oil of vegetable or animal origin, a minerai oil, alkyl esters of such oils or mixtures of such oils and oil dérivatives. The amount of oil additive in the formulation according to the invention is generally from 0.01 to 10 %, based on the mixture to be applied. For example, the oil additive can be added to a spray tank în the desired concentration after a spray mixture has been prepared. Preferred oil additives comprise minerai oils or an oil of vegetable origin, for example rapeseed oil, olive oil or sunflower oil, emuisified vegetable oil, alkyl esters of oils of vegetable origin, for example the methyl dérivatives, or an oil of animal origin, such as fish oil or beeftallow. Preferred oil additives comprise alkyl esters of Ce-Czz fatty acids, especially the methyl dérivatives of Ci2-Cte fatty acids, for example the methyl esters of I au rie acid, paîmitic acid and oleic acid (methyl laurate, methyl palmitate and methyl oleate, respectively). Many oil dérivatives are known from the Compendium of Herbicide Adjuvants, 10^lh Edition, Southern Illinois University, 2010.

The formulations generaliy comprise from 0.1 to 99 % by weight, especially from 0.1 to 95 % by weight, of compounds of component (A) and component (B) and from 1 to 99.9 % by weight of a formulation adjuvant which preferabiy includes from 0 to 25 % by weight of a surface-active substance. Whereas commercial products may preferabiy be formulated as concentrâtes, the end user will normally employ dilute formulations.

The rates of application vary within wide limits and dépend on the nature of the soil, the method of application, the crop plant, the pest to be controlled, the prevailing climatic conditions, and other factors governed by the method of application, the time of application and the target crop. As a general guideline compounds may be applied at a rate of from 1 to 2000 l/ha, especially from 10 to 1000 l/ha.

Certain mixture compositions comprising a compound of formula (I) described above may show a synergistic effect. This occurs whenever the action of an active ingrédient combination is greater than the sum of the actions of the individual components. The action to be expected E for a given active ingrédient combination obeys the so-called COLBY formula and can be calculated as follows (COLBY, S.R. Calculating synergistic and antagonistic responses of herbicide combination. Weeds, Vol. 15, pages 20-22; 1967):

ppm = milligrams of active ingrédient (= a.i.) per liter of spray mixture

X = % action by active ingrédient A) using p ppm of active ingrédient Y = % action by active ingrédient B) using g ppm of active ingrédient.

According to COLBY, the expected (additive) action of active ingrédients A)+B) using p+q ppm of active ingrédient is:

If the action actually observed (O) is greater than the expected action (E), then the action of the combination is super-addttive, i.e. there is a synergistic effect. In mathematical terms, synergism corresponds to a positive value for the différence of (O-E). In the case of purely complementary addition of activities (expected açtivity), said différence (O-E) is zéro. A négative value of said différence (O-E) signais a loss of açtivity compared to the expected açtivity.

However, besides the actual synergistic action with respect to fungicidal açtivity, the composition according to the invention may also hâve further surprising advantageous properties. Examples of such advantageous properties that may be mentioned are: more advantageous degradability; improved toxicoiogical and/or ecotoxicologicaî behaviour; or improved characteristics of the useful plants including: emergence, crop yields, more developed root System, tiilering increase, increase in plant height, bigger ieaf blade, less dead basal leaves, stronger tillers, greener leaf colour, less fertilizers needed, less seeds needed, more productive tillers, earlier flowering, early grain maturrty, less plant verse (lodging), increased shoot growth, improved plant vigor, and early germination.

The composition according to the invention can be applied to the phytopathogenic microorgamsms, the useful plants, the locus thereof, the propagation material thereof, storage goods or technical materials threatened by microorganism attack.

The composition according to the invention may be applied before or after infection ofthe useful plants, the propagation material thereof, storage goods or technical materials by the microorganisms,

The amount of a composition according to the invention to be applied, will dépend on various factors, such as the compounds employed; the subject of the treatment, such as, for example plants, soil or seeds; the type of treatment, such as, for example spraying, dusting or seed dressing; the purpose of the treatment, such as, for example prophylactic or therapeutic; the type of fungi to be controlled or the application time.

When applied to the useful plants component (A) is typically applied at a rate of 5 to 2000 g a.i./ha, particularly 1Oto 1000 g a.i./ha, e.g. 50, 75, 100 or 200 g a.i./ha, typically in association with 1 to 5000 g a.i./ha, particularly 2 to 2000 g a.i./ha, e.g. 100, 250, 500, 800, 1000,1500 g a.i./ha of component (B).

In agricultural practice the application rates ofthe composition according to the invention dépend on the type of effect desired, and typically range from 20 to 4000 g of total composition per hectare.

When the composition according to the invention is used for treating seed, rates of 0.001 to 50 g of a compound of component (A) per kg of seed, preferably from 0.01 to 10g per kg of seed, and 0.001 to 50 g of a compound of component (B), per kg of seed, preferably from 0.01 to 10g per kg of seed, are generally sufficient.

For the avoidance of doubt, where a fiterary reference, patent application, or patent, is cited within the text ofthis application, the entire text of said citation is herein incorporated by reference.

EXAMPLES

The Examples which foliow serve to illustrate the invention.

The compounds (and compositions) ofthe invention may be distinguished from known compounds (and compositions) by virtue of greater efficacy at low application rates, which can be verified by the person skilled in the art using the experimental procedures outlined in the Examples, using lower application rates if necessary, for example 50 ppm, 12.5 ppm, 6 ppm, 3 ppm, 1.5 ppm or 0.2 ppm of active ingredient(s).

Throughout this description, températures are given m degrees Celsius and ¹ m.p. means melting point.

LC/MS means Liquid Chromatography Mass Spectroscopy and the description ofthe apparatus and the methods is as follows:

Method G:

Spectra were recorded on a Mass Spectrometer from Waters (SQD, SQDII Single quadrupole mass spectrometer) equipped with an electrospray source (Polarity: positive and négative ions), Capillary: 3.00 kV, Cône range: 30 V, Extractor: 2.00 V, Source Température: 150°C, Desolvation Température: 350°C, Cône Gas Flow: 50 l/ti, Desolvation Gas Flow: 650 l/h, Mass range: 100 to 900 Da) and an Acquity UPLC from Waters: Binary pump, heated column compartment, diode-array detector and ELSD detector. Column: Waters UPLC HSS T3,1.8 pm, 30 x 2,1 mm, Temp: 60 °C, DAD Waveiength range (nm): 210 to 500, Solvent Gradient: A = water + 5% MeOH + 0.05 % HCOOH, B= Acetonitrile + 0.05 % HCOOH, gradient: 10-100% B in 1.2 min; Flow(ml/min) 0.85

Method H;

Spectra were recorded on a Mass Spectrometer from Waters (SQD, SQDII Single quadrupole mass spectrometer) equipped with an electrospray source (Polarity: positive and négative ions), Capillary: 3.00 kV, Cône range: 30V, Extractor: 2.00 V, Source Température: 150°C, Desolvation Température: 350’C, Cône Gas Flow: 50 l/h, Desolvation Gas Flow: 650 l/h, Mass range: 100 to 900 Da) and an Acquity UPLC from Waters: Binary pump, heated column compartment, diode-array detector and ELSD detector. Column: Waters UPLC HSS T3, 1.8 pm, 30 x 2.1 mm, Temp: 60 °C, DAD Waveiength range (nm): 210 to 500, Solvent Gradient: A = water + 5% MeOH + 0.05 % HCOOH, B- Acetonitrile + 0.05 % HCOOH, gradient: 10-100% B in 2.7 min; Flow (ml/min) 0.85

Method I:

Spectra were recorded on a Mass Spectrometer (ACQUITY UPLC) from Waters (SQD, SQDII or ZQ Single quadrupole mass spectrometer) equipped with an electrospray source (Polarity: positive or négative ions, Capillary (kV) 3.5, Cône (V) 30.00, Extractor (V) 3.00, Source Température (°C) 150, Desolvation Température (^CC) 400, Cône Gas Flow (L/Hr) 60, Desolvation Gas Flow (L/Hr) 700, Mass range: 140 to 800 Da) and an Acquity UPLC from Waters: Binary pump, heated column compartment and diode-array detector. Solvent degasser, binary pump, heated column compartment and diode-array detector. Solvent degasser, binary pump, heated column compartment and diode-array detector. Column: Waters ACQUITY UPLC HSS T3; Column length: 30 mm; Internai diameter of column: 2.1 mm; Particle Size: 1.8 pm; Température: 60°C, DAD Waveiength range (nm): 210 to 400. Solvent Gradient A: Water/Methanol 9:1,0.1% formic acid and Solvent B: Acetonitriie,0.1% formic acid

Time (minutes) A (%) B (%) Flow rate (ml/min) 0 100 0 0.75

2.5 0 100 0.75

2.8 0 100 0.75

3.0 100 0 0.75

Method J:

Spectre were recorded on a Mass Spectrometer 6410 Triple Quadruple Mass Spectrometer from Agilent Technologies equipped with an electrospray source (Positive and Négative Polarity Switch, Capillary (kV) 4.00, Scan Type MS2 Scan, Fragmentor (V) 100.00, Gas Température (°C) 350, Gas Flow (L/min) 11, Nebulizer Gas (psi) 45, Mass range : 110 to 1000 Da) and an Agiient 1200 Sériés HPLC: DAD Wavelength range : 210 to 400 nm, Column : KINETEX EVO C18, Column length : 50 mm, Internai diameter of column : 4.6 mm, Particle Size ; 2.6 pm, Column oven température : 40°C

Gradient conditions:

Solvent A: Water with 0.1% formic acid : Acetonitrile : : 95 : 5 v/v

Solvent B: Acetonitrile with 0.1% formic acid

15	Time (minutes)	A (%)	B (%)	Flow rate (ml/min)
	0	90	10	1.8
	0.9	0	100	1.8
	1.8	0	100	1.8
	2.2	90	10	1.8
20	2.5	90	10	1.8

Where necessary, enantiomerically pure final compounds may be obtained from racemic materials as appropriate via standard physical séparation techniques, such as reverse phase chiral chromatography, or through stereoselective synthetic techniques, eg, by using chiral starting materials.

Formulation Examples

Wettable powders	a)	b)	c)
active ingrédients [components (A) and (δ)]	25 %	50 %	75%
sodium lignosulfonate	5%	5 %	-
sodium lauryl sulfate	3%	-	5 %
sodium diisobutylnaphthatenesulfonate	-	6%	10%
phénol polyethylene glycol ether	-	2%	-
(7-8 mol of ethylene oxide)
highly dispersed silicic acid	5%	10 %	10%
Kaolin	62%	27 %

The active ingrédient is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill, affording wettable powders that can be diluted with water to give suspensions ofthe desired concentration.

Powders for dry seed treatment	a)	b)	C)
active ingrédients [components (A) and (B)]	25%	50 %	75 %
light minerai oil	5%	5%	5%
highly dispersed silicic acid	5%	5 %	-
Kaolin	65%	40%	-
Talcum	-	-	20%

The active ingrédient is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill, affording powders that can be used directly for seed treatment.

Emulsifiable concentrate
active ingrédients [components (A) and (B)]	10%
octylphenol polyethyîene glycol ether	3%
(4-5 mol of ethylene oxide)
calcium dodecylbenzenesulfonate	3%
castor oil polyglycol ether (35 mol of ethylene oxide)	4%
Cycloh exano ne	30%
xylene mixture	50 %

Emulsions of any required dilution, which can be used in plant protection, can be obtained from this concentrate by dilution with water.

Dusts	a)	b)	C)
active ingrédients [components (A) and (B)]	5%	6%	4 %
talcum	95%	-	-
Kaolin	-	94%	-
minera] filler	-	-	96 %

Ready-for-use dusts are obtained by mixing the active ingrédient with the carrier and grinding the mixture in a suitable mill. Such powders can also be used for dry dressings for seed.

Extruder granules active ingrédients [components (A) and (B)] 15 % sodium lignosulfonate 2 % carboxymethylcellulose 1 %

Kaolin 82 %

The active ingrédient is mixed and ground with the adjuvants, and the mixture is moistened with water. The mixture is extruded and then dried in a stream of air.

Coated granules active ingrédients [components (A) and (B)] 8 % polyethylene glycol (mol. wt. 200) 3 %

Kaolin

89%

The finely ground active ingrédient is uniformly applied, in a mixer, to the kaolin moistened with polyethylene glycol. Non-dusty coated granules are obtained in this manner.

Suspension concentrate active ingrédients [components (A) and (B)] 40 % propylene glycol 10 % nonylphénol polyethylene glycol ether (15 mol of ethylene oxide) 6 %

Sodium lignosulfonate 10 % carboxymethylcelluîose 1 % silicone oil (in the form of a 75 % émulsion in water) 1 %

Water 32 %

The finely ground active ingrédient is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired dilution can be obtained by dilution with water. Using 10 such dilutions, living plants as well as plant propagation material can be treated and protected against infestation by microorganisms, by spraying, pouring or immersion.

Flowabte concentrate forseed treatment active ingrédients [components (A) and (B)] 40 % propylene glycol 5 % copolymer butanol PO/EO 2 % tristyrenephenofe with 10-20 moles EO 2 %

1,2-benzisothiazolin-3-one (in the form of a 20% solution in water) 0.5 % monoazo-pigment calcium sait 5 %

Silicone oil (in the form of a 75 % émulsion in water) 0.2 %

Water 45.3%

The finely ground active ingrédient is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired dilution can be obtained by dilution with water. Using such dilutions, living plants as well as plant propagation material can be treated and protected against infestation by microorganisms, by spraying, pouring or immersion.

Slow Release Capsule Suspension parts of a combination ofthe active ingrédients [components (A) and (B)] is mixed with 2 parts of an aromatic solvent and 7 parts oftoîuenedîisocyanate/polymethylene-poîyphenylisocyanate-mixture (8:1). This mixture is emulsified in a mixture of 1.2 parts of polyvinylalcohol, 0.05 parts of a defoamer and 51.6 parts of water until the desired particle size is achieved. To this émulsion a mixture of 2.8 parts 1,6diaminohexane in 5.3 parts of water is added. The mixture is agitated until the polymerization reaction is completed. The obtained capsule suspension is stabilized by adding 0,25 parts of a thickener and 3 parts of a dispersing agent. The capsule suspension formulation contains 28% ofthe active ingrédients. The medium capsule diameter is 8-15 microns. The resulting formulation is applied to seeds as an aqueous suspension in an apparatus suitable forthat purpose.

List of Abbreviations:

CDCh = chloroform-d “C = degrees Celsius

DCM = dichloromethane

DMF = dimethylformamide

DMSO = dimethyl sulfoxide d = doublet

EtOAc = ethyl acetate h = hour(s)

HCl = hydrochloric acid

M = molar min = minutes

MHz = mega hertz mp = melting point

Pd2(dba)s = Tris(dibenzylideneacetone)dipalladium(0) ppm = parts per million

RT = room température

Rt = rétention time rh = relative humidity s = singlet t = triplet

THF = tetratiydrofuran

LCMS = Liquid Chromatography Mass Spectrometry (description of the apparatus and the methods used for LC/MS analysis are given above)

Préparation examples:

Example 1: Préparation of methyl (Z)-2-[5-(4-cyclopropyltriazol-2-yl)-2-methyl-phenoxy]-3-methoxyprop-2-enoate (X.11)

Step 1 :

To a solution of 5-bromo-2-methylphenol (53.47 mmol, 10.00 g) and methyl 2-bromoacetate (1.5 equiv., 80.20 mmol, 12.27 g, 7.44 mL) in tetrahydrofuran (0.5 moi/L, 106.9 mL) at room température was added potassium carbonate (2 equiv., 106,9 mmol, 14.78 g), and the light brown suspension was heated to 65 °C for 2 h and then allowed to cool down to room température overnight. The reaction mixture was diluted with EtOAc and washed with water. The aqueous phase was extracted with EtOAc, and the total combined organic layer was washed with water, brine, dried with NaaSCX, filtered and concentrated in vacuo to gîve methyl 2-(5-bromo-2-methyi-phenoxy)acetate (47.22 mmol, 15.89 g, 88% yield) as a brown liquid. The crude oil was siightly contamînated with residual methyl-2-bromoacetate but was taken directly to the next step without further purification.

LCMS (Method H), Rt = 1.59 min, MS: (M+1) = 259, 261 ; ¹H NMR (400 MHz, CDCb) δ ppm 2.25 (s, 3 H) 3.84 (s, 3 H) 4.66 (s, 2 H) 6.84 (d, 1 H) 7.05 (m, 2 H)

Step 2:

Part 1: To a solution of 2-(5-bromo-2-methyl-phenoxy)acetate (20.8 g, 80.3 mmol) and methyl formate (6.0 equiv., 482 mmol, 29.5 g, 30.5 mL) in tetrahydrofuran (0.5 mol/L, 161 mL) at room température under argon was added sodium methoxide (20 equiv., 161 mmol, 9.13 g) portionwise. The réaction was siightly exothermic and was kept below 30 °C with the assistance of a room température water bath. The reaction mixture was stirred at room température for 1 h and quenched by the slow addition of an aqueous saturated solution of NaHCOs. The two phases were separated, and the aqueous phase was extracted with EtOAc. The total combined organic layer was washed with aqueous saturated solution of NaHCOs, brine, dried with Na2SO4, filtered and concentrated in vacuo to give methyl-2-(5-bromo-2methyl-phenoxy)-3-hydroxy-prop-2-enoate, which was taken directly to the next step without further purification.

LCMS (Method G), Rt = 0.80 and 0.90 min, MS: (M+1) = 287, 289

Part 2: To a solution ofthe crude methyl-2-(5-bromO'2'methyl·phenoxy)-3-hydΓoxy-pΓOp-2-enoate and drmethyl sulfate (1.2 equiv., 93.2 mmol, 11.8 g, 8.8 mL) in DM F (0.5 mol/L, 155 mL) at room température under argon was added potassium carbonate (1.5 equiv., 117 mmol, 16.3 g), and the reaction mixture was stirred at room température for 2 h. The reaction mixture was quenched by the slow addition of water, and the mixture was extracted with EtOAc. The total combined organic layer was washed with aqueous saturated solution of NaHCOs, brine, dried with NazSOi, filtered and concentrated in vacuo. The residue was purified by flash chromatography (cyclohexane:EtOAc) to give methyl (Z)-2-(5-bromo2-methyl-phenoxy)-3-methoxy-prop-2-enoate (59.6 mmol, 18.0 g, 75 % yield) as an off-white solid.

LCMS (Method G), Rt = 1.02 min, MS: (M+1) = 301,303; Ή NMR (400 MHz, CDCh) δ ppm 2.31 (s, 3

H) 3.74 (s, 3 H) 3.91 (s, 3 H) 6.86 (d, 1 H) 7.05 (m, 2 H) 7.35 (s, 1 H)

Step 3:

A solution oftetramethyl-t-BuXphos (0.10 equiv., 0.066 mmol, 0.033 g) and Pdz(dba)3 (0.05 equiv., 0.033 mmol, 0.031 g) in 1 mL toluene under argon was heated at 110^oC for 3 minutes, and the mixture was then allowed to coo! down to room température. The pre-formed palladium catalyst was transferred to a mixture of methy! (Z)-2-(5-bromo-2-methyl-phenoxy)-3-methoxy-prop-2-enoate (0.66 mmol, 0.20 g), 4cyclopropyl-2H-triazo!e (1.1 equiv., 0.73 mmol, 0.080 g) and potassium carbonate (2.0 equiv., 1.33 mmol, 0.184 g) in toiuene (0.2 mol/L, 3.3 mL) at room température and the obtained dark brown suspension was heated to 110°C for 1 h. The reaction mixture was allowed to cool down to room température, then EtOAc was added. The organic phase was washed with water, and the aqueous was extracted with EtOAc. The total combined organic layer was washed with brine, dried with NazSOi, filtered and concentrated in vacuo. The residue was purified by flash chromatography (cyclohexane:EtOAc) to give methyl (Z)-2-[5-(4-cyclopropyltriazol-2-yl)-2-methyl-phenoxy]-3-methoxyprop-2-enoate (0.23 mmol, 0.075 g, 34 % yield).

LCMS (Method G), Rt = 1.07 min, MS: (M+1) = 330; ’H NMR (400 MHz, CDCh) δ ppm 0.88 (m, 2 H) 1.04 (m, 2 H) 2.03 (m, 1 H) 2.40 (s, 3 H) 3.74 (s, 3 H) 3.91 (s, 3 H) 7.24 (d, 1 H) 7.40 (s, 1 H) 7.41 (d, 1 H) 7.46 (s, 1 H) 7.58 (dd, 1 H)

Example 2: Préparation of methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoro methyl) pyrazol-1yl)phenoxy]prop-2-enoate (X.08)

A solution oftetramethyl-t-BuXphos (0.10 equiv., 0.050 mmol, 0.025 g) and Pdz(dba)s (0.05 equiv., 0.025 mmol, 0.024 g) in 1 mL toluene under argon was heated at IIO^C for 3 minutes. This mixture was then allowed to cool down to room température. The pre-formed active palladium catalyst was transferred to a mixture of methyl (Z)-2-(5-bromo-2-methyl-phenoxy)-3-methoxy-prop-2-enoate (0.50 mmol, 0.15 g), 3-(trifluoromethyt)-1H-pyrazole (1.2 equiv., 0.60 mmol, 0.082 g) and potassium carbonate (2.0 equiv., 1.0 mmol, 0.138 g) in toluene (0.2 mol/L, 2.5 mL) at room température and the obtained dark brown suspension was heated to 110°C for 1 h. The reaction mixture was allowed to cool down to room température, then EtOAc was added. The organic phase was washed with water, and the aqueous was extracted with EtOAc. The total combined organic layer was washed with brine, dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (cyclohexane:EtOAc) to give methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate (0,28 mmol, 0.10 g, 56 % yield) as a white solid.

mp: 154-156°C; LCMS (Method G), Rt= 1.07 min, MS: (M+1) = 357; ¹H NMR (400 MHz, CDCh) δ ppm 2.40 (s, 3 H) 3.75 (s, 3 H) 3.93 (s, 3 H) 6.69 (m, 1 H) 7.10 (d, 1 H) 7.19 - 7.30 (m. 2 H) 7.40 (s, 1 H) 7.87 (m, 1 H)

Using the synthetic techniques described both above and below, compounds of formula (I) may be prepared accordingly.

Where necessary, enantiomerically pure final compounds may be obtained from racemic materials as appropriate via standard physical séparation techniques, such as reverse phase chiral chromatography, or through stereoselective synthetic techniques, (eg, by using chiral starting materials).

Table T1 : Meltinq point (mp) data and/or rétention times (Rt) for compounds X.01 to X.12 according to formula (il

Entry	Compound structure	Compound name	Rt (min)	Mass charge [M+H]	LCMS Method	mp (’C)
X.01	H	methyl (Z)-3methoxy-2-[2methyl-5-(3propylpyrazol-1yl)phenoxy]prop2-enoate	1.77	331	H	91 - 94
X.02	^xo	methyl (Z)-3methoxy-2-[2methyl-5-(3-secbutylpyrazol-1yfjphenoxyjprop2-enoate	1.90	345	H	110- 113
X.03	o—	methyl (Z)-2-[5-(3isopropoxypyrazol -1-yl)-2-methylphenoxy]-3methoxy-prop-2enoate	1.78	347	H	94- 97

Entry	Compound structure	Compound name	Rt (min)	Mass charge [M+H]	LCMS Method	mp CC)
X.04	o 0 -i/ o	methyl (Z)-2-[5-(3cyclobutylpyrazol1-yl)-2-methylphenoxy]-3methoxy-prop-2enoate	1.76	343.25	1	91 - 94
X.05		methyl (Z)-2-[5-(3isobutylpyrazol-1yl)-2-methylphenoxy]-3methoxy-prop-2enoate	1.82	345.27	1	76- 80
X.06	Xi	methyl (Z)-2-[5-(3isopropylpyrazol1-yl)-2-methylphenoxy]-3methoxy-prop-2enoate	1.72	331.26	1	88- 91
X.07	Cl / 1) tji î	methyl (Z)-2-[5-(3cyclopropylpyrazo l-1-yl)-2-methylphenoxy]-3methoxy-prop-2enoate	1.03	329	G	115 - 118
X.08	r=s\ f	methyl (Z)-3methoxy-2-[2methyl-5-[3(trifluoromethyl)py razol-1 yl]phenoxy]prop2-enoate	1.07	357	G	154- 156

Entry	Compound structure	Compound name	Rt (min)	Mass charge [M+H]	LCMS Method	mp CC)
X.09	0 c— ,	methyl (Z)-3methoxy-2-[2methyL5-(4propyltriazol-2yl)phenoxy]prop2-enoate	1.15	332	G
X.10	X °^x	methyl (Z)-3methoxy-2-[2methyl-5-[4(trifluoromethyl)tri azol-2yl]phenoxy]prop2-enoate				107- 109
X.11	1 v O ° k	methyl (Z)-2-[5-(4cyclopropyltriazol2-yl)-2-methylphenoxy]-3methoxy-prop-2enoate	1.07	330	G
X.12	1 Nia/ '	methyl (Z)-2-[5-(4isopropyltriazol-2yl)-2-methyl· phenoxy]-3methoxy-prop-2enoate	1.14	332	G

BIOLOGICAL EXAMPLES:

General exemples of leaf disk tests in well plates:

Leaf disks or leaf segments of various plant species are eut from plants grown in a greentiouse. The eut leaf disks or segments are placed in multiwell plates (24-well format) onto water agar. The leaf disks are sprayed with a test solution before (preventative) or after (curative) inoculation. Compounds to be lested are prepared as DMSO solutions (max. 10 mg/mL) which are diluted to the appropriate concentration with 0.025% Tween20 just before spraying. The inoculated leaf disks or segments are incubated under defined conditions (température, relative humidity, light, etc.) according to the respective test system. A single évaluation of disease level is carried out 3 to 14 days after inoculation, depending on the pathosystem. Percent disease control relative to the untreated check leaf disks or segments is then calculated.

General exemples of liquid culture tests in well plates:

Mycelia fragments or conidia suspensions of a fungus prepared either freshly from liquid cultures of the fungus or from cryogénie storage, are directly mixed into nutrient broth. DMSO solutions ofthe test compound (max. 10 mg/mL) are diluted with 0.025% Tween20 by a factor of 50 and 10 pl of this solution is pipetted into a microtiter plate (96-well format), The nutrient broth containing the fungal spores/mycelia fragments is then added to give an end concentration ofthe tested compound. The test plates are incubated in the dark at 24°C and 96% relative humidity, The inhibition of fungal growth is determined photometrically after 2 to 7 days, depending on the pathosystem, and percent antifungal activity relative to the untreated check is calculated.

Example A1 : Fungicidal activity against Puccinia recondita f. sp. tritici / wheat / leaf dise preventative (Brown rust)

Wheat leaf segments cv. Kanzier are placed on agar in multiwell plates (24-weli format) and sprayed with the formulated test compound diiuted in water. The leaf disks are inoculated with a spore suspension of the fungus 1 day after application. The inoculated leaf segments are incubated at 19 °C and 75% rh under a light régime of 12 h light / 12 h darkness in a climate cabinet and the activity of a compound is assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf segments (7-9 days after application).

The following compounds gave at least 80% control of Puccinia recondita f. sp. tritici at 200 ppm when compared to untreated control under the same conditions, which showed extensive disease development:

Compounds (from Table Tl) X.01, X.02, X.03, X.04, X.05, X.06, X.07, X.08, X.09, X.10, X.11 and X.12.

Example A2: Fungicidal activity against Puccinia recondita f. sp. frff/c// wheat / leaf dise curative (Brown rust)

Wheat leaf segments cv. Kanzler are placed on agar in multiwell plates (24-well format). The leaf segments are inoculated with a spore suspension ofthe fungus. Plates are stored in darkness at 19 °C and 75% rh. The formulated test compound diluted in water is applied 1 day after inoculation. The leaf segments are incubated at 19 °C and 75% rh under a light régime of 12 h light /12 h darkness in a climate cabinet and the activity of a compound is assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf segments (6 8 days after application).

Compounds (from Table T1) X.01, X.03, X.04, X.05, X.06, X.07, X.09, X.10, X.11 and X.12.

Example A3: Fungicidal activity against Phakopsora pachyrhizi I soybean / leaf dise preventative (Asian soybean rust)

Soybean leaf disks are placed on agar in multiwell plates (24-well format) and sprayed with test solutions. After drying, the leaf disks are inoculated with a spore suspension of the fungus. After appropriate incubation the activity of a compound is assessed approx.12 dpi (days after inoculation) as préventive fungicidal activity.

The following compounds gave at least 80% control of Phakopsora pachyrhizi at 67 ppm when compared to untreated control under the same conditions, which showed extensive disease development:

Compounds (from Table T1) X.01, X.02, X.03, X.04, X.05, X.06, X.07, X.08, X.09, X.10, X.11 and X.12.

Example A4: Fungicidal activity against Glomereüa iagenarium (Colletoîrichum iagenarium} liquid culture / cucumber / preventative (Anthracnose)

Conidia of the fungus from cryogénie storage are directly mixed into nutrient broth (PDB potato dextrose broth). After placing a (DMSO) solution of test compound into a microtiter plate (96-well format), the nutrient broth containing the fungal spores is added. The test plates are incubated at 24 °C and the inhibition of growth is measured photometrically 3-4 days after application.

The following compounds gave at least 80% control of Glomereiia iagenarium at 6.7 ppm when compared to untreated control under the same conditions, which showed extensive disease development:

Further biolgical test examples relating to fungicidal compositions comprising a mixture of components (A) and (B) as active ingrédients:

Examole B1: Preventative açtivity against Glomerella lagenarium syn. Coiletotrichum fagenarium (anthracnose ofcucurbits)

Conidia of the tlingus from cryogénie storage were directly mixed into nutrient broth (PDB potato dextrose broth). A DMSO solution ofthe test compounds was placed into a microtiter plate (96-well 10 format) and the nutrient broth containing the fungal spores was added to it. The test plates were incubated at 24 °C and the inhibition of growth was determined photometrically after 72 hrs at 620 nm.

The following mixture compositions (B:A) atthe reported concentration (in ppm) in table B1-1 gave at least 80% disease control in this test (Glomerella laaenarium svn. Cotietotnchum laaenarium).

Table B1-1

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
glyphosate	X.01	1 : 1	0.1 + 0.1
glyphosate	X.01	3 : 1	0.3 + 0.1
chlorothalonil	X.01	10 : 1	0.3 + 0.03
chlorothalonil	X.01	1 : 1	0.1 + 0.1
chlorothalonil	X.01	3 : 1	0.3 + 0.1
mancozeb	X.01	1 : 1	0,1 +0,1
mancozeb	X.01	3 : 1	0.3 + 0.1
propiconazole	X.01	1 : 1	0.1 +0,1
propiconazole	X.01	3 : 1	0.3 + 0.1
dlsodium phosphonate	X.01	1 : 1	0.1 +0,1
dîsodium phosphonate	X.01	3 : 1	0.3 + 0.1
fenpropimorph	X.01	1 : 1	0.1 +0.1
fenpropimorph	X.01	3 : 1	0.3 + 0.1
fenpropidin	X.01	1 : 1	0.1 +0.1
fenpropidin	X.01	3 : 1	0.3 + 0.1
hexaconazole	X.01	1 : 1	0.1 +0.1
hexaconazole	X.01	3 : 1	0.3 + 0.1
paclobutrazol	X.01	1 : 1	0.1 + 0.1
paclobutrazol	X.01	3 : 1	0.3 + 0.1

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B : A)
tnnexapac-ethyl	X.D1	1 : 1	0.1 +0.1
tnnexapac-ethy!	X.01	3 : 1	0.3 + 0.1
flutriafol	X.01	1 : 1	0.1 +0.1
flutriafol	X.01	3 : 1	0.3 + 0.1
difenoconazole	X.01	1 : 1	0.1 +0.1
difenoconazole	X.01	3 : 1	0.3 + 0.1
fludioxonil	X.01	10 : 3	0.1 +0,03
fludioxonil	X.01	10 : 1	0.3 + 0.03
fludioxonil	X.01	1 : 1	0.1 + 0.1
fludioxonil	X.01	3 : 1	0.3 + 0.1
cyproconazoie	X.01	1 : 1	0.1 + 0.1
cyproconazoie	X.01	3 : 1	0.3 + 0.1
acibenzoiar S-methyl	X.01	1 : 1	0.1 + 0.1
acibenzolar S-methyl	X.01	3 : 1	0.3 + 0.1
trifloxystrobîn	X.01	10 : 3	0.1 + 0.03
trifloxystrobîn	X.01	10 : 1	0.3 + 0.03
trifloxystrobîn	X.01	1 : 1	0.1 + 0.1
trifioxystrobin	X.01	3 : 1	0.3 + 0.1
folpet	X.01	1 : 1	0.1 + 0.1
folpet	X.01	3 : 1	0.3 + 0.1
azoxystrobin	X.01	10 : 3	0.1 + 0.03
azoxystrobin	X.01	10 : 1	0.3 + 0.03
azoxystrobin	X.01	1 : 1	0.1 +0.1
azoxystrobin	X.01	3 : 1	0.3 + 0.1
pyraclostrobin	X.01	10 : 3	0.1 +0.03
pyraclostrobin	X.01	10 : 1	0.3 + 0.03
pyraclostrobin	X.01	1 : 1	0.1 +0.1
pyraclostrobin	X.01	3 : 1	0.3 + 0.1
picoxystrobin	X.01	10 : 3	0.1 +0.03
picoxystrobin	X.01	10 : 1	0.3 + 0.03
picoxystrobin	X.01	1 : 1	0.1 +0.1
picoxystrobin	X.01	3 : 1	0.3 + 0.1
sulphur	X.01	10 : 3	0.1 +0.03
sulphur	X.01	10 : 1	0.3 + 0.03

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
sulphur	X.01	1 : 1	0.1 + 0.1
sulphur	X.01	3 : 1	0.3 + 0.1
tebuconazole	X.01	1 : 1	0.1 +0.1
tebuconazole	X.01	3 : 1	0.3 + 0.1
prothioconazole	X.01	10:3	0.1 +0.03
prothioconazole	X.01	10 :1	0.3 + 0.03
prothioconazole	X.01	1 : 1	0.1 +0.1
prothioconazole	X.01	3 : 1	0.3 + 0.1
fluopyram	X.01	1 : 1	0.1 +0.1
fluopyram	X.01	3 : 1	0.3 + 0.1
copper oxychloride	X.01	1 : 1	0.1 +0.1
copper oxychloride	X.01	3 : 1	0.3 + 0.1
benzovindiflupyr	X.01	10 : 3	0.1 +0.03
benzovindiflupyr	X.01	10 : 1	0.3 + 0.03
benzovindiflupyr	X.01	1 : 1	0.1 +0.1
benzovindiflupyr	X.01	3 : 1	0.3 + 0.1
isopyrazam	X.01	1 : 1	0.1 +0.1
isopyrazam	X.01	3 : 1	0.3 + 0.1
pydiflumetofen	X.01	1 : 1	0.1 +0.1
pydiflumetofen	X.01	3 : 1	0.3 + 0.1
fluxapyroxad	X.01	1 : 1	0.1 +0.1
fluxapyroxad	X.01	3 : 1	0.3 + 0.1
quinofumelin	X.01	10 : 3	0.1 + 0.03
quinofumeiin	X.01	10 : 1	0.3 + 0.03
quinofumelin	X.01	1 : 1	0.1 + 0.1
quinofumelin	X.01	3 : 1	0.3 + 0.1
isoflucypram	X.01	1 : 1	0.1 + 0.1
isoflucypram	X.01	3 : 1	0.3 + 0.1
mefentrifluconazole	X.01	1 : 1	0.1 + 0.1
mefentrifluconazole	X.01	3 : 1	0.3 + 0.1
ipflufenoquin	X.01	10 : 3	0.1 + 0.03
ipflufenoquin	X.01	10 : 1	0.3 + 0.03
ipflufenoquin	X.01	1 : 1	0.1 +0.1
ipflufenoquin	X.01	3 : 1	0.3 + 0.1

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
metyltetra proie	X.01	10 : 3	0.1 + 0.03
metyltetra proie	X.01	10 : 1	0.3 + 0.03
metyltetra proie	X.01	1 : 1	O.1 + 0.1
metyltetraprole	X.01	3 : 1	0.3 + 0.1
aminopyrifen	X.01	10 : 3	0.1 + 0.03
aminopyrifen	X.01	10 :1	0.3 + 0.03
aminopyrifen	X.01	1 : 1	0.1 + 0.1
aminopyrifen	X.01	3 : 1	0.3 + 0.1
florylpicoxamid	X.01	10 : 3	0.1 + 0.03
florylpicoxamid	X.01	10 : 1	0.3 + 0.03
florylpicoxamid	X.01	1 : 1	0.1 + 0.1
florylpicoxamid	X.01	3 : 1	0.3 + 0.1
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yt)propan-2-ol	X.01	1 : 1	0.1 + 0.1
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.01	3 : 1	0.3 + 0.1
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3- d imethyl-buty I] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.01	10 : 3	0.1 + 0.03
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1_T3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyf]amino]propanoate	X.01	10 : 1	0.3 + 0.03
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3- d imethyl-buty I] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyridine-2-carbonyl]amino]propanoate	X.01	1 : 1	0.1 + 0.1
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3- d imethyl-buty I] (2S)-2-[[3-(acetoxymethoxy)-4- m ethoxy-py rid in e-2-ca rbonyl]a mino] pro pan oate	X.01	3 : 1	0.3 + 0.1
(Z,2E)-5-[1-(2,4-dichloropheny1)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.01	10 : 3	0.1 + 0.03
(Z,2E)~5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.01	10 : 1	0.3 + 0.03
(Z,2E)-5-[1-(2_I4-dich!orophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethy!-pent-3-enamide	X.01	1 : 1	0.1 + 0.1

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.01	3 : 1	0.3 + 0.1
chlorothalonil	X.08	10 : 1	0.3 + 0.03
chlorothalonil	X.08	3 : 1	0.3 + 0.1
trifloxystrobin	X.08	10 : 3	0.1 +0.03
trifloxystrobin	X.08	10 : 1	0.3 + 0.03
trifloxystrobin	X.08	1 : 1	0.1 + 0.1
trifloxystrobin	X.08	3 : 1	0.3 + 0.1
azoxystrobin	X.08	10 : 3	0.1 + 0.03
azoxystrobin	X.08	10 : 1	0.3 + 0.03
azoxystrobin	X.08	1 : 1	0.1 + 0.1
azoxystrobin	X.08	3 : 1	0.3 + 0.1
pyraclostrobin	X.08	10 : 3	0.1 +0.03
pyraclostrobin	X.08	10 ; 1	0.3 + 0.03
pyraclostrobin	X.08	1 : 1	0.1 +0.1
pyraclostrobin	X.08	3 : 1	0.3 + 0.1
picoxystrobin	X.08	10 : 3	0.1 + 0.03
picoxystrobin	X.08	10 : 1	0.3 + 0.03
picoxystrobin	X.08	1 : 1	0.1 + 0.1
picoxystrobin	X.08	3 : 1	0.3 + 0.1
benzovindiflupyr	X.08	10 : 1	0.3 + 0.03
benzovindiflupyr	X.08	3 : 1	0.3 + 0.1
quinofumelin	X.08	10 : 3	0.1 +0.03
quinofumelin	X.08	10 : 1	0.3 + 0.03
quinofumelin	X.08	1 : 1	0.1 +0.1
quinofumelin	X.08	3 ; 1	0.3 + 0.1
ipflufenoquin	X.08	10 :1	0.3 + 0.03
ipflufenoquin	X.08	1 : 1	0.1 +0.1
ipflufenoquin	X.08	3 : 1	0.3 + 0.1
metyltetraprole	X.08	10 : 3	0.1 + 0.03
metyltetraprole	X.08	10 : 1	0.3 + 0.03
metyltetraprole	X.08	1 : 1	0.1 + 0.1
metyltetraprole	X.08	3 : 1	0.3 + 0.1
florylpicoxamid	X.08	10 : 3	0.1 + 0.03

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
florylpicoxamid	X.08	10 :1	0.3 + 0.03
florylpicoxamid	X.08	1 : 1	0.1 +0.1
florylpicoxamid	X.08	3 : 1	0.3 + 0.1
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3- di methyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- meth oxy-py ridine-2-ca rbonyi]a mino] pro pa n oate	X.08	10 : 3	0.1 + 0.03
[(1 S,2S)-2-(4-fluoro-2-methyl-pheny 1)-1,3- dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyridine-2-carbonyl]a mino] propanoate	X.08	10 : 1	I 0.3 + 0.03
[(1 S,2S)-2-(4-fiuoro-2-methyi-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]a mino] propanoate	X.08	1 : 1	0.1 +0.1
[(1 S,2S)-2-(4-fiuoro-2-methyl-phenyl)-1,3- dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.08	3 : 1	0.3 + 0.1
(Z,2E)-5-[1-(2,4-dichlorophenyî)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.08	10 : 3	0.1 + 0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.08	10 : 1	0.3 + 0.03
(Z,2E)-5-[1-(2,4-dichioropheny!)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.08	1 : 1	0.1 + 0.1
(Z,2E)-5-[1-(2,4-dichiorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.08	3 : 1	0.3 + 0.1
glyphosate	X.06	1 : 1	0.1 + 0.1
glyphosate	X.06	3 : 1	0.3 + 0.1
chlorothalonil	X.06	10 : 1	0.3 + 0.03
chlorothalonil	X.06	1 : 1	0.1 +0.1
chlorothalonil	X.06	3 ; 1	0.3 + 0.1
mancozeb	X.06	1 : 1	0.1 +0.1
mancozeb	X.06	3 : 1	0.3 + 0.1
propiconazole	X.06	1 : 1	0.1 +0.1
propiconazole	X.06	3 : 1	0.3 + 0.1
disodium phosphonate	X.06	1 : 1	0.1 +0.1
disodium phosphonate	X.06	3 : 1	0.3 + 0.1

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
fenpropimorph	X.06	1 : 1	0.1 + 0.1
fenpropimorph	X.06	3 : 1	0.3 + 0.1
fenpropidin	X.06	1 : 1	0.1 + 0.1
fenpropidin	X.06	3 : 1	0.3 + 0.1
hexaconazole	X.06	1 : 1	0.1 +0.1
hexaconazole	X.06	3 : 1	0.3 + 0.1
paclobutrazol	X.06	1 : 1	0.1 + 0.1
paclobutrazol	X.06	3 : 1	0.3 + 0.1
trinexapac-ethyl	X.06	1 : 1	0.1 + 0.1
trinexapac-ethyl	X.06	3 : 1	0.3 + 0.1
flutriafol	X.06	1 : 1	0.1 + 0.1
flutriafol	X.06	3 : 1	0.3 + 0.1
difenoconazole	X.06	1 : 1	0.1 + 0.1
difenoconazole	X.06	3 : 1	0.3 + 0.1
fludioxonil	X.06	1 : 1	0.1 +0.1
fludioxonil	X.06	3 : 1	0.3 + 0.1
cyproconazole	X.06	1 : 1	0.1 +0.1
cyproconazole	X.06	3 : 1	0.3 + 0.1
acibenzolar S-methyl	X.06	1 : 1	0.1 + 0.1
acibenzolar S-methyl	X.06	3 : 1	0.3 + 0.1
trifloxystrobin	X.06	10 : 3	0.1 + 0.03
trifloxystrobin	X.06	10 : 1	0.3 + 0.03
trifloxystrobin	X.06	1 : 1	0.1 + 0.1
trifloxystrobin	X.06	3 : 1	0.3 + 01
folpet	X.06	1 : 1	0.1 + 0.1
folpet	X.06	3 : 1	03 + 0.1
azoxystrobin	X.06	10 : 3	0.1 + 0.03
azoxystrobin	X.06	10 : 1	0.3 + 0.03
azoxystrobin	X.06	1 : 1	0.1 +0.1
azoxystrobin	X.06	3 : 1	0.3 + 0.1
pyraclostrobin	X.06	10:3	0.1 +0,03
pyraclostrobin	X.06	10 ; 1	0.3 + 0.03
pyraclostrobin	X.06	1 : 1	0.1 +0.1
pyraclostrobin	X.06	3 ; 1	0.3 + 0.1

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
picoxystrobin	X.06	10 : 3	0.1 +0.03
picoxystrobin	X.06	10 : 1	0.3 + 0.03
picoxystrobin	X.06	1 : 1	0.1 +0.1
picoxystrobin	X.06	3 : 1	0.3 + 0.1
sulphur	X.06	10 :1	0.3 + 0.03
sulphur	X.06	1 : 1	0.1 + 0.1
sulphur	X.06	3 : 1	0.3 + 0.1
tebuconazole	X.06	1 : 1	0.1 + 0.1
tebuconazole	X.06	3 : 1	0.3 + 0.1
proth ioconazole	X.06	10 ; 1	0.3 + 0.03
proth ioconazole	X.06	1 : 1	0.1 +0.1
prothioconazole	X.06	3 : 1	0.3 + 0.1
fluopyram	X.06	1 : 1	0.1 +0.1
fluopyram	X.06	3 : 1	0.3 + 0.1
copper oxychloride	X.06	1 : 1	0.1 +0.1
copperoxychloride	X.06	3 : 1	0.3 + 0.1
benzovindiflupyr	X.06	10 : 1	0.3 + 0.03
benzovindiflupyr	X.06	1 : 1	0.1 + 0.1
benzovindiflupyr	X.06	3 : 1	0.3 + 0.1
isopyrazam	X.06	1 : 1	0.1 + 0.1
isopyrazam	X.06	3 : 1	0.3 + 0.1
pydiflumetofen	X.06	1 : 1	0.1 + 0.1
pydiflumetofen	X.06	3 : 1	0.3 + 0.1
fluxapyroxad	X.06	1 : 1	0.1 +0.1
fluxapyroxad	X.06	3 : 1	0.3 + 0.1
quinofumelin	X.06	10 :3	0.1 +0.03
quinofumelin	X.06	10 :1	0.3 + 0.03
quinofumelin	X.06	1 : 1	0.1 +0.1
quinofumelin	X.06	3 : 1	0.3 + 0.1
isoflucypram	X.06	1 : 1	0.1 +0.1
isoflucypram	X.06	3 : 1	0.3 + 0.1
mefe ntrifluco n azole	X.06	1 : 1	0.1 +0.1
mefentrifluconazole	X.06	3 : 1	0.3 + 0.1
ipfiufenoquin	X.06	10 : 3	0.1 +0.03

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
ipflufenoquin	X.06	10 : 1	0.3 + 0.03
ipflufenoquin	X.06	1 : 1	0.1 +0.1
ipflufenoquin	X.06	3 : 1	0.3 + 0.1
metyltetraprole	X.06	10 : 3	0.1 +0.03
metyltetraprole	X.06	10 :1	0.3 + 0.03
metyltetraprole	X.06	1 : 1	0.1 + 0.1
metyltetraprole	X.06	3 : 1	0.3 + 0.1
aminopyrifen	X.06	10 : 1	0.3 + 0.03
aminopyrifen	X.06	1 : 1	0.1 + 0.1
aminopyrifen	X.06	3 : 1	0.3 + 0.1
florylpicoxamid	X.06	10 : 3	0.1 + 0.03
florylpicoxamid	X.06	10 : 1	0.3 + 0.03
florylpicoxamid	X.06	1 : 1	0.1 +0.1
florylpicoxamid	X.06	3 : 1	0.3 + 0.1
2-(6-(4- bro mo ph enoxy)-2-(trifl u oromethy l)-3py ridy 1]-1-(1,2,4-triazo I-1 -y l)propan-2-ol	X.06	1 : 1	0.1 +0.1
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.06	3 : 1	0.3 + 0.1
[(1 S,2S)-2-(4-fluoro-2-methyl-pheny1)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.06	10 : 3	0.1 + 0.03
((1 S,2S)-2-(4-fluoro-2-methyl-pheny 1)-1,3- dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyridine-2-carbonyl]amino]propanoate	X.06	10 :1	0.3 + 0.03
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-py rid ine-2-carbonyl]a min o] propanoate	X.06	1 : 1	0.1 + 0.1
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-py rid in e-2-carbonyl]a min o] pro panoate	X.06	3 : 1	0.3 + 0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.06	10 : 3	0.1 + 0.03
(Z,2E)-5-(1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimîno-N,3-dimethyl-pent-3-enamide	X.06	10 : 1	0.3 + 0.03

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
(Z,2E)-5-(1-(2,4-dichiorophenyl)py razol-3-yl]oxy- 2-methoxyimino-N,3-dimethyi-pent-3-enamide	X.06	1 : 1	0.1 + 0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.06	3 : 1	0.3 + 0.1
glyphosate	X.10	1 : 1	0.1 + 0.1
glyphosate	X.10	3 : 1	0.3+0.1
chlorothalonil	X.10	10 : 1	0.3 + 0.03
chlorothalonil	X.10	1 : 1	0.1 + 0.1
chlorothalonil	X.10	3 : 1	0.3 + 0.1
mancozeb	X.10	1 : 1	0.1 + 0.1
mancozeb	X.10	3 : 1	0.3 + 0.1
propiconazole	X.10	1 : 1	0.1 + 0.1
propiconazole	X.10	3 : 1	0.3+0.1
disodium phosphonate	X.10	1 : 1	0.1 + 0.1
disodium phosphonate	X.10	3 : 1	0.3 + 0.1
fenpropimorph	X.10	1 : 1	0.1 +0.1
fenpropimorph	X.10	3 : 1	0.3 + 0.1
fenpropidin	X.10	1 : 1	0.1 + 0.1
fenpropidin	X.10	3 : 1	0.3 + 0.1
hexaconazole	X.10	1 : 1	0.1 + 0.1
hexaconazole	X.10	3 : 1	0.3+0.1
paclobutrazol	X.10	1 : 1	0.1 + 0.1
paclobutrazol	X.10	3 : 1	0.3+0.1
trinexapac-ethyl	X.10	1 : 1	0.1 + 0.1
trinexapac-ethyl	X.10	3 : 1	0.3 + 0.1
flutriafol	X.10	1 : 1	0.1 +0.1
flutriafol	X.10	3 : 1	0.3 + 0.1
difenoconazole	X.10	1 : 1	0.1 + 0.1
difenoconazole	X.10	3 : 1	0.3 + 0.1
fludioxonil	X.10	1 : 1	0.1 + 0.1
fludioxonil	X.10	3 : 1	0.3 + 0.1
cyproconazole	X.10	1 : 1	0.1 + 0.1
cyproconazole	X.10	3 : 1	0.3+ 0.1
acibenzolar S-methyl	X.10	1 : 1	0.1 + 0.1

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
acibenzolar S-methyl	X.10	3 : 1	0.3 + 0.1
trifloxystrobin	X.10	10 : 3	0.1 + 0.03
trifloxystrobin	X.10	10 : 1	0.3 + 0.03
trifloxystrobin	X.10	1 : 1	0.1 +0.1
trifloxystrobin	X.10	3 : 1	0.3 + 0.1
folpet	X.10	1 : 1	0.1 + 0.1
folpet	X.10	3 : 1	0,3 + 0,1
azoxystrobin	X.10	10 : 3	0.1 + 0.03
azoxystrobin	X.10	10 : 1	0.3 + 0.03
azoxystrobin	X.10	1 : 1	0.1 + 0.1
azoxystrobin	X.10	3 : 1	0.3 + 0.1
pyraclostrobin	X.10	10 : 3	0.1 + 0.03
pyraclostrobin	X.10	10 : 1	0.3 + 0.03
pyraclostrobin	X.10	1 : 1	0.1 +0.1
pyraclostrobin	X.10	3 : 1	0.3 + 0.1
picoxystrobin	X.10	10 : 3	0.1 +0.03
picoxystrobin	X.10	10 : 1	0.3 + 0.03
picoxystrobin	X.10	1 : 1	0.1 + 0.1
picoxystrobin	X.10	3 : 1	0,3 + 0.1
sulphur	X.10	1 : 1	0.1 + 0.1
sulphur	X.10	3 : 1	0.3 + 0.1
tebuconazole	X.10	1 : 1	0.1 + 0.1
tebuconazole	X.10	3 : 1	0.3 + 0.1
prothioconazole	X.10	1 : 1	0.1 + 0.1
prothioconazole	X.10	3 : 1	0.3 + 0.1
fluopyram	X.10	1 : 1	0.1 +0.1
fluopyram	X.10	3 : 1	0.3 + 0.1
copper oxychloride	X.10	1 : 1	0.1 + 0.1
copper oxychloride	X.10	3 : 1	0.3 + 0.1
benzovindiflupyr	X.10	10 : 1	0,3 + 0.03
benzovindiflupyr	X.10	1 : 1	0.1 + 0.1
benzovindiflupyr	X.10	3 : 1	0.3 + 0.1
isopyrazam	X.10	1 : 1	0.1 + 0.1
isopyrazam	X.10	3 : 1	0.3 + 0.1

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
pydiflumetofen	X.10	1 : 1	0.1 + 0.1
pydiflumetofen	X.10	3 : 1	0.3 + 0.1
fluxapyroxad	X.10	1 : 1	0.1 + 0.1
fluxapyroxad	X.10	3 : 1	0.3 + 0.1
quinofumelin	X.10	10 : 3	0.1 + 0.03
quinofumelin	X.10	10 :1	0.3 + 0.03
quinofumelin	X.10	1 : 1	0.1 +0,1
quinofumelin	X.10	3 : 1	0.3 + 0,1
isoflucypram	X.10	1 : 1	0.1 + 0.1
isoflucypram	X.10	3 : 1	0.3 + 0.1
mefentrifluconazole	X.10	1 : 1	0.1 + 0.1
mefentrifluconazole	X.10	3 : 1	0.3 + 0.1
ipflufenoquin	X.10	10 : 1	0.3 + 0.03
ipflufenoquin	X.10	1 : 1	0.1 + 0.1
ipflufenoquin	X.10	3 : 1	0.3 + 0.1
metyltetraprole	X.10	10 : 3	0.1 + 0.03
metyltetraprole	X.10	10 :1	0.3 + 0.03
metyltetraprole	X.10	1 : 1	0.1 +0.1
metyltetraprole	X.10	3 : 1	0.3 + 0.1
aminopyrifen	X.10	1 : 1	0.1 + 0.1
aminopyrifen	X.10	3 : 1	0.3 + 0.1
florylpicoxamid	X.10	10 : 3	0.1 + 0.03
florylpicoxamid	X.10	10 : 1	0.3 + 0.03
florylpicoxamid	X.10	1 : 1	0.1 + 0.1
florylpicoxamid	X.10	3 : 1	0.3 + 0.1
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3py ridy I]-1 - (1,2,4-triazol-1 -yl) pro pan-2-ol	X.10	1 : 1	0.1 + 0.1
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3py ridy Ι]-1-(1,2,4ΊΠ3ζοΙ-1 -y l)propan-2-ol	X.10	3 : 1	0.3 + 0.1
((1 S,2S)-2-(4-fluoΓO-2-methyl·pheπyl)-1,3- dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.10	1 ; 1	0.1 +0.1

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
((1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyi] (2S)-2-[i3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.10	3 : 1	0.3 + 0.1
(Z ,2 E)-5-(1-(2,4-dichlorophenyl)py razol-3-yl]oxy2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.10	10 : 3	0.1 + 0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl)oxy2-methoxy imino-N, 3-d imethyl-pent-3-ena mîde	X.10	10 : 1	0.3 + 0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.10	1 : 1	0.1 +0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxy imino-N, 3-d imethyl-pent-3-enamide	X.10	3 ; 1	0.3 + 0.1
glyphosate	X.09	10 : 3	0.1 +0.03
glyphosate	X.09	10 :1	0.3 + 0.03
glyphosate	X.09	1 ; 1	0.1 +0.1
glyphosate	X.09	3 : 1	0.3 + 0.1
chlorothalonil	X.09	10 ; 3	0.1 + 0.03
chlorothalonii	X.09	10 :1	0.3 + 0.03
chlorothalonil	X.09	1 : 1	0.1 +0.1
chlorothalonil	X.09	3 ; 1	0.3 + 0.1
mancozeb	X.09	10 : 3	0.1 +0.03
mancozeb	X.09	10 : 1	0.3 + 0.03
mancozeb	X.09	1 : 1	0.1 +0.1
mancozeb	X.09	3 : 1	0.3 + 0.1
propiconazole	X.09	10 : 3	0.1 +0.03
propiconazole	X.09	10 : 1	0.3 + 0.03
propiconazole	X.09	1 : 1	0.1 + 0.1
propiconazole	X.09	3 : 1	0.3 + 01
disodium phosphonate	X.09	10 : 3	0.1 + 0.03
disodium phosphonate	X.09	10 : 1	0.3 + 0.03
disodium phosphonate	X.09	1 : 1	0.1 + 0.1
disodium phosphonate	X.09	3 : 1	0.3 + 0.1
fenpropimorph	X.09	10 : 3	0.1 + 0.03
fenpropimorph	X.09	10 :1	0.3 + 0.03
fenpropimorph	X.09	1 : 1	0.1 +0.1

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B : A)
fenpropimorph	X.09	3 : 1	0.3 + 0.1 —
fenpropidin	X.09	10 : 3	0.1 + 0.03
fenpropidin	X.09	10 : 1	0.3 + 0.03
fenpropidin	X.09	1 : 1	0.1 + 0.1
fenpropidin	X.09	3 : 1	0.3 + 0.1
hexaconazole	X.09	10 : 3	0.1 + 0.03
hexaconazole	X.09	10 : 1	0.3 + 0.03
hexaconazole	X.09	1 : 1	0.1 + 0.1
hexaconazole	X.09	3 : 1	0.3 + 0.1
paclobutrazol	X.09	10 : 3	0.1 + 0.03
paclobutrazol	X.09	10 : 1	0.3 + 0.03
paclobutrazol	X.09	1 : 1	0.1 +0.1
paclobutrazol	X.09	3 : 1	0.3 + 0.1
trinexapac-ethyl	X.09	10 ;3	0.1 +0.03
trinexapac-ethyl	X.09	10 : 1	0.3 + 0,03
trinexapac-ethyl	X.09	1 : 1	0,1 +0,1
trinexapac-ethyl	X.09	3 : 1	0.3 + 0,1
flutriafol	X.09	10 : 3	0.1 +0,03
flutriafol	X.09	10 :1	0.3 + 0.03
flutriafol	X.09	1 : 1	0.1 +0,1
flutriafol	X.09	3 : 1	0.3 + 0,1
difenoconazole	X.09	10 : 3	0,1 + 0.03
difenoconazole	X.09	10 : 1	0.3 + 0.03
difenoconazole	X.09	1 : 1	0.1 + 0.1
difenoconazole	X.09	3 : 1	0.3 + 0.1
fludioxonil	X.09	10 : 3	0.1 + 0.03
fludioxonil	X.09	10 : 1	0.3 + 0.03
fludioxonil	X.09	1 : 1	Û.1 + 0.1
fludioxonil	X.09	3 : 1	0.3 + 01
cyproconazole	X.09	10 : 3	0.1 + 0.03
cyproconazole	X.09	10 : 1	0.3 + 0.03
cyproconazole	X.09	1 : 1	0.1 + 0.1
cyproconazole	X.09	3 : 1	0.3 + 0.1
acibenzolar S-methyl	X.09	10 : 3	0.1 + 0.03

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
acibenzolar S-methyl	X.09	10 : 1	0.3 + 0.03
acibenzolar S-methyl	X.09	1 : 1	0.1 + 0.1
acibenzolar S-mettiyl	X.09	3 : 1	0.3 + 0.1
trifloxystrobin	X.09	10 : 3	0.1 + 0.03
trifloxystrobin	X.09	10 : 1	0.3 + 0.03
trifloxystrobin	X.09	1 : 1	0.1 + 0.1
trifloxystrobin	X.09	3 : 1	0.3 + 0.1
folpet	X.09	10 : 3	0.1 +0.03
folpet	X.09	10 : 1	0.3 + 0.03
folpet	X.09	1 : 1	0.1 +0.1
folpet	X.09	3 : 1	0.3 + 0.1
azoxystrobin	X.09	10 : 3	0.1 +0.03
azoxystrobin	X.09	10 : 1	0.3 + 0.03
azoxystrobin	X.09	1 : 1	0.1 +0.1
azoxystrobin	X.09	3 : 1	0.3 + 0.1
pyraciostrobin	X.09	10 : 3	0.1 +0.03
pyraciostrobin	X.09	10 : 1	0.3 + 0.03
pyraciostrobin	X.09	1 : 1	0.1 +0.1
pyraciostrobin	X.09	3 : 1	0.3 + 0.1
picoxystrobin	X.09	10 : 3	0.1 +0.03
picoxystrobin	X.09	10 : 1	0.3 + 0.03
picoxystrobin	X.09	1 : 1	0.1 + 0.1
picoxystrobin	X.09	3 : 1	0.3 + 01
sulphur	X.09	10 : 3	0.1 +0.03
sulphur	X.09	10 : 1	0.3 + 0.03
sulphur	X.09	1 : 1	0.1 +0.1
sulphur	X.09	3 : 1	0.3 + 0.1
tebuconazole	X.09	10 :3	0.1 + 0.03
tebuconazole	X.09	10 : 1	0.3 + 0.03
tebuconazole	X.09	1 : 1	0.1 +0.1
tebuconazole	X.09	3 : 1	0.3 + 0.1
prothioconazole	X.09	10 : 3	0.1 + 0.03
prothioconazole	X.09	10 :1	0.3 + 0.03
prothioconazole	X.09	1 : 1	0.1 +0.1

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
prothioconazole	X.09	3 : 1	0.3 + 0.1
fluopyram	X.09	10 : 3	0.1 + 0.03
fluopyram	X.09	10 : 1	0.3 + 0.03
fluopyram	X.09	1 : 1	0.1 +0.1
fluopyram	X.09	3 : 1	0.3 + 0.1
copper oxychloride	X.09	10 : 3	0.1 +0.03
copper oxychloride	X.09	10 : 1	0.3 + 0.03
copper oxychloride	X.09	1 ; 1	0.1 +0.1
copper oxychloride	X.09	3 : 1	0.3 + 0.1
benzovindiflupyr	X.09	10 : 3	0.1 + 0.03
benzovindiflupyr	X.09	10 : 1	0.3 + 0.03
benzovindiflupyr	X.09	1 : 1	0.1 + 0.1
benzovindiflupyr	X.09	3 : 1	0.3 + 0.1
isopyrazam	X.09	10 : 3	0.1 + 0.03
isopyrazam	X.09	10 : 1	0.3 + 0.03
isopyrazam	X.09	1 : 1	0.1 + 0.1
isopyrazam	X.09	3 : 1	0.3 + 0.1
pydiflumetofen	X.09	10 : 3	0.1 +0.03
pydiflumetofen	X.09	TO : 1	0.3 + 0.03
pydiflumetofen	X.09	1 : 1	0.1 +0.1
pydiflumetofen	X.09	3 : 1	0.3 + 0.1
fluxapyroxad	X.09	10 : 3	0.1 +0.03
fluxapyroxad	X.09	10 : 1	0.3 + 0.03
fluxapyroxad	X.09	1 : 1	0.1 +0.1
fluxapyroxad	X.09	3 : 1	0.3 + 0.1
quinofumelin	X.09	10 : 3	0.1 +0.03
quinofumelin	X.09	10 : 1	0.3 + 0.03
quinofumelin	X.09	1 : 1	0.1 +0.1
quinofumelin	X.09	3 : 1	0.3 + 0.1
isoflucypram	X.09	10 : 3	0.1 + 0.03
isoflucypram	X.09	10 : 1	0.3 + 0.03
isoflucypram	X.09	1 : 1	0.1 +0.1
isoflucypram	X.09	3 : 1	0.3 + 0.1
mefentrifluconazole	X.09	10 : 3	0.1 +0.03

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
mefentrifluconazole	X.09	10 : 1	0.3 + 0.03
mefentrifluconazole	X.09	1 : 1	0.1 + 0.1
mefentrifluconazole	X.09	3 : 1	0.3 + 0.1
ipflufenoquin	X.09	10 : 3	0.1 +0.03
ipflufenoquin	X.09	10 : 1	0.3 + 0,03
ipflufenoquin	X.09	1 : 1	0.1 +0.1
ipflufenoquin	X.09	3 : 1	0.3 + 0.1
metyltetraprole	X.09	10 : 3	0.1 + 0.03
metyltetraprole	X.09	10 : 1	0.3 + 0.03
metyltetraprole	X.09	1 : 1	0.1 + 0.1
metyltetraprole	X.09	3 : 1	0.3 + 0.1
aminopyrifen	X.09	10 : 3	0.1 + 0.03
aminopyrifen	X.09	10 : 1	0.3 + 0.03
aminopyrifen	X.09	1 : 1	0.1 + 0.1
aminopyrifen	X.09	3 : 1	0.3 + 0.1
florylpicoxamid	X.09	10 : 3	0.1 + 0.03
florylpicoxamid	X.09	10 : 1	0.3 + 0.03
florylpicoxamid	X.09	1 : 1	0.1 +0.1
florylpicoxamid	X.09	3 : 1	0.3 + 0.1
2-[6-(4-bromophenoxy)-2-(tnfluoromethyi)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.09	10 :3	0.1 +0,03
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1 -(1,2,4-triazol-1 -yi)propan-2-ol	X.09	10 :1	0,3 + 0.03
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.09	1 : 1	0,1 +0.1
2-[6-(4-bromophenoxy)-2-(triflu oromethy l)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.09	3 : 1	0,3 + 0.1
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl- butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyrid ine-2-carbonyl]a min o] propanoate	X.09	10 : 3	0.1 + 0.03
[(1S,2S)-2-(4-fluoro-2-methyi-phenyl)-1,3- dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyridine-2-carbonyl]a min o] propanoate	X.09	10 : 1	0.3 + 0.03

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.09	1 : 1	0.1 + 0.1
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dîmethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyrîdine-2-carbonyl]amino]propanoate	X.09	3 : 1	0.3 + 0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyt-pent-3-enamide	X.09	10 : 3	0.1 + 0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.09	10 : 1	0.3 + 0.03
(Z,2E)-5-(1-(2,4-dich 1orophenyi)py razol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.09	1 : 1	0.1 +0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.09	3 : 1	0.3 + 0.1

The following mixture compositions at the reported concentration (in ppm) in tables B1-2 to B1-5 gave the following disease control in this test (Glomeraiia laaenarium syn. Colietotrichum iagenarium).

Fungicidal activity was evaluated on a 100-0 scale (100 = no disease growth; 0 = well completely covered by mycélium).

Table B1-2

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
chlorothalonil	X.01	0.1 + 0.03	0	70	70	70
chlorothalonil	X.01	0.3 + 0.03	20	70	100	76
ftudioxonil	X.01	0.1 + 0.03	0	70	90	70
fludioxonil	X.01	0.3 + 0.03	0	70	90	70
sulphur	X.01	0.1 + 0.03	0	70	90	70
sulphur	X.01	0.3 + 0.03	0	70	100	70
prothioconazole	X.01	0.1 + 0.03	20	70	90	76
prothioconazole	X.01	0.3 + 0.03	50	70	100	85

Component B	Component A	Concentration (B + A)	Açtivity (%)	COLBY Expected Açtivity (%)
ppm	B	A	B +A
benzovindiflupyr	X.01	0.1 + 0.03	50	70	100	85
benzovindiflupyr	X.01	0.3 + 0.03	100	70	100	100
ipflufenoquin	X.01	0.1 +0.03	20	70	100	76
ipflufenoquin	X.01	0.3 + 0.03	100	70	100	100
aminopyrifen	X.01	0.1 +0.03	20	70	90	76
amlnopyrifen	X.01	0.3 + 0.03	50	70	100	85
[(1S,2S)-2-(4fluoro-2-methylphenyl)-1,3dimethyl-butyl] (2S)-2-[[3(acetoxymethoxy) -4-methoxypyridine-2carbonyl]amino]pr opanoate	X.01	0.1 + 0.03	20	70	90	76
[(1S,2S)-2-(4fluoro-2-methylphenyl)-1,3dimethyl-butyl] (2S)-2-[[3(acetoxy meth oxy) -4-methoxypyridine-2carbonyl]amino]pr opanoate	X.01	0.3 + 0.03	70	70	100	91

Table B1-3

Component B	Component A	Concentration (B + A)	Açtivity (%)	COLBY Expected Açtivity (%)
ppm	B	A	B + A
chlorothalonil	X.08	0.1 + 0.03	0	0	0	0
chlorothalonil	X.08	0.3 + 0.03	20	0	100	20
chlorothalonil	X.08	0.1 +0.1	0	0	0	0

Component B chlorothalonil	Component A X.08	Concentration (B+A)	Activity (%)	COLBY Expected Activity (%) 20
ppm 0.3 + 0.1	B 20	A 0	B + A 100
sulphur	X.08	0.1 +0.03	0	0	0	0
sulphur	X.08	0.3 + 0.03	0	0	0	0
sulphur	X.08	0.1 +0.1	0	0	20	0
sulphur	X.08	0.3 + 0.1	0	0	70	0
prothioconazole	X.08	0.1 + 0.03	20	0	20	20
prothioconazoie	X.08	0.3 + 0.03	50	0	70	50
prothioconazole	X.08	0.1 +0.1	20	0	50	20
prothioconazole	X.08	0.3 + 01	50	0	70	50
benzovindiflupyr	X.08	0.1 +0.03	50	0	70	50
benzovindiflupyr	X.08	0.3 + 0.03	100	0	100	100
benzovindiflupyr	X.08	0.1 +0.1	50	0	70	50
benzovindiflupyr	X.08	0.3 + 0.1	100	0	100	100
ipflufenoquin	X.08	0.1 +0.03	20	0	70	20
ipflufenoquin	X.08	0.3 + 0.03	100	0	100	100
ipflufenoquin	X.08	0.1 +0.1	20	0	90	20
ipflufenoquin	X.08	0.3 + 0.1	1ÛÛ	0	100	100
aminopyrifen	X.08	0.1 +0.03	20	0	20	20
aminopyrifen	X.08	0.3 + 0.03	50	0	50	50
aminopyrifen	X.08	0.1 + 0.1	20	0	70	20
aminopyrifen	X.08	0.3 + 0.1	50	0	70	50
[(1S,2S)-2-(4-fluoro-2methyl-phenyl)-1,3dimethyl-butyf] (2S)-2-[[3(acetoxymethoxy)-4methoxy-pyridine-2ca rbony l]a mino]propa n oat e	X.08	0.1 +0.03	20	0	90	20
[(1S,2S)-2-(4-fiuoro-2methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3(acetoxymethoxy)-4methoxy-pyridine-2carbonyl]amino]propanoat e	X.08	0.3 + 0.03	70	0	100	70

100

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity W
ppm	B	A	B + A
[(1S,2S)-2-(4-fluoro-2methy l-pheny 1)-1,3dimethyl-butyl] (2S)-2-[[3(acetoxymethoxy)-4methoxy-pyridine-2carbonyl]amino]propanoat e	X.08	0.1 + 0.1	20	0	90	20
[(1S,2S)-2-(4-fluoro-2methyl-phenyl)-1,3dimethyl-butyI] (2S)-2-[[3(acetoxymethoxy)-4methoxy-pyridine-2carbonyl]amino]propanoat e	X.08	0.3 + 0.1	70	0	90	70

Table B1-4

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity W
ppm	B	A	B + A
chlorothalonil	X.06	0.1 + 0.03	0	20	20	20
chlorothalonil	X.06	0.3 + 0.03	20	20	100	36
fludioxonil	X.06	0.1 +0.03	0	20	50	20
fludioxonil	X.06	0.3 + 0.03	0	20	70	20
sulphur	X.06	0.1 +0.03	0	20	50	20
sulphur	X.06	0.3 + 0.03	0	20	90	20
prothioconazole	X.06	0.1 +0.03	20	20	70	36
prothioconazole	X.06	0.3 + 0.03	50	20	90	60
copper oxychloride	X.06	0.1 + 0.03	0	20	20	20
copper oxychloride	X.06	0.3 + 0.03	0	20	50	20
benzovindiflupyr	X.06	0.1 + 0.03	50	20	70	60
benzovindiflupyr	X.06	0.3 + 0.03	100	20	100	100
pydiflumetofen	X.06	0.1 +0.03	0	20	20	20

101

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
pydiflumetofen	X.06	0.3 + 0.03	0	20	50	20
fluxapyroxad	X.06	0.1 +0.03	0	20	20	20
fluxapyroxad	X.06	0.3 + 0.03	0	20	50	20
ipfiufenoquin	X.06	0.1 + 0.03	20	20	100	36
ipfiufenoquin	X.06	0.3 + 0.03	100	20	100	100
aminopyrifen	X.06	0.1 + 0.03	20	20	70	36
aminopyrifen	X.06	0.3 + 0.03	50	20	90	60
[(1S,2S)-2-(4-fluoro-2methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[]3(acetoxymethoxy)-4methoxy-pyridine-2carbonyl]ami no] propanoate	X.06	0.1 + 0.03	20	20	90	36
[(1S,2S)-2-(4-fluoro-2methy l-pheny 1)-1,3dimethyl-butyl] (2S)-2-[[3(acetoxymethoxy)-4methoxy-py rid ine-2carbonyl]amino]propanoate	X.06	0.3 + 0.03	70	20	90	76

Table B1-5

Component B	Component A	Concentration (B+A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
chlorothalonil	X.10	0.1 +0.03	0	0	0	0
chlorothalonil	X.10	0.3 + 0.03	20	0	100	20
trinexapac-ethyl	X.10	0.1 +0.03	0	0	0	0
trinexapac-ethyl	X.10	0.3 + 0.03	0	0	20	0
trifloxystrobin	X.10	0.1 +0.03	90	0	90	90
trifloxystrobin	X.10	0.3 + 0.03	90	0	100	90
picoxystrobin	X.10	0.1 +0.03	90	0	90	90
picoxystrobin	X.10	0.3 + 0.03	90	0	100	90
benzovindiflupyr	X.10	0.1 +0.03	50	0	70	50
benzovindiflupyr	X.10	0.3 + 0.03	100	0	100	100

102

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
ipflufenoquin	X.10	0.1 + 0.03	20	0	50	20
ipflufenoquin	X.10	0.3 + 0.03	100	0	100	100
metyltetraprole	X.10	0.1 +0.03	90	0	90	90
metyltetraprole	X.10	0.3 + 0.03	90	0	100	90

Example B2: Preventative activity against Septoria glycines (brown spot):

Conidia of the fungus harvested from a fresh culture grown on artificial media, were directly mixed into 5 nutrient broth (PDB potato dextrose broth). A DMSO solution of the test compounds was placed into a microtiter plate (96-well format) and the nutrient broth containing the fungal spores was added to it. The test plates were incubated at 24 °C and the inhibition of growth was determined photometrically after 72 hrs.

The following mixture compositions (B:A) at the reported concentration (in ppm) in table B2-1 gave at least 80% disease control in this test (Septoria glycines).

Table B2-1

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
glyphosate	X.01	10 : 3	0.1 +0.03
glyphosate	X.01	10 : 1	0.3 + 0.03
glyphosate	X.01	1 : 1	0.1 +0.1
glyphosate	X.01	3 : 1	0.3 + 0.1
chlorothaionil	X.01	10 : 3	0.1 +0.03
chlorothaionil	X.01	10 : 1	0.3 + 0.03
chlorothaionil	X.01	1 : 1	0.1 +0.1
chlorothaionil	X.01	3 : 1	0.3 + 0.1
mancozeb	X.01	10 : 3	0.1 +0.03
mancozeb	X.01	10 : 1	0.3 + 0.03
mancozeb	X.01	1 : 1	0.1 +0.1
mancozeb	X.01	3 : 1	0.3 + 0.1
propiconazole	X.01	10 : 3	0.1 +0.03
propiconazole	X.01	10 :1	0.3 + 0.03
propiconazole	X.01	1 : 1	0.1 +0.1

103

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
propiconazole	X.01	3 : 1	0.3 + 0.1
disodium phosphonate	X.01	10 : 3	0.1 +0.03
disodium phosphonate	X.01	10 : 1	0.3 + 0.03
disodium phosphonate	X.01	1 : 1	0.1 +0.1
disodium phosphonate	X.01	3 : 1	0.3 + 0.1
fenpropimorph	X.01	10 : 3	0.1 +0.03
fenpropimorph	X.01	10 : 1	0.3 + 0.03
fenpropimorph	X.01	t : 1	0.1 + 0.1
fenpropimorph	X.01	3 : 1	0.3 + 0.1
fenpropidin	X.01	10 : 3	0.1 + 0.03
fenpropidin	X.01	10 : 1	0.3 + 0.03
fenpropidin	X.01	1 : 1	0.1 +0.1
fenpropidin	X.01	3 : 1	0.3 + 0.1
hexaconazole	X.01	10 : 3	0.1 +0.03
hexaconazole	X.01	10 : 1	0.3 + 0.03
hexaconazole	X.01	1 : 1	0.1 +0.1
hexaconazole	X.01	3 : 1	0.3 + 0.1
paclobutrazol	X.01	10 : 3	0.1 +0.03
paclobutrazol	X.01	10 : 1	0.3 + 0.03
paclobutrazol	X.01	1 : 1	0.1 + 0.1
paclobutrazol	X.01	3 : 1	0.3 + 0.1
trinexapac-ethyl	X.01	10 : 3	0.1 + 0.03
trinexapac-ethyl	X.01	10 : 1	0.3 + 0.03
trinexapac-ethyl	X.01	1 : 1	0.1 + 0.1
trinexapac-ethyl	X.01	3 : 1	0.3 + 0.1
flutriafol	X.01	10 : 3	0.1 +0.03
flutriafol	X.01	10 : 1	0.3 + 0.03
flutriafol	X.01	1 : 1	0.1 +0.1
flutriafol	X.01	3 : 1	0.3 + 0.1
difenoconazole	X.01	10 : 3	0.1 +0.03
difenoconazole	X.01	10 : 1	0.3 + 0.03
difenoconazole	X.01	1 : 1	0.1 +0.1
difenoconazole	X.01	3 : 1	0.3 + 0.1
fludioxonil	X.01	10 : 3	0.1 +0.03

104

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
fludioxonil	X.01	10 :1	0.3 + 0.03
fludioxonil	X.01	1 : 1	0.1 +0.1
fludioxoni I	X.01	3 : 1	0.3 + 0.1
cyproconazole	X.01	10 : 3	0.1 +0.03
cyproconazole	X.01	10 : 1	0.3 + 0.03
cyproconazole	X.01	1 : 1	0.1 +0.1
cyproconazole	X.01	3 : 1	0.3 + 0.1
acibenzolar S-methyl	X.01	10 : 3	0.1 + 0.03
acibenzolar S-methyl	X.01	10 : 1	0.3 + 0.03
acibenzolar S-methyl	X.01	1 ; 1	0.1 +0.1
acibenzolar S-methyl	X.01	3 ; 1	0.3 + 0.1
trifloxystrobin	X.01	10 : 3	0.1 +0.03
trifloxystrobin	X.01	10 : 1	0.3 + 0.03
trifloxystrobin	X.01	1 ; 1	0.1 +0.1
trifloxystrobin	X.01	3 : 1	0.3 + 0.1
folpet	X.01	10 : 3	0.1 +0.03
folpet	X.01	10 : 1	0.3 + 0.03
folpet	X.01	1 : 1	0.1 +0.1
folpet	X.01	3 : 1	0.3 + 0.1
azoxystrobïn	X.01	10 : 3	0.1 + 0.03
azoxystrobïn	X.01	10 : 1	0.3 + 0.03
azoxystrobïn	X.01	1 : 1	0.1 + 0.1
azoxystrobïn	X.01	3 : 1	0.3 + 0.1
pyraclostrobîn	X.01	10 : 3	0.1 +0.03
pyraclostrobîn	X.01	10 : 1	0.3 + 0.03
pyraclostrobîn	X.01	1 : 1	0.1 +0.1
pyraclostrobîn	X.01	3 : 1	0.3 + 0.1
picoxystrobin	X.01	10 : 3	0.1 +0.03
picoxystrobin	X.01	10 : 1	0.3 + 0.03
picoxystrobin	X.01	1 : 1	0.1 +0.1
picoxystrobin	X.01	3 : 1	0.3 + 0.1
sulphur	X.01	10 : 3	0.1 +0.03
sulphur	X.01	10 : 1	0.3 + 0.03
sulphur	X.01	1 : 1	0.1 +0.1

105

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
sulphur	X.01	3 : 1	0.3 + 0.1
tebuconazole	X.01	10 : 3	0.1 + 0.03
tebuconazole	X.01	10 : 1	0.3 + 0.03
tebuconazole	X.01	1 : 1	0.1 +0.1
tebuconazole	X.01	3 : 1	0.3 + 0.1
prothioconazole	X.01	10 : 3	0.1 +0,03
prothioconazole	X.01	10 : 1	0.3 + 0.03
prothioconazole	X.01	1 : 1	0,1 +0.1
prothioconazole	X.01	3 : 1	0.3 + 0.1
fluopyram	X.01	10 : 3	0.1 +0.03
fluopyram	X.01	10 : 1	0.3 + 0.03
fluopyram	X.01	1 : 1	0.1 +0.1
fluopyram	X.01	3 : 1	0.3 + 0.1
copper oxychloride	X.01	10 : 3	0.1 + 0.03
copper oxychloride	X.01	10 : 1	0.3 + 0.03
copper oxychloride	X.01	1 : 1	0.1 + 0.1
copper oxychloride	X.01	3 : 1	0.3 + 0.1
benzovindiflupyr	X.01	10 : 3	0.1 + 0.03
benzovindiflupyr	X.01	10 : 1	0.3 + 0.03
benzovindiflupyr	X.01	1 : 1	0.1 +0.1
benzovindiflupyr	X.01	3 : 1	0.3 + 0.1
isopyrazam	X.01	10 : 3	0.1 +0.03
isopyrazam	X.01	10 : 1	0.3 + 0,03
isopyrazam	X.01	1 : 1	0.1 +0.1
isopyrazam	X.01	3 : 1	0.3 + 0,1
pydiflumetofen	X.01	10 : 3	0.1 +0.03
pydiflumetofen	X.01	10 : 1	0.3 + 0.03
pydiflumetofen	X.01	1 : 1	0.1 +0.1
pydiflumetofen	X.01	3 : 1	0.3 + 0,1
fluxapyroxad	X.01	10 : 3	0.1 +0.03
fluxapyroxad	X.01	10 : 1	0.3 + 0.03
fluxapyroxad	X.01	1 : 1	0.1 +0.1
fluxapyroxad	X.01	3 : 1	0.3 + 0.1
quinofumelin	X.01	10 : 3	0.1 +0,03

106

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B; A)
quinofumelin	X.01	10 : 1	0.3 + 0.03
quinofumelin	X.01	1 : 1	0.1 +0.1
quinofumelin	X.01	3 : 1	0.3 + 0.1
isoflucypram	X.01	10 : 3	0.1 +0.03
isoflucypram	X.01	10 :1	0.3 + 0.03
isoflucypram	X.01	1 : 1	0 1 +0.1
isoflucypram	X.01	3 : 1	0.3+ 0.1
mefentrifluconazole	X.01	10 : 3	0.1 + 0.03
mefentrifluconazole	X.01	10 : 1	0.3 + 0.03
mefentrifluconazole	X.01	1 : 1	0.1 + 0.1
mefentrifluconazole	X.01	3 : 1	0.3 + 0.1
ipflufenoquin	X.01	10 : 3	0.1 +0.03
ipflufenoquin	X.01	10 : 1	0.3 + 0.03
ipflufenoquin	X.01	1 : 1	0.1 +0.1
ipflufenoquin	X.01	3 ; 1	0.3 + 0.1
metyltetraprole	X.01	10 : 3	0.1 +0.03
metyltetraprole	X.01	10 : 1	0.3 + 0.03
metyltetraprole	X.01	1 : 1	0.1 +0.1
metyltetraprole	X.01	3 : 1	0.3 + 0.1
aminopyrifen	X.01	10 ; 3	0.1 +0.03
aminopyrifen	X.01	10 :1	0.3 + 0.03
aminopyrifen	X.01	1 : 1	0.1 +0.1
aminopyrifen	X.01	3 : 1	0.3 + 0.1
florylpicoxamid	X.01	10 : 3	0.1 +0.03
florylpicoxamid	X.01	10 :1	0.3 + 0.03
florylpicoxamid	X.01	1 : 1	0.1 +0.1
florylpicoxamid	X.01	3 : 1	0.3 + 0.1
florylpicoxamid	X.01	1:50	0.02+0.1
florylpicoxamid	X.01	1:25	0.02+0.05
florylpicoxamid	X.01	2:25	0.02+0.025
florylpicoxamid	X.01	4:25	0.02+0.0125
florylpicoxamid	X.01	8:25	0.02+0.00625
florylpicoxamid	X.01	1:100	0.01+0.1
florylpicoxamid	X.01	1:50	0.01+0.05

107

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
florylpicoxamid	X.01	1:25	0.01+0.025
florylpicoxamid	X.01	2:25	0.01+0.0125
2-[6-(4-bromophenoxy)-2-(trifliJOromethyl)-3pyridyl]-1-(1,2,4-triazoM-yl)propan-2-ol	X.01	10 : 3	0.1 + 0.03
2-[6-(4-bromophenoxy)-2-(trif]uofomethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.01	10 : 1	0.3 + 0.03
2-[6-(4~bromopfienoxy)-2-(trifluoromethyl)-3pyridyl]-1 -(1,2,4-tnazoH-yl)propan-2-ol	X.01	1 : 1	0.1 +0.1
2-[6-(4-bromophenoxy)-2-(lrifluoromethyl)-3pyridyl]-1-(1 ^A-triazoM-yOpropan^-ol	X.01	3 : 1	0.3 + 0.1
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethykbutyl] (2S)-2-[[3-(acetoxymethoxy)-4mefhoxy-pyridine-2-carbonyl]amino]propanoate	X.01	10 : 3	0.1 + 0.03
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-cait>onyl]amino]propanoate	X.01	10 : 1	0.3 + 0.03
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3- dimethyl-butyl] (2S)-2-[[3-(acefoxymethoxy)-4- methoxy-pyridine-2-carbonyl]amino]propanoate	X.01	1 : 1	0.1 +0.1
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyrid in e-2-carbonyl]amîno] propanoate	X.01	3 : 1	0.3 + 0.1
(Z,2E)-5-[T(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.01	10 : 3	0.1 +0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazo!-3-yl]oxy- 2’methoxyimino-N,3-dimethyl-pent-3-enamide	X.01	10 : 1	0.3 + 0.03
(Z,2E)5-[1-(2,4-dichlorophenyl)pyrazol-3-y!]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.01	1 : 1	0.1 +0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-y!]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.01	3 : 1	0.3 + 0.1
[(1 S,2S)-1 -methyl-2-(o-tolyl)propylJ (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.01	6:10	0.06+0,1

108

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2- ca rbony Daminolpropanoate	X.01	6:5	0.06+0.05
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.01	12:5	0.06+0.025
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propa noy loxy-py ridine-2carbony[)amino]propanoate	X.01	24.5	0.06+0.0125
[(1S,2S)-1-methyl-2-(0-tOlyl)propylj (2S)-2-[(4met h oxy- 3- p ro p a η o y ioxy- py rid i n e-2carbonyl)amino]propanoate	X.01	48:5	0.06+0.00625
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4meth oxy-3-propanoy loxy-py rid ine-2carbonyl)amino]propanoate	X.01	3:10	0.03+0.1
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4metboxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.01	3:5	0.03+0.05
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-pro pa noy loxy-py ridine-2carbonyl)amino]propanoate	X.01	6:5	0.03+0.025
[(1S,2S)-1-methyl-2-(o-tolyi)propyî] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.01	12:5	0.03+0.0125
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl] benza mide	X.01	200:1	20+0.1
N-^-fluorophenyiHqS-Qrifliiorornethylj-I^Aoxadiazol-3-yl]benzamide	X.01	400:1	20+0.05
N-(2-fluorophenyl)-4-[5-(trifluorometh y 1)-1,2,4oxadiazo l-3-y I] benza mide	X.01	800:1	20+0.025
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxad iazo l-3-y I] benza mid e	X.01	1600:1	20+0.0125
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yllbenzamide	X.01	100:1	10+0.1

109

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
N-(2-fluorophenylH-[5-(trifluoromethyl)-1,2,4oxadiazol-S-yllbenzamide	X.01	200:1	10+0.05
N-(2-fluorophenyi)-4-[5-(trifluoromethyl)-1,2_l4oxadiazol-3-ylJbenzamide	X.01	400:1	10+0.025
N-(2-fluorophenyl)-4-[5~(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.01	800:1	10+0.0125
glyphosate	X.08	3 ; 1	0.3 + 0.1
chlorothalonil	X.08	10 : 1	0.3 + 0.03
chlorothalonil	X.08	1 : 1	0.1 +0.1
chlorothalonil	X.08	3 : 1	0.3 + 0.1
mancozeb	X.08	1 : 1	0.1 +0.1
mancozeb	X.08	3 : 1	0.3 + 0.1
propiconazole	X.08	10 : 3	0.1 +0.03
propiconazole	X.08	10 : 1	0.3 + 0.03
propiconazole	X.08	1 : 1	0.1 + 0.1
propiconazole	X.08	3 : 1	0.3 + 0.1
fenpropimorph	X.08	10 : 3	0.1 + 0.03
fenpropimorph	X.08	10 : 1	0.3 + 0.03
fenpropimorph	X.08	1 : 1	0.1 + 0.1
fenpropimorph	X.08	3 : 1	0.3 + 0.1
fenpropidin	X.08	10 : 1	0.3 + 0.03
fenpropidin	X.08	3 : 1	0.3 + 0.1
hexaconazole	X.08	10 : 3	0.1 +0.03
hexaconazole	X.08	10 : 1	0.3 + 0.03
hexaconazole	X.08	1 : 1	0.1 +0.1
hexaconazole	X.08	3 : 1	0.3 + 0.1
paclobutrazol	X.08	3 : 1	0.3 + 0.1
trinexapac-ethyl	X.08	3 : 1	0.3 + 0.1
flutriafol	X.08	10 : 1	0.3 + 0.03
flutriafol	X.08	1 : 1	0.1 +0.1
flutriafol	X.08	3 : 1	0.3 + 0.1
difenoconazole	X.08	10 : 3	0.1 +0.03
difenoconazole	X.08	10 : 1	0.3 + 0.03
difenoconazole	X.08	1 : 1	0.1 + 0.1

110

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B : A)
difenoconazole	X.08	3 : 1	0.3 + 0.1
fludioxonil	X.08	1 : 1	0.1 +0.1
fludioxonil	X.08	3 : 1	0.3 + 0.1
cyproconazole	X.08	10 : 1	0.3 + 0.03
cyproconazole	X.08	1 : 1	0.1 +0.1
cyproconazole	X.08	3 : 1	03 + 0.1
trifloxystrobin	X.08	10 : 3	0.1 +0.03
trifloxystrobin	X.08	10 : 1	0.3 + 0.03
trifloxystrobin	X.08	1 : 1	0.1 + 0.1
trifloxystrobin	X.08	3 : 1	0.3 + 0.1
folpet	X.08	10 : 1	0.3 + 0.03
folpet	X.08	3 : 1	0.3 + 0.1
azoxystrobin	X.08	10 : 1	0.3 + 0.03
azoxystrobin	X.08	1 : 1	0.1 +0.1
azoxystrobin	X.08	3 : 1	0.3 + 0.1
pyraclostrobin	X.08	10 : 3	0.1 +0.03
pyraclostrobin	X.08	10 ; 1	0.3 + 0.03
pyraclostrobin	X.08	1 : 1	0.1 +0.1
pyraclostrobin	X.08	3 ; 1	0.3 + 0.1
picoxystrobin	X.08	10 : 3	0.1 +0.03
picoxystrobin	X.08	10 :1	0.3 + 0.03
picoxystrobin	X.08	1 : 1	0.1 + 0.1
picoxystrobin	X.08	3 : 1	0.3 + 0.1
sulphur	X.08	3 : 1	0.3 + 0.1
tebuconazole	X.08	10 : 3	0.1 +0.03
tebuconazole	X.08	10 : 1	0.3 + 0.03
tebuconazole	X.08	1 : 1	0.1 + 0.1
tebuconazole	X.08	3 : 1	0.3 + 0.1
prothioconazole	X.08	10 : 3	0.1 + 0.03
prothioconazole	X.08	10 : 1	0.3 + 0.03
prothioconazole	X.08	1 : 1	0.1 + 0.1
prothioconazole	X.08	3 : 1	0.3 + 0.1
fluopyram	X.08	3 : 1	0.3 + 0.1
copper oxychloride	X.08	3 : 1	0.3 + 01

111

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
benzovindiflupyr	X.08	10 : 3	0.1 +0.03
benzovindiflupyr	X.08	10 : 1	0.3 + 0.03
benzovindiflupyr	X.08	1 : 1	0.1 + 0.1
benzovindiflupyr	X.08	3 : 1	0.3 + 0.1
isopyrazam	X.08	10 : 3	0.1 +0.03
isopyrazam	X.08	10 : 1	0.3 + 0.03
isopyrazam	X.08	1 : 1	0.1 + 0.1
isopyrazam	X.08	3 : 1	0.3 + 0.1
pydiflumetofen	X.08	10 : 3	0.1 + 0.03
pydiflumetofen	X.08	10 : 1	0.3 + 0.03
pydiflumetofen	X.08	1 : 1	0.1 +0.1
pydiflumetofen	X.08	3 : 1	0.3 + 0.1
fluxapyroxad	X.08	10 ; 1	0.3 + 0.03
fluxapyroxad	X.08	1 : 1	0.1 +0.1
fluxapyroxad	X.08	3 : 1	0.3 + 0.1
isoflucypram	X.08	10 : 3	0.1 +0.03
isoflucypram	X.08	10 : 1	0.3 + 0.03
isoflucypram	X.08	1 : 1	0.1 + 0.1
isoflucypram	X.08	3 : 1	0.3 + 0.1
mefentriflucon azoie	X.08	10 : 3	0.1 + 0.03
mefentriflucon azole	X.08	10 : 1	0.3 + 0.03
mefentrifluconazole	X.08	1 : 1	0.1 + 0.1
mefe ntrifluco n azo le	X.08	3 : 1	0.3 + 0.1
ipflufenoquin	X.08	10 ; 3	0.1 +0.03
ipflufenoquin	X.08	10 : 1	Û.3 + 0.03
ipflufenoquin	X.08	1 : 1	0.1 +0.1
ipflufenoquin	X.08	3 : 1	0.3 + 0,1
metyltetraprole	X.08	10 : 3	0.1 +0.03
metyltetraprole	X.08	10 :1	0.3 + 0.03
metyltetraprole	X.08	1 : 1	0.1 +0.1
metyltetraprole	X.08	3 : 1	03 + 0.1
aminopyrifen	X.08	3 : 1	0.3 + 0.1
florylpicoxamid	X.08	10 : 3	0.1 +0.03
florylpicoxamid	X.08	10 ; 1	0.3 + 0.03

112

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
florylpicoxamid	X.08	1 : 1	0.1 +0.1
florylpicoxamid	X.08	3 ; 1	0.3 + 0.1
florylpicoxamid	X.08	1:10	0.02+0.2
florylpicoxamid	X.08	1:5	0.02+0.1
florylpicoxamid	X.08	2:5	0.02+0.05
florylpicoxamid	X.08	4:5	0.02+0.025
florylpicoxamid	X.08	8:5	0.02+0.0125
florylpicoxamid	X.08	1:20	0.01+0.2
florylpicoxamid	X.08	1:10	0.01+0.1
florylpicoxamid	X.08	1:5	0.01+0,05
florylpicoxamid	X.08	2:5	0.01+0.025
florylpicoxamid	X.08	4:5	0.01+0.0125
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1 -(1,2_T4-triazol~1 -yl)propan~2-ol	X.08	10 : 3	0.1 +0.03
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1 -(1,2,4-triazol-1 -yl)propan-2-ol	X.08	10 : 1	0.3 + 0.03
2-[6-(4-bromophenoxy)-2-(trifiuoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.08	1 : 1	0.1 + 0.1
2-[6-(4-bromophenoxy)-2-(trïfluoromethyl)-3pyridyl]-!-(1,2,44riazol-1-yi)propan-2-ol	X.08	3 : 1	0.3 + 0.1
[(1S_>2S)-2-(4-fluoro-2-methy^phenyl)-1_I3- dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyridine-2-carbonyl]amino]propanoate	X.08	10 : 3	0.1 +0.03
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-cafbonyl]amino]propanoate	X.08	10 : 1	0.3 + 0.03
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-buîyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.08	1 : 1	0.1 +0.1
[(1 S,2S)-2-(4-fluoro-2-methyl’phenyl)-1,3dimethyl-bulyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]aminû]propanoate	X.08	3 : 1	0.3 + 0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dîmethyl-pent-3-enamide	X.08	10 : 3	0.1 +0.03

113

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
(Z,2E)-541-(2,4-dichlorophenyl)pyrazo!-3-yl]oxy- 2-methoxyimino-N,3-dimettiyl-pent-3-enamide	X.08	10 : 1	0.3 + 0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.08	1 : 1	0.1 +0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.08	3 : 1	0.3 + 0.1
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2- carbonyl)amino] propan oate	X.08	3:10	0.06+0.2
[(1 S,2S)-1-mettiyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3'propanoyloxy-pyridine-2- carbonyl)aminolpropanoate	X.08	3:5	0.06+0.1
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.08	6:5	0.06+0.05
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.08	12:5	0.06+0.025
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2- carbonyl)amino]propanoate	X.08	24:5	0.06+0.0125
[(1S,2S)-1-methy[-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyi)amino]propanoate	X.08	3:20	0.03+0.2
[(1S,2S)-Tmethyi-2-(o-tolyl)propyl] (2S>-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.08	3:10	0.03+0.1
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.08	6:10	0.03+0.05
[(IS^SM-mettiyl-Z-ÎO-tolyOpropyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)aminolpropanoate	X.08	12:10	0.03+0.025

114

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B; A)
[(1S,2S)-1-methyl-2-(o-tolyl)propyl) (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.08	24110	0.03+0.0125
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yi]benzamide	X.08	100:1	20+0.2
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.08	200:1	20+0.1
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.08	400:1	20+0.05
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.08	800:1	20+0.025
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-y)]benzamide	X.08	50:1	10+0.2
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.08	100:1	10+0.1
N-(2-iluorophenyl)-4-[5-(trifluoromethyi)-1,2,4oxadiazol-3-yl]benzamide	X.08	200:1	10+0.05
N-(2-fluorophenyl)-4-[5-(trifluoromethyi)-1,2,4oxadiazol-3-yl]benzamide	X.08	400:1	10+0.025
glyphosate	X.06	10 : 3	0.1 +0.03
glyphosate	X.06	10 : 1	0.3 + 0.03
glyphosate	X.06	1 : 1	0.1 +0.1
glyphosate	X.06	3 ; 1	0.3 + 0.1
chlorothalonil	X.06	10 : 3	0.1 +0.03
chlorothalonil	X.06	10 : 1	0.3 + 0.03
chlorothalonil	X.06	1 : 1	0.1 +0.1
chlorothalonil	X.06	3 : 1	0.3 + 0.1
mancozeb	X.06	10 ; 3	0.1 +0.03
mancozeb	X.06	10 : 1	0.3 + 0.03
mancozeb	X.06	1 ; 1	0.1 +0.1
mancozeb	X.06	3 : 1	0.3 + 0.1
propiconazole	X.06	10 : 3	0.1 +0.03
propiconazole	X.06	10 : 1	0.3 + 0.03
propiconazole	X.06	1 : 1	0.1 +0.1

115

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
propiconazole	X.06	3 : 1	0.3 + 0.1
disodium phosphonate	X.06	10 : 3	0.1 +0.03
disodium phosphonate	X.06	10 : 1	0.3 + 0.03
disodium phosphonate	X.06	1 : 1	0.1 +0.1
disodium phosphonate	X.06	3 : 1	03 + 0.1
fenpropimorph	X.06	10 : 3	0.1 +0.03
fenpropimorph	X.06	10 : 1	0.3 + 0.03
fenpropimorph	X.06	1 : 1	0.1 + 0.1
fenpropimorph	X.06	3 : 1	0.3 + 0.1
fenpropidin	X.06	10 : 3	0.1 + 0.03
fenpropidin	X.06	10 : 1	0.3 + 0.03
fenpropidin	X.06	1 : 1	0.1 +0.1
fenpropidin	X.06	3 : 1	0.3 + 0.1
hexaconazole	X.06	10 : 3	0.1 +0.03
hexaconazole	X.06	10 ; 1	0.3 + 0.03
hexaconazole	X.06	1 : 1	0.1 +0.1
hexaconazole	X.06	3 : 1	0.3 + 0.1
paclobutrazol	X.06	10 ; 3	0.1 +0.03
paclobutrazol	X.06	10 ; 1	0.3 + 0.03
paclobutrazol	X.06	1 : 1	0.1 +0.1
paclobutrazol	X.06	3 : 1	0.3 + 0.1
trinexapac-ethyl	X.06	10 : 3	0.1 +0.03
trinexapac-ethyl	X.06	10 : 1	0.3 + 0.03
trinexapac-ethyl	X.06	1 : 1	0.1 +0.1
trinexapac-ethyl	X.06	3 : 1	0.3 + 01
flutriafol	X.06	10 : 3	0.1 + 0.03
flutriafol	X.06	10 : 1	0.3 + 0.03
flutriafol	X.06	1 : 1	0.1 + 0.1
flutriafol	X.06	3 : 1	0.3 + 0.1
difenoconazole	X.06	10 : 3	0.1 + 0.03
difenoconazole	X.06	10 : 1	0.3 + 0.03
difenoconazole	X.06	1 : 1	0.1 + 0.1
difenoconazole	X.06	3 : 1	0.3 + 0.1
fludioxonil	X.06	10 : 3	0.1 + 0.03

116

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
fludioxonil	X.06	10 : 1	0.3 + 0.03
fludioxonil	X.06	1 : 1	0.1 + 0.1
fludioxonil	X.06	3 : 1	0.3 + 0.1
cyproconazole	X.06	10 : 3	0.1 + 0.03
cyproconazole	X.06	TO : 1	0.3 + 0.03
cyproconazole	X.06	1 : 1	0.1 +0.1
cyproconazole	X.06	3 : 1	0.3 + 0.1
acibenzolar S-methyl	X.06	1 : 1	0.1 +0.1
acibenzolar S-methyl	X.06	3 : 1	0.3 + 0.1
trifloxystrobin	X.06	10 : 3	0.1 +0.03
trifloxystrobin	X.06	10 : 1	0.3 + 0.03
trifloxystrobin	X.06	1 : 1	0.1 + 0.1
trifloxystrobin	X.06	3 : 1	03 + 0.1
folpet	X.06	10 : 1	0.3 + 0.03
folpet	X.06	1 : 1	0.1 +0.1
folpet	X.06	3 : 1	0.3 + 0.1
azoxystrobin	X.06	10 : 3	0.1 +0.03
azoxystrobin	X.06	10 ; 1	0.3 + 0.03
azoxystrobin	X.06	1 ; 1	0.1 +0.1
azoxystrobin	X.06	3 : 1	0.3 + 0.1
pyraclostrobin	X.06	10 : 3	0.1 +0.03
pyraclostrobin	X.06	10 : 1	0.3 + 0.03
pyraclostrobin	X.06	1 : 1	0.1 +0.1
pyraclostrobin	X.06	3 : 1	0.3 + 01
picoxystrobin	X.06	10 : 3	0.1 + 0.03
picoxystrobin	X.06	10 : 1	0.3 + 0.03
picoxystrobin	X.06	1 : 1	0.1 + 0.1
picoxystrobin	X.06	3 : 1	0.3 + 01
sulphur	X.06	10 : 3	0.1 + 0.03
sulphur	X.06	10 : 1	0.3 + 0.03
sulphur	X.06	1 : 1	0.1 +0.1
sulphur	X.06	3 : 1	0.3 + 0.1
tebuconazole	X.06	10 : 3	0.1 +0.03
tebuconazole	X.06	10 : 1	0.3 + 0.03

117

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
tebuconazole	X.06	1 : 1	0.1 +0.1
tebuconazole	X.06	3 : 1	0.3 + 0.1
prothioconazole	X.06	10 : 3	0.1 + 0.03
prothioconazole	X.06	10 : 1	0.3 + 0.03
prothioconazole	X.06	1 : 1	0.1 +0.1
prothioconazole	X.06	3 : 1	0.3 + 0.1
fluopyram	X.06	10 : 3	0.1 +0.03
fluopyram	X.06	10 : 1	0.3 + 0.03
fluopyram	X.06	1 : 1	0.1 +0.1
fluopyram	X.06	3 : 1	0.3 + 0.1
copper oxychloride	X.06	10 : 3	0.1 +0.03
copper oxy ch loride	X.06	10 : 1	0.3 + 0.03
copper oxychloride	X.06	1 : 1	0.1 +0.1
copper oxychloride	X.06	3 : 1	0.3 + 0.1
benzovindiflupyr	X.06	10 : 3	0.1 + 0.03
benzovindiflupyr	X.06	10 ; 1	0.3 + 0.03
benzovindiflupyr	X.06	1 : 1	0.1 + 0.1
benzovindiflupyr	X.06	3 : 1	0.3 + 0,1
isopyrazam	X.06	10 : 3	0.1 +0.03
isopyrazam	X.06	10 : 1	0.3 + 0.03
isopyrazam	X.06	1 : 1	0.1 +0.1
isopyrazam	X.06	3 : 1	0.3 + 0.1
pydiflumetofen	X.06	10 : 3	0.1 +0.03
pydiflumetofen	X.06	10 : 1	0.3 + 0.03
pydiflumetofen	X.06	1 : 1	0.1 +0.1
pydiflumetofen	X.06	3 : 1	0.3 + 0.1
fluxapyroxad	X.06	10 : 3	0.1 +0.03
fluxapyroxad	X.06	TO : 1	0.3 + 0.03
fluxapyroxad	X.06	1 : 1	0.1 +0.1
fluxapyroxad	X.06	3 : t	0.3 + 0.1
quinofumelin	X.06	10 : 3	0.1 +0.03
quinofumelin	X.06	10 : 1	0.3 + 0.03
quinofumelin	X.06	1 : 1	0.1 +0.1
quinofumelin	X.06	3 : 1	0.3 + 0.1

117

118

Component B	Component A (compound)	Ratio B:A	Conc, (ppm) (B : A)
isoflucypram	X.06	10 : 3	0.1 +0,03
isoflucypram	X.06	10 : 1	0,3 + 0,03
isoflucypram	X.06	1 : 1	0.1 + 0.1
isoflucypram	X.06	3 : 1	03 + 0.1
mefentriflucon azo le	X.06	10 ; 3	0.1 +0.03
mefentriflucon azole	X.06	10 : 1	0.3 + 0.03
mefentriflucon azole	X.06	1 : 1	0.1 + 0.1
mefentriflucon azole	X.06	3 : 1	0.3 + 0.1
ipflufenoquin	X.06	10 : 3	0.1 + 0.03
ipflufenoquin	X.06	10 : 1	0.3 + 0.03
ipflufenoquin	X.06	1 : 1	0.1 +0.1
ipflufenoquin	X.06	3 : 1	0.3 + 0.1
metyltetraprole	X.06	10 : 3	0.1 +0.03
metyltetraprole	X.06	10 : 1	0.3 + 0.03
metyltetraprole	X.06	1 : 1	0.1 +0.1
metyltetraprole	X.06	3 : 1	0.3 + 0.1
aminopyrifen	X.06	10 : 3	0.1 +0.03
aminopyrifen	X.06	10 : 1	0.3 + 0.03
aminopyrifen	X.06	1 : 1	0.1 +0.1
aminopyrifen	X.06	3 : 1	0.3 + 0.1
florylpicoxamid	X.06	10 : 3	0.1 +0.03
florylpicoxamid	X.06	10 : 1	0.3 + 0.03
florylpicoxamid	X.06	1 : 1	0.1 +0.1
florylpicoxamid	X.06	3 : 1	0.3 + 0.1
florylpicoxamid	X.06	1:50	0.02+0.1
florylpicoxamid	X.06	1:25	0.02+0.05
florylpicoxamid	X.06	2:25	0.02+0.025
florylpicoxamid	X.06	4:25	0.02+0.0125
florylpicoxamid	X.06	8:25	0.02+0.00625
florylpicoxamid	X.06	1:100	0.01+0.1
florylpicoxamid	X.06	1:50	0.01+0.05
florylpicoxamid	X.06	1:25	0.01+0.025
florylpicoxamid	X.06	2:25	0,01+0.0125

119

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyi]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.06	10 : 3	0.1 +0.03
2-[6-(4-bromophenoxy)-2-(tritluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.06	10 : 1	0.3 + 0.03
2-[6-(4-bromophenoxy)-2-(tdfluoromethyl)-3pyndyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.06	1 : 1	0.1 +0.1
2-[6-(4-bromophenoxy)-2-(trifluoromethyi)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.06	3 : 1	0.3 + 0.1
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyi]amino]propanoate	X.06	10 : 3	0.1 +0.03
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyndine-2-carbonyl]aminolpropanoate	X.06	10 : 1	0.3 + 0.03
[(1 S,2S)-2-(4-fluoro-2- methy l-phenyl)-1,3- dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-py ridin e-2-ca rbony I] aminojpro pa noate	X.06	1 : 1	0.1 +0.1
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyndine-2-carbonyl]amino]propa noate	X.06	3 : 1	0.3 + 0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.06	10 : 3	0.1 +0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyîmino-N,3-dimethyl-pent-3-enamide	X.06	10 : 1	0.3 + 0.03
(Z,2E)-5-[1-(2₁4-dichlorophenyl)pyrazol-3-yl]oxyZ-methoxyîmino-N.S-dimethyl-pent-S-enamide	X.06	1 : 1	0.1 + 0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2methoxyimino-N,3-dimethyl-pent-3-enamide	X.06	3 : 1	0.3 + 0.1
[(1 S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoy loxy-py ridine-2carbonyl)amino]prapa noate	X.06	6:10	0.06+0.1
Ê(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propa noy loxy-py ridine-2carbonyl)amino]propa noate	X.06	6:5	0.06+0.05

120

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1S,2S)-1-methyl-2-(o-toly!)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.06	12:5	0.06+0.025
[(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.06	24:5	0.06+0.0125
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4me1hoxy-3-propanoyloxy-pyridine-2- carbonyl)amino]propanoate	X.06	48:5	0.06+0.00625
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (25)-24(4- m et h oxy- 3- pro pa n oy I oxy- py rid i n e -2carbonyl)aminolpropanoate	X.06	3:10	0.03+0.1
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.06	3:5	0.03+0.05
[(1S,2S)-1-methyl-2~(o-tolyl)propylJ (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbony!)amino]propanoate	X.06	6:5	0.03+0.025
[(1 S,2S)-1-methy l-2-(o-tolyl) propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.06	12:5	0.03+0.0125
N-(2-fluorophenyl)-445-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.06	200:1	20+0.1
N-(2-fluorophenyl)-4-[5-(trifluoromethy[)-1,2_r4oxadiazol-3-yl]benzamide	X.06	400:1	20+0.05
N-(2-fluorophenyl)-4-[5-(trifluoromethyi)-1,2,4oxadiazol-3-yl]benzamide	X.06	800:1	20+0.025
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3~yl]benzamide	X.06	1600:1	20+0.0125
N-(2-fluorophenyl)-4-[5-(trifluoromettiyf)-1,2_I4oxadiazol-3-yl]benzamide	X.06	100:1	10+0.1
N-(2-fluoropheny!)-4-[5-(Îrifluoromethyl)-1,2_I4oxad iazo l-3-y I] benza mid e	X.06	200:1	10+0.05

121

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazof-3-yl]benzamide	X.06	400:1	10+0.025
N-(2-fluorophenyl)-4-[5-(trif1uoromethyl)-1,2,4oxadiazol-3-yl]benzamîde	X.06	800:1	10+0.0125
glyphosate	X.10	1 ; 1	0.1 +0.1
glyphosate	X.10	3 : 1	0.3 + 0.1
chlorothalonil	X.10	1 ; 1	0.1 +0.1
chlorothalonil	X.10	3 : 1	0.3 + 0.1
mancozeb	X.10	1 : 1	0.1 +0.1
mancozeb	X.10	3 : 1	0.3 + 0.1
propiconazole	X.10	10 : 3	0.1 +0.03
propiconazole	X.10	10 : 1	0.3 + 0.03
propiconazole	X.10	1 : 1	0.1 +0.1
propiconazole	X.10	3 : 1	0.3 + 0.1
disodium phosphonate	X.10	1 : 1	0.1 +0.1
disodium phosphonate	X.10	3 : 1	0.3 + 0.1
fenpropimorph	X.10	1 : 1	0.1 +0.1
fenpropimorph	X.10	3 : 1	0.3 + 0.1
fenpropidîn	X.10	t : 1	0.1 + 0.1
fenpropidîn	X.10	3 : 1	0.3 + 0.1
hexaconazole	X.10	10 : 3	0.1 +0.03
hexaconazole	X.10	10 : 1	0.3 + 0.03
hexaconazole	X.10	1 : 1	0.1 +0.1
hexaconazole	X.10	3 : 1	0.3 + 0.1
paclobutrazol	X.10	1 : 1	0.1 + 0.1
paclobutrazol	X.10	3 : 1	0.3 + 0.1
trinexapac-ethyi	X.10	1 : 1	0.1 + 0.1
trinexapac-ethyl	X.10	3 : 1	0.3 + 0.1
flutriafol	X.10	1 : 1	0.1 + 0.1
flutriafol	X.10	3 : 1	0.3 + 0.1
difenoconazole	X.10	10 : 3	0.1 + 0.03
difenoconazole	X.10	10 ; 1	0.3 + 0.03
difenoconazole	X.10	1 : 1	0.1 +0.1
difenoconazole	X.10	3 : 1	0.3 + 0.1

122

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
fludioxonil	X.10	1 : 1	0.1 +0.1
fludioxonil	X.10	3 : 1	0.3 + 0.1
cyproconazole	X.10	10 : 1	0.3 + 0.03
cyproconazole	X.1D	1 : 1	0.1 +0.1
cyproconazole	X.10	3 : 1	0.3 + 0.1
acibenzolar S-methyl	X.10	1 : 1	0.1 +0.1
acibenzolar S-methyl	X.10	3 : 1	0.3 + 0.1
trifloxystrobin	X.10	10 : 3	0.1 + 0.03
trifloxystrobin	X.10	10 : 1	0.3 + 0,03
trifloxystrobin	X.10	1 : 1	0.1 + 0.1
trifloxystrobin	X.10	3 : 1	0.3 + 0.1
folpet	X.10	1 : 1	0.1 + 0.1
folpet	X.10	3 : 1	0.3 + 0.1
azoxystrobin	X.10	10 : 1	0.3 + 0.03
azoxystrobin	X.10	1 : 1	0.1 +0.1
azoxystrobin	X.10	3 : 1	0.3 + 0.1
pyraclostrobin	X.10	10 : 3	0.1 +0.03
pyraclostrobin	X.10	10 : 1	0.3 + 0.03
pyraclostrobin	X.10	1 : 1	0.1 +0.1
pyraclostrobin	X.10	3 : 1	0.3 + 0.1
picoxystrobin	X.10	10 : 3	0.1 +0.03
picoxystrobin	X.10	10 : 1	0.3 + 0.03
picoxystrobin	X.10	1 : 1	0.1 +0.1
picoxystrobin	X.10	3 : 1	0.3 + 0.1
sulphur	X.10	1 : 1	0.1 +0.1
sulphur	X.10	3 : 1	03 + 0,1
tebuconazole	X.10	10 :1	0.3 + 0.03
tebuconazole	X.10	1 : 1	0.1 + 0.1
tebuconazole	X.10	3 : 1	0.3 + 0.1
prothioconazole	X.10	10 : 3	0.1 +0.03
prothioconazole	X.10	10 : 1	0.3 + 0.03
prothioconazole	X.10	1 : 1	0.1 +0.1
prothioconazole	X.10	3 : 1	0.3 + 0.1
fluopyram	X.10	1 : 1	0.1 +0.1

123

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
fluopyram	X.10	3 : 1	0.3 + 0.1
copper oxychloride	X.10	1 : 1	0.1 + 0.1
copper oxychloride	X.10	3 : 1	0.3 + 0.1
benzovindiflupyr	X.10	1 : 1	0.1 +0.1
benzovindiflupyr	X.10	3 : 1	0.3 + 0.1
isopyrazam	X.10	1 : 1	0.1 +0.1
isopyrazam	X.10	3 : 1	03 + 0.1
pydiflumetofen	X.10	10 : 3	0.1 +0.03
pydiflumetofen	X.10	10 : 1	0.3 + 0.03
pydiflumetofen	X.10	1 : 1	0.1 +0.1
pydiflumetofen	X.10	3 : 1	0.3 + 0.1
fluxapyroxad	X.10	1 : 1	0.1 +0.1
fluxapyroxad	X.10	3 : 1	0.3 + 0.1
quinofumelin	X.10	1 : 1	0.1 +0.1
quinofumelin	X.10	3 ; 1	0.3 + 0.1
isoflucypram	X.10	10 : 1	0.3 + 0.03
isoflucypram	X.10	1 : 1	0.1 +0.1
isoflucypram	X.10	3 : 1	0.3 + 0.1
mefentrifluco n azo le	X.10	10 : 3	0.1 +0.03
mefentrifluconazole	X.10	10 : 1	0.3 + 0.03
mefentrifluconazole	X.10	1 ; 1	0.1 +0.1
mefentrifluconazole	X.10	3 : 1	0.3 + 0.1
ipflufenoquin	X.10	1 : 1	0.1 +0.1
ipflufenoquin	X.10	3 : 1	0.3 + 0.1
metyltetraprole	X.10	10 : 3	0.1 + 0.03
metyltetraprole	X.10	10 : 1	0.3 + 0.03
metyltetra proie	X.10	1 : 1	0.1 +0.1
metyltetraprole	X.10	3 : 1	0.3 + 0.1
aminopyrifen	X.10	1 : 1	0.1 +0.1
aminopyrifen	X.10	3 : 1	0.3 + 0.1
florylpicoxamid	X.10	10 : 3	0.1 + 0.03
florylpicoxamid	X.10	10 : 1	0.3 + 0.03
florylpicoxamid	X.10	1 : 1	0.1 + 0.1
florylpicoxamid	X.10	3 : 1	0.3 + 0.1

124

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B : A)
florylpicoxamid	X.10	1:50	0.02+0.1
florylpicoxamid	X.10	1:25	0.02+0.05
florylpicoxamid	X.10	2:25	0.02+0.025
florylpicoxamid	X.10	4:25	0.02+0.0125
florylpicoxamid	X.10	8:25	0.02+0.00625
florylpicoxamid	X.10	16:25	0.02+0.003125
florylpicoxamid	X.10	1:100	0.01+0.1
florylpicoxamid	X.10	1:50	0.01+0.05
florylpicoxamid	X.10	1:25	0.01+0.025
florylpicoxamid	X.10	2:25	0.01+0.0125
florylpicoxamid	X.10	4:25	0.01+0.00625
florylpicoxamid	X.10	8:25	0.01+0.003125
2-[6-(4-bromophenoxy)'2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan'2-ol	X.10	10 : 3	0.1 +0.03
2-[6-(4-b rom o prie noxy)-2-(tri fluoré methyl)· 3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2’Ol	X.10	10 : 1	0.3 + 0.03
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.10	1 : 1	0.1 +0.1
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]’1-(1,2,4-triazol-1-yl)propan-2-ol	X.10	3 : 1	0.3 + 0.1
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.10	10 : 3	0.1 +0.03
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.10	10 : 1	0.3 + 0.03
[(1 S,2S)-2-(4’fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyrîdine-2-carbonyl]amino] propanoate	X.10	1 : 1	0.1 +0.1
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-py rid ine-2-ca rbonyl]a mi no]pro pa noate	X.10	3 : 1	0.3 + 0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3’yl]oxy- 2-methoxyimînO’N,3-dimethyl-pent-3-enamide	X.10	10 : 3	0.1 +0.03

125

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazo!-3-yl]oxy- 2-methoxyimino-N,3-dimethyi-pent-3-enamide	X.10	10 : 1	0.3 + 0.03
(Z,2E)-5-[1-(2,4-dich!orophenyi)pyrazol-3-yl]oxy- 2-methoxyimrno-N,3-dimethy!-pent-3-enamjde	X.10	1 : 1	0.1 +0.1
(Z,2 E)-5-[1 - (2,4-d ichlorophenyl)py razol-3-y I] oxy2-methoxyimino-N,3-dimethyl·pen^3-enamide	X.10	3 : 1	0.3 + 0.1
[(1 S,2S)-1 -methyl-2-(o-toly[)propyl] (2S)-2-[(4methoxy-3-propa noy loxy- py rid ine-2carbonyl)amino]propanoate	X.10	6:10	0.06+0.1
[(1 S,2S)-1 -methyl-2-(o-toiyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoale	X.10	6:5	0.06+0.05
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyioxy-pyridine-2carbonyl)amino]propanoate	X.10	12:5	0.06+0.025
[(1S,2S)-1-methyl-2-(o-tolyl)propylj (2S)-2-[(4- methoxy-3-propa noy loxy- pyridine-2carbonyl)amino]propanoate	X.10	24:5	0.06+0.0125
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.10	48:5	0.06+0.00625
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-proparioyloxy-pyridine-2carbonyl)amino]propanoate	X.10	96:5	0.06+0.003125
[(1S,2S)-1-methyl-2-(o-tolyi)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.10	3:10	0.03+0.1
[(1S,2S)-1-methyl-2-(o-tolyt)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.10	3:5	0.03+0,05
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4* methoxy-3-propanoyloxy-pyridine-2- carbonyl)amino]propanoate	X.10	6:5	0.03+0.025

126

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.10	12:5	0.03+0.0125
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.10	24:5	0.03+0.00625
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyndine-2carbonyl)amino]piOpanoate	X.10	48:5	0.03+0.003125
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.10	200:1	20+0.1
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yllbenzamide	X.10	400:1	20+0.05
N-(2-fiuorophenyl)-4-[5-(tnfluoromethyl)-1,2,4oxadiazoi-3-yl]benzamide	X.10	800:1	20+0.025
N-(2-fluorophenyl)-4-\|5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.10	1600:1	20+0.0125
N-(2-fl uorophenyl)-4-[5-(trifluoromethy 1)-1,2,4oxadiazol-3-yl]benzamide	X.10	3200:1	20+0.00625
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]be nza mide	X.10	100:1	10+0.1
N-(2-fluorophenyl)-4-[5-(trifluoromethyf)-1,2,4oxadiazol-3-y f]be nzamid e	X.10	200:1	10+0.05
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadîazol-3-yl]be nza mid e	X.10	400:1	10+0.025
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]be nza mide	X.10	800:1	10+0.0125
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadrazol-3-yl]be nza mid e	X.10	1600:1	10+0.00625
glyphosate	X.09	10 : 3	0.1 +0.03
glyphosate	X.09	10 : 1	0.3 + 0.03
glyphosate	X.09	1 : 1	0.1 + 0.1
glyphosate	X.09	3 : 1	0.3 + 0.1
chlorothalonil	X.09	10 : 3	0.1 +0.03

127

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
chlorothalonil	X.09	10 : 1	0.3 + 0.03
chlorothalonil	X.09	1 : 1	0.1 +0.1
chlorothalonil	X.09	3 : 1	0.3 + 0.1
mancozeb	X.09	10 : 3	0.1 +0.03
mancozeb	X.09	10 : 1	0.3 + 0.03
mancozeb	X.09	1 : 1	0.1 +0.1
mancozeb	X.09	3 : 1	0.3 + 0.1
propiconazole	X.09	10 : 3	0.1 +0.03
propiconazole	X.09	10 : 1	0.3 + 0.03
propiconazole	X.09	1 : 1	0.1 + 0.1
propiconazole	X.09	3 : 1	0.3 + 0.1
disodium phosphonate	X.09	10 : 3	0.1 + 0.03
disodium phosphonate	X.09	10 : 1	0.3 + 0.03
disodium phosphonate	X.09	1 : 1	0.1 +0.1
disodium phosphonate	X.09	3 : 1	0.3 + 0.1
fenpropimorph	X.09	10 : 3	0.1 +0.03
fenpropimorph	X.09	10 : 1	0.3 + 0.03
fenpropimorph	X.09	1 : 1	0.1 +0.1
fenpropimorph	X.09	3 : 1	0.3 + 0.1
fenpropidin	X.09	10 : 3	0.1 +0.03
fenpropidin	X.09	10 : 1	0.3 + 0.03
fenpropidin	X.09	1 : 1	0.1 +0.1
fenpropidin	X.09	3 : 1	0.3 + 0.1
hexaconazole	X.09	10 : 3	0.1 +0.03
hexaconazole	X.09	10 : 1	0.3 + 0.03
hexaconazole	X.09	1 : 1	0.1 +0.1
hexaconazole	X.09	3 : 1	0.3 + 0.1
paclobutrazol	X.09	10 : 3	0.1 +0.03
paclobutrazol	X.09	10 : 1	0.3 + 0,03
paclobutrazol	X.09	1 : 1	0.1 +0.1
paclobutrazol	X.09	3 : 1	0.3 + 0.1
trinexapac-ethyl	X.09	10 : 3	0.1 +0.03
trinexapac-ethyl	X.09	10 : 1	0.3 + 0.03
trinexapac-ethyl	X.09	1 : 1	0.1 +0.1

128

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
trinexapac-ethyl	X.09	3 : 1	0.3 + 0.1
flutriafol	X.09	10 : 3	0.1 +0.03
flutriafol	X.09	10 :1	0.3 + 0.03
flutriafol	X.09	1 : 1	0.1 +0.1
flutriafol	X.09	3 : 1	03 + 0.1
difenoconazole	X.09	10 : 3	0.1 +0.03
difenoconazole	X.09	10 :1	0.3 + 0.03
difenoconazole	X.09	1 : 1	0.1 +0.1
difenoconazole	X.09	3 : 1	0.3 + 0.1
fludioxonil	X.09	10 : 3	0.1 +0.03
fludioxonil	X.09	10 : 1	0.3 + 0.03
fludioxonil	X.09	1 : 1	0.1 +0.1
fludioxonil	X.09	3 : 1	0.3 + 0.1
cyproconazole	X.09	10 : 3	0.1 +0.03
cyproconazole	X.09	10 : 1	0.3 + 0,03
cyproconazole	X.09	1 : 1	0.1 + 0.1
cyproconazole	X.09	3 : 1	0.3 + 0.1
acibenzolar S-methyl	X.09	10 : 3	0.1 + 0.03
acibenzolar S-methyl	X.09	10 ; 1	0.3 + 0.03
acibenzolar S-methyl	X.09	1 : 1	0.1 +0.1
acibenzolar S-methyl	X.09	3 : 1	0.3 + 0.1
trifloxystrobin	X.09	10 : 3	0.1 +0.03
trifloxystrobin	X.09	10 : 1	0.3 + 0.03
trifloxystrobin	X.09	1 : 1	0.1 +0.1
trifloxystrobin	X.09	3 : 1	0.3 + 0.1
folpet	X.09	10 ; 3	0.1 +0.03
folpet	X.09	10 : 1	0.3 + 0.03
folpet	X.09	1 : 1	0.1 +0.1
folpet	X.09	3 ; 1	0.3 + 0.1
azoxystrobin	X.09	10 : 3	0.1 +0.03
azoxystrobin	X.09	10 : 1	0.3 + 0.03
azoxystrobin	X.09	1 : 1	0.1 +0.1
azoxystrobin	X.09	3 : 1	0.3 + 0.1
pyraciostrobin	X.09	10 : 3	0.1 +0.03

129

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
pyraclostrobin	X.09	10 : 1	0.3 + 0.03
pyraclostrobin	X.09	1 : 1	0.1 +0.1
pyraclostrobin	X.09	3 : 1	0.3 + 0.1
picoxystrobin	X.09	10 : 3	0.1 +0.03
picoxystrobin	X.09	10 : 1	0.3 + 0.03
picoxystrobin	X.09	1 : 1	0.1 + 0.1
picoxystrobin	X.09	3 : 1	0.3 + 0.1
sulphur	X.09	10 : 3	0.1 + 0.03
sulphur	X.09	10 :1	0.3 + 0.03
sulphur	X.09	1 : 1	0.1 +0.1
sulphur	X.09	3 : 1	0.3 + 0.1
tebuconazole	X.09	10 : 3	0.1 +0.03
tebuconazole	X.09	10 : 1	0.3 + 0.03
tebuconazole	X.09	1 : 1	0.1 +0.1
tebuconazole	X.09	3 : 1	0.3 + 0.1
prothioconazole	X.09	10 : 3	0.1 +0.03
prothioconazole	X.09	10 : 1	0.3 + 0.03
prothioconazole	X.09	1 : 1	0.1 +0.1
prothioconazole	X.09	3 : 1	0.3 + 0.1
fluopyram	X.09	10 : 3	0.1 +0.03
fluopyram	X.09	10 : 1	0.3 + 0.03
fluopyram	X.09	1 : 1	0.1 +0.1
fluopyram	X.09	3 : 1	0.3 + 0.1
copper oxychloride	X.09	10 : 3	0.1 +0.03
copper oxychloride	X.09	10 : 1	0.3 + 0.03
copper oxychloride	X.09	1 : 1	0.1 + 0.1
copper oxychloride	X.09	3 : 1	0.3 + 0.1
benzovindiflupyr	X.09	10 : 3	0.1 + 0.03
benzovindiflupyr	X.09	10 : 1	0.3 + 0.03
benzovindiflupyr	X.09	1 : 1	0.1 + 0.1
benzovindiflupyr	X.09	3 : 1	0.3 + 0.1
isopyrazam	X.09	10 : 3	0.1 +0.03
isopyrazam	X.09	10 :1	0.3 + 0.03
isopyrazam	X.09	1 : 1	0.1 +0.1

130

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
isopyrazam	X.09	3 : 1	0.3 + 0.1
pydiflumetofen	X.09	10 : 3	0.1 +0.03
pydiflumetofen	X.09	10 : 1	0.3 + 0.03
pydiflumetofen	X.09	1 : 1	0.1 +0.1
pydiflumetofen	X.09	3 ; 1	0.3 + 0.1
fluxapyroxad	X.09	10 : 3	0.1 +0.03
fluxapyroxad	X.09	10 : 1	0.3 + 0.03
fluxapyroxad	X.09	1 : 1	0.1 + 0.1
fluxapyroxad	X.09	3 : 1	0.3 + 0.1
quinofumelin	X.09	10 : 3	0.1 +0.03
quinofumelin	X.09	10 : 1	0.3 + 0.03
quinofumelin	X.09	1 : 1	0.1 +0.1
quinofumelin	X.09	3 : 1	0.3 + 0.1
isoflucypram	X.09	10 : 3	0.1 +0.03
isoflucypram	X.09	10 : 1	0.3 + 0.03
isoflucypram	X.09	1 : 1	0.1 +0.1
isoflucypram	X.09	3 : 1	0.3 + 0.1
mefentrifluconazole	X.09	10 : 3	0.1 + 0.03
mefentrifluconazole	X.09	10 : 1	0.3 + 0.03
mefentrifluconazole	X.09	1 : 1	0.1 +0.1
mefentrifluconazole	X.09	3 : 1	0.3 + 0.1
ipflufenoquin	X.09	10 : 3	0.1 + 0.03
ipflufenoquin	X.09	10 : 1	0.3 + 0.03
ipflufenoquin	X.09	1 : 1	0.1 +0.1
ipflufenoquin	X.09	3 : 1	0.3 + 0.1
metyltetraprole	X.09	10 : 3	0.1 +0.03
metyltetraprole	X.09	10 :1	0.3 + 0.03
metyltetraprole	X.09	1 : 1	0.1 +0.1
metyltetraprole	X.09	3 ; 1	0.3 + 0.1
aminopyrifen	X.09	10 : 3	0.1 +0.03
aminopyrifen	X.09	10 : 1	0.3 + 0.03
aminopyrifen	X.09	1 : 1	0.1 +0.1
aminopyrifen	X.09	3 : 1	0.3 + 0.1
florylpicoxamid	X.09	10 : 3	0.1 +0.03

131

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B : A)
florylpicoxamid	X.09	10 : 1	0.3 + 0.03
florylpicoxamid	X.09	1 : 1	0.1 + 0.1
florylpicoxamid	X.09	3 : 1	0.3 + 0.1
florylpicoxamid	X.09	1:2	0.02+0.04
florylpicoxamid	X.09	1:1	0.02+0.02
florylpicoxamid	X.09	2:1	0.02+0.01
florylpicoxamid	X.09	4:1	0.02+0.005
florylpicoxamid	X.09	8:1	0.02+0.0025
florylpicoxamid	X.09	1:4	0.01+0.04
florylpicoxamid	X.09	1:2	0.01+0.02
florylpicoxamid	X.09	1:1	0.01+0.01
florylpicoxamid	X.09	2:1	0.01+0.005
florylpicoxamid	X.09	4:1	0.01+0.0025
2-[6-(4-bromoplienoxy)-2-(trifluoromethyl)-3pyridy 1]-1 -(1,2,4-triazol-1-yl)propan-2-ol	X.09	10 : 3	0.1 +0.03
2-[6-(4’bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.09	10 : 1	0.3 + 0.03
2-[6-(4-bromophenoxy)-2-(trifliJoromethyl)-3pyridyl]-1-(1,2,4-lriazol-1-yl)propan-2-ol	X.09	1 : 1	0.1 +0.1
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazoi-1-yl)propan-2-ol	X.09	3 : 1	0.3 + 0.1
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dîmethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyridine-2-carbonyl]a min o] propanoate	X.09	10 : 3	0.1 + 0.03
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridirte-2-carbonyf]amino]propanoate	X.09	10 : 1	0.3 + 0.03
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.09	1 : 1	0.1 +0.1
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyî] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.09	3 : 1	0.3 + 0.1

132

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethy[-pent-3-enamide	X.09	10 : 3	0.1 +0.03
(Z,2E)-5qi-(2,4-dichlorophenyt)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dîmethyl-pent-3-enamide	X.09	10 : 1	0.3 + 0.03
(Z₁2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.09	1 : 1	0.1 +0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.09	3 : 1	0.3 + 0.1
[(1S,2S)-1-methy!-2-(o-tolyl)propylJ (28)-2-((4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.09	3:2	0.06+0.04
[(1 S,28)-1 -methyl-2-(o-tolyl)propyl] (23)-2-((4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.09	3:1	0.06+0.02
[(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4melhoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.09	6:1	0.06+0.01
[(1 S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.09	12:1	0.06+0.005
[(1S,2S)-1-methyl-2-(o-tolyl)propy1] (2S)-2-«4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.09	24:1	0.06+0.0025
[(1S,2S)-1-methyi-2-(o-tolyl)propyl] (28)-2-((4methoxy-3-propa n oy !oxy-py ridin e-2carbonyl)amino]propanoate	X.09	48:1	0,06+0.00125
((1 S,2S)-1 -methyl-2-(o-tolyl)propyt] (23)-2-((4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.09	3:4	0.03+0.04
[(1S,2S)-1-methyl-2-(o-tolyl)propylj (2S)-2-[(4- metiioxy-3-propanoyloxy-pyridîne-2carbonyl)amino]propanoate	X.09	3:2	0.03+0.02

133

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1S,2S)-1-methyl-2-(o-tolyl)propyi] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyi)amino]propanoate	X.09	3:1	0.03+0.01
[(1S,2S)-1-methy !-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino] propan oate	X.09	6:1	0.03+0.005
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2- carbonyl)amino]propanoate	X.09	12:1	0.03+0.0025
[(1S,2S)-1-methyl-2-(o-tolyl)propyfJ (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.09	24:1	0.03+0.00125
N-(2-fluorophenyl)-4-[5-(trîfluoramethyl)-1,2,4oxadiazol-3-yl]benzamide	X.09	500:1	20+0,04
N-(2-f)uorophenyl)-4-[5-(trîfluoromethyl)-1,2,4oxadiazoi-3-yl]benzamide	X.09	1000:1	20+0.02
N-(2-fluorophenyl)-4-[5-(trifluoromethy 1)-1,2,4oxadiazol-3-yi]benzamide	X.09	2000:1	20+0.01
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.09	4000:1	20+0.005
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.09	8000:1	20+0.0025
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadîazol-3-yllbenzamide	X.09	250:1	10+0.04
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.09	500:1	10+0.02
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.09	1000:1	10+0.01
N-(2-fluorophenyl)-4-[5-(trifluoromettiyl)-1,2,4oxadiazol-3-yl]benzamide	X.09	2000:1	10+0.005

The following mixture compositions atthe reported concentration (rn ppm) in tables B2-2 to B2-6 gave the following disease control in this test Septoria glycines (brown spot). Fungicidal activity was evaluated on a 100-0 scale (100 = no disease growth; 0 = well completely covered by mycélium).

134

Table B2-2

Component A	Component B	Concentration (B+A)	Activity (%)	COLBY Expected Activity (%)
Ppm	B	A	B + A
[(1S,2S)-1-methyl-2-(o- tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amîno]propanoate	X.01	0.06+0.0125	0	90	100	90
[(IS^SM-methyl^otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyrrdine-2carbonyl)amino]propanoate	X.01	0.06+0.00625	0	70	90	70
[(1S ,2S)-1-methy 1-2-(0- tolyi)propyl] (2S)-2-[(4methoxy-3-proparioyioxypyridine-2carbonyl)amino]propanoate	X.01	0.06+0.003125	0	20	70	20
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.01	0.03+0.0125	0	90	100	90
[(1S,2S)-1-methyl-2-(o- tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyrtdine-2carbonyl)amino] propanoate	X.01	0.03+0.00625	0	70	70	70
[(1 S,2S)-1-methy 1-2-(0- tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.01	0.03+0.003125	0	20	50	20
florylpicoxamid	X.01	0.02+0.0125	20	90	100	92
florylpicoxamid	X.01	0.02+0.00625	20	70	90	76

135

Component A	Component B	Concentration (B +A)	Activity (%)	COLBY Expected Activity (%)
Ppm	B	A	B + A
florylpicoxamid	X.01	0.02+0.003125	20	20	70	36
florylpicoxamid	X.01	0.01+0.0125	0	90	100	90
florylpicoxamid	X.01	0.01+0.00625	0	70	70	70
florylpicoxamid	X.01	0.01+0.003125	0	20	50	20

Table B2-3

Component A	Component B	Concentration (B+A)	Activity (%)	COLBY Expected Activity (%)
PPm	B	A	B + A
propiconazole	X.08	0.1 + 0.03	90	70	100	97
propiconazole	X.08	0.3 + 0.03	100	70	100	100
propiconazole	X.08	0.1 +0.1	0	70	100	70
propiconazole	X.08	0.3 + 0.1	0	70	100	70
fenpropimorph	X.08	0.1 + 0.03	20	70	90	76
fenpropimorph	X.08	0.3 + 0.03	50	70	100	85
fenpropimorph	X.08	0.1 +0.1	20	70	100	76
fenpropimorph	X.08	0.3 + 0.1	50	70	100	85
flutriafol	X.08	0.1 + 0.03	20	70	70	76
flutriafol	X.08	0.3 + 0.03	70	70	90	91
flutriafol	X.08	0.1 +0.1	20	70	90	76
flutriafol	X.08	0.3 + 0.1	70	70	100	91
cyproconazole	X.08	0.1 +0.03	50	70	70	85
cyproconazole	X.08	0.3 + 0.03	70	70	100	91
cyproconazole	X.08	0.1 + 0.1	0	70	100	70
cyproconazole	X.08	0.3 + 0.1	50	70	100	85
trifloxystrobin	X.08	0.1 +0.03	90	70	100	97
trifloxystrobin	X.08	0.3 + 0.03	100	70	100	100
trifloxystrobin	X.08	0.1 + 0.1	0	70	100	70
trifloxystrobin	X.08	0.3 + 0.1	0	70	100	70
azoxystrobin	X.08	0.1 + 0.03	70	70	70	91
azoxystrobin	X.08	0.3 + 0.03	100	70	90	100

136

Component A	Component S	Concentration (B + A)	Activîty (%)	COLBY Expected Activîty (%)
PPm	B	A	B +A
azoxystrobin	X.08	0.1 +0.1	0	70	90	70
azoxystrobin	X.08	0.3 + 0.1	0	70	90	70
pyraclostrobin	X.08	0.1 +0.03	100	70	100	100
pyraclostrobin	X.08	0,3 + 0,03	100	70	100	100
pyraclostrobin	X.08	0.1 + 0.1	0	70	100	70
pyraclostrobin	X.08	03 + 0.1	0	70	100	70
picoxystrobin	X.08	0.1 + 0.03	90	70	100	97
picoxystrobin	X.08	0.3 + 0.03	90	70	100	97
picoxystrobin	X.08	0.1 +0.1	0	70	100	70
picoxystrobin	X.08	0.3 + 0.1	20	70	100	76
tebuconazole	X.08	0.1 +0,03	50	70	90	85
tebuconazole	X.08	0.3 + 0.03	90	70	100	97
tebuconazole	X.08	0.1 + 0.1	0	70	90	70
tebuconazoie	X.08	0.3 + 0.1	50	70	100	85
prothioconazole	X.08	0.1 + 0.03	90	70	100	97
prothioconazole	X.08	0.3 + 0.03	90	70	100	97
prothioconazole	X.08	0.1 + 0.1	20	70	100	76
prothioconazole	X.08	0.3 + 0.1	50	70	100	85
benzovindiflupyr	X.08	0.1 + 0.03	70	70	90	91
benzovindiflupyr	X.08	0.3 + 0.03	70	70	100	91
benzovindiflupyr	X.08	0.1 + 0.1	0	70	100	70
benzovindiflupyr	X.08	03 + 0.1	0	70	100	70
fluxapyroxad	X.08	0.1 + 0.03	50	70	70	85
fluxapyroxad	X.08	0.3 + 0.03	70	70	100	91
fluxapyroxad	X.08	0.1 +0.1	0	70	100	70
fluxapyroxad	X.08	0.3 + 0.1	0	70	100	70
mefentrifluconazole	X.08	0.1 + 0.03	100	70	100	100
mefentrifluconazole	X.08	0.3 + 0,03	100	70	100	100

137

Component A	Component B	Concentration (B + A)	Activity (%)	COLBY Expected Activity W
ppm	B	A	B + A
mefentrifluconazole	X.08	0.1 + 0.1	20	70	100	76
mefentriflucon azo le	X.08	0.3 + 0.1	50	70	100	85
ipflufenoquin	X.08	0.1 + 0.03	0	70	90	70
ipflufenoquin	X.08	0.3 + 0.03	0	70	100	70
ipflufenoquin	X.08	0.1 + 0.1	50	70	100	85
ipflufenoquin	X.08	0.3 + 0.1	90	70	100	97
metyltetraprole	X.08	0.1 + 0.03	100	70	100	100
metyitetraprole	X.08	0.3 + 0.03	100	70	100	100
metyltetraprole	X.08	0.1 +0.1	0	70	100	70
metyitetraprole	X.08	0.3 + 0.1	0	70	100	70
aminopyrifen	X.08	0.1 + 0.03	0	70	70	70
aminopyrifen	X.08	0.3 + 0.03	20	70	70	76
aminopyrifen	X.08	0.1 + 0.1	0	70	70	70
aminopyrifen	X.08	0.3 + 0.1	0	70	90	70
florylpicoxamid	X.08	0.02+0.025	20	70	100	76
florylpicoxamid	X.08	0.02+0.0125	20	20	90	36
florylpicoxamid	X.08	0.02+0.00625	20	0	70	20
florylpicoxamid	X.08	0.01+0.025	0	70	100	70
florylpicoxamid	X.08	0.01+0.0125	0	20	90	20
florylpicoxamid	X.08	0.01+0.00625	0	0	70	0
2-[6-(4-bromophenoxy)-2(trifluoromethyl)-3-pyridyl]1-(1,2,4-triazol-1-yl)propan2-ol	X.08	0.1 +0.03	100	70	100	100
2-[6-(4-bromophenoxy)-2(trifluoromethyl)-3-pyridyl]1 -(1,2,4-triazol-1 -yl)propan2-oi	X.08	0.3 + 0.03	100	70	100	100
2-[6-(4-bromophenoxy)-2(trifiuoromethyf)-3-pyridyl]1 -(1,2,4-triazol-1 -yl)propan2-ol	X.08	0.1 + 0.1	50	70	100	85

138

Component A	Component B	Concentration (B + A)	Activîty (%)	COLBY Expected Activîty (%)
ppm	B	A	B + A
2-[6-(4-bromophenoxy)-2(triftu oromethy l)-3-pyridyl]1 -(1,2,4-triazol-1-yl)propan2-o I	X.08	0.3 + 0.1	70	70	100	91
[(1S,2S)-2-(4-fluoro-2methy l-phen y 1)-1,3- dimethyl-butyl] (2S)-2-[[3(acetoxymethoxy)-4methoxy-pyridine-2carbonyl]amino]propanoate	X.08	0.1 + 0.03	90	70	90	97
[(1S,2S)-2-(4-fluoro-2methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3(acetoxymethoxy)-4methoxy-pyridine-2carbonyl]amîno]propanoate	X.08	0.3 + 0.03	100	70	100	100
[(1S,2S)-2-(4-fluoro-2methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3(acetoxymethoxy)-4methoxy-pyridine-2carbonyl]amino]propanoate	X.08	0.1 + 0.1	0	70	100	70
[(1S,2S)-2-(4-fluoro-2methy l-pheny 1)-1,3dimethyl-butyl] (2S)-2-[[3(acetoxy meth oxy)-4methoxy-pyridine-2carbonyl]amino]propanoate	X.08	0.3 + 0.1	0	70	100	70
[(1S,2S)-1-methyl-2-(o- tolyl)propyl] (2S)-2-[(4~ methoxy-3-propanoyloxypyridîne-2carbonyl)amino]propanoate	X.08	0.06+0.025	0	70	100	70

139

Component A	Component B	Concentration (B+A)	Açtivity (%)	COLBY Expected Açtivity (%)
ppm	B	A	B + A
[(1S,2S)-1-methyl-2-(o- to!yl)propyî] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.08	0.06+0.0125	0	20	100	20
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.08	0.06+0.00625	0	0	70	0
[(1S,2S)-1-methy 1-2-(0to1yl)propyfj (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.08	0.03+0.05	0	90	100	90
[(1S,2S)-1-methyl-2-(otoiyl)propyi] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyî)amino]propanoate	X.08	0.03+0.025	0	70	100	70
[(1S,2S)-1-methyî-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.08	0.03+0.0125	0	20	90	20
[(1S,2S)-1-methyl-2-(o- tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.08	0.03+0.00625	0	0	50	0
N-(2-fluoropheny!)-4-[5(trifluoromethyÎ)-l ,2,4oxadiazol-3-yl]benzamide	X.08	20+0.025	0	70	90	70

140

Component A	Component B	Concentration (B+A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
N-(2-fluorophenyl)-4-[5(trifluoro methyl)-1,2,4oxadiazol-3-yl]benzamide	X.08	20+0.0125	0	20	70	20
N-(2-fluorophenyl)-4-[5(trifluoro methyl)-1,2,4oxadiazol-3-yl]benzamide	X.08	10+0.025	0	70	90	70
N-(2-fluorophenyl)-4-[5(trifluoromethyl)-l ,2,4oxadiazol-3-yl]benzamide	X.08	10+0.0125	0	20	70	20

Table B2-4

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.06	0.06+0.025	0	90	100	90
[(1S,2S)-1-methyl-2-(o- tolyl)propyl] (2S)-2-[(4rnethoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.06	0.06+0.0125	0	70	100	70
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-	X.06	0.06+0.00625	0	50	90	50

Component B pyridine-2carbonyl)amino]propanoate	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
PPm	B	A	B + A
[(1S,2S)-1-methy l-2-(otolyl)propyl] (2S)-2-[(4- methoxy-3-propa noy loxypy rid ine-2carbony[)amino] propan oate	X.06	0.06+0.003125	0	0	70	0
[(1S,2S)-1-methyl-2-(0tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.06	0.03+0.025	0	90	100	90
[(1S,2S)-1-methyl-2-(o- tolyl)propyi] (25)-2-((4methoxy-3-propa noy ioxypyridine-2carbonyl)amino]propanoate	X.06	0.03+0.0125	0	70	90	70
[(1S,2S)-1-methyl-2-(otolyl)propyl] (23)-2-((4methoxy-3-propanoyloxypyridine-2carbonyl)amîno]propanoate	X.06	0.03+0.00625	0	50	70	50
[(1S,2S)-1-methyl-2-(otolyljpropyl] (2S)-2-[(4meth oxy-3-propanoy loxypyridine-2carbonyl)amino]propanoate	X.06	0.03+0.003125	0	0	50	0
N-(2-flLiorophenyl)-4-[5(trifluoromethyl)-l ,2,4oxadiazol-3-yl]benzamide	X.06	20+0.025	0	90	100	90
N-(2-fluorophenyl)-4-[5(trifluoromethyl)-l ,2,4oxadiazol-3-yl}benzamide	X.06	20+0.0125	0	70	90	70

142

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
N-(2-fl uoropheny 1)-4-(5(trifluoromethyl)-l ,2,4oxadiazol-3-yl]benzamtde	X.06	20+0.00625	0	50	50	50
N-(2-fluoré phen y 1)-4-(5(trifluoromethyl)-l ,2,4oxadiazol-3-yl]benzamide	X.06	10+0.025	0	90	100	90
N-(2-fluoropheny 1)-4-(5(trifluoro methyl)-1,2,4oxadiazol-3-yl]benzamide	X.06	10+0.0125	0	70	90	70
N-(2-fluoropheny1)-4-[5(trifiuoromethyl)-l ,2,4oxadiazol-3-yl]benzamide	X.06	10+0.00625	0	50	50	50
florylpicoxamid	X.06	0.02+0.0125	20	70	100	76
florylpicoxamid	X.06	0.02+0.00625	20	50	90	60
florylpicoxamid	X.06	0.02+0.003125	20	0	50	20
florylpicoxamid	X.06	0.01+0.0125	0	70	100	70
florylpicoxamid	X.06	0.01+0.00625	0	50	70	50
florylpicoxamid	X.06	0.01+0.003125	0	0	50	0

Table B2-5

Component B	Component A	Concentration (B+A)	Activity (%)	COLBY Expected Activity (%)
Ppm	B	A	B + A
fenpropimorph	X.10	0.1 + 0.03	20	0	50	20
fenpropimorph	X.10	0.3 + 0.03	50	0	70	50
fenpropidin	X.10	0.1 + 0.03	0	0	20	0
fenpropidin	X.10	0.3 + 0.03	50	0	50	50
paclobutrazol	X.10	0.1 + 0.03	0	0	20	0
paclobutrazo!	X.10	0.3 + 0.03	50	0	50	50
cyproconazole	X.10	0.1 +0.03	50	0	50	50
cyproconazole	X.10	0.3 + 0.03	70	0	90	70
trifloxystrobin	X.10	0.1 +0.03	90	0	100	90

143

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
trifloxystrobin	X.10	0.3 + 0.03	100	0	100	100
prothioconazole	X.10	0.1 + 0.03	90	0	90	90
prothioconazole	X.10	0.3 + 0.03	90	0	100	90
ipflufenoquin	X.10	0.1 + 0.03	0	0	0	0
ipflufenoquin	X.10	0.3 + 0.03	0	0	20	0
aminopyrifen	X.10	0.1 + 0.03	0	0	20	0
aminopyrifen	X.10	0.3 + 0.03	20	0	20	20
[(1S,2S)-1-methyl-2-(o- tolyl)propylj (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.10	0.06+0.0125	0	90	100	90
I(1S,2S)-1-methyl-2-(o- totyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.10	0.06+0.00625	0	90	100	90
[(1S,2S)-1-methyl-2-(o- tolyi)propyl] (2S)-2-[(4methoxy-3-propanoyfoxypyridine-2carbonyl)amino]propanoate	X.10	0.06+0,003125	0	70	100	70
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3- propa n oyloxypyridine-2carbonyl)amino]propanoate	X.10	0,03+0.0125	0	90	100	90
[(is,2S)-i-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-pro pa noy loxypyridine-2carbonyl)amino]propanoate	X.10	0.03+0.00625	0	90	100	90

Component B	Component A	Concentration (B + A)	Activîty (%)	COLBY Expected Activîty (%)
ppm	B	A	B + A
[(1 S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.10	0.03+0.003125	0	70	90	70
N-(2-fluorophenyl)-4-[5(trifluoromethyl)-l ,2,4oxadiazoi-3-yl]benzamide	X.10	20+0,0125	0	90	100	90
N-(2Tuorophenyl)-4-[5(triftuoromethyl)-l ,2,4oxadiazol-3-yl]benzamide	X.10	10+0.0125	0	90	100	90
florylpicoxamid	X.10	0.02+0.0125	20	90	100	92
florylpicoxamid	X.10	0.02+0.00625	20	90	100	92
florylpicoxamid	X.10	0.02+0.003125	20	70	100	76
florylpicoxamid	X.10	0.01+0.0125	0	90	100	90
florylpicoxamid	X.10	0.01+0.00625	0	90	100	90
florylpicoxamid	X.10	0.01+0.003125	0	70	90	70

Table B2-6

Component B	Component A	Concentration (B + A)	Activîty (%)	COLBY Expected Activîty (%)
ppm	B	A	B + A
[(1S,2S)-1-methyl-2-(o- tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxypyridine-2carbonyl)amino] propanoate	X.09	0.06+0.0025	0	70	90	70
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.09	0.06+0.00125	0	50	90	50

145

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
[(1 S, 2S)-1 -met hy l-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.09	0.03+0.0025	0	70	90	70
[(1S,2S)-1-methyl-2-(o- tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.09	0.03+0.00125	0	50	90	50
florylpicoxamid	X.09	0.02+0.005	20	90	100	92
florylpicoxamid	X.09	0.02+0.0025	20	70	100	76
florylpicoxamid	X.09	0.02+0.00125	20	50	70	60
florylpicoxamid	X.09	0.01+0.005	0	90	100	90
florylpicoxamid	X.09	0.01+0.0025	0	70	100	70
florylpicoxamid	X.09	0.01+0.00125	0	50	70	50

Example B3: Preventative activity against Septoria tritici (leaf biotch):

Conidia of the fungus from cryogénie storage were directly mixed into nutrient broth (PDB potato dextrose broth). A DMSO solution of the test compounds was placed into a microtiter plate (96-well format) and the nutrient broth containing the fungal spores was added to it. The test plates were incubated at 24 °C and the inhibition of growth was determined photometrically after 72 hrs.

The following mixture compositions (B:A) atthe reported concentration (in ppm) in table B3-1 gave at least 80% disease control in this test (Septoria tritici).

Table B3-1

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
glyphosate	X.01	10 : 3	0.1 + 0.03
glyphosate	X.01	10 : 1	0.3 + 0.03
glyphosate	X.01	1 : 1	0.1 + 0.1

146

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
glyphosate	X.01	3 : 1	0.3 + 0.1
chlorothalonil	X.01	10 : 3	0.1 +0.03
chlorothalonil	X.01	10 :1	0.3 + 0.03
chlorothalonil	X.01	1 : 1	0.1 +0.1
chlorothalonil	X.01	3 : 1	0.3 + 0.1
mancozeb	X.01	10 : 3	0.1 + 0.03
mancozeb	X.01	10 : 1	0.3 + 0.03
mancozeb	X.01	1 : 1	0.1 + 0.1
mancozeb	X.01	3 : 1	0.3 + 0.1
propiconazole	X.01	10 : 3	0.1 + 0.03
propiconazole	X.01	10 : 1	0.3 + 0.03
propiconazole	X.01	1 : 1	0.1 +0.1
propiconazole	X.01	3 : 1	0.3 + 0.1
disodium phosphonate	X.01	10 : 3	0.1 +0.03
disodium phosphonate	X.01	10 : 1	0.3 + 0.03
disodium phosphonate	X.01	1 : 1	0.1 +0.1
disodium phosphonate	X.01	3 : 1	0.3 + 0.1
fenpropimorph	X.01	10 : 3	0.1 + 0.03
fenpropimorph	X.01	10 : 1	0.3 + 0.03
fenpropimorph	X.01	1 : 1	0.1 + 0.1
fenpropimorph	X.01	3 : 1	0.3 + 0.1
fenpropidin	X.01	10 : 3	0.1 + 0.03
fenpropidin	X.01	10 : 1	0.3 + 0.03
fenpropidin	X.01	1 : 1	0.1 + 0.1
fenpropidin	X.01	3 : 1	0.3 + 0.1
hexaconazole	X.01	10 : 3	0.1 + 0.03
hexaconazole	X.01	10 : 1	0.3 + 0.03
hexaconazole	X.01	1 : 1	0.1 + 0.1
hexaconazole	X.01	3 : 1	0.3 + 0.1
paclobutrazol	X.01	10 : 3	0.1 + 0.03
paclobutrazol	X.01	10 : 1	0.3 + 0.03
paclobutrazol	X.01	1 : 1	0.1 + 0.1
paclobutrazol	X.01	3 : 1	0.3 + 0.1
trinexapac-ethyl	X.01	10 : 3	0.1 + 0.03

147

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
trinexapac-ethyl	X.01	10 :1	0.3 + 0.03
trinexapac-ethyl	X.01	1 : 1	0.1 + 0.1
trinexapac-ethyl	X.01	3 : 1	0.3 + 0.1
flutriafol	X.01	10 : 3	0.1 + 0.03
flutriafol	X.01	10 :1	0.3 + 0.03
flutriafol	X.01	1 : 1	0.1 +0.1
flutriafol	X.01	3 : 1	0.3 + 0.1
difenoconazole	X.01	10 : 3	0.1 + 0.03
difenoconazole	X.01	10 : 1	0.3 + 0.03
difenoconazole	X.01	1 : 1	0.1 + 0.1
difenoconazole	X.01	3 : 1	0.3 + 0.1
fludioxonil	X.01	10 : 3	0.1 + 0.03
fludioxonil	X.01	10 : 1	0.3 + 0.03
fludioxonil	X.01	1 : 1	0.1+0.1
fludioxonil	X.01	3 : 1	0.3 + 0.1
cyproconazole	X.01	10 : 3	0.1 + 0.03
cyproconazole	X.01	10 : 1	0.3 + 0.03
cyproconazole	X.01	1 : 1	0.1 + 0.1
cyproconazole	X.01	3 : 1	0.3 + 0.1
acibenzolar S-methyl	X.01	10 : 3	0.1 + 0.03
acibenzolar S-methyl	X.01	10 : 1	0.3 + 0.03
acibenzolar S-methyl	X.01	1 : 1	0.1 + 0.1
acibenzolar S-methyl	X.01	3 : 1	0.3 + 0.1
trifloxystrobin	X.01	10 : 3	0.1 + 0.03
trifloxystrobin	X.01	10 : 1	0.3 + 0.03
trifloxystrobin	X.01	1 : 1	0.1 + 0.1
trifloxystrobin	X.01	3 : 1	0.3 + 0.1
folpet	X.01	10 : 3	0.1 + 0.03
folpet	X.01	10 :1	0.3 + 0.03
folpet	X.01	1 : 1	0.1 +0.1
folpet	X.01	3 : 1	0.3 + 0.1
azoxystrobin	X.01	10 : 3	0.1 +0.03
azoxystrobin	X.01	10 :1	0.3 + 0.03
azoxystrobin	X.01	1 : 1	0.1 +0.1

148

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
azoxystrobin	X.01	3 : 1	0.3 + 0.1
pyraclostrobin	X.01	10 : 3	0.1 + 0.03
pyraclostrobin	X.01	10 : 1	0.3 + 0.03
pyraclostrobin	X.01	1 : 1	0.1 + 0.1
pyraclostrobin	X.01	3 : 1	0.3 + 0.1
picoxystrobin	X.01	10 : 3	0.1 + 0.03
picoxystrobin	X.01	10 : 1	0.3 + 0.03
picoxystrobin	X.01	1 : 1	0.1 + 0.1
picoxystrobin	X.01	3 : 1	0.3 + 0.1
sulphur	X.01	10 : 3	0.1 + 0.03
sulphur	X.01	10 ; 1	0.3 + 0.03
sulphur	X.01	1 : 1	0.1 + 0.1
sulphur	X.01	3 : 1	0.3 + 0.1
tebuconazole	X.01	10 : 3	0.1 +0.03
tebuconazole	X.01	10 : 1	0.3 + 0.03
tebuconazole	X.01	1 : 1	0.1 +0.1
tebuconazole	X.01	3 : 1	0.3 + 0.1
prothioconazole	X.01	10 : 3	0.1 +0.03
prothioconazole	X.01	10 : 1	0.3 + 0.03
prothioconazole	X.01	1 : 1	0.1 +0.1
prothioconazole	X.01	3 : 1	0.3 + 0.1
fluopyram	X.01	10 : 3	0.1 + 0.03
fluopyram	X.01	10 : 1	0.3 + 0.03
fluopyram	X.01	1 : 1	0.1 + 0.1
fluopyram	X.01	3 : 1	0.3 + 0.1
copper oxychloride	X.01	10 : 3	0.1 +0.03
copper oxychloride	X.01	10 : 1	0.3 + 0.03
copper oxychloride	X.01	1 : 1	0.1 + 0.1
copper oxychloride	X.01	3 : 1	0.3 + 0.1
benzovindiflupyr	X.01	10 : 3	0.1 + 0.03
benzovindiflupyr	X.01	10 : 1	0.3 + 0.03
benzovindiflupyr	X.01	1 : 1	0.1 + 0.1
benzovindiflupyr	X.01	3 : 1	0.3 + 0.1
isopyrazam	X.01	10 : 3	0.1 + 0.03

149

Component B	Component A (compound)	Ratio B:A	Conc, (ppm) (B: A)
isopyrazam	X.01	10 : 1	0.3 + 0.03
isopyrazam	X.01	1 : 1	0.1 +0.1
isopyrazam	X.01	3 : 1	0.3 + 0.1
pydiflumetofen	X.01	10 : 3	0.1 +0.03
pydiflumetofen	X.01	10 : 1	0.3 + 0.03
pydiflumetofen	X.01	1 : 1	0.1 +0.1
pydiflumetofen	X.01	3 : 1	0.3 + 0.1
fluxapyroxad	X.01	10 : 3	0.1 +0.03
fluxapyroxad	X.01	10 : 1	0.3 + 0.03
fluxapyroxad	X.01	1 : 1	0.1 + 0.1
fluxapyroxad	X.01	3 : 1	0.3 + 0.1
quinofumelin	X.01	10 : 3	0.1 + 0.03
quinofumelin	X.01	10 : 1	0.3 + 0.03
quinofumelin	X.01	1 : 1	0.1 + 0.1
quinofumelin	X.01	3 : 1	0.3 + 0.1
isoflucypram	X.01	10 : 3	0.1 + 0.03
isoflucypram	X.01	10 ; 1	0.3 + 0.03
isoflucypram	X.01	1 : 1	0.1 + 0.1
isoflucypram	X.01	3 : 1	0.3 + 0.1
mefentrifluconazole	X.01	10 : 3	0.1 + 0.03
mefe ntriflucon azo le	X.01	10 : 1	0.3 + 0.03
mefentrifluconazole	X.01	1 : 1	0.1 + 0.1
mefe ntriflucon azo le	X.01	3 : 1	0.3 + 0.1
ipfiufenoquin	X.01	10 : 3	0.1 + 0.03
ipfiufenoquin	X.01	10 : 1	0.3 + 0.03
ipfiufenoquin	X.01	1 : 1	0.1 + 0.1
ipfiufenoquin	X.01	3 : 1	0.3 + 0.1
metyltetra proie	X.01	10 : 3	0.1 + 0.03
metyltetra proie	X.01	10 : 1	0.3 + 0.03
metyltetra proie	X.01	1 : 1	0.1 + 0.1
metyltetra proie	X.01	3 : 1	0.3 + 0.1
aminopyrifen	X.01	10 : 3	0.1 + 0.03
aminopyrifen	X.01	10 :1	0.3 + 0.03
aminopyrifen	X.01	1 : 1	0.1 +0.1

150

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
aminopyrifen	X.01	3 : 1	0.3 + 0.1
florylpicoxamid	X.01	10 :3	0.1 + 0.03
florylpicoxamid	X.01	10 :1	0.3 + 0.03
florylpicoxamid	X.01	1 : 1	0.1 + 0.1
florylpicoxamid	X.01	3 : 1	0.3 + 0.1
florylpicoxamid	X.01	1:50	0.02+0.1
florylpicoxamid	X.01	1:25	0.02+0.05
florylpicoxamid	X.01	2:25	0.02+0.025
florylpicoxamid	X.01	4:25	0.02+0.0125
florylpicoxamid	X.01	8:25	0.02+0.00625
florylpicoxamid	X.01	16:25	0.02+0.003125
florylpicoxamid	X.01	1:100	0.01+0.1
florylpicoxamid	X.01	1:50	0.01+0.05
florylpicoxamid	X.01	1:25	0.01+0.025
florylpicoxamid	X.01	2:25	0.01+0.0125
florylpicoxamid	X.01	4:25	0.01+0.00625
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.01	10 : 3	0.1 +0.03
2-[6-(4-bromophenoxy)-2-(trifluoromelhyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.01	10 : 1	0.3 + 0.03
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazoi-1-yl)propan-2-ol	X.01	1 : 1	0.1 +0.1
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyll-l-d^^-triazol-l-yOpropan^-ol	X.01	3 : 1	0.3 + 0.1
[(1 S_T2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amîno]propanoate	X.01	10 : 3	0.1 + 0.03
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3- dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyridine-2-carbonyl]amino]propanoate	X.01	10 : 1	0.3 + 0.03
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3- dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4~ methoxy-pyridine-2-carbonyl]amino]propanoate	X.01	1 : 1	0.1 +0.1

151

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3- dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyridine-2-carbonylJamino]propanoate	X.01	3 : 1	0.3 + 0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.01	10 : 3	0.1 +0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.01	10 : 1	0.3 + 0.03 i
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yi]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.01	1 : 1	0.1 + 0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.01	3 : 1	0.3 + 0.1
[(1 S,2S)-1-methyi-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.01	6:10	0.06+0.1
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4meth oxy-3-propa noy loxy-py rid ine-2carbonyl)amino]propanoate	X.01	6:5	0.06+0.05
[(1 S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propa noy loxy-py ridine-2carbonyl)amino]propanoate	X.01	12:5	0.06+0.025
[(1 S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.01	24:5	0.06+0.0125
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.01	48:5	0.06+0.00625
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propa noy loxy-py rid ine-2carbonyl)amino]propanoate	X.01	96:5	0.06+0.003125
[(1S,2S)-1-methyl-2-(o-tolyl)propylJ (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.01	3:10	0.03+0.1

152

Comportent B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3~ propan oyloxy-pyrid ine-2carbonyl)amino[propanoate	X.01	3:5	0.03+0.05
[(1 S,2S)-1 -methy I-2- (o-tolyI) propyI] (2S)-2-[(4meth oxy-3-propanoy loxy-py rid ine-2carbonyl)amino]propanoate	X.01	6:5	0.03+0.025
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.01	12:5	0.03+0.0125
[(1 S,2S>-1-methyl-2-(o-tolyl)propyl[ (2S) 2-[(4methoxy-3-propan oytoxy-pyridîne-2carbonyl)amino]propanoate	X.01	24:5	0.03+0.00625
[(1S,2S)-1-methyl-2-(o-tolyl)propyt] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.01	48:5	0.03+0.003125
N-(2-fliJOrophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.01	200:1	20+0.1
N-(2-fluorophenyi)-4-[5-(trifluoro methyl)-1,2,4oxadiazol-3-yl]benzamide	X.01	400:1	20+0.05
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.01	800:1	20+0.025
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadîazol-3-yl]benzamide	X.01	1600:1	20+0.0125
N-(2-fIuorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.01	100:1	10+0.1
N-(2-fluoraphenyl)-4-(5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.01	200:1	10+0.05
N-(2-fluorophenyl)-4-[5-(trifluo romethy l)-1,2,4oxadiazoî-3-yl]benzamide	X.01	400:1	10+0.025
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.01	800:1	10+0.0125
chlorothalonil	X-08	10 ; 3	0.1 +0.03
chlorothalonil	X.08	10 :1	0.3 + 0.03
chlorothalonil	X.08	1 : 1	0.1 +0.1

153

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
chlorothalonil	X.08	3 : 1	0.3 + 0.1
propiconazole	X.08	10 : 1	0.3 + 0.03
propiconazole	X.08	3 : 1	0.3 + 0.1
fenpropidin	X.08	1 : 1	0.1 + 0.1
fenpropidin	X.08	3 : 1	0.3 + 0.1
hexaconazole	X.08	10:3	0.1 +0.03
hexaconazole	X.08	10 :1	0.3 + 0.03
hexaconazole	X.08	1 : 1	0.1 + 0.1
hexaconazole	X.08	3 : 1	0.3 + 0.1
difenoconazole	X.08	10 : 3	0.1 + 0.03
difenoconazole	X.08	10 : 1	0.3 + 0.03
difenoconazole	X.08	1 : 1	0.1 + 0.1
difenoconazole	X.08	3 : 1	0.3 + 0.1
fludioxonil	X.08	10 : 1	0.3 + 0.03
fludioxonil	X.08	3 : 1	0.3 + 0.1
cyproconazole	X.08	10 : 1	0.3 + 0.03
cyproconazole	X.08	1 : 1	0.1 +0.1
cyproconazole	X.08	3 : 1	0.3 + 0.1
trifloxystrobin	X.08	10:3	0.1 +0.03
trifloxystrobin	X.08	10 : 1	0.3 + 0.03
trifloxystrobin	X.08	1 : 1	0.1 +0.1
trifloxystrobin	X.08	3 : 1	0.3 + 0.1
folpet	X.08	3 : 1	0.3 + 0.1
azoxystrobin	X.08	10 : 3	0.1 + 0.03
azoxystrobin	X.08	10 : 1	0.3 + 0.03
azoxystrobin	X.08	1 : 1	0.1 + 0.1
azoxystrobin	X.08	3 : 1	0.3 + 0.1
pyraclostrobin	X.08	10 : 3	0.1 + 0.03
pyraclostrobin	X.08	10 : 1	0.3 + 0.03
pyraclostrobin	X.08	1 : 1	0.1 + 0.1
pyraclostrobin	X.08	3 : 1	0.3 + 0.1
picoxystrobin	X.08	10 : 3	0.1 + 0.03
picoxystrobin	X.08	10 : 1	0.3 + 0.03
picoxystrobin	X.08	1 : 1	0.1 + 0.1

154

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
picoxystrobin	X.08	3 : 1	0.3 + 0.1
prothioconazofe	X.08	10 : 3	0.1 + 0.03
prothioconazole	X.08	10 : 1	D.3 + 0.03
profil ioconazole	X.08	1 : 1	0.1 + 0.1
prothioconazole	X.08	3 : 1	0.3 + 0.1
fluopyram	X.08	3 : 1	Û.3 + 0.1
benzovindiflupyr	X.08	10 : 1	0.3 + 0.03
benzovindiflupyr	X.08	1 : 1	0.1 +0.1
benzovindiflupyr	X.08	3 : 1	0.3 + 0.1
isopyrazam	X.08	10 :1	0.3 + 0.03
isopyrazam	X.08	1 : 1	0.1 +0.1
isopyrazam	X.08	3 : 1	0.3 + 0.1
pydiflumetofen	X.08	10 :3	0.1 +0.03
pydiflumetofen	X.08	10 :1	0.3 + 0.03
pydiflumetofen	X.08	1 ; 1	0.1 + 0.1
pydiflumetofen	X.08	3 : 1	0.3 + 0.1
fluxapyroxad	X.08	10 ; 1	0.3 + 0.03
fluxapyroxad	X.08	1 : 1	0.1 + 0.1
fluxapyroxad	X.08	3 : 1	0.3 + 0.1
quinofumelin	X.08	1 : 1	0.1 + 0.1
quinofumelin	X.08	3 : 1	0.3 + 0.1
isoflucypram	X.08	10 : 3	0.1 + 0.03
isoflucypram	X.08	10 : 1	0.3 + 0.03
isoflucypram	X.08	1 : 1	0.1 + 0.1
isoflucypram	X.08	3 : 1	0.3 + 0.1
mefentrifluconazole	X.08	10 : 3	0.1 + 0.03
mefentrifluconazole	X.08	10 : 1	0.3 + 0.03
mefentrifluconazole	X.08	1 : 1	0.1 + 0.1
mefentrifluconazole	X.08	3 : 1	0.3 + 0.1
ipflufenoquin	X.08	10 : 3	0.1 + 0.03
ipflufenoquin	X.08	10 : 1	0.3 + 0.03
ipflufenoquin	ΧΌ8	1 : 1	0.1 + 0.1
ipflufenoquin	X.08	3 : 1	0.3 + 0.1
metyltetraprole	X.08	10 : 3	0.1 + 0.03

155

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
metyltetraprole	X.08	10 : 1	0.3 + 0.03
metyltetraprole	X.08	1 : 1	0.1 + 0.1
metyltetraprole	X.08	3 : 1	0.3 + 0.1
aminopyrifen	X.08	10 : 3	0.1 + 0.03
aminopyrifen	X.08	10 : 1	0.3 + 0.03
aminopyrifen	X.08	1 : 1	0.1 +0.1
aminopyrifen	X.08	3 : 1	0.3 + 0.1
florylpicoxamid	X.08	10 : 3	0.1 +0.03
florylpicoxamid	X.08	10 : 1	0.3 + 0.03
florylpicoxamid	X.08	1 : 1	0.1 + 0.1
florylpicoxamid	X.08	3 : 1	0.3 + 0.1
florylpicoxamid	X.08	1:10	0.02+0.2
florylpicoxamid	X.08	1:5	0.02+0.1
florylpicoxamid	X.08	2:5	0.02+0.05
florylpicoxamid	X.08	4:5	0.02+0.025
florylpicoxamid	X.08	8:5	0.02+0.0125
florylpicoxamid	X.08	16:5	0.02+0.00625
florylpicoxamid	X.08	1:20	0.01+0.2
florylpicoxamid	X.08	1:10	0.01+0.1
florylpicoxamid	X.08	1:5	0.01+0.05
florylpicoxamid	X.08	2:5	0.01+0.025
florylpicoxamid	X.08	4:5	0.01+0.0125
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.08	10 : 3	0.1 + 0.03
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.08	10 : 1	0.3 + 0.03
2-[6-(4-bromophenoxy)-2-(trifiuoromethyl)“3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-o!	X.08	1 : 1	0.1 + 0.1
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.08	3 : 1	0.3 + 0.1
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4meth oxy-pyrid ine-2-ca rbonyl]a mino] pro pa n oate	X.08	10 : 3	0.1 +0.03

156

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyi-butyf] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyi]amino]propanoate	X.08	10 :1	0.3 + 0.03
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino] propanoate	X.08	1 : 1	0.1 +0.1
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl] amino] propanoate	X.08	3 : 1	0.3 + 0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-metÎioxyimino-N,3-dimethyl-pent-3-enamide	X.08	10 : 3	0.1 + 0.03
(Z,2E)-5-[1-(2,4-dichiorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.08	10 ; 1	0.3 + 0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.08	1 : 1	0.1 + 0.1
(Z,2E)-5-[T(2₁4-dichlorophenyl)pyrazol-3-y!]oxy- 2-methoxy imino-N,3-di methy l-pent-3-enamide	X.08	3 : 1	0.3 + 0.1
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyrîdine-2- carbonyl) amino] propanoate	X.08	3:10	0.06+0.2
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)ami no] propanoate	X.08	3:5	0.06+0.1
[(1S,2S)-1-methyi-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propan oyloxy-py ridine-2carbonyl)amino]propanoate	X.08	6:5	0.06+0.05
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4m ethoxy-3- propanoyloxy-pyridine-2carbonyl)amîno]propanoate	X.08	12:5	0.06+0.025
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S>-2-[(4methoxy-3-propanoyloxy-pyridine-2carbony[)amino]propanoate	X.08	24:5	0.06+0.0125

157

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- m et h o xy-3 - pro pa n oy 1 oxy- py rid in e-2carbonyl)amino]propanoate	X.08	48:5	0.06+0.00625
K1S_T2S)-1-methy(-2-(o-tolyl)propylJ (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbony!)amino]propanoate	X.08	3:20	0.03+0.2
[(1S,2S)-1 -methyl-2-(o-tolyl)propyl) (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.08	3:10	0.03+0.1
[(1S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanQyloxy-pyridine-2carbonyl)amino]propanoate	X.08	6:10	0.03+0.05
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propan oy loxy-pyridîne-2carbonyl)amîno]propanoate	X.08	12:10	0.03+0.025
[(1S,2S)-1-melhyl-2-(o-tolyl)propyl] (2S>-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino)propanoate	X.08	24:10	0.03+0.0125
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4meth oxy-3-propa noy loxy-py rid ine-2carbonyl)amino]propanoate	X.08	48:10	0.03+0.00625
N-(2-fl<JOrophenyi)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.08	100:1	20+0.2
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.08	200:1	20+0.1
N-(2-fluorophenyl)-4-[5-(trifkjoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.08	400:1	20+0.05
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.08	800:1	20+0.025
N-(2-fluorophenyl)-4-(5-(trifluoromethyi)-1,2,4oxadiazol-3-yl]benzamide	X.08	50:1	10+0.2
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.08	100:1	10+0.1

158

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazo!-3-yl]benzamide	X.08	200:1	10+0.05
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.08	400:1	10+0.025
glyphosate	X.06	1 : 1	0.1 +0.1
glyphosate	X.06	3 : 1	0.3 + 0.1
chlorothalonil	X.06	10 : 3	0.1 + 0.03
chlorothalonil	X.06	10 : 1	0.3 + 0.03
chlorothalonil	X.06	1 : 1	0.1 + 0.1
chlorothalonil	X.06	3 : 1	0.3 + 0.1
mancozeb	X.06	1 : 1	0.1 + 0.1
mancozeb	X.06	3 : 1	0.3 + 0.1
propiconazole	X.06	10 :1	0.3 + 0.03
propiconazole	X.06	1 : 1	0.1 +0,1
propiconazole	X.06	3 : 1	0.3 + 0.1
disodium phosphonate	X.06	1 : 1	0.1 + 0.1
disodium phosphonate	X.06	3 : 1	0.3 + 0.1
fenpropimorph	X.06	1 : 1	0.1 + 0.1
fenpropimorph	X.06	3 : 1	0.3 + Û.1
fenpropidin	X.06	1 : 1	0.1 + 0.1
fenpropidin	X.06	3 : 1	0.3 + 0.1
hexaconazole	X.06	10 :3	0.1 +0.03
hexaconazole	X.06	10 :1	0.3 + 0.03
hexaconazole	X.06	1 : 1	0.1 + 0.1
hexaconazole	X.06	3 : 1	0.3 + 0.1
paclobutrazol	X.06	1 : 1	0.1 + 0.1
paclobutrazol	X.06	3 : 1	0.3 + 0.1
trinexapac-ethyl	X.06	1 : 1	0.1 + 0.1
trinexapac-ethyl	X.06	3 : 1	0.3 + 0.1
flutriafol	X.06	1 : 1	0.1 + 0.1
flutriafol	X.06	3 : 1	0.3 + 0.1
difenoconazole	X.06	10 : 3	0.1 + 0.03
difenoconazole	X.06	10 : 1	0.3 + 0.03
difenoconazole	X.06	1 : 1	0.1 + 0.1

159

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
difenoconazole	X.06	3 : 1	0.3 + 0.1
fludioxonil	X.06	10 : 1	0.3 + 0.03 _
fludioxonil	X.06	1 : 1	0.1 + 0.1
fludioxonil	X.06	3 : 1	0.3 + 0.1
cyproconazoie	X.06	10 :1	0.3 + 0.03 _
cyproconazoie	X.06	1 : 1	0.1 + 0.1
cyproconazoie	X.06	3 : 1	0.3 + 0.1
acibenzolar S-methyl	X.06	1 : 1	0.1 + 0.1
aci benzol a r S-methyl	X.06	3 : 1	0.3 + 0.1
trifloxystrobîn	X.06	10 : 3	0.1 + 0.03
trifloxystrobîn	X.06	10 : 1	0.3 + 0.03
trifloxystrobîn	X.06	1 : 1	0.1 + 0.1
trifloxystrobîn	X.06	3 : 1	0.3 + 0.1
folpet	X.06	10 :1	0.3 + 0.03
folpet	X.06	1 : 1	0.1 + 0.1
folpet	X.06	3 : 1	0.3 + 0.1
azoxystrobin	X.06	10 : 3	0.1 + 0.03
azoxystrobin	X.06	10 : 1	0.3 + 0.03
azoxystrobin	X.06	1 : 1	0.1 +0,1
azoxystrobin	X.06	3 : 1	0.3 + 0.1
pyraclostrobin	X.06	10 : 3	0.1 + 0.03
pyraclostrobin	X.06	10 : 1	0.3 + 0.03
pyraclostrobin	X.06	1 : 1	0.1 + 0.1
pyraclostrobin	X.06	3 : 1	0.3 + 0.1
picoxystrobin	X.06	10 : 3	0.1 +0.03
picoxystrobin	X.06	10 : 1	0.3 + 0.03
picoxystrobin	X.06	1 : 1	0.1 +0.1
picoxystrobin	X.06	3 : 1	0.3 + 0.1
sulphur	X.06	1 : 1	0.1 + 0.1
sulphur	X.06	3 : 1	0.3 + 0.1
tebuconazole	X.06	1 : 1	0.1 + 0.1
tebuconazole	X.06	3 : 1	0.3 + 0.1
prothioconazole	X.06	10 : 3	0.1 + 0.03
prothioconazole	X.06	10 : 1	0.3 + 0.03

160

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
prothioconazole	X.06	1 : 1	0.1 + 0.1
prothioconazole	X.06	3 : 1	0.3 + 0.1
fluopyram	X.06	10 : 1	0.3 + 0.03
fluopyram	X.06	1 : 1	0.1 +0.1
fluopyram	X.06	3 : 1	0.3 + 01
copper oxychloride	X.06	1 : 1	0.1 +0.1
copper oxychloride	X.06	3 : 1	0.3 + 0.1
benzovindiflupyr	X.06	10 : 3	0.1 +0.03
benzovindiflupyr	X.06	10 : 1	0.3 + 0.03
benzovindiflupyr	X.06	1 : 1	0.1 + 0.1
benzovindiflupyr	X.06	3 : 1	0.3 + 0.1
isopyrazam	X.06	10 : 3	0.1 +0.03
isopyrazam	X.06	10 : 1	0.3 + 0.03
isopyrazam	X.06	1 : 1	0.1 + 0.1
isopyrazam	X.06	3 : 1	0.3 + 0.1
pydiflumetofen	X.06	10 : 3	0.1 + 0.03
pydiflumetofen	X.06	10 : 1	0.3 + 0.03
pydiflumetofen	X.06	1 : 1	0.1 + 0.1
pydiflumetofen	X.06	3 : 1	0.3 + 0.1
fluxapyroxad	X.06	10 : 1	0.3 + 0.03
fluxapyroxad	X.06	1 : 1	0.1 +0.1
fluxapyroxad	X.06	3 : 1	0.3 + 0.1
quinofumelin	X.06	10 : 1	0.3 + 0.03
quinofumelin	X.06	1 : 1	0.1 +0.1
quinofumelin	X.06	3 : 1	0.3 + 0.1
isoflucypram	X.06	10 : 3	0.1 +0.03
isoflucypram	X.06	10 : 1	0.3 + 0.03
isoflucypram	ΧΌ6	1 : 1	0.1 + 0.1
isoflucypram	X.06	3 : 1	Û.3 + 0.1
mefentrifluconazole	X.06	10 : 3	0.1 + 0.03
mefentrifluconazole	X.06	10 : 1	0.3 + 0.03
mefentrifluconazole	X.06	1 : 1	0.1 + 0.1
mefentrifluconazole	X.06	3 : 1	0.3 + 0.1
ipflufenoquin	X.06	10 : 3	0.1 + 0.03

161

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
ipflufenoquin	X.06	10 : 1	0.3 + 0.03
ipflufenoquin	X.06	1 : 1	0.1 + 0.1
ipflufenoquin	X.06	3 : 1	0.3 + 0.1
metyltetraprole	X.06	10 : 3	0.1 + 0.03
metyltetraprole	X.06	10 : 1	0.3 + 0.03
metyltetraprole	X.06	1 : 1	0.1 + 0.1
metyltetraprole	X.06	3 : 1	0.3 + 0.1
aminopyrifen	X.06	10 : 3	0.1 + 0.03
aminopyrifen	X.06	10 : 1	0.3 + 0.03
aminopyrifen	X.06	1 : 1	0.1 + 0.1
aminopyrifen	X.06	3 : 1	0.3 + 0.1
florylpicoxamid	X.06	10 : 3	0.1 +0.03
florylpicoxamid	X.06	10 ; 1	0.3 + 0.03
florylpicoxamid	X.06	1 : 1	0.1 +0.1
florylpicoxamid	X.06	3 : 1	0.3 + 0.1
florylpicoxamid	X.06	1:50	0.02+0.1
florylpicoxamid	X.06	1:25	0.02+0.05
florylpicoxamid	X.06	2:25	0.02+0.025
florylpicoxamid	X.06	4:25	0.02+0.0125
florylpicoxamid	X.06	8:25	0.02+0.00625
florylpicoxamid	X.06	16:25	0.02+0.003125
florylpicoxamid	X.06	1:100	0.01+0.1
florylpicoxamid	X.06	1:50	0.01+0.05
florylpicoxamid	X.06	1:25	0.01+0.025
florylpicoxamid	X.06	2:25	0.01+0.0125
florylpicoxamid	X.06	4:25	0.01+0.00625
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyi]-1-(1,2,4-triazol-1-yt)propan-2-ol	X.06	10 : 3	0.1 + 0.03
2-[6-(4-bromophenoxy)-2-(trifiuoromethyl)-3pyridyl]-1 -(1,2,4-triazol-1 -yl)propan-2-ol	X.06	10 : 1	0.3 + 0.03
2-[6-(4-bromophenoxy)-2’(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-oi	X.06	1 : 1	0.1 +0.1
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-tnazol-1-yl)propan-2-ol	X.06	3 : 1	0.3 + 0.1

162

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1 S_I2S)’2-¢4-Πuoro-2-methyl·pheny^)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyndine-2-carbonyl]a mino] propanoate	X.06	10 : 3	0.1 + 0.03
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyridine-2-carbonyl]a mino] propanoate	X.06	10 : 1	0.3 + 0.03
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyI] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]a mino] propanoate	X.06	1 : 1	0.1 + 0.1
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyridine-2'Carbonyl]a mino] propanoate	X.06	3 : 1	0.3 + 0,1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazoi-3-y!]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.06	10 : 3	0.1 + 0.03
(Z,2E)-5-[1-(2,4-drchlorophenyl)pyrazo!-3-yl]oxy- 2-methoxyίmino-N,3-dimethyl·pent-3-enamide	X.06	10 : 1	0.3 + 0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazo[-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.06	1 : 1	0.1 + 0.1
(Z,2E)-5-[1'(2,4-dichlorophenyl)pyrazol-3-yf]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.06	3 : 1	0.3 + 0.1
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoytoxy-pyridine-2carbonyl)amino]propanoate	X.06	6:10	0.06+0.1
[(1S,2S)-1-methyl-2-(o-tolyl)propyJ] (2S)-2-[(4- methoxy-3-propanoyîoxy-pyridine-2carbonyf)a mino] propanoate	X.06	6:5	0.06+0.05
[(1S,2S)-1-methyl-2-(o4olyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)a mino] propanoate	X.06	12:5	0.06+0.025
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- meth oxy-3- propan oyloxy-pyrid ine-2carbonyf)amino]propanoate	X.06	24:5	0.06+0.0125

163

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3- propanoy loxy-pyrid ine-2carbonyt)amino]propanoate	X.06	48:5	0.06+0.00625
[(1S,2S)-1-methyl-2-(o-toiyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)aminolpropanoate	X.06	96:5	0.06+0.003125
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoy loxy-pyrid in e-2carbonyl)amino]propanoate	X.06	3:10	0.03+0.1
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3- propan oyioxy-pyrid ine-2carbonyl)amino]propanoate	X.06	3:5	0.03+0.05
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyIoxy-pyridine-2carbonyl)amino]propanoate	X.06	6:5	0.03+0.025
[(1S,2S)-1-methyl-2-(o-tolyl)propyf] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X 06	12:5	0.03+0.0125
E(1S,2S)-1-methyi-2-(o-tolyl)prûpyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2- carbonyl) ami no] propanoate	X.06	24:5	0.03+0.00625
[(1S,2S)-1-methyi-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)ami no] propanoate	X.06	48:5	0.03+0.003125
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1₁2,4oxadiazol-3-yl]benzamide	X.06	200:1	20+0.1
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.06	400:1	20+0.05
N-(2-fliJorophenyi)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.06	800:1	20+0.025
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1_l2,4oxadiazol-3-yl]benzamide	X.06	1600:1	20+0.0125
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.06	100:1	10+0.1

164

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.06	200:1	10+0.05
N-(2-fluoré phenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.06	400:1	10+0.025
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.06	800:1	10+0.0125
glyphosate	X.10	1 : 1	0.1 + 0.1
glyphosate	X.10	3 : 1	0.3 + 0.1
chlorothalonil	X.10	10 : 1	0.3 + 0.03
chlorothalonil	X.10	1 : 1	0.1 + 0.1
chlorothalonil	X.10	3 : 1	0.3 + 0.1
mancozeb	X.10	1 : 1	0.1 + 0.1
mancozeb	X.10	3 : 1	0.3 + 0.1
propiconazole	X.10	1 : 1	0.1 + 0.1
propiconazole	X.10	3 : 1	0.3 + 0.1
disodium phosphonate	X.10	1 : 1	0.1 + 0.1
disodium phosphonate	X.10	3 : 1	0.3 + 0.1
fenpropimorph	X.10	1 : 1	0.1 + 0.1
fenpropimorph	X.10	3 : 1	0.3 + 0.1
fenpropidin	X.10	1 : 1	0.1 +0.1
fenpropidin	X.10	3 : 1	0.3 + 0.1
hexaconazole	X.10	10 : 1	0.3 + 0.03
hexaconazole	X.10	1 : 1	0.1 + 0.1
hexaconazole	X.10	3 : 1	0.3 + 0.1
paclobutrazol	X.10	1 : 1	0.1 + 0.1
paclobutrazol	X.10	3 : 1	0.3 + 0.1
trinexapac-ethyl	X.10	1 : 1	0.1 + 0.1
trinexapac-ethyl	X.10	3 : 1	0.3 + 0.1
flutriafol	X.10	1 : 1	0.1 + 0.1
flutriafol	X.10	3 : 1	0.3 + 0.1
difenoconazole	X.10	10 : 1	0.3 + 0.03
difenoconazole	X.10	1 : 1	0.1 + 0.1
difenoconazole	X.10	3 : 1	0.3 + 0.1
fludioxonil	X.10	1 : 1	0.1 + 0.1

165

Component B	Component A (compound)	Ratio B:A	Conc, (ppm) (B: A)
fludioxonil	X.10	3 : 1	0.3 + 0.1
cyproconazole	X.10	1 : 1	0.1 + 0.1
cyproconazole	X.10	3 : 1	0.3 + 0.1
acibenzolar S-methyl	X.10	1 : 1	0.1 + 0.1
acibenzolar S-methyl	X.10	3 : 1	0.3 + 0.1
trifloxystrobin	X.10	10 : 3	0.1 + 0,03
trifloxystrobin	X.10	10 : 1	0.3 + 0.03
trifloxystrobin	X.10	1 : 1	0.1 + 0,1
trifloxystrobin	X.10	3 : 1	0.3 + 0.1
folpet	X.10	1 : 1	0.1 + 0.1
folpet	X.10	3 : 1	0.3 + 0.1
azoxystrobin	X.10	10 : 3	0.1 + 0,03
azoxystrobin	X.10	10 : 1	0.3 + 0.03
azoxystrobin	X.10	1 : 1	0.1 + 0.1
azoxystrobin	X.10	3 : 1	0.3 + 0.1
pyraclostrobin	X.10	10 : 3	0.1 + 0,03
pyraclostrobin	X.10	10 : 1	0,3 + 0.03
pyraclostrobin	X.10	1 : 1	0.1 + 0.1
pyraclostrobin	X.10	3 : 1	0.3 + 0.1
picoxystrobin	X.10	10 : 3	0.1 + 0.03
picoxystrobin	X.10	10 : 1	0.3 + 0.03
picoxystrobin	X.10	1 : 1	0.1 + 0.1
picoxystrobin	X.10	3 : 1	0.3 + 0.1
sulphur	X.10	1 : 1	0.1 + 0.1
sulphur	X.10	3 : 1	0.3 + 0,1
tebuconazole	X.10	1 : 1	0.1 + 0.1
tebuconazole	X.10	3 : 1	0.3 + 0.1
prothioconazole	X.10	10 : 3	0.1 + 0.03
prothioconazole	X.10	10 : 1	0.3 + 0.03
prothioconazole	X.10	1 : 1	0.1 + 0,1
prothioconazole	X.10	3 : 1	0.3 + 0.1
fluopyram	X.10	1 : 1	0.1 + 0.1
fluopyram	X.10	3 : 1	0.3 + 0.1
copper oxychloride	X.10	1 : 1	0.1 + 0.1

166

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B : A)
copperoxychloride	X.10	3 : 1	0.3 + 0,1
benzovindiflupyr	X.10	1 : 1	0.1 + 0.1
benzovindiflupyr	X.10	3 : 1	0.3 + 0.1
isopyrazam	X.10	10 : 1	0.3 + 0.03
isopyrazam	X.10	1 : 1	0.1 + 0.1
isopyrazam	X.10	3 : 1	0.3 + 0,1
pydiflumetofen	X.10	10 : 3	0.1 + 0.03
pydiflumetofen	X.10	10 : 1	0.3 + 0.03
pydiflumetofen	X.10	1 : 1	0.1 + 0.1
pydiflumetofen	X.10	3 : 1	0.3 + 0.1
fluxapyroxad	X.10	10 : 1	0.3 + 0.03
fluxapyroxad	X.10	1 : 1	0.1 + 0.1
fluxapyroxad	X.10	3 : 1	0.3 + 0.1
quinofumeiin	X.10	1 : 1	0.1 + 0.1
quinofumeiin	X.10	3 : 1	0.3 + 0.1
isoflucypram	X.10	10 : 3	0.1 + 0.03
isoflucypram	X.10	10 : 1	0.3 + 0.03
isoflucypram	X.10	1 : 1	0.1 + 0.1
isoflucypram	X.10	3 : 1	0.3 + 0.1
mefentrifluconazole	X.10	10 : 3	0.1 + 0.03
mefentrifluconazole	X.10	10 : 1	0.3 + 0.03
mefentrifluconazole	X.10	1 : 1	0.1 + 0.1
mefentrifluconazole	X.10	3 : 1	0,3 + 0.1
ipflufenoquin	X.10	1 : 1	0,1 + 0.1
ipflufenoquin	X.10	3 : 1	0,3 + 0.1
metyltetraprole	X.10	10 : 3	0.1 +0.03
metyltetraprole	X.10	10 : 1	0.3 + 0.03
metyltetraprole	X.10	1 : 1	0.1 +0.1
metyltetraprole	X.10	3 : 1	0,3 + 0.1
amlnopyrifen	X.10	10 : 3	0,1 + 0.03
aminopyrifen	X.10	10 : 1	0.3 + 0.03
amlnopyrifen	X.10	1 : 1	0.1 + 0.1
aminopyrifen	X.10	3 : 1	0.3 + 0.1
florylpicoxamid	X.10	10 : 3	0,1 + 0.03

167

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
florylpicoxamid	X.10	10 : 1	0.3 + 0.03
florylpicoxamid	X.10	1 : 1	0.1 + 0.1
florylpicoxamid	X.10	3 : 1	0.3 + 0.1
florylpicoxamid	X.10	1:50	0.02+0.1
florylpicoxamid	X.10	1:25	0.02+0.05
florylpicoxamid	X.10	2:25	0.02+0.025
florylpicoxamid	X.10	4:25	0.02+0.0125
florylpicoxamid	X.10	8:25	0.02+0.00625
florylpicoxamid	X.10	16:25	0.02+0.003125
florylpicoxamid	X.10	1:100	0.01+0.1
florylpicoxamid	X.10	1:50	0.01+0.05
florylpicoxamid	X.10	1:25	0.01+0.025
florylpicoxamid	X.10	2:25	0.01+0.0125
florylpicoxamid	X.10	4:25	0.01+0.00625
florylpicoxamid	X.10	8:25	0.01+0.003125
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.10	10 : 3	0.1 +0.03
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.10	10 : 1	0.3 + 0.03
2-[6-(4-brornophenoxy)-2-(trifluoromethyl)-3pyridyn-l-tl^^-triazol-l-ynpropan^-ol	X.10	1 : 1	0.1 +0.1
2-[6-(4-bromophenoxy)'2-(trifltJoromethyl)-3py ridy 1]-1 -(1,2,4-triazo I-1 -y I) propa n-2-ol	X.10	3 : 1	0.3 + 0.1
«1 S,2S)-2-(4-fluoro-2-mettiyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl] a mino] propanoate	X.10	10 : 3	0.1 +0.03
[(1 S,2S)-2-(4-fluoro-2-mefhyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyridine’2~carbonyl]a min o] propanoate	X.10	10 : 1	0.3 + 0.03
[(1S,2S)-2-(4-fluoro-2-methyl-plienyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyridine-2-carbonyi]a mino] propanoate	X.10	1 : 1	0.1 + 0,1

168

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyi] {2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridtne-2-carbonyl]amrno]prapa noate	X.10	3 : 1	0.3 + 0.1
(Z₁2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.10	10 :3	0.1 + 0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.10	10 : 1	0.3 + 0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enarTiide	X.10	1 ; 1	0.1 +0.1
(Z^EJ-Sqi-^A-dîchlorophenyljpyrazol-S-ylJoxy2-methoxyimino-N_I3dimethyl-pent-3-enamide	X.10	3 : 1	0.3 + 0.1
[(1S,2S)-1-methyl-2-(o-tolyl)propylJ (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2- ca rbony l)a mi no]propa noate	X.10	6:10	0.06+0.1
[(1S,2S)-1-methyl-2-(o-tolyl)propylJ (2S)-2-[(4meth oxy-3-propa noy loxy- py rid ine-2ca rbony l)amino]propanoate	X.10	6:5	0,06+0.05
[(1S,2S)-1-methyk2-(o-tolyl)propyl] (2S)-2-[(4meth oxy-3-propanoy loxy-py rid ine-2carbonyl)amîno]propanoate	X.10	12:5	0.06+0.025
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4meth oxy-3-propanoy loxy- py rid ine-2carbonyl)amino]propanoate	X.10	24:5	0.06+0.0125
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)aminolpropanoate	X.10	48:5	0.06+0.00625
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.10	96:5	0.06+0.003125
[(1S,2S)-Tmethyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3- propanoy loxy-py rid ine-2carbonyl)amino]propanoate	X.10	3:10	0.03+0.1

169

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.10	3:5	0.03+0.05
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4meth oxy-3-propa noy loxy-pyrid ine-2carbonyl)amino]propanoate	X.10	6:5	0,03+0.025
[(1S,2S)-1-methyl-2-(o-to!yl)propyl] (2S)-2-[(4meth oxy-3-propanoy loxy-pyrid ine-2carbonyl)amino]propanoate	X.10	12:5	0.03+0.0125
[(1S,2S)-1 -methyl-2-(o-toiyl)propyl] (2S)-2-[(4meth oxy-3-propanoy loxy-pyrid ine-2carbonyl)amino]propanoate	X.10	24:5	0.03+0.00625
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4meth oxy-3-propanoy loxy-pyrid ine-2carbonyl)amino]propanoate	X.10	48:5	0.03+0.003125
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.10	200:1	20+0,1
N-(2-fluorophenyl)-4-[5-(triffuoromethy 1)-1,2,4oxadiazol-3-yi]benzamide	X.10	400:1	20+0.05
N-(2-fluorophenyl)-4-[5-(trifiuoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.10	800:1	20+0.025
N-(2-fluorophenyl)-4-[5-(trifluoromethy 1)-1,2,4oxadiazol-3-yl]benzamide	X.10	1600:1	20+0.0125
N-(2-fluorophenyl)-4-[5-(trifluoromethy 1)-1,2,4oxadiazol-3-yl]benzamide	X.10	3200:1	20+0.00625
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-y t]be nza m id e	X.10	100:1	10+0,1
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.10	200:1	10+0.05
N-(2-fl uorophenyl)-4-[5-(trifluoro methyl)-1,2,4oxadiazol-3-yllbenzamide	X.10	400:1	10+0,025
N-(2-fluoré phenyl)-4-[5-(trifluoromethy 1)-1,2,4oxadiazol-3-yllbenzamîde	X.10	800:1	10+0,0125

170

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadîazol-3-y Ijbenza m id e	X.10	1600:1	10+0.00625
glyphosate	X.09	10 : 3	0.1 +0.03
glyphosate	X.09	10 : 1	0.3 + 0.03
glyphosate	X.09	1 : 1	0.1 + 0.1
glyphosate	X.09	3 : 1	0.3 + 0.1
chlorothalonil	X.09	10 : 3	0.1 +0.03
chlorothalonil	X.09	10 : 1	0.3 + 0,03
chlorothalonil	X.09	1 : 1	0.1 + 0.1
chlorothalonil	X.09	3 : 1	0.3 + 0,1
mancozeb	X.09	10 : 3	0.1 + 0.03
mancozeb	X.09	10 : 1	0.3 + 0.03
mancozeb	X.09	1 : 1	0.1 + 0,1
mancozeb	X.09	3 : 1	0.3 + 0.1
propiconazole	X.09	10 : 3	0.1 + 0.03
propiconazole	X.09	10 : 1	0.3 + 0.03
propiconazoie	X.09	1 : 1	0.1 + 0.1
propiconazole	X.09	3 : 1	0.3 + 0.1
disodium phosphonate	X.09	10 : 3	0.1 + 0.03
disodium phosphonate	X.09	10 : 1	0.3 + 0.03
disodium phosphonate	X.09	1 : 1	0.1 + 0.1
disodium phosphonate	X.09	3 : 1	0.3 + 0.1
fenpropimorph	X.09	10 : 3	0.1 + 0.03
fenpropimorph	X.09	10 ; 1	0.3 + 0.03
fenpropimorph	X.Û9	1 : 1	0.1 + 0.1
fenpropimorph	X.09	3 : 1	0.3 + 0.1
fenpropidin	X.09	10 : 3	0.1 + 0.03
fenpropidin	X.09	10 : 1	0.3 + 0.03
fenpropidin	X.09	1 : 1	0.1 + 0.1
fenpropidin	X.09	3 : 1	0.3 + 0.1
hexaconazole	X.09	10 : 3	0.1 + 0.03
hexaconazole	X.09	10 : 1	0.3 + 0.03
hexaconazole	X.09	1 : 1	0.1 + 0.1
hexaconazole	X.09	3 : 1	0.3 + 0.1

171

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
paclobutrazol	X.09	10 : 3	0.1 + 0.03
paclobutrazol	X.09	10 : 1	0.3 + 0.03
paclobutrazol	X.09	1 : 1	0.1 +0.1
paclobutrazol	X.09	3 : 1	0.3 + 0.1
trinexapac-ethyl	X.09	10 : 3	0.1 +0.03
trînexapac-ethyl	X.09	10 : 1	0.3 + 0.03
trinexapac-ethyl	X.09	1 : 1	0.1 +0.1
trinexapac-ethyl	X.09	3 ; 1	0,3 + 0.1
flutriafol	X.09	10 : 3	0.1 +0.03
flutriafol	X.09	10 : 1	0.3 + 0.03
flutriafol	X.09	1 : 1	0.1 +0.1
flutriafol	X.09	3 : 1	0.3 + 0.1
difenoconazole	X.09	10 : 3	0.1 +0.03
difenoconazole	X.09	10 : 1	0.3 + 0.03
difenoconazole	X.09	1 : 1	0.1 +0.1
difenoconazole	X.09	3 : 1	0.3 + 0.1
fludioxonil	X.09	10 : 3	0.1 +0.03
fludioxonil	X.09	10 : 1	0.3 + 0.03
fludioxonil	X.09	1 : 1	0.1 + 0.1
fludioxonil	X.09	3 : 1	0.3 + 0.1
cyproconazole	X.09	10 : 3	0.1 + 0.03
cyproconazole	X.09	10 : 1	0.3 + 0.03
cyproconazole	X.09	1 : 1	0.1 + 0.1
cyproconazole	X.09	3 : 1	0.3 + 0.1
acibenzolar S-methyl	X.09	10 : 3	0.1 + 0.03
acibenzolar S-methyl	X.09	10 : 1	0.3 + 0.03
acibenzolar S-methyl	X.09	1 : 1	0.1 + 0.1
acibenzolar S-methyl	X.09	3 : 1	0.3 + 0.1
trifloxystrobin	X.09	10 : 3	0.1 + 0.03
trifloxystrobin	X.09	10 : 1	0.3 + 0.03
trifloxystrobin	X.09	1 : 1	0.1 + 0.1
trifloxystrobin	X.09	3 ; 1	0.3 + 0.1
folpet	X.09	10 : 3	0.1 +0.03
folpet	X.09	10 : 1	0.3 + 0.03

172

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
folpet	X.09	1 : 1	0.1 +0.1
folpet	X.09	3 : 1	0.3 + 0.1
azoxystrobin	X.09	10 : 3	0.1 + 0.03
azoxystrobin	X.09	10 : 1	0.3 + 0.03
azoxystrobin	X.09	1 : 1	0.1 + 0.1
azoxystrobin	X.09	3 : 1	0.3 + 0.1
pyraciostrobin	X.09	10 : 3	0.1 + 0.03
pyraciostrobin	X.09	10 : 1	0.3 + 0.03
pyraciostrobin	X.09	1 : 1	0.1 + 0.1
pyraciostrobin	X.09	3 : 1	0.3 + 0.1
picoxystrobin	X.09	10 : 3	0.1 + 0.03
picoxystrobin	X.09	10 : 1	0.3 + 0.03
picoxystrobin	X.09	1 : 1	0.1 + 0.1
picoxystrobin	X.09	3 : 1	Û.3 + 0.1
sulphur	X.09	10 : 3	0.1 + 0.03
sulphur	X.09	10 : 1	0.3 + 0.03
sulphur	X.09	1 : 1	0.1 + 0.1
sulphur	X.09	3 : 1	0.3 + 0.1
tebuconazole	ΧΌ9	10 : 3	0.1 + 0.03
tebuconazole	X.09	10 : 1	0.3 + 0.03
tebuconazole	X.09	1 : 1	0.1 + 0.1
tebuconazole	X.09	3 : 1	0.3 + 0.1
prothioconazole	X.09	10 : 3	0.1 + 0.03
proth ioconazole	X.09	10 : 1	0.3 + 0.03
prothioconazole	X.09	1 : 1	0.1 + 0.1
prothioconazole	X.09	3 : 1	0.3 + 0.1
fluopyram	X.09	10 : 3	0.1 + 0.03
fluopyram	X.09	10 : 1	0.3 + 0.03
fluopyram	X.09	1 : 1	0.1 + 0.1
fluopyram	X.09	3 : 1	0.3 + 0.1
copper oxychloride	X.09	10 : 3	0.1 + 0.03
copper oxychloride	X.09	10 : 1	0.3 + 0.03
copper oxychloride	X.09	1 : 1	0.1 + 0.1
copper oxychloride	X.09	3 : 1	0.3 + 0.1

173

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
benzovindiflupyr	X.09	10 : 3	0.1 + 0.03
benzovindiflupyr	X.09	10 : 1	0.3 + 0.03
benzovindiflupyr	X.09	1 : 1	0.1 + 0.1
benzovindiflupyr	X.09	3 : 1	0.3 + 0.1
isopyrazam	X.09	10 : 3	0.1 + 0.03
isopyrazam	X.09	10 : 1	0.3 + 0.03
isopyrazam	X.09	1 ; 1	0.1 + 0.1
isopyrazam	X.09	3 : 1	0.3 + 0.1
pydiflumetofen	X.09	10 : 3	0.1 + 0.03
pydiflumetofen	X.09	10 : 1	0.3 + 0.03
pydiflumetofen	X.09	1 : 1	0.1 + 0.1
pydiflumetofen	X.09	3 : 1	0.3 + 0.1
fluxapyroxad	X.09	10 : 3	0.1 + 0.03
fluxapyroxad	X.09	10 : 1	0.3 + 0.03
fluxapyroxad	X.09	1 : 1	0.1 + 0.1
fluxapyroxad	X.09	3 : 1	0.3 + 0.1
quinofumelin	X.09	10 : 3	0.1 + 0.03
quinofumelin	X.09	10 : 1	0.3 + 0.03
quinofumelin	X.09	1 : 1	0.1 + 0.1
quinofumelin	X.09	3 : 1	0.3 + 0.1
isoflucypram	X.09	10 : 3	0.1 + 0.03
isoflucypram	X.09	10 : 1	0.3 + 0.03
isoflucypram	X.09	1 : 1	0.1 + 0.1
isoflucypram	X.09	3 : 1	0.3 + 0.1
mefe ntrifluco n azo le	X.09	10 : 3	0.1 + 0.03
mefe ntrifluco n azo le	X.09	10 : 1	0.3 + 0.03
mefe ntrifluco n azo le	X.09	1 : 1	0.1 + 0.1
mefentrifluco n azo le	X.09	3 : 1	0.3 + 0.1
ipflufenoquin	X.09	10 : 3	0.1 + 0.03
ipflufenoquin	X.09	10 : 1	0.3 + 0.03
ipflufenoquin	X.09	1 : 1	0.1 + 0.1
ipflufenoquin	X.09	3 : 1	0.3 + 0.1
metyltetraprole	X.09	10 : 3	0.1 + 0.03
metyltetraprole	X.09	10 : 1	0.3 + 0.03

174

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
metyltetraprole	X.09	1 : 1	0.1 + 0.1
metyltetraprole	X.09	3 : 1	0.3+ 0.1
aminopyrifen	X.09	10 : 3	0.1 + 0.03
aminopyrifen	X.09	10 : 1	0.3 + 0.03
aminopyrifen	X.09	1 : 1	0.1 + 0.1
aminopyrifen	X.09	3 : 1	0.3 + 0.1
florylpicoxamid	X.09	10 : 3	0.1 + 0.03
florylpicoxamid	X.09	10 : 1	0.3 + 0.03
florylpicoxamid	X.09	1 : 1	0.1 + 0.1
florylpicoxamid	X.09	3 : 1	0.3 + 0.1
florylpicoxamid	X.09	1:2	0.02+0.04
florylpicoxamid	X.09	1:1	0.02+0.02
florylpicoxamid	X.09	2:1	0.02+0.01
florylpicoxamid	X.09	4:1	0.02+0.005
florylpicoxamid	X.09	8:1	0.02+0.0025
florylpicoxamid	X.09	16:1	0.02+0.00125
florylpicoxamid	X.09	1:4	0.01+0.04
florylpicoxamid	X.09	1:2	0.01+0.02
florylpicoxamid	X.09	1:1	0.01+0.01
florylpicoxamid	X.09	2:1	0.01+0.005
florylpicoxamid	X.09	4:1	0.01+0.0025
2-[6-(4-bromophenoxy)-2-(triflooromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.09	10 : 3	0.1 + 0.03
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.09	10 : 1	0.3 + 0.03
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.09	1 : 1	0.1 + 0.1
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3ρνΓίΰγΙ]-1-(1,2,44π3ΖθΙ-1-νί)ρΓορ3η-2Ό1	X.09	3 : 1	0.3 + 0.1
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3- dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-py rid in e-2-carbonyl]amino] propanoate	X.09	10 : 3	0.1 + 0.03

175

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1 S,2S)-2-(4-iluoro-2-methyl-phenyî)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.09	10 : 1	0.3 + 0.03
[(1 S,2S)-2-(4-flLioro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyridine-2-ca rbony l]amino]propanoate	X.09	1 : 1	0.1 +0.1
[(1 S,2S)-2-(4-flLfOro-2-methyl-phenyi)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonylIaminoÎpropanoate	X.09	3 : 1	0.3 + 0.1
(Z,2E)-5-[1-(2_l4-dichlOΓOphenyl)pyrazol·3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.09	10 : 3	0.1 +0.03
(Z,2E)-5-[1-(2,4-dîchlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N₁3-dimethyl-pent-3-enamide	X.09	10 : 1	0.3 + 0.03
(Z_l2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.09	1 : 1	0.1 +0.1
(Z_l2E)-5-[1-(2,4-dichlorophenyl)pyrazo!-3’yl]oxy- 2-methoxyimino-N,3-drmethyl-pent-3-enamide	X.09	3 : 1	0.3 + 0.1
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3- propanoy loxy-py rid ine-2carbonyl)amino]propanoate	X.09	3:2	0.06+0.04
[(1S,2S)-1-methyl-2-(o-toJyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.09	3:1	0.06+0.02
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propan oyloxy-pyrid ine-2carbonyl)amîno]propanoate	X.09	6:1	0.06+0.01
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (23)-2-((4- methoxy-3-propanoy!oxy-pyridine-2carbonyl)amino]propanoate	X.09	12:1	0.06+0.005
[(1S,2S)-1-methyl-2-(o-toiyl)propylJ (23)-2-((4methoxy-3- propan oyloxy-pyrid ine-2carbonyl)amino]propanoate	X.09	24:1	Û.06+0.Û025

176

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1 S,2S)-1 -methyl-2-(o-tolyl)propy1] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)aminolpropanoate	X.09	48:1	0.06+0.00125
[(1 S,2S)-1 -methyl-2-(o-tolyDpropyl] (2S)-2-[(4meihoxy-3-propanoyloxy-pyridine-2- carbonyl)amino]propanoate	X.09	3:4	0.03+0.04
[(1S,2S)-1-methyl-2-(O-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.09	3:2	0.03+0.02
[(1S,2S)-1-methyl-2-(o-1olyi)propyl[ (2S)-2-[(4me1hoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.09	3:1	0.03+0.01
[(1 S,2S)-1 -methyl-2-(o-1olyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.09	6:1	0.03+0.005
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4meth oxy-3-propanoy loxy-py rid ine-2carbonyl)amino]propanoate	X.09	12:1	0.03+0.0025
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4meth oxy-3-propanoy loxy-pyrid ine-2carbonyl)amino]propanoate	X.09	24:1	0.03+0.00125
N-(2-fluorophenyl)'445-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.09	500:1	20+0.04
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yi]benzamide	X.09	1000:1	20+0.02
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadîazol-3-yl]benzamide	X.09	2000:1	20+0.01
N-(2-fluorophenyl)-4-[5-(tnfluoromethyt)-1,2,4oxadiazol-3-yl]benzamide	X.09	4000:1	20+0.005
N-(2-fluorophenyl)-4-[5-(trifIuoromethyi)-1,2,4oxadiazol-3-yl]benzamide	X.09	8000:1	20+0.0025
N-(2-fluorophenyl)-4-[5-(trifluoromethy[)-1,2,4oxadiazol-3-y f] b e nza m ide	X.09	250:1	10+0.04

177

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
N-(2-fluorophenyl)-4-[5-(trifluoromethyi)-1,2,4oxadiazol-3-yi]benzamide	X.09	500:1	10+0.02
N-(2-fIuorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]be nza mide	X.09	1000:1	10+0.01
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]be nza m id e	X.09	2000:1	10+0.005
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.09	4000:1	10+0.0025

The following mixture compositions atthe reported concentration (in ppm) in tables B3-2 to B3-6 gave the following disease control in this test Septoria tritici (leaf blotch). Fungicidal activity was evaluated on a 100-0 scale (100 = no disease growth; 0 = well completely covered by mycélium).

Table B3-2

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoat e	X.01	0.06+0.0125	70	90	100	97
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyioxypyridine-2carbonyl)amino]propanoat e	X.01	0.06+0.00625	70	50	100	85
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2-	X.01	0.06+0.003125	70	20	90	76

178

Component B carbonyl)amino]propanoat e	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity W
ppm	B	A	B+A
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyi)amino]propanoat e	X.01	0.03+0.0125	50	90	100	95
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoy!oxypyridine-2carbonyl)amino]propa noat e	X.01	0.03+0.00825	50	50	90	75
[(1S,2S)-1-methyl-2-(o- toly!)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoat e N-(2-fluorophenyl)-4-(5(trifluoromethyl)-l ,2,4oxadiazol-3-yl]benzamide	X.01 X.01	0.03+0.003125 20+0.0125	50 0	20 90	70 100	60 90
N-(2-ftuorophenyl)-4-[5(trifluoromethyl)-l ,2,4oxadiazol-3-y Ijbenza mid e	X.01	10+0.0125	0	90	100	90
florylpicoxamid	X.01	0.02+0.0125	20	90	100	92
florylpicoxamid	X.01	0.02+0.00625	20	70	90	76
florylpicoxamid	X.01	0.02+0.003125	20	20	70	36
florylpicoxamid	X.01	0.01+0.0125	0	90	100	90
florylpicoxamid	X.01	0.01+0.00625	0	70	70	70
florylpicoxamid	X.01	0.01+0.003125	0	20	50	20

Table B3-3

179

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
chlorothalonil	X.08	0.1 +0.03	20	50	90	G0
chlorothalonil	X.08	0.3 + 0.03	70	50	100	85
chlorothalonil	X.08	0.1 + 0.1	20	70	100	76
chlorothalonil	X.08	0.3 + 0.1	70	70	100	91
fenpropidin	X.08	0.1 +0.03	0	50	50	50
fenpropidin	X.08	0.3 + 0.03	0	50	50	50
fenpropidin	X.08	0.1 + 0.1	0	70	90	70
fenpropidin	X.08	0.3 + 0.1	0	70	90	70
fludioxonil	X.08	0.1 + 0.03	0	50	50	50
fludioxonil	X.08	0.3 + 0.03	20	50	90	60
fludioxonil	X.08	0.1 + 0.1	0	70	70	70
fludioxonil	X.08	0,3 + 0.1	20	70	90	76
cyproconazole	X.08	0.1 + 0.03	20	50	50	60
cyproconazole	X.08	0.3 + 0.03	50	50	90	75
cyproconazole	X.08	0.1 + 0.1	20	70	90	76
cyproconazole	X.08	0.3 + 0.1	50	70	100	85
folpet	X.08	0.1 +0.03	0	50	20	50
folpet	X.08	0.3 + 0.03	0	50	70	50
folpet	X.08	0.1 +0.1	0	70	70	70
folpet	X.08	0.3 + 0.1	0	70	100	70
benzovindiflupyr	X.08	0.1 +0.03	50	50	70	75
benzovindiflupyr	X.08	0.3 + 0.03	70	50	100	85
benzovindiflupyr	X.08	0.1 + 0.1	50	70	100	85
benzovindiflupyr	X.08	0.3 + 0.1	70	70	100	91
isopyrazam	X.08	0.1 + 0.03	50	50	70	75
isopyrazam	X.08	0.3 + 0.03	70	50	100	85
isopyrazam	X.08	0.1 + 0.1	50	70	100	85

180

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
isopyrazam	X.08	0.3 + 0.1	70	70	100	91
quinofumelin	X.08	0.1 + 0.03	0	50	50	50
quinofumelin	X.08	0.3 + 0.03	0	50	70	50
quinofumelin	X.08	0.1 + 0.1	0	70	90	70
quinofumelin	X.08	0.3 + 0.1	0	70	100	70
ipflufenoquin	X.08	0.1 + 0.03	0	50	90	50
ipflufenoquin	X.08	0.3 + 0.03	20	50	90	60
ipflufenoquin	X.Û8	0.1 + 0.1	0	70	100	70
ipflufenoquin	X.08	0.3 + 0.1	20	70	100	76
florylpicoxamid	X.08	0.02+0.025	20	70	100	76
florylpicoxamid	X.08	0.02+0.0125	20	20	90	36
florylpicoxamid	X.08	0.02+0.00625	20	0	70	20
florylpicoxamid	X.08	0.01+0.025	0	70	100	70
florylpicoxamid	X.08	0.01+0.0125	0	20	90	20
florylpicoxamid	X.08	0.01+0.00625	0	0	70	0
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.08	0.06+0.025	70	90	100	97
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.08	0.06+0.0125	70	20	100	76
[(1S,2S)-1-methyl-2-(otolyl)propyl] (28)-2-((4methoxy-3- propan oy loxypyridine-2carbonyl)amino]propanoate	X.08	0.06+0.00625	70	0	100	70
[(1S,2S)-1-mefhyl-2-(o- tolyl)propyl] (28)-2-((4-	X.08	0.03+0.025	50	90	100	95

181

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate
[(1S_T2S)-1-methyl-2-(oto!yl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.08	0.03+0.0125	50	20	100	60
[(1S,2S)-1-methyl-2-(oto1yl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.08	0.03+0.00625	50	0	70	50
N-(2-fluorophenyl)-4-[5(trifluoromethyl)-l ,2,4oxadiazol-3-yl]benzamide	X.08	20+0.025	0	90	100	90
N-(2-fluorophenyl)-4-[5(trifluoromethyl)-l ,2,4oxadiazof-3-yl]benzamide	X.08	20+0.0125	0	20	70	20
N-(2-fluorophenyl)-4-[5(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.08	10+0.025	0	90	100	90
N-(2-fluoropheny!)-4-[5(tiifluoromethyl)-l ,2,4oxad iazo l-3-y IJbenza m ide	X.08	10+0.0125	0	20	70	20

Table B3-4

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
chlorothalonil	X.06	0.1 +0.03	20	70	100	76
chlorothalonil	X.06	0.3 + 0.03	70	70	100	91

182

Component B	Component A	Concentration (B+A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
fludioxonil	X.06	0.1 +0.03	0	70	70	70
fludioxonil	X.06	0.3 + 0.03	20	70	90	76
folpet	X.06	0.1 +0.03	0	70	70	70
folpet	X.06	0.3 + 0.03	0	70	90	70
ipflufenoquin	X.06	0.1 +0.03	0	70	90	70
ipflufenoquin	X.06	0.3 + 0.03	20	70	100	76
florylpicoxamid	X.06	0.02+0.0125	20	70	100	76
florylpicoxamid	X.06	0.02+0.00625	20	50	90	60
florylpicoxamid	X.06	0.02+0.003125	20	0	50	20
florylpicoxamid	X.06	0.01+0.0125	0	70	100	70
florylpicoxamid	X.06	0.01+0.00625	0	50	70	50
florylpicoxamid	X.06	0.01+0.003125	0	0	50	0
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyioxypyridine-2carbonyl)amino]propa noate	X.06	0.06+0.0125	70	90	100	97
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoy1oxypyridine-2carbonyl)amino]propanoate	X.06	0.06+0.00625	70	50	100	85
[(1S,2S)-1-methy!-2-(o- tolyl)propyl) (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.06	0.06+0.003125	70	20	90	76
[(1S,2S)-1-methyl-2-(o- tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propa noate	X.06	0.03+0.0125	50	90	100	95
«1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-	X.06	0.03+0.00625	50	50	90	75

183

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
pyridine-2carbonyi)amino]propanoate
[(1S,2S)-1-methyl-2-(o- tolyl)propyl] (2S)-2-[(4methoxy-3- propan oyloxypyridine-2- carbonyl)aminojpropanoate	X.06	0.03+0.003125	50	20	70	60
N-(2-fluorophenyl)-4-[5(trifluoromethyl)-l ,2,4oxadiazol-3-yl]benzamide	X.06	20+0.0125	0	90	100	90
N-(2-fluorophenyl)-4-[5(trifluoromethy l)-1,2,4oxadiazol-3-yl]benzamide	X.06	10+0.0125	0	90	100	90

Table B3-5

Component B	Component A	Concentration (B+A)	Activity (%)	COLBY Expected Activity (%>
ppm	B	A	B + A
chlorothalonil	X.10	0.1 + 0.03	20	0	20	20
chlorothalonil	X.10	0.3 + 0.03	70	0	100	70
fludioxonil	X.10	0.1 + 0.03	0	0	20	0
fludioxonil	X.10	0.3 + 0.03	20	0	70	20
cyproconazole	X.10	0.1 + 0.03	20	0	20	20
cyproconazole	X.10	0.3 + 0.03	50	0	70	50
fluopyram	X.10	0.1 + 0.03	0	0	20	0
fluopyram	X.10	0.3 + 0.03	50	0	50	50
isopyrazam	X.10	0.1 + 0.03	50	0	50	50
isopyrazam	X.10	0.3 + 0.03	70	0	90	70
florylpicoxamid	X.10	0.02+0.0125	20	90	100	92
florylpicoxamid	X.10	0.02+0.00625	20	90	100	92
florylpicoxamid	X.10	0.02+0.003125	20	70	100	76
florylpicoxamid	X.10	0.01+0.0125	0	90	100	90
florylpicoxamid	X.10	0.01+0.00625	0	90	100	90
florylpicoxamid	X.10	0.01+0.003125	0	70	90	70

184

Table B3-6

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
[(1S,2S)-1-methyl-2-(o- tolyl)propyl] (2S)-2-[(4- πί et h oxy- 3- pro pa η o y loxypyridine-2carbonyl)amino]propanoate	X.09	0.06+0.005	70	90	100	97
[(1S,2S)-1-methyl-2-(o- to!yl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.09	0.06+0.0025	70	70	100	91
[(1S,2S)-1-methyl-2-(o- tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)aminolpropanoate	X.09	0.06+0.00125	70	20	100	76
[(1S,2S)-1-methyl-2-(o- tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.09	0.03+0.005	50	90	100	95
[(1S,2S)-1-methyl-2-(o- toiyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyrîdine-2carbonyl)amino]propanoate	X.09	0.03+0.0025	50	70	100	85
[(1S,2S)-1-methyl-2-(o~ toiyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.09	0.03+0.00125	50	20	90	95

185

Component B	Component A	Concentration (B +A)	Activit	/ <%)	COLBY Expected Activity (%)
ppm	B	A	B + A
N-(2-fluorophenyl)-4-[5(trifluoromethyl)-l ,2,4oxadiazol-3-yl]benzamrde	X.09	20+0.005	0	90	100	90
N-(2-fluorophenyl)~4-[5(trifluoromethyl)-l ,2,4oxadiazol-3-yl]benzamrde	X.09	20+0.0025	0	70	90	70
N-(2-fluoropheny])-4-[5(trifluoromethyl)-l ,2,4oxadiazol-3-yl]benzamide	X.09	20+0.00125	0	20	50	20
N-(2-fluoropheny 1)-4-(5(trifluoromethyl)-l ,2,4oxadiazol-3-yl]benzamide	X.09	10+0.005	0	90	100	90
N-(2-fluorophenyI)-4-[5(trifluoromethyl)-1,2,4oxadiazo\|-3-yl]benzamide	X.09	10+0.0025	0	70	90	70
N-(2-fluoro pheny 1)-4-(5(trifluoromethyl)-l ,2,4oxadiazol-3-yl]benzamide	X.09	10+0.00125	0	20	50	20
florylpicoxamid	X.09	0.02+0.005	20	90	100	92
florylpicoxamid	X.09	0.02+0.0025	20	70	100	76
florylpicoxamid	X.09	0.02+0.00125	20	50	70	60
florylpicoxamid	X.09	0.01+0.005	0	90	100	90
florylpicoxamid	X.09	0.01+0.0025	0	70	100	70
florylpicoxamid	X.09	0.01+0.00125	0	50	70	50

Exemple B4: Preventative activity against Mvcosphaerella arachidis syn. Cercospora arachidtcola (Brown leaf spot of peanut) :

Conidia ofthe fungus from cryogénie storage were directiy mixed into nutrient broth (PDB potato dextrose broth). A DMSO solution ofthe test compounds was placed into a microtiter plate (96-wel! format) and the nutrient broth containing the fungal spores was added to it. The test piates were incubated at 24°C and the inhibition of growth was determined photometricaliy after approximately 5-6 days at 620 nm.

186

The following mixture compositions (B:A) at the reported concentration (în ppm) în table 84-1 gave at least 80% disease control in this test (Mycosphaerella arachidis).

Table B4-1

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
glyphosate	X.01	10 : 3	0.1 +0.03
glyphosate	X.01	10 : 1	0.3 + 0.03
glyphosate	X.01	1 : 1	0.1 +0.1
glyphosate	X.01	3 : 1	0.3 + 0.1
chlorothalonil	X.01	10 : 3	0.1 +0.03
chlorothalonil	X.01	10 : 1	0.3 + 0.03
chlorothalonil	X.01	1 : 1	0.1 +0.1
chlorothalonil	X.01	3 : 1	0.3 + 0.1
mancozeb	X.01	10 : 3	0.1 +0.03
mancozeb	X.01	10 : 1	0.3 + 0.03
mancozeb	X.01	1 : 1	0.1 +0.1
mancozeb	X.01	3 : 1	0.3 + 0.1
propiconazole	X.01	10 : 3	0.1 +0.03
propiconazole	X.01	10 : 1	0.3 + 0.03
propiconazole	X.01	1 : 1	0.1 +0.1
propiconazole	X.01	3 : 1	0.3 + 0.1
disodium phosphonate	X.01	10 : 3	0.1 +0.03
disodium phosphonate	X.01	10 : 1	0.3 + 0.03
disodium phosphonate	X.01	1 : 1	0.1 +0.1
disodium phosphonate	X.01	3 : 1	0.3 + 0.1
fenpropimorph	X.01	10 : 3	0.1 +0.03
fenpropimorph	X.01	10 : 1	0.3 + 0.03
fenpropimorph	X.01	1 : 1	0.1 +0.1
fenpropimorph	X.01	3 : 1	0.3 + 0.1
fenpropidin	X.01	10 : 3	0.1 +0.03
fenpropidin	X.01	10 :1	0.3 + 0.03
fenpropidin	X.01	1 : 1	0.1 + 0.1
fenpropidin	X.01	3 : 1	0.3 + 0.1
hexaconazole	X.01	10 : 3	0.1 +0.03
hexaconazole	X.01	10 :1	0.3 + 0.03

187

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
hexaconazoie	X.01	1 : 1	0.1 +0.1
hexaconazoie	X.01	3 : 1	0.3 + 0.1
paclobutrazol	X.01	10 : 3	0.1 + 0.03
paclobutrazol	X.01	10 : 1	0.3 + 0.03
paclobutrazol	X.01	1 : 1	0.1 +0.1
paclobutrazol	X.01	3 : 1	0.3 + 0.1
trinexapac-ethyl	X.01	10 : 3	0.1 +0.03
trinexapac-ethyl	X.01	10 : 1	0.3 + 0.03
trinexapac-ethyl	X.01	1 : 1	0.1 +0.1
trinexapac-ethyl	X.01	3 : 1	0.3 + 0.1
flutrîafol	X.01	10 : 3	0.1 +0.03
flutrîafol	X.01	10 : 1	0.3 + 0.03
flutrîafol	X.01	1 : 1	0.1 +0.1
flutrîafol	X.01	3 : 1	0.3 + 0.1
difenoconazole	X.01	10 : 3	0.1 +0.03
difenoconazole	X.01	10 : 1	0.3 + 0.03
difenoconazole	X.01	1 : 1	0.1 + 0.1
difenoconazole	X.01	3 : 1	0.3 + 0.1
fludioxonil	X.01	1 : 1	0.1 + 0.1
fludioxonil	X.01	3 : 1	0.3 + 0.1
cyproconazole	X.01	10 : 1	0.3 + 0.03
cyproconazole	X.01	1 : 1	0.1 + 0.1
cyproconazole	X.01	3 : 1	0.3 + 0.1
acibenzolar S-methyl	X.01	10 : 3	0.1 + 0.03
acibenzolar S-methyl	X.01	10 : 1	0.3 + 0.03
acibenzolar S-methyl	X.01	1 : 1	0.1 + 0.1
acibenzolar S-methyl	X.01	3 : 1	Û.3 + 0.1
trifloxystrobin	X.01	10 : 3	0.1 + 0.03
trifloxystrobin	X.01	10 ; 1	0.3 + 0.03
trifloxystrobin	X.01	1 : 1	0.1 + 0.1
trifloxystrobin	X.01	3 : 1	0.3 + 0.1
folpet	X.01	10 : 3	0.1 + 0.03
folpet	X.01	10 : 1	0.3 + 0.03
folpet	X.01	1 ; 1	0.1 + 0.1

188

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
folpet	X.01	3 : 1	0.3 + 0.1
azoxystrobin	X.01	10 : 3	O.1 + 0.03
azoxystrobin	X.01	10 : 1	0.3 + 0.03
azoxystrobin	X.01	1 : 1	0.1 + 0.1
azoxystrobin	X.01	3 : 1	0.3 + 0.1
pyraclostrobin	X.01	10 : 3	O.1 + 0.03
pyraclostrobin	X.01	10 : 1	0.3 + 0.03
pyraclostrobin	X.01	1 : 1	0.1 + 0.1
pyraclostrobin	X.01	3 : 1	0.3 + 0.1
picoxystrobin	X.01	10 : 3	0.1 + 0.03
picoxystrobin	X.01	10 : 1	0.3 + 0.03
picoxystrobin	X.01	1 : 1	0.1 + 0.1
picoxystrobin	X.01	3 : 1	0.3 + 0.1
sulphur	X.01	10 : 3	0.1 + 0.03
sulphur	X.01	10 : 1	0.3 + 0.03
sulphur	X.01	1 : 1	0.1 + 0.1
sulphur	X.01	3 : 1	0.3 + 0.1
tebuconazole	X.01	10 : 1	0.3 + 0.03
tebuconazole	X.01	1 : 1	0.1 + 0.1
tebuconazole	X.01	3 : 1	0.3 + 0.1
prothioconazole	X.01	10 : 3	0.1 + 0.03
prothioconazole	X.01	10 : 1	0.3+ 0.03
prothioconazole	X.01	1 : 1	0.1 + 0.1
prothioconazole	X.01	3 : 1	0.3+ 0.1
fluopyram	X.01	10 : 3	0.1 + 0.03
fluopyram	X.01	10 : 1	0.3+ 0.03
fluopyram	X.01	1 : 1	0.1 + 0.1
fluopyram	X.01	3 : 1	03 + 0.1
copper oxychloride	X.01	10 : 3	0.1 + 0.03
copper oxychloride	X.01	10 : 1	0.3+ 0.03
copper oxychloride	X.01	1 : 1	0.1 + 0.1
copper oxychloride	X.01	3 : 1	0.3 + 0.1
benzovindiflupyr	X.01	10 : 3	0.1 + 0.03
benzovindiflupyr	X.01	10 : 1	0.3 + 0.03

189

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
benzovindiflupyr	X.01	1 : 1	0.1 + 0.1
benzovindiflupyr	X.01	3 : 1	0.3 + 0.1
isopyrazam	X.01	10 : 3	0.1 + 0.03
isopyrazam	X.01	10 : 1	0.3 + 0.03
isopyrazam	X.01	1 : 1	0.1 + 0.1
isopyrazam	X.01	3 : 1	0.3 + 0.1
pydiflumetofen	X.01	10 : 3	0.1 + 0.03
pydiflumetofen	X.01	10 : 1	0.3 + 0.03
pydiflumetofen	X.01	1 : 1	0.1 +0.1
pydiflumetofen	X.01	3 : 1	0.3 + 0.1
fluxapyroxad	X.01	10 : 3	0.1 +0.03
fluxapyroxad	X.01	10 : 1	0.3 + 0.03
fluxapyroxad	X.01	1 : 1	0.1 + 0.1
fluxapyroxad	X.01	3 : 1	0.3 + 0.1
quinofumelin	X.01	10 : 3	0.1 + 0.03
quinofumelin	X.01	10 : 1	0.3 + 0.03
quinofumelin	X.01	1 : 1	0.1 + 0.1
quinofumelin	X.01	3 : 1	0.3 + 0.1
isoflucypram	X.01	10 : 3	0.1 + 0.03
isoflucypram	X.01	10 : 1	0.3 + 0.03
isoflucypram	X.01	1 : 1	0.1 + 0.1
isoflucypram	X.01	3 : 1	0.3 + 0.1
mefentrifluconazole	X.01	10 : 3	0.1 + 0.03
mefentrifluconazole	X.01	10 : 1	0.3 + 0.03
mefentrifluconazole	X.01	1 : 1	0.1 +0.1
mefentrifluconazole	X.01	3 : 1	0.3 + 0.1
ipflufenoquin	X.01	10 : 3	0.1 +0.03
ipflufenoquin	X.01	10 :1	0.3 + 0.03
ipflufenoquin	X.01	1 : 1	0.1 +0.1
ipflufenoquin	X.01	3 : 1	0.3 + 0.1
metyltetraprole	X.01	10 : 3	0.1 +0.03
metyltetraprole	X.01	10 : 1	0.3 + 0.03
metyltetraprole	X.01	1 : 1	0.1 +0,1
metyltetraprole	X.01	3 : 1	0.3 + 0,1

190

Component δ	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
aminopyrifen	X.01	10 : 3	0.1 + 0.03
aminopyrifen	X.01	10 : 1	0.3 + 0.03
aminopyrifen	X.01	1 : 1	0.1 + 0.1
aminopyrifen	X.01	3 : 1	0.3 + 0.1
florylpicoxamid	X.01	10 : 3	0.1 + 0.03
florylpicoxamid	X.01	10 : 1	0.3 + 0.03
florylpicoxamid	X.01	1 : 1	0.1 + 0.1
florylpicoxamid	X.01	3 : 1	0.3 + 0.1
florylpicoxamid	X.01	1:50	0.02+0.1
florylpicoxamid	X.01	1:25	0.02+0.05
florylpicoxamid	X.01	2:25	0.02+0.025
florylpicoxamid	X.01	4:25	0.02+0.0125
florylpicoxamid	X.01	8:25	0.02+0.00625
florylpicoxamid	X.01	16:25	0.02+0.003125
florylpicoxamid	X.01	1:100	0.01+0.1
florylpicoxamid	X.01	1:50	0.01+0.05
florylpicoxamid	X.01	1:25	0.01+0.025
florylpicoxamid	X.01	2:25	0.01+0.0125
florylpicoxamid	X.01	4:25	0.01+0.00625
florylpicoxamid	X.01	8:25	0.01+0.003125
2-[6-(4bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.01	10 : 3	0.1 + 0.03
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.01	10 : 1	0.3 + 0.03
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.01	1 : 1	0.1 +0.1
2-[6-(4-bromophenoxy)-2'(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.01	3 : 1	0.3 + 0.1
[(1 S,2S)-2-(4-flLioro-2-methyl-phenyl)-1,3dimethyl-butyi] (2S)-2-[[3'(acetoxymethoxy)-4mettioxy-pyridine-2-carbonyl]amino] propanoate	X.01	10 : 3	0.1 + 0.03
[(1 S,2S)-2-(4”fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.01	10 : 1	0.3 + 0.03

191

Component B	Component A (compound)	Ratio B;A	Conc. (ppm) (B: A)
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3- dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyrid ine-2-carbo ny I] a mine] propa noate	X.01	1 : 1	0.1 + 0.1
[(1S,2S)-2-(4-fiuoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]a mino] propanoate	X.01	3 : 1	0.3 + 0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.01	10 : 3	0.1 +0.03
(Z,2E)-5-[1-(2,4’dîchlorophenyl)pyrazo[-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-penl·3-enamide	X.01	10 : 1	0.3 + 0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.01	1 : 1	0.1 +0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy' 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.01	3 : 1	0.3 + 0.1
[(1 S,2S)-1-methyl-2-(o-tolyl) propyl] (2S)-2-[(4- methoxy-3-propan oyioxy-pyrid ine-2carbonyl)amrno]propanoate	X.01	6:10	0.06+0.1
[<1S,2S)-1-methyI-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl) ami no] propa noate	X.01	6:5	0.06+0.05
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propa noy loxy- py rid ine-2carbonyl)amino]propanoate	X.01	12:5	0.06+0.025
[(1S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4meth oxy-3-propanoy loxy- py rid ine-2carbonyl)amino]propanoate	X.01	24:5	0.06+0.0125
[(1S,2S)-1-methyl-2-(o-to!yl)propyl] (2S)-2-[(4meth oxy-3-propanoy loxy-pyrid ine-2carbonyl)amino]propanoate	X.01	48:5	0.06+0.00625
[(1 S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3- propanoy loxy-pyrrd ine-2carbonyl)amino] propanoate	X.01	96:5	0.06+0.003125

192

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1 S,28)-1-methy 1-2-(o-tolyl) propyl] (28)-2-((4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.01	3:10	0.03+0.1
[(1S ,2S)-1-methy I-2-(o-tolyl) propyl] (28)-2-((4- methoxy-3-propanoyioxy-pyridine-2carbonyl)aminolpropanoate	X.01	3:5	0.03+0.05
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)a min o] propanoate	X.01	6:5	0.03+0.025
[(1S ,2S)-1-methyl-2-(o-tolyl) propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.01	12:5	0.03+0.0125
[(1 S,28)-1 -methyl-2-(o-toly1) propyl] (2S)-2-[(4methoxy-3-propanoyioxy-pyridîne-2carbonyl)amino] propanoate	X.01	24:5	0.03+0.00625
[(1S,2S)-1~methyl-2-(o-tolyl)propyl] (28)-2-((4methoxy-3-propan oyloxy-py ridine-2carbonyl)amino]propanoate	X.01	48:5	0.03+0.003125
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.01	200:1	20+0.1
N-(2-tlLforopheny1)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.01	400:1	20+0.05
N-(2-fluorophenyl)-4-[5-(trifluoromethy 1)-1,2,4oxadiazol-3-yl]benzamide	X.01	800:1	20+0.025
N-(2-fl uorophenyl)-4-[5-(trifluoro methy 1)-1,2,4oxadiazol-3-y l]benza mid e	X.01	100:1	10+0.1
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-y l]benza mide	X.01	200:1	10+0.05
N-(2-fluorophenyl)-4-[5-(triflLioromethyl)-1₁2_]4oxadiazol-3-yl]benzamide	X.01	400:1	10+0.025
glyphosate	X.08	1 ; 1	0.1 +0.1
glyphosate	X.08	3 : 1	0.3 + 0.1
chlorothalonil	X.08	10 : 3	0.1 + 0.03
chlorothalonil	X.08	10 : 1	0.3 + 0.03

193

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
chlorothalonil	X.08	1 : 1	0.1 +0.1
chlorothalonil	X.08	3 : 1	0.3 + 0.1
mancozeb	X.08	1 : 1	0.1 +0.1
mancozeb	X.08	3 : 1	0.3 + 0.1
propiconazole	X.08	10 :3	0.1 +0.03
propiconazole	X.08	10 : 1	0.3 + 0.03
propiconazole	X.08	1 : 1	0.1 + 0.1
propiconazole	X.08	3 : 1	0.3 + 0.1
disodium phosphonate	X.08	1 : 1	0.1 +0.1
disodium phosphonate	X.08	3 : 1	0.3 + 0.1
fenpropimorph	X.08	10 :3	0.1 +0.03
fenpropimorph	X.08	10 : 1	0.3 + 0.03
fenpropimorph	X.08	1 : 1	0.1 +0.1
fenpropimorph	X.08	3 ; 1	0.3 + 0.1
fenpropidin	X.08	1 : 1	0.1 +0.1
fenpropidin	X.08	3:1	0.3 + 0.1
hexaconazole	X.08	10 : 3	0.1 +0.03
hexaconazole	X.08	10 ; 1	0.3 + 0.03
hexaconazole	X.08	1 ; 1	0.1 +0.1
hexaconazole	X.08	3 : 1	0.3 + 0.1
paclobutrazol	X.08	1 : 1	0.1 +0.1
paclobutrazol	X.08	3 : 1	03 + 0.1
trinexapac-ethyl	X.08	1 : 1	0.1 + 0.1
trinexapac-ethyl	X.08	3 : 1	0.3 + 0.1
flutriafol	X.08	1 : 1	0.1 + 0.1
flutriafol	X.08	3 : 1	0.3 + 0.1
difenoconazole	X.08	10 : 3	0.1 +0.03
difenoconazole	X.08	10 : 1	0.3 + 0.03
difenoconazole	X.08	1 : 1	0.1 + 0.1
difenoconazole	X.08	3 : 1	0.3 + 0.1
cyproconazole	X.08	10 : 1	0.3 + 0.03
cyproconazole	X.08	1 ; 1	0.1 + 0.1
cyproconazole	X.08	3 : 1	0.3 + 0.1
acibenzofar S-methyl	X.08	1 : 1	0.1 + 0.1

194

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B; A)
acibenzolar S-methyl	X.08	3 : 1	0.3 + 0.1
trifloxystrobin	X.08	10 : 3	0.1 + 0.03
trifloxystrobin	X.08	10 : 1	0.3 + 0.Û3
trifloxystrobin	X.08	1 : 1	0.1 + 0.1
trifloxystrobin	X.08	3 : 1	0.3 + 0.1
folpet	X.08	10 : 1	0.3 + 0.03
folpet	X.08	1 : 1	0.1 +0.1
folpet	X.08	3 : 1	0.3 + 0.1
azoxystrobin	X.08	10 : 3	0.1 + 0.03
azoxystrobin	X.08	10 : 1	0.3 + 0.03
azoxystrobin	X.08	1 : 1	0.1 +0.1
azoxystrobin	X.08	3 : 1	0.3 + 0.1
pyraclostrobin	X.08	10 : 3	0.1 +0.03
pyraclostrobin	X.08	10 : 1	0.3 + 0.03
pyraclostrobin	X.08	1 : 1	0.1 +0.1
pyraclostrobin	X.08	3 : 1	0.3 + 0.1
picoxystrobin	X.08	10 : 3	0.1 +0.03
picoxystrobin	X.08	10 :1	0.3 + 0.03
picoxystrobin	X.08	1 : 1	0.1 +0.1
picoxystrobin	X.08	3 : 1	0.3 + 0.1
sulphur	X.08	1 : 1	0.1 + 0.1
sulphur	X.08	3 : 1	0.3 + 0.1
tebuconazole	X.08	10 : 1	0.3 + 0.03
tebuconazole	X.08	1 : 1	0.1 +0.1
tebuconazole	X.08	3 : 1	0.3 + 0.1
prothioconazole	X.08	10 : 3	0.1 +0.03
prothioconazole	X.08	10 : 1	0.3 + 0.03
prothioconazole	X.08	1 : 1	0.1 +0.1
prothioconazole	X.08	3 : 1	0.3 + 0.1
fluopyram	X.08	10 : 1	0.3 + 0.03
fluopyram	X.08	1 : 1	0.1 +0.1
fluopyram	X.08	3 : 1	0.3 + 0.1
copper oxychloride	X.08	1 : 1	0.1 +0.1
copper oxychloride	X.08	3 : 1	0.3 + 0.1

195

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
benzovindiflupyr	X.08	10 : 3	0.1 +0.03
benzovindiflupyr	X.08	10 : 1	0.3 + 0.03
benzovindiflupyr	X.08	1 : 1	0.1 + 0.1
benzovindiflupyr	X.08	3 : 1	0.3 + 0.1
isopyrazam	X.08	10 : 3	0.1 + 0.03
isopyrazam	X.08	10 : 1	0.3 + 0.03
isopyrazam	X.08	1 : 1	0.1 +0.1
isopyrazam	X.08	3 : 1	0.3 + 0.1
pydiflumetofen	X.08	10 : 3	0.1 + 0.03
pydiflumetofen	X.08	10 : 1	0.3 + 0.03
pydiflumetofen	X.08	1 : 1	0.1 + 0,1
pydiflumetofen	X.08	3 : 1	0.3 + 0.1
fluxapyroxad	X.08	10 : 3	0.1 + 0,03
fluxapyroxad	X.08	10 : 1	0.3 + 0.03
fluxapyroxad	X.08	1 : 1	0.1 + 0,1
fluxapyroxad	X.08	3 : 1	0.3 + 0.1
quinofumelin	X.08	1 : 1	0.1 + 0.1
quinofumelin	X.08	3 : 1	0.3 + 0.1
isoflucypram	X.08	10 : 3	0.1 + 0.03
isoflucypram	X.08	10 : 1	0.3 + 0.03
isoflucypram	X.08	1 : 1	0.1 + 0.1
isoflucypram	X.08	3 : 1	0.3 + 0.1
mefentrifluconazole	X.08	10 : 3	0.1 + 0.03
mefentrifluconazole	X.08	10 : 1	0.3 + 0.03
mefentrifluconazole	X.08	1 : 1	0.1 + 0.1
mefentrifluconazole	X.08	3 : 1	0.3 + 0.1
ipflufenoquin	X.08	1 : 1	0.1 + 0.1
ipflufenoquin	X.08	3 : 1	0,3 + 0.1
metyltetraprole	X.08	10 : 3	0,1 + 0,03
metyltetraprole	X.08	10 : 1	0.3 + 0.03
metyltetraprole	X.08	1 : 1	0.1 + 0.1
metyltetraprole	X.08	3 : 1	0.3 + 0.1
aminopyrifen	X.08	10 : 3	0.1 + 0.03
aminopyrifen	X.08	10 : 1	0.3 + 0.03

196

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
aminopyrifen	X.08	1 : 1	0.1 +0.1
aminopyrifen	X.08	3 : 1	0.3 + 0.1
florylpicoxamid	X.08	10 : 3	0.1 +0.03
florylpicoxamid	X.08	10 : 1	0.3 + 0.03
florylpicoxamid	X.08	1 : 1	0.1 + 0.1
florylpicoxamid	X.08	3 : 1	0.3 + 0.1
florylpicoxamid	X.08	1:10	0.02+0.2
florylpicoxamid	X.08	1:5	0.02+0.1
florylpicoxamid	X.08	2:5	0.02+0.05
florylpicoxamid	X.08	4:5	0.02+0.025
florylpicoxamid	X.08	8:5	0.02+0.0125
florylpicoxamid	X.08	16:5	0.02+0.00625
florylpicoxamid	X.08	1:20	0.01+0.2
florylpicoxamid	X.08	1:10	0.01+0.1
florylpicoxamid	X.08	1:5	0.01+0.05
florylpicoxamid	X.08	2:5	0.01+0.025
florylpicoxamid	X.08	4:5	0.01+0.0125
florylpicoxamid	X.08	8:5	0.01+0.00625
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.08	10 : 3	0.1 + 0.03
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazot-1-yl)propan-2-ol	X.08	10 : 1	0.3 + 0.03
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.08	1 : 1	0.1 +0.1
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.08	3 : 1	0.3 + 0.1
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3- dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyridine-2-carbonyl]amino]propanoate	X.08	10 : 3	0.1 + 0.03
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)’1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.08	10 : 1	0.3 + 0.03

197

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl](2S)-2-[[3-(acetoxymethoxy)’4methoxy-pyridine-2-carbonyl]amino]propanoate	X.08	1 : 1	0.1 +0.1
[(1 S2S)-2-(4-fluoro-2-methyl-pheiiyl)-1,3dimethyl-butyi] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl)amino]propanoate	X.08	3 : 1	0.3 + 0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.08	10 : 3	0.1 +0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.08	10 : 1	0.3 + 0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxyZ-methoxyimino-N^-dimethyl-peni-S-enamide	X.08	1 : 1	0.1 +0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamrde	X.08	3 : 1	0.3 + 0.1
[(1 S,2S)-1 -methyl-2-(o-tolyf)propyl] (2S)-2-[(4meth oxy-3-propa noy loxy- py rid ine-2carbonyl)amino]piOpanoate	X.08	3:10	0.06+0.2
[(1S,2S)-1-methyl-2-(o-lolyl)propyl] (2S)-2-[(4- meth oxy-3-propanoy loxy- py rid ine-2ca rbony l)a mino]propanoate	X.08	3:5	0.06+0.1
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- meth oxy-3-propanoy loxy- py rid ine-2carbonyl)amino]propanoate	X.08	6:5	0.06+0.05
[(1S,2S)-1-methyl-2-(o-tolyDpropyl] (2S)-2-[(4- meth oxy-3-propanoy loxy-pyrid ine-2carbonyl)amino]propanoate	X.08	12:5	0.06+0.025
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- meth oxy-3-propanoy loxy-pyrid ine-2carbonyl)amino]propanoate	X.08	24:5	0.06+0.0125
[(1S,2S)-1-methyl-2-(o-tolyl)propyt] (2S)-2-[(4meth oxy-3-propanoy loxy-pyrid ine-2carbony))amino]propanoate	X.08	48:5	0.06+0.00625

198

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1S,2S)-1-methyi-2-(o-tolyl)propylJ (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.08	3:20	0.03+0.2
[(1S,2SM-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3- propan oyloxy-pyridine-2carbony!)amino]propanoate	X.08	3:10	0.03+0.1
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.08	6:10	0.03+0.05
[(1S,2S)-1-methyl-2-(o-toiyl)propy]] (2S)-2-f(4meth oxy-3-propanoy loxy-pyrid ine-2carbonyl)amino]propanoate	X.08	12:10	0.03+0.025
[(1S,2S)-1-methyl-2-(o-tolyl)propyl) (2S)-2-[(4meth oxy-3-propanoy loxy-pyrid ine-2carbonyl)amino]propanoate	X.08	24:10	0.03+0.0125
[(1 S,2S)-1 -methyl-2-(o-tolyI)propyI] (2S)-2-[(4methoxy-3-propa noy loxy-pyrid ine-2carbonyl)amino]propanoate	X.08	48:10	0.03+0.00625
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazo!-3-yl]benzamide	X.08	100:1	20+0.2
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamîde	X.08	200:1	20+0.1
N-(2-fluoropheny!)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.08	400:1	20+0.05
N-(2-fl uorophenyl)-4-[5-(trifluoro methy 1)-1,2,4oxadiazol-3-yl]benzamide	X.08	800:1	20+0.025
N-(2-fl u orophenyl)-4-[5-(trifluoro methy 1)-1,2,4oxadiazol-3-yl]benzamide	X.08	50:1	10+0.2
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.08	100:1	10+0.1
N-(2-fluorophenyl)-4-[5-(trifluoromethy 1)-1,2,4oxadiazol-3-yl]benzamide	X.08	200:1	10+0.05
N-(2-fluorophenyl)-4-[5-(trifliJoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.08	400:1	10+0.025

199

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
glyphosate	X.06	10 : 3	0.1 + 0.03
glyphosate	X.06	10 : 1	0.3 + 0.03
glyphosate	X.06	1 : 1	0.1 + 0.1
glyphosate	X.06	3 : 1	03 + 0,1
chtorothalonil	X.06	10 : 3	0.1 + 0.03
chlorotha lonil	X.06	10 : 1	0.3 + 0.03
chtorothalonil	X.06	1 : 1	0.1 + 0.1
chtorothalonil	X.06	3 : 1	0.3 + 0.1
mancozeb	X.06	10 : 3	0.1 + 0.03
mancozeb	X.06	10 : 1	0.3 + 0.03
mancozeb	X.06	1 : 1	0.1 + 0.1
mancozeb	X.06	3 : 1	0.3 + 0.1
propiconazole	X.06	10 : 3	0.1 + 0.03
propiconazole	X.06	10 : 1	0.3 + 0.03
propiconazole	X.06	1 : 1	0.1 + 0.1
propiconazole	X.06	3 : 1	0.3 + 0.1
disodium phosphonate	X.06	10 : 3	0.1 + 0.03
disodium phosphonate	X.06	10 : 1	0.3 + 0.03
disodium phosphonate	X.06	1 : 1	0.1 +0,1
disodium phosphonate	X.06	3 : 1	0,3 + 0.1
fenpropimorph	X.06	10 : 3	0.1 +0,03
fenpropimorph	X.06	10 : 1	0.3 + 0,03
fenpropimorph	X.06	1 : 1	0.1 +0.1
fenpropimorph	X.06	3 : 1	0.3 + 0.1
fenpropidin	X.06	10 : 3	0,1 +0.03
fenpropidin	X.06	10 : 1	0,3 + 0.03
fenpropidin	X.06	1 : 1	0.1 + 0.1
fenpropidin	X.06	3 : 1	0.3 + 0.1
hexaconazole	X.06	10 : 3	0.1 + 0.03
hexaconazole	X.06	10 : 1	0.3 + 0.03
hexaconazole	X.06	1 : 1	0.1 + 0.1
hexaconazole	X.06	3 : 1	0.3 + 0.1
paclobutrazol	X.06	10 : 3	0.1 +0.03
paclobutrazol	X.06	10 : 1	0.3 + 0.03

200

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
paclobutrazol	X.06	1 : 1	0.1 + 0.1
paclobutrazol	X.06	3 : 1	0.3 + 0.1
trinexapac-ethyl	X.06	10 : 3	0.1 + 0.03
trinexapac-ethyl	X.06	10 : 1	0.3 + 0.03
trinexapac-ethyl	X.06	1 : 1	0.1 + 0.1
trinexapac-ethyl	X.06	3 : 1	0.3 + 0.1
flutriafol	X.06	1 : 1	0.1 + 0.1
flutriafol	X.06	3 : 1	0.3 + 0.1
difenoconazole	X.06	10 : 3	0.1 +0.03
difenoconazole	X.06	10 :1	0.3 + 0.03
difenoconazole	X.06	1 : 1	0.1 + 0.1
difenoconazole	X.06	3 : 1	0.3 + 0.1
fludioxonil	X.06	1 : 1	0.1 + 0.1
fludioxonil	X.06	3 : 1	0.3 + 0.1
cyproconazole	X.06	10 : 1	0.3 + 0.03
cyproconazole	X.06	1 : 1	0.1 + 0.1
cyproconazole	X.06	3 : 1	0.3 + 0.1
acibenzolar S-methyl	X.06	10 : 3	0.1 +0.03
acibenzolar S-methyl	X.06	10 : 1	0.3 + 0.03
acibenzolar S-methyl	X.06	1 : 1	0.1 + 0.1
acibenzolar S-methyl	X.06	3 : 1	0.3 + 0.1
trifloxystrobin	X.06	10 : 3	0.1 + 0.03
trifloxystrobin	X.06	10 : 1	0.3 + 0.03
trifloxystrobin	X.06	1 : 1	0.1 + 0.1
trifloxystrobin	X.06	3 : 1	0.3 + 0.1
folpet	X.06	10 : 3	0.1 + 0.03
folpet	X.06	10 : 1	0.3 + 0.03
folpet	X.06	1 ; 1	0.1 + 0.1
folpet	X.06	3 : 1	0.3+ Û.1
azoxystrobin	X.06	10 : 3	0.1 + 0.03
azoxystrobin	X.06	10 : 1	0.3+ 0.03
azoxystrobin	X.06	1 : 1	0.1 + 0.1
azoxystrobin	X.06	3 : 1	0.3+ 0.1
pyraclostrobin	X.06	10 : 3	0.1 + 0.03

201

Comportent B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
pyraciostrobin	X.06	10 : 1	0.3 + 0.03
pyraciostrobin	X.06	1 : 1	0.1 +0.1
pyraciostrobin	X.06	3 : 1	0.3 + 0.1
picoxystrobin	X.06	10 : 3	0.1 +0.03
picoxystrobin	X.06	10 : 1	0.3 + 0.03
picoxystrobin	X.06	1 : 1	0.1 +0.1
picoxystrobin	X.06	3 : 1	0.3 + 0.1
sulphur	X.06	10 : 3	0.1 +0.03
sulphur	X.06	10 : 1	0.3 + 0.03
sulphur	X.06	1 : 1	0.1 +0.1
sulphur	X.06	3 : 1	03 + 0.1
tebuconazole	X.06	10 : 1	0.3 + 0.03
tebuconazole	X.06	1 : 1	0.1 +0.1
tebuconazole	X.06	3 : 1	0.3 + 0.1
prothioconazole	X.06	10 : 3	0.1 + 0.03
prothioconazole	X.06	10 : 1	0.3 + 0.03
prothioconazole	X.06	1 : 1	0.1 +0.1
prothioconazole	X.06	3 : 1	0.3 + 0.1
fluopyram	X.06	10 : 3	0.1 +0.03
fluopyram	X.06	10 : 1	0.3 + 0.03
fluopyram	X.06	1 : 1	0.1 + 0.1
fluopyram	X.06	3 : 1	0.3 + 0.1
copper oxychloride	X.06	10 : 3	0.1 +0.03
copper oxychloride	X.06	10 : 1	0.3 + 0.03
copper oxychloride	X.06	1 : 1	0.1 +0.1
copper oxychloride	X.06	3 : 1	0.3 + 0.1
benzovindiflupyr	X.06	10 : 3	0.1 + 0.03
benzovindiflupyr	X.06	10 : 1	0.3 + 0.03
benzovindiflupyr	X.06	1 : 1	0.1 +0.1
benzovindiflupyr	X.06	3 : 1	0.3 + 0.1
isopyrazam	X.06	10 : 3	0.1 +0.03
isopyrazam	X.06	10 : 1	0.3 + 0.03
isopyrazam	X.06	1 : 1	0.1 + 0.1
isopyrazam	X.06	3 : 1	0.3 + 0.1

202

Component B	Component A (compound)	Ratio B:A	Conc, (ppm) (B: A)
pydiflumetofen	X.06	10 : 3	0.1 + 0.03
pydiflumetofen	X.06	10 : 1	0.3 + 0.03
pydiflumetofen	X.06	1 : 1	0.1 + 0.1
pydiflumetofen	X.06	3 : 1	0.3 + 0.1
fluxapyroxad	X.06	10 : 3	0.1 + 0.03
fluxapyroxad	X.06	10 : 1	0.3 + 0.03
fluxapyroxad	X.06	1 : 1	0.1 + 0.1
fluxapyroxad	X.06	3 : 1	0.3 + 0.1
quinofumelin	X.06	10 : 3	0.1 + 0.03
quinofumelin	X.06	10 : 1	0.3 + 0.03
quinofumelin	X.06	1 : 1	0.1 +0.1
quinofumelin	X.06	3 : 1	0.3 + 0.1
isoflucypram	X.06	10 i 3	0.1 +0.03
isoflucypram	X.06	10 : 1	0.3 + 0.03
isoflucypram	X.06	1 : 1	0.1 +0.1
isoflucypram	X.06	3 : 1	0.3 + 0.1
mefentrifluconazole	X.06	10 : 3	0.1 +0.03
mefentrifluco n azole	X.06	10 : 1	0.3 + 0.03
mefentrifluconazole	X.06	1 : 1	0.1 +0.1
mefentrifluconazole	X.06	3 : 1	0.3 + 0.1
ipflufenoquin	X.06	10 : 3	0.1 +0.03
ipflufenoquin	X.06	10 : 1	0.3 + 0.03
ipflufenoquin	X.06	1 : 1	0.1 +0.1
ipflufenoquin	X.06	3 : 1	0.3 + 0.1
metyltetraprole	X.06	10 : 3	0.1 +0.03
metyltetraprole	X.06	10 ; 1	0.3 + 0.03
metyltetraprole	X.06	1 : 1	0.1 +0.1
metyltetraprole	X.06	3 : 1	0.3 + 0.1
aminopyrifen	X.06	10 : 3	0.1 +0.03
aminopyrifen	X.06	10 : 1	0.3 + 0.03
aminopyrifen	X.06	1 : 1	0.1 +0.1
aminopyrifen	X.06	3 : 1	0.3 + 0.1
florylpicoxamid	X.06	10 : 3	0.1 + 0.03
florylpicoxamid	X.06	10 : 1	0.3 + 0.03

203

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
florylpicoxamid	X.06	1 : 1	0.1 +0.1
florylpicoxamid	X.06	3 : 1	0.3 + 0.1
florylpicoxamid	X.06	1:50	0.02+0.1
florylpicoxamid	X.06	1:25	0.02+0.05
florylpicoxamid	X.06	2:25	0.02+0.025
florylpicoxamid	X.06	4:25	0.02+0.0125
florylpicoxamid	X.06	8:25	0.02+0.00625
florylpicoxamid	X.06	16:25	0.02+0.003125
florylpicoxamid	X.06	1:100	0.01+0.1
florylpicoxamid	X.06	1:50	0.01+0.05
florylpicoxamid	X.06	1:25	0.01+0.025
florylpicoxamid	X.06	2:25	0.01+0.0125
florylpicoxamid	X.06	4:25	0.01+0.00625
florylpicoxamid	X.06	8:25	0.01+0.003125
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyi]-1-(1,2,44riazol’1-yl)propan-2-ol	X.06	10 : 3	0.1 + 0.03
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.06	10 : 1	0.3 + 0.03
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.06	1 : 1	0.1 +0.1
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.06	3 : 1	0.3 + 0.1
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.06	10 : 3	0.1 +0.03
[(1S,2S)-2-(4-fluoro-2-methyî-phenyl)-1,3- di methyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- methoxy-pyridine-2-carbonyl]amino]propanoate	X.06	10 : 1	0.3 + 0.03
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- meth oxy-pyrid ine-2-carbo ny l]amin o] propa noate	X.06	1 : 1	0.1 + 0.1
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.06	3 ; 1	0.3 + 0.1

204

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
(Z,2E)5-[1-(2,4-dichlorophenyf)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.06	10 : 3	0.1 + 0.03
(Z,2E)-5-[1-(2,4-dichloropheny[)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamrde	X.06	10 : 1	0.3 + 0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazoi-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent'3-enamide	X.06	1 : 1	0.1 + 0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol·3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.06	3 : 1	0.3 + 0.1
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4meth oxy-3-propa noy loxy- py rid ine-2carbonyl)amino]propanoate	X.06	6:10	0.06+0.1
[(1S,2SM-methyl-2-(o4olyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.06	6:5	0.06+0.05
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propa noy loxy- py rid ine-2carbonyl)amino]propanoate	X.06	12:5	0.06+0.025
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.06	24:5	0.06+0.0125
[(1 S,2S)-1 -methyl-2-(o-tolyt)propyl] (2S)-2-[(4methoxy-3-propa noy loxy- py rid ine-2carbonyl)amino]propanoate	X.06	48:5	0.06+0.00625
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propa noy loxy-py rid ine-2carbonyl)amino]propanoate	X.06	96:5	0.06+0.003125
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propa noy loxy- pyridine-2carbonyl)amino]propanoate	X.06	3:10	0.03+0.1
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2- carbonyl)amino]propanoate	X.06	3:5	0.03+0.05

205

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2- ca rbony I) amino]propanoate	X.06	6:5	0.03+0.025
[(1 S,2S)-1 -methyl-2-(o-toly!)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino] propanoate	X.06	12:5	0.03+0.0125
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.06	24:5	0.03+0.00625
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino] propanoate	X.06	48:5	0.03+0.003125
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benza mid e	X.06	200:1	20+0,1
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.06	400:1	20+0.05
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yi]benzamide	X.06	800:1	20+0.025
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.06	1600:1	20+0.0125
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-y]]benzamide	X.06	100:1	10+0.1
N-(2-fluorophenyl)-4-[5-(trifIuoromethyl)-1,2,4oxadiazoi-3-yl]benzamide	X.06	200:1	10+0.05
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.06	400:1	10+0.025
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.06	800:1	10+0.0125
glyphosate	X.10	1 : 1	0.1 + 0,1
glyphosate	X.10	3 : 1	0.3 + 0,1
chlorothalonil	X.10	10 : 1	0.3 + 0.03
chlorothalonil	X.10	1 : 1	0,1 +0.1
chlorothalonil	X.10	3 : 1	0.3 + 0.1
mancozeb	X.10	1 : 1	0.1 +0.1

206

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
mancozeb	X.10	3 : 1	0.3 + 0.1
propiconazole	X.10	10 : 3	0.1 + 0.03
propiconazole	X.10	10 : 1	0.3 + 0.03
propiconazole	X.10	1 : 1	0.1 + 0.1
propiconazole	X.10	3 : 1	0.3 + 0.1
disodium phosphonate	X.10	1 : 1	0.1 + 0.1
disodium phosphonate	X.10	3 : 1	0.3 + 0.1
fenpropimorph	X.10	10 : 3	0.1 + 0.03
fenpropimorph	X.10	10 : 1	0.3 + 0.03
fenpropimorph	X.10	1 : 1	0.1 + 0.1
fenpropimorph	X.10	3 : 1	0.3 + 0.1
fenpropidin	X.10	1 : 1	0.1 + 0.1
fenpropidin	X.10	3 : 1	0.3 + 0.1
hexaconazole	X.10	10 : 3	0.1 + 0.03
hexaconazole	X.10	10 : 1	0.3 + 0.03
hexaconazole	X.10	1 : 1	0.1 + 0.1
hexaconazole	X.10	3 : 1	0.3 + 0.1
paclobutrazol	X.10	1 : 1	0.1 + 0.1
paclobutrazol	X.10	3 : 1	0.3 + 0.1
trinexapac-ethyl	X.10	1 : 1	0.1 + 0.1
trinexapac-ethyl	X.10	3 : 1	0.3 + 0.1
flutriafol	X.10	1 : 1	0.1 + 0.1
flutriafol	X.10	3 : 1	0.3 + 0.1
difenoconazole	X.10	10 : 3	0.1 + 0.03
difenoconazole	X.10	10 : 1	0.3 + 0.03
difenoconazole	X.10	1 : 1	0.1 + 0.1
difenoconazole	X.10	3 : 1	0.3 + 0.1
fludioxonil	X.10	1 : 1	0.1 +0.1
fludioxonil	X.10	3 : 1	0.3 + 0.1
cyproconazole	X.10	10 : 1	0.3 + 0.03
cyproconazole	X.10	1 : 1	0.1 +0.1
cyproconazole	X.10	3 : 1	0.3 + 0.1
acibenzolar S-methyl	X.10	1 : 1	0.1 +0.1
acibenzolar S-methyl	X.10	3 : 1	0.3 + 0.1

207

Component B	Component A (compound)	Ratio B:A	Conc. (ppm)
(B: A)
trifloxystrobin	X.10	10 : 3	0.1 + 0.03
trifloxystrobin	X.10	10 : 1	0.3 + 0.03
trîfloxystrobin	X.10	1 : 1	0.1 + 0.1
trifloxystrobin	X.10	3 : 1	0.3 + 0.1
folpet	X.10	1 : 1	0.1 + 0.1
folpet	X.10	3 : 1	0.3 + 0.1
azoxystrobin	X.10	10 : 3	0.1 +0.03
azoxystrobin	X.10	10 : 1	0.3 + 0.03
azoxystrobin	X.10	1 : 1	0.1 +0.1
azoxystrobin	X.10	3 : 1	0.3 + 0.1
pyraciostrobin	X.10	10 : 3	0.1 +0.03
pyraciostrobin	X.10	10 : 1	0.3 + 0.03
pyraciostrobin	X.10	1 : 1	0.1 + 0.1
pyraciostrobin	X.10	3 : 1	0.3 + 0.1
picoxystrobin	X.10	10 ; 3	0.1 + 0.03
picoxystrobin	X.10	10 : 1	0.3 + 0.03
picoxystrobin	X.10	1 : 1	0.1 + 0.1
picoxystrobin	X.10	3 : 1	0.3 + 0.1
sulphur	X.10	1 : 1	0.1 +0.1
sulphur	X.10	3 : 1	0.3 + 0.1
tebuconazole	X.10	10 : 1	0.3 + 0.03
tebuconazole	X.10	1 : 1	0.1 + 0.1
tebuconazole	X.10	3 : 1	0.3 + 0.1
prothioconazole	X.10	10 : 3	0.1 + 0.03
prothioconazole	X.10	10 : 1	0.3 + 0.03
prothioconazole	X.10	1 : 1	0.1 + 0.1
prothioconazole	X.10	3 : 1	0.3 + 0.1
fluopyram	X.10	10 : 1	0.3 + 0.03
fluopyram	X.10	1 : 1	0.1 +0.1
fluopyram	X.10	3 : 1	0.3 + 0.1
copper oxychloride	X.10	1 : 1	0.1 + 0.1
copper oxychloride	X.10	3 : 1	0.3 + 0.1
benzovindiflupyr	X.10	10 : 3	0.1 + 0.03
benzovindiflupyr	X.10	10 : 1	0.3 + 0.03_________

208

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
benzovindiflupyr	X.10	1 : 1	0.1 +0.1
benzovindiflupyr	X.10	3 : 1	0.3 + 0.1
isopyrazam	X.10	10 : 3	0.1 +0.03
isopyrazam	X.10	10 : 1	0.3 + 0.03
isopyrazam	X.10	1 : 1	0.1 + 0.1
isopyrazam	X.10	3 : 1	0.3 + 0.1
pydiflumetofen	X.10	10 : 3	0.1 +0.03
pydiflumetofen	X.10	10 : 1	0.3 + 0.03
pydiflumetofen	X.10	1 : 1	0.1 +0.1
pydiflumetofen	X.10	3 : 1	0.3 + 0.1
fluxapyroxad	X.10	10 : 3	0.1 +0.03
fluxapyroxad	X.10	10 i 1	0.3 + 0.03
fluxapyroxad	X.10	1 : 1	0.1 +0.1
fluxapyroxad	X.10	3 : 1	0.3 + 0.1
quinofumelin	X.10	1 ; 1	0.1 +0.1
quinofumelin	X.10	3 ; 1	0.3 + 0.1
isoflucypram	X.10	10 : 3	0.1 +0.03
isoflucypram	X.10	10 : 1	0.3 + 0.03
isoflucypram	X.10	1 : 1	0.1 +0.1
isoflucypram	X.10	3 : 1	0.3 + 0.1
mefentrifluconazole	X.10	10 : 3	0.1 +0.03
mefentrifluconazole	X.10	10 : 1	0.3 + 0.03
mefentrifluconazole	X.10	1 : 1	0.1 +0.1
mefentrifluconazole	X.10	3 : 1	0.3 + 0.1
ipflufenoquin	X.10	1 : 1	0.1 +0.1
ipflufenoquin	X.10	3 : 1	0.3 + 0.1
metyltetraprole	X.10	10 : 3	0.1 + 0.03
metyltetraprole	X.10	10 : 1	0.3 + 0.03
metyltetraprole	X.10	1 : 1	0.1 + 0.1
metyltetraprole	X.10	3 : 1	0.3 + 0.1
aminopyrifen	X.10	10 : 3	0.1 + 0.03
aminopyrifen	X.10	10 : 1	0.3 + 0.03
aminopyrifen	X.10	1 : 1	0.1 +0.1
aminopyrifen	X.10	3 : 1	0.3 + 0.1

209

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
florylpicoxamid	X.10	10 : 3	0.1 + 0.03
florylpicoxamid	X.10	10 : 1	0.3 + 0.03
florylpicoxamid	X.10	1 : 1	0.1 + 0.1
florylpicoxamid	X.10	3 : 1	0.3 + 0.1
florylpicoxamid	X.10	1:50	0.02+0,1
florylpicoxamid	X.10	1:25	0.02+0.05
florylpicoxamid	X.10	2:25	0.02+0.025
florylpicoxamid	X.10	4:25	0.02+0.0125
florylpicoxamid	X.10	8:25	0.02+0.00625
florylpicoxamid	X.10	16:25	0.02+0.003125
florylpicoxamid	X.10	1:100	0.01+0.1
florylpicoxamid	X.10	1:50	0.01+0.05
florylpicoxamid	X.10	1:25	0.01+0.025
florylpicoxamid	X.10	2:25	0.01+0.0125
florylpicoxamid	X.10	4:25	0.01+0.00625
florylpicoxamid	X.10	8:25	0.01+0.003125
2-[6-(4-bromophenoxy)-2-(tnfluoromethyi)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.10	10 : 3	0.1 +0.03
2-[6-(4-bromophenoxy)-2-(tnfiuoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yi)propan-2-ol	X.10	10 : 1	0.3 + 0.03
2-[6-(4-bromophenoxy)-2-(trif!uoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yi)propan-2-ol	X.10	1 : 1	0.1 + 0.1
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridylM-(1,2,4-triazol-1-yi)propan-2-ol	X.10	3 : 1	0.3 + 0.1
[(1S,2S)-2-(4-fluoro-2-methy)-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyrid ine-2-carbo ny I] a mino] propa noate	X.10	10 : 3	0.1 +0,03
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.10	10 : 1	0.3 + 0.03
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propa noate	X.10	1 : 1	0.1 + 0.1

210

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B; A)
[(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3drmethyl-butyl] (2S)-2-[[3-(acetoxymelhoxy)-4- methoxy-pyridine-2-carbony!]amino] propanoate	X.10	3 : 1	0.3 + 0.1
(Z,2E)-5-(1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.10	10 : 3	0.1 + 0.03
(ZÎEj-S-il-CZA-dichlorophenyQpyrazot-S-ylloxy2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.10	10 : 1	0.3 + 0.03
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.10	1 : 1	0.1 + 0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyiniino-N,3-dimethyl-pent-3-enamide	X.10	3 : 1	0.3 + 0.1
[(1S,2S)-1-methyl-2-(o-tolyl>propy1] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2ca rbony l)a minolpropanoate	X.1Û	6:10	0.06+0.1
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propa noy loxy-py rid ine-2carbonyl)amino]propanoate	X.10	6:5	0.06+0.05
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propa noy loxy-py rid rne-2carbonyl)amino]propanoate	X.10	12:5	0.06+0.025
[(1 S,2S)-1 -methyl-2-(o-tolyl)propylj (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.10	24:5	0.06+0.0125
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propan oyloxy-pyridine-2carbonyl)amino]propanoate	X.10	48:5	0.06+0.00625
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoy1oxy-pyridine-2carbonyl)amino]propanoate	X.10	96:5	0.06+0,003125
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4- meîhoxy-3-propa noy loxy-py rid ine-2ca rbony l)amino]propanoate	X.10	3:10	0.03+0,1

211

Component B	Component A (compound)	Ratio 8:A	Conc. (ppm) (B: A)
[(1S,2S)-1-methyl-2-(o-tolyl)propyl) (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.10	3:5	0.03+0.05
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.10	6:5	0.03+0.025
K1S,2S)-1-methyl-2-(O-tolyl)propyl] (2S)-2-[(4- methoxy-3-propa noy loxy-py ridine-2carbonyl)amino]propanoate	X.10	12:5	0.03+0.0125
K1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4methoxy-3-propa noy loxy-py ridine-2carbonyl)amino]propanoate	X.10	24:5	0,03+0.00625
[(1S,2S)-1-methyI-2-(o-toly1)propylJ (2S)-2-[(4- methoxy-3- propa n oyloxy-pyridine-2carbonyl)amino] propan oate	X.10	48:5	0.03+0.003125
N-(2-fl uorophenyl)-4-[5-(trifluorornethy 1)-1,2,4oxadiazol-3-yl]be nza mide	X.10	200:1	20+0.1
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.10	400:1	20+0.05
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.10	800:1	20+0.025
N-(2-fluorophenyl)-4-[5-(trîfluoromethyi)-1,2,4oxadiazot-3-yl]benzamide	X.10	1600:1	20+0.0125
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.10	3200:1	20+0.00625
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-y IJbenza mîd e	X.10	100:1	10+0.1
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadîazol-3-yllbenzamide	X.10	200:1	10+0.05
N-(2-fluorophenyl)-4-[5-(trifkJoromethyl)-1,2,4oxadiazol-3-y l]be nza mide	X.10	400:1	10+0.025
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.10	800:1	10+0.0125

212

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.10	1600:1	10+0.00625
glyphosate	X.09	10 : 3	0.1 +0.03
glyphosate	X.09	10 : 1	0.3 + 0.03
glyphosate	X.09	1 : 1	0.1 + 0.1
glyphosate	X.09	3 : 1	0.3 + 0.1
chlorothalonil	X.09	10 : 3	0.1 +0.03
chlorothalonil	X.09	10 : 1	0.3 + 0.03
chlorothalonil	X.09	1 : 1	0.1 +0.1
chlorothalonil	X.09	3 : 1	0.3 + 0.1
mancozeb	X.09	10 : 3	0.1 +0.03
mancozeb	X.09	10 : 1	0.3 + 0.03
mancozeb	X.09	1 : 1	0.1 +0.1
mancozeb	X.09	3 : 1	0.3 + 0.1
propiconazole	X.09	10 ; 3	0.1 +0.03
propiconazole	X.09	10 : 1	0.3 + 0.03
propiconazole	X.09	1 : 1	0.1 + 0.1
propiconazole	X.09	3 : 1	0.3 + 0.1
disodium phosphonate	X.09	10 : 3	0.1 + 0.03
disodium phosphonate	X.09	10 : 1	0.3 + 0.03
disodium phosphonate	X.09	1 : 1	0.1 + 0.1
disodium phosphonate	X.09	3 : 1	0.3 + 0.1
fenpropimorph	X.09	10 : 3	0.1 + 0.03
fenpropimorph	X.09	10 : 1	0.3 + 0.03
fenpropimorph	X.09	1 : 1	0.1 + 0.1
fenpropimorph	X.09	3 : 1	0.3 + 0.1
fenpropidîn	X.09	10 : 3	0.1 +0.03
fenpropidîn	X.09	10 : 1	0.3 + 0.03
fenpropidîn	X.09	1 : 1	0.1 + 0.1
fenpropidîn	X.09	3 : 1	0.3 + 0.1
hexaconazole	X.09	10 : 3	0.1 +0.03
hexaconazole	X.09	10 : 1	0.3 + 0.03
hexaconazole	X.09	1 ; 1	0.1 +0.1
hexaconazole	X.09	3 : 1	0.3 + 0.1

213

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
paclobutrazol	X.09	10 : 3	0.1 + 0.03
paclobutrazol	X.09	10 : 1	0.3 + 0.03
paclobutrazol	X.09	1 : 1	0.1 + 0.1
paclobutrazol	X.09	3 : 1	0.3 + 0.1
trinexapac-ethyl	X.09	10 : 3	0.1 + 0.03
trinexapac-ethyl	X.09	10 : 1	0.3 + 0.03
trinexapac-ethyl	X.09	1 : 1	0.1 + 0.1
trinexapac-ethyl	X.09	3 : 1	0.3 + 0.1
flutriafol	X.09	10 : 3	0.1 +0.03
flutriafol	X.09	10 : 1	0.3 + 0.03
flutriafol	X.09	1 : 1	0.1 +0.1
flutriafol	X.09	3 : 1	0.3 + 0.1
difenoconazole	X.09	10 : 3	0.1 +0.03
difenoconazole	X.09	10 : 1	0.3 + 0.03
difenoconazole	X.09	1 : 1	0.1 +0.1
difenoconazole	X.09	3 : 1	0.3 + 0.1
fludioxonil	X.09	10 : 3	0.1 +0.03
fludioxonil	X.09	10 : 1	0.3 + 0.03
fludioxonil	X.09	1 : 1	0.1 +0.1
fludioxonil	X.09	3 : 1	0.3 + 0.1
cyproconazole	X.09	10 : 3	0.1 +0.03
cyproconazole	X.09	10 : 1	0.3 + 0.03
cyproconazole	X.09	1 : 1	0.1 + 0.1
cyproconazole	X.09	3 : 1	0.3 + 0.1
acibenzolar S-methyl	X.09	10 : 3	0.1 +0.03
acibenzolar S-methyl	X.09	10 : 1	0.3 + 0.03
acibenzolar S-methyl	X.09	1 : 1	0.1 + 0.1
acibenzolar S-methyl	X.09	3 : 1	0.3 + 0.1
trifloxystrobin	X.09	10 : 3	0.1 + 0.03
trifloxystrobin	X.09	10 : 1	0.3 + 0.03
trifloxystrobin	X.09	1 : 1	0.1 + 0.1
trifloxystrobin	X.09	3 : 1	0.3 + 0.1
folpet	X.09	10 : 3	0.1 + 0.03
folpet	X.09	10 : 1	0.3 + 0.03

214

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
folpet	X.09	1 : 1	0.1 + 0.1
folpet	X.09	3 : 1	0.3 + 0.1
azoxystrobin	X.09	10 : 3	0.1 + 0.03
azoxystrobin	X.09	10 : 1	0.3 + 0.03
azoxystrobin	X.09	1 : 1	0.1 + 0.1
azoxystrobin	X.09	3 : 1	0.3 + 0.1
pyraclostrobin	X.09	10 : 3	0.1 + 0.03
pyraclostrobin	X.09	10 : 1	0.3 + 0.03
pyraclostrobin	X.09	1 : 1	0.1 + 0.1
pyraclostrobin	X.09	3 : 1	0.3 + 0.1
picoxystrobin	X.09	10 : 3	0.1 + 0.03
picoxystrobin	X.09	10 : 1	0.3 + 0.03
picoxystrobin	X.09	1 : 1	0.1 + 0.1
picoxystrobin	X.09	3 : 1	0.3 + 0.1
sulphur	X.09	10 : 3	0.1 + 0.03
sulphur	X.09	10 : 1	0.3 + 0.03
sulphur	X.09	1 : 1	0.1 + 0.1
sulphur	X.09	3 : 1	0.3 + 0.1
tebuconazole	X.09	10 : 3	0.1 +0.03
tebuconazole	X.09	10 : 1	0.3 + 0.03
tebuconazole	X.09	1 : 1	0.1 + 0.1
tebuconazole	X.09	3 : 1	0.3 + 0.1
prothioconazole	X.09	10 : 3	0.1 +0.03
prothioconazole	X.09	10 : 1	0.3 + 0.03
prothioconazole	X.09	1 : 1	0.1 +0.1
prothioconazole	X.09	3 : 1	0.3 + 0.1
fluopyram	X.09	10 : 3	0.1 +0.03
fluopyram	X.09	10 : 1	0.3 + 0.03
fluopyram	X.09	1 : 1	0.1 + 0.1
fluopyram	X.09	3 : 1	0.3 + 0.1
copper oxychloride	X.09	10 : 3	0.1 + 0.03
copper oxychloride	X.09	10 : 1	0.3 + 0.03
copper oxychloride	X.09	1 : 1	0.1 + 0.1
copper oxychloride	X.09	3 : 1	0.3 + 0.1

215

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
benzovindiflupyr	X.09	10 : 3	0.1 + 0.03
benzovindiflupyr	X.09	10 : 1	0.3 + 0.03
benzovindiflupyr	X.09	1 : 1	0.1 + 0.1
benzovindiflupyr	X.09	3 : 1	0.3 + 0.1
isopyrazam	X.09	10 : 3	0.1 + 0.03
isopyrazam	X.09	10 : 1	0.3 + 0.03
isopyrazam	X.09	1 : 1	0.1 + 0.1
isopyrazam	X.09	3 : 1	0.3 + 0.1
pydiflumetofen	X.09	10 : 3	0.1 + 0.03
pydiflumetofen	X.09	10 : 1	0.3 + 0.03
pydiflumetofen	X.09	1 : 1	0.1 + 0.1
pydiflumetofen	X.09	3 : 1	0.3 + 0.1
fluxapyroxad	X.09	10 : 3	0.1 + 0.03
fluxapyroxad	X.09	10 : 1	0.3 + 0.03
fluxapyroxad	X.09	1 : 1	0.1 + 0.1
fluxapyroxad	X.09	3 : 1	0.3 + 0.1
quinofumelin	X.09	10 : 3	0.1 + 0.03
quinofumelin	X.09	10 : 1	0.3 + 0.03
quinofumelin	X.09	1 : 1	0.1 + 0.1
quinofumelin	X.09	3 : 1	0.3 + 0.1
isoflucypram	X.09	10 : 3	0.1 +0.03
isoflucypram	X.09	10 : 1	0.3 + 0.03
isoflucypram	X.09	1 : 1	0.1 + 0.1
isoflucypram	X.09	3 ; 1	0.3 + 0.1
mefentrifluconazole	X.09	10 i 3	0.1 +0.03
mefentrifluconazole	X.09	10 : 1	0.3 + 0.03
mefentrifluconazole	X.09	1 : 1	0.1 +0.1
mefentrifluco n azote	X.09	3 ; 1	0.3 + 0.1
ipflufenoquin	X.09	10 : 3	0.1 + 0.03
ipflufenoquin	X.09	10 : 1	0.3 + 0.03
ipflufenoquin	X.09	1 : 1	0.1 + 0.1
ipflufenoquin	X.09	3 : 1	0.3 + 0.1
metyltetraprole	X.09	10 : 3	0.1 + 0.03
metyltetraprole	X.09	10 : 1	0.3 + 0.03

216

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
metyltetraprole	X.09	1 : 1	0.1 + 0.1
metyltetraprole	X.09	3 : 1	0.3 + 0.1
aminopyrifen	X.09	10 : 3	0.1 + 0.03
aminopyrifen	X.09	10 : 1	0.3 + 0.03
aminopyrifen	X.09	1 : 1	0.1 + 0.1
aminopyrifen	X.09	3 : 1	0.3 + 0.1
florylpicoxamid	X.09	10 : 3	0.1 + 0.03
florylpicoxamid	X.09	10 : 1	0.3 + 0.03
florylpicoxamid	X.09	1 : 1	0.1 + 0.1
florylpicoxamid	X.09	3 : 1	0.3 + 0.1
florylpicoxamid	X.09	1:2	0.02+0.04
florylpicoxamid	X.09	1:1	0.02+0.02
florylpicoxamid	X.09	2:1	0.02+0.01
florylpicoxamid	X.09	4:1	0.02+0.005
florylpicoxamid	X.09	8:1	0.02+0.0025
florylpicoxamid	X.09	16:1	0.02+0.00125
florylpicoxamid	X.09	1:4	0.01+0.04
florylpicoxamid	X.09	1:2	0.01+0.02
florylpicoxamid	X.09	1:1	0.01+0.01
florylpicoxamid	X.09	2:1	0.01+0.005
florylpicoxamid	X.09	4:1	0.01+0.0025
florylpicoxamid	X.09	8:1	0.01+0.00125
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)'3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.09	10 : 3	0.1 +0.03
2-[6-(4-bromophenoxy)-2-(tnf!uoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-y!)propan-2-ol	X.09	10 : 1	0.3 + 0.03
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol	X.09	1 : 1	0.1 + 0.1
2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yi)propan-2-ol	X.09	3 : 1	0.3 + 0.1
[(1 S,2S)-2-(4-fluoro-2-methyl-pheny 1)-1,3- dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4- meth oxy-pyrid ine-2-carbony l]a mine] propa noate	X.09	10 : 3	0.1 + 0.03

217

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino] propanoate	X.09	10 : 1	0.3 + 0.03
[(1 S,2S)-2-(4-f!uoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonyl]amino]propanoate	X.09	1 : 1	0.1 + 0.1
[(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3dimethyl-butyl] (2S)-2-[[3-(acetoxymethoxy)-4methoxy-pyridine-2-carbonylJamino]propanoate	X.09	3 : 1	0.3 + 0.1
(Z,2E)-5-[1-(2,4-dichloropheny[)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dÎmethyl-pent-3-enamide	X.09	10 : 3	0.1 + 0.03
(Z ,2 E)-5-[1 -(2,4-d ichloro ph enyl)py razol-3-y I] oxy2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.09	10 : 1	0.3 + 0.03
(Z,2E)-5-[1-(2,4-dichlorophenyi)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.09	1 : 1	0.1 + 0.1
(Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy- 2-methoxyimino-N,3-dimethyl-pent-3-enamide	X.09	3 : 1	0.3 + 0.1
[(1S,2S)-1-methyl-2-(o-tolyl)propylJ (2S)-2-[(4methoxy-3- propa n oy loxy-pyrid ine-2carbonyl)amino]propanoate	X.09	3:2	0.06+0.04
[(1S,2S)-1-methyl-2-(o-tolyl)propy!] (2S)-2-[(4meth oxy-3-propanoy loxy-pyrid ine-2carbonyl)amino]propanoate	X.09	3:1	0.06+0.02
[(1S,2S)-1-methyl-2-(o-tolyl)propylJ (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.09	6:1	0.06+0.01
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propa noy loxy-pyrid ine-2carbonyl)amino]propanoate	X.09	12:1	0.06+0.005
[(1S,2S)-1-methyl-2-(o-tolyf)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.09	24:1	0.06+0.0025

218

Component B	Component A (compound)	Ratio B:A	Conc. (ppm) (B: A)
[(1 S,2S)-1 -methyl-2-(o-tolyf)propyl] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2- carbonyl)amino]propanoate	X.09	48:1	0.06+0.00125
[(1 S,2S)-1 -metiiyl-2-(o-tolyl)propyl] (2S)-2-[(4- methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.09	3:4	0.03+0.04
[(1 S,2S)-1 -methyl-2-(o-tolyl)propyl\| (2S)-2-[(4methoxy-3-propan oyloxy-pyridine-2carbonyl)amino]propanoate	X.09	3:2	0.03+0.02
[(1S,2S)-1-methyl-2-(o-tolyl)propylJ (2S)-2-[(4- methoxy-3-propan oyloxy-pyridi ne-2carbonyl)amino]propanoaîe	X.09	3:1	0.03+0.01
[(1S ,25)-1-methyl-2-(o-tolyl)propyl) (2S)-2-[(4- methoxy-3-propanoyfoxy-pyridine-2carbony!)amino]propanoate	X.09	6:1	0.03+0.005
[(1S ,2S)-1 -methy I-2- (û-toly I) propy I] (2S)-2-[(4methoxy-3-propanoyloxy-pyridine-2carbonyl)amino]propanoate	X.09	12:1	0.03+0.0025
[(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4m et h oxy- 3- p ro pa η o y loxy- py ri d i n e-2carbonyl)amino]propanoate	X.09	24:1	0.03+0.00125
N-(2-fluorophenyl)-4-[5-(trifluoromethyi)-1,2,4oxadiazol-3-yl]benzamide	X.09	500:1	20+0.04
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.09	1000:1	20+0.02
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]benzamide	X.09	2000:1	20+0.01
N-(2-fluorophenyl)-4-[5(tnfluoromethyl)-1,2,4oxadiazol-3-ylJbenzamide	X.09	4000:1	20+0.005
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1_l2,4oxadiazol-3-y l[benza m ide	X.09	250:1	10+0.04
N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1_T2,4oxadiazol-3-y!]benzamide	X.09	500:1	10+0.02

219

Component B	Component A (compound)	Ratio B;A	Conc. (ppm) (B: A)
N-(2-fluorophenyl)-4-[5-(trifIuoromethyl)-1,2,4oxadiazol-3-yl]benza mide	X.09	1000:1	10+0.01
N-(2-fl uorophenyl)-4-[5-(trifIuoromethy 1)-1,2,4oxadiazol-3-yl]benzamide	X.09	2000:1	10+0.005

The following mixture compositions at the reported concentration (in ppm) in tables 84-2 to B4-5 gave the following disease control in this test Mycosphaeretla arachidis syn. Cercospora arachidicoia (Brown leaf spot of peanut). Fungicidal activity was evaluated on a 100-0 scale (100 = no disease growth; 0 = well completely covered by mycélium).

Table B4-2

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
[(1S,2S)-1-methyl-2-(o- tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino]propanoate	X.01	0.03+0.0125	70	70	100	91
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)a min o] propan oate	X.01	0.03+0.00625	70	20	100	76
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propa noy loxypy rid ine-2carbonyl)amino]propanoate	X.01	0.03+0.003125	70	0	100	70

Table B4-3

220

Component B	Component A	Concentration (B + A)	Activîty (%)	COLBY Expected Activîty (%)
ppm	B	A	B +A
chlorothalonil	X.08	0.1 + 0.03	0	70	90	70
chlorothalonil	X.08	0.3 + 0.03	90	70	100	97
folpet	X.08	0.1 +0.03	20	70	70	76
folpet	X.08	0.3 + 0.03	20	70	90	76
Florylpicoxamid	X.08	0.02+0.0125	90	20	100	92
Florylpicoxamid	X.08	0.01+0.0125	70	20	100	76
[(1S,2S)-1-methyl-2-(o- tolyi)propyî] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2- ca rbony I) a mino] propa noate	X.08	0.03+0.025	70	70	100	91
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbonyl)amino] propa noate	X.08	0.03+0.0125	70	50	100	85
[(IS^SJ-l-methyl^-iotolyl)propyi] (2S)-2-[(4methoxy-3-propa noy loxypyridine-2carbonyl)amino]propanoate	X.08	0.03+0.00625	70	0	100	70

Table B4 -3

Component B	Component A	Concentration (B + A)	Activîty (%)	COLBY Expected Activîty (%)
ppm	B	A	B + A
[(1S,2S)-1-methyl-2-(o- toiyl)propyl] (2S)-2-[(4methoxy-3- propanoy loxypyridine-2carbonyl)amîno]propanoate	X.06	0.03+0.0125	70	90	100	97

221

[(1 S,2S)-1-methy 1-2-(0- to1yl)propyl] (2S)-2-((4methoxy-3- propan oyloxypyridine-2carbonyl)amino]propanoate	X.06	0.03+0.00625	70	50	100	85
[(1S,2S)-1-methy i-2-(o- tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridîne-2carbonyl)amino]propanoate	X.06	0.03+0.003125	70	20	100	76

Table B4 -4

Component B	Component A	Concentration (B + A)	Activity (%)	COLBY Expected Activity (%)
ppm	B	A	B + A
chlorothalonil	X.10	0.1 + 0.03	0	0	0	0
chlorothalonil	X.10	0.3 + 0.03	90	0	100	90
folpet	X.10	0.1 +0.03	20	0	20	20
folpet	X.10	0.3 + 0.03	20	0	50	20
fluopyram	X.10	0.1 +0.03	0	0	20	0
fluopyram	X.10	0.3 + 0.03	90	0	90	90
isoflucypram	X.10	0.1 + 0.03	90	0	100	90
isoflucypram	X.10	0.3 + 0.03	100	0	100	100
aminopyrifen	X.10	0.1 + 0.03	90	0	100	90
aminopyrifen	X.10	0.3 + 0.03	100	0	100	100
[(1S,2S)-1-methyl-2-(otolyl)propyl] (2S)-2-[(4mef hoxy-3- pro pa noyloxypyridine-2carbonyl)amino]propanoate	X.10	0.03+0.00625	70	90	100	97
[(1S,2S)-1-methyl-2-(otolyljpropyi] (2S)-2-[(4meth oxy-3-propa noy loxypyridine-2carbonyl)amino]propanoate	X.10	0.03+0.003125	70	70	100	91

222

Table B4 -5

Component B	Component A	Concentration (B + A)	Activity {%)	COLBY Expected Activity (%)
ppm	B	A	B + A
[(1S,2S)-1-methyl-2-(o- tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2carbo ny I) a mino]propa noate	X.09	0.03+0.005	70	90	100	97
[(1S,2S)-1-methyl-2-(o- tolyl)propyl] (2S)-2-[(4methoxy-3-propanoyloxypyridine-2ca rbo ny I) a mino]propa noate	X.09	0.03+0.0025	70	50	100	85
[(1S,2S)-1-methyl-2-(o- tolyl)propyl] (2S)-2-[(4- m et h oxy- 3- pro pa η o y I oxypyrrdine-2carbonyl) amino] propanoate	X.09	0.03+0.00125	70	20	100	76
florylpicoxamid	X.08	0.02+0.0125	90	20	100	92
florylpicoxamid	X.08	0.01+0.0125	70	20	100	76
florylpicoxamid	X.08	0.02+0.0125	90	20	100	92
florylpicoxamid	X.08	0.01+0.0125	70	20	100	76

Example B5: Preventative activity against Phakopsora pachyrhïzi (Soybean rust):

Whole soybean plants are treated with the recited active ingrédients 4 weeks after planting. 1 day after sprayîng leaf disks are eut from the first trifolrate leaf. Five répétitions at each rate are conducted. The 10 leaf disks are inoculated with Phakopsora pachyrhïzi (Asian soybean rust) one day after treatment.

Evaluation ofthe leafdisks is conducted 11 to 14 days after inoculation and the activity is derived from the relation ofthe treated vs untreated, înfested check (100 = no disease, no damage to the leaf, 0 = high infestation, leaf damaged heavily). The rates ofthe active ingrédients used are given in the tables as g active ingrédient (a.i.)/ha.

The resuits are shown in the tables below;

223

Table B5-1 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.01 (g/ha)	Trifloxystrobin (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
18	0		85
9	0		78
4.5	0		61
2.25	0		12
0	18		19
0	9		0
0	4.5		3
0	2.25		0
9	9	1:1	87	78
4.5	4.5	1:1	67	62
2.25	2.25	1:1	33	12

Table B5-2 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.01 (g/ha)	Azoxystrobin (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
18	0		85
9	0		78
4.5	0		61
2.25	0		12
0	18		9
0	9		23
0	4.5		15
0	225		0
9	9	1:1	99	83
4.5	4.5	1:1	88	67
2.25	2.25	1:1	72	12

Table B5-3 - Activity (% of untreated) against Phakopsora pachyrhizi

•	224
	Compound X.01 (g/ha)	Metyltetraprole (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
18	0		97
9	0		94
4.5	0		87
2.25	0		33
0	18		67
0	9		7
0	4.5		0
0	2.25		1
9	9	1:1	93	95
4.5	4.5	1:1	94	87
2.25	2.25	1:1	69	34
2.25	4.5	1:2	78	33

Table B5-4 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.01 (g/ha)	Pyraciostrobin (g/ha)	Compound: Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
18	0		97
9	0		94
4.5	0		87
2.25	0		33
0	18		13
0	9		1
0	4.5		0
0	2.25		0
9	9	1:1	97	94
4.5	4.5	1:1	91	87
2.25	2.25	1:1	81	33
2.25	4.5	1:2	25	33

Table B5-5 - Activity (% of untreated) against Phakopsora pachyrhizi

225

Compound X.01 (g/ha)	Prothioconazole (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
9	0		90
4.5	0		82
2.25	0		65
0	90		94
0	45		80
0	22.5		47
9	90	1:10	97	99
4.5	45	1:10	98	96
2.25	22.5	1:10	99	82
4.5	90	1:20	97	99

Table B5-6 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.01 (g/ha)	Difenoconazole (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
9	0		90
4.5	0		82
2.25	0		65
0	90		24
0	45		10
0	22.5		3
9	90	1:10	98	93
4.5	45	1:10	95	84
2.25	22.5	1:10	89	66
4.5	90	1:20	92	86

Table B5-7 - Activity f% of untreated) against Phakopsora pachyrhizi

Compound X.01 (g/ha)	Cyproconazoie (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
9	0		90
4.5	0		82

226

•
	Compound X.01 (g/ha)	Cyproconazole (g/ha)	Compound : Mixing partner	Observed Açtivity (%)	COLBY Expected Açtivity (%)
	2.25	0		65
	0	90		84
	0	45		69
	0	22.5		15
	9	90	1:10	98	98
	4.5	45	1:10	100	94
	2.25	22.5	1:10	99	70
	4.5	90	1:20	99	97

Table 85-8 - Açtivity (% of untreated) against Phakopsora pachyrhizi

Compound X.01 (g/ha)	Benzovindiflupyr (g/ha)	Compound : Mixing partner	Observed Açtivity (%)	COLBY Expected Açtivity (%)
9	0		85
4.5	0		69
2.25	0		24
0	9		99
0	4.5		80
0	2.25		34
9	9	1:1	99	100
4.5	4.5	1:1	97	94
2.25	2.25	1:1	59	50
4.5	9	1:2	94	100

Table B5-9 - Açtivity (% of untreated) against Phakopsora pachyrhizi

Compound X.01 (g/ha)	Fluxapyroxad (g/ha)	Compound : Mixing partner	Observed Açtivity (%)	COLBY Expected Açtivity (%)
9	0		85
4.5	0		69
2.25	0		24
0	9		66

•	227
	Compound X.01 (g/ha)	Fluxapyroxad (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
0	4.5		7
0	2.25		8
9	9	1:1	80	95
4.5	4.5	1:1	52	71
2.25	2.25	1:1	33	30
4.5	9	1:2	83	89

Table B5-10 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.01 (g/ha)	isoflucypram (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
9	0		85
4.5	0		69
2.25	0		24
0	9		0
0	4.5		1
0	2.25		2
9	9	1:1	83	85
4.5	4.5	1:1	79	69
2.25	2.25	1:1	47	25
4.5	9	1:2	71	69

Table B5-11 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.01 (g/ha)	Fenpropidin (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.5	0		78
2.25	0		44
0	450		77
0	225		72
4.5	450	1:100	95	95
2.25	225	1:100	96	84

228

Table B5-12 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.01 (g/ha)	Trinexapac-ethyl (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.5	0		64
2.25	0		31
0	45		0
0	22.5		0
4.5	45	1:10	91	64
2.25	22.5	1:10	37	31

Table B5-13 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.01 (g/ha)	Glyphosate (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.50	0		66
2.25	0		35
0	90		0
0	45		1
4.50	90	1:20	71	66
2.25	45	1:20	38	35

Table B5-14 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.01 (g/ha)	Mefentrifluconazole (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.50	0		95
2.25	0		78
0	45		20
0	22.5		1
4.50	45	1:10	97	96
2.25	22.5	1:10	97	78

Table B5-15 - Activity (% of untreated) against Phakopsora pachyrhizi

229

Compound X.01 (g/ha)	Copper oxychloride (g/ha)	Compound : Mixing partner	Observed Activîty (%)	COLBY Expected Activîty (%)
4.50	0		95
2.25	0		78
0	45		5
0	22.5		2
4.50	45	1:10	95	95
2.25	22.5	1:10	89	78

Table B5-16 - Activitv (% of untreated) against Phakopsora pachyrhizi

Compound X.08 (g/ha)	Fenpropidin (g/ha)	Compound : Mixing partner	Observed Activîty (%)	COLBY Expected Activîty (%)
4.5	0		19
2.25	0		23
0	450		77
0	225		72
4.5	450	1:100	92	81
2.25	225	1:100	93	79

Table B5-17 - Activitv (% of untreated) against Phakopsora pachyrhizi

Compound X,08 (g/ha)	Mancozeb (g/ha)	Compound : Mixing partner	Observed Activîty (%)	COLBY Expected Activîty (%)
4.5	0		19
2.25	0		23
0	450		34
0	225		20
4.5	450	1:100	64	47
2.25	225	1:100	74	38

Table B5-18 - Activitv (% of untreated) against Phakopsora pachyrhizi

230

Compound X.08 (g/ha)	Trinexapac-ethyl (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.5	0		10
2.25	0		1
0	45		0
0	22.5		0
4.5	45	1:10	89	10
2.25	22.5	1:10	73	1

Table B5-19 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.08 (g/ha)	Fludioxonil (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.50	0		13
2.25	0		1
0	900		1
0	450		0
4.50	900	1:200	58	13
2.25	450	1:200	1	1

Table B5-20 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.08 (g/ha)	Glyphosate (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.50	0		13
2.25	0		1
0	90		0
0	45		1
4.50	90	1:20	53	13
2.25	45	1:20	36	2

Table B5-21 - Activity (% of untreated) against Phakopsora pachyrhizi

231

Compound X.08 (g/ha)	Mefentrifluconazole (g/ha)	Compound : Mixing partner	Observed Açtivity (%)	COLBY Expected Açtivity (%)
4.50	0		86
2.25	0		60
0	45		20
0	22.5		1
4.50	45	1:10	96	89
2.25	22.5	1:10	91	60

Table B5-22 - Açtivity (% of untreated) against Phakopsora pachyrhizi

Compound X.08 (g/ha)	Trifloxystrobin (g/ha)	Compound ; Mixing partner	Observed Açtivity (%)	COLBY Expected Açtivity (%)
18	0		38
9	0		19
4.5	0		19
2.25	0		13
0	18		19
0	9		0
0	4.5		3
0	2.25		0
9	9	1:1	70	19
4.5	4.5	1:1	33	22
2.25	2.25	1:1	0	13

Table B5-23 - Açtivity (% of untreated) against Phakopsora pachyrhizi

Compound X.08 (g/ha)	Azoxystrobin (g/ha)	Compound : Mixing partner	Observed Açtivity (%)	COLBY Expected Açtivity (%)
18	0		38
9	0		19
4.5	0		19
2.25	0		13

232

Compound X.08 (g/ha)	Azoxystrobin (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
0	18		9
0	9		23
0	4.5		15
0	2,25		0
9	9	1:1	75	38
4.5	4.5	1:1	58	31
2.25	2.25	1:1	14	13

Table B5-24 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.08 (g/ha)	Metyltetraprole (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
18	0		77
9	0		85
4.5	0		67
2.25	0		14
0	18		67
0	9		7
0	4.5		0
0	2.25		1
9	9	1:1	69	86
4.5	4.5	1:1	65	67
2.25	2.25	1:1	31	15
2.25	4.5	1:2	82	14

Table B5-25 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.08 (g/ha)	Pyraclostrobin (g/ha)	Compound: Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
18	0		77
9	0		85
4.5	0		67

233

Compound X.08 (g/ha)	Pyraclostrobin (g/ha)	Compound: Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
2.25	0		14
0	18		13
0	9		1
0	4.5		0
0	2.25		0
9	9	1:1	86	85
4.5	4.5	1:1	73	67
2.25	2.25	1:1	13	14
2,25	4.5	1:2	55	14

Table B5-26 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.08 (g/ha)	Prothioconazole (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
9	0		78
4.5	0		66
2.25	0		7
0	90		94
0	45		80
0	22.5		47
9	90	1:10	97	99
4.5	45	1:10	91	93
2.25	22.5	1:10	81	51
4,5	90	1:20	95	98

Table B5-27 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.08 (g/ha)	Difenoconazole (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
9	0		78
4.5	0		66
2.25	0		7

234

Compound X.08 (g/ha)	Difenoconazole (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
0	90		24
0	45		10
0	22.5		3
9	90	1:10	98	83
4.5	45	1:10	95	69
2.25	22.5	1:10	89	9
4.5	90	1:20	92	74

Table B5-28 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.08 (g/ha)	Cyproconazole (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
9	0		78
4.5	0		66
2.25	0		7
0	90		84
0	45		69
0	22.5		15
9	90	1:10	98	97
4.5	45	1:10	52	89
2.25	22.5	1:10	62	21
4.5	90	1:20	85	95

Table B5-29 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.08 (g/ha)	Benzovindiflupyr (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
9	0		86
4.5	0		51
2.25	0		11
0	9		99
0	4.5		80

235

Compound X.08 (g/ha)	Benzovindiflupyr (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
0	2.25		34
9	9	1:1	98	100
4.5	4.5	1:1	90	90
2.25	2.25	1:1	67	41
4.5	9	1:2	100	100

Table B5-30 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.06 (g/ha)	Metyltetraprole (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
18	0		97
9	0		97
4.5	0		61
2.25	0		10
0	18		67
0	9		7
0	4.5		0
0	2.25		1
9	9	1:1	96	97
4.5	4.5	1:1	90	61
2.25	2.25	1:1	43	12
2.25	4.5	1:2	46	10

Table B5-31 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.06 (g/ha)	Pyraciostrobin (g/ha)	Compound: Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
18	0		97
9	0		97
4.5	0		61
2.25	0		10

•	236
Compound X.06 (g/ha)	Pyraclostrobin (g/ha)	Compound: Mixing partner	Observed Açtivity (%)	COLBY Expected Açtivity (%)
	0	18		13
	0	9		1
	0	4.5		0
	0	2.25		0
	9	9	1:1	88	97
	4.5	4.5	1:1	72	61
	2.25	2.25	1:1	51	10
	2.25	4.5	1:2	52	10

Tabie B5-32 - Açtivity (% of untreated) against Phakopsora pachyrhizi

Compound X.06 (g/ha)	Prothioconazole (g/ha)	Compound : Mixing partner	Observed Açtivity (%)	COLBY Expected Açtivity (%)
9	0		81
4.5	0		48
2.25	0		13
0	90		94
0	45		80
0	22.5		47
9	90	1:10	95	99
4.5	45	1:10	90	90
2.25	22.5	1:10	68	54
4.5	90	1:20	96	97

Table B5-33 - Açtivity (% of untreated) against Phakopsora pachyrhizi

Compound X.06 (g/ha)	Difenoconazole (g/ha)	Compound : Mixing partner	Observed Açtivity (%)	COLBY Expected Açtivity (%)
9	0		81
4.5	0		48
2.25	0		13
0	90		24

237

Compound X.06 (g/ha)	Difenoconazole (g/ha)	Compound : Mixing partner	Observed Activîty (%)	COLBY Expected Activîty (%)
0	45		10
0	22,5		3
9	90	1:10	97	86
4.5	45	1:10	88	53
2.25	22,5	1:10	50	15
4.5	90	1:20	91	61

Table B5-34 - Activitv (% of untreated) against Phakopsora pachyrhizi

Compound X,06 (g/ha)	Cyproconazole (g/ha)	Compound : Mixing partner	Observed Activîty (%)	COLBY Expected Activîty (%)
9	0		81
4.5	0		48
2.25	0		13
0	90		84
0	45		69
0	22.5		15
9	90	1:10	98	97
4.5	45	1:10	98	84
2.25	22.5	1:10	89	26
4,5	90	1:20	98	92

Table B5-35 - Activitv (% of untreated) against Phakopsora pachyrhizi

Compound X.06 (g/ha)	Benzovindiflupyr (g/ha)	Compound : Mixing partner	Observed Activîty (%)	COLBY Expected Activîty (%)
9	0		93
4.5	0		73
2.25	0		9
0	9		99
0	4.5		80
0	2.25		34

238

Compound X.06 (g/ha)	Benzovindiflupyr (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
9	9	1:1	98	100
4.5	4.5	1:1	86	95
2.25	2.25	1:1	74	40
4.5	9	1:2	97	100

Table B5-36 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.09 (g/ha)	Fenpropidin (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.5	0		94
2.25	0		51
0	450		77
0	225		72
4.5	450	1:100	97	99
2.25	225	1:100	98	86

Table B5-37 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.09 (g/ha)	Mancozeb (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.5	0		94
2.25	0		51
0	450		34
0	225		20
4.5	450	1:100	93	96
2.25	225	1:100	73	61

Table B5-38 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.09 (g/ha)	Trinexapac-ethyl (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.5	0		95
2.25	0		34

239

Compound X.09 (g/ha)	Trinexapac-ethyl (g/ha)	Compound ; Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
0	45		0
0	22.5		0
4.5	45	1:10	93	95
2.25	22.5	1:10	73	34

Table B5-39 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.09 (g/ha)	Fludioxonil (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.50	0		78
2,25	0		13
0	900		1
0	450		0
4.50	900	1:200	83	78
2.25	450	1:200	73	13

Table B5-40 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.09 (g/ha)	Glyphosate (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.50	0		78
2.25	0		13
0	90		0
0	45		1
4.50	90	1:20	93	78
2.25	45	1:20	81	14

Table B5-41 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.09 (g/ha)	Mefentrifluco n azo le (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.50	0		96
2.25	0		90

240

Compound X.09 (g/ha)	Mefentrifluconazole (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
0	45		20
0	22.5		1
4.50	45	1:10	97	97
2.25	22.5	1:10	98	90

Table B5-42 - Activity (% of untreated) against Phakopsora pachyrhizî

Compound X.09 (g/ha)	Metyltetraprole (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
18	0		97
9	0		97
4.5	0		93
2.25	0		45
0	18		67
0	9		7
0	4.5		0
0	2.25		1
9	9	1:1	97	98
4.5	4.5	1:1	84	93
2.25	2.25	1:1	71	46
2.25	4.5	1:2	88	45

Table 85-43 - Activity /% of untreated) against Phakopsora pachyrhizî

Compound X.09 (g/ha)	Pyraclostrobin (g/ha)	Compound: Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
18	0		97
9	0		97
4.5	0		93
2.25	0		45
0	18		13

	241
	Compound X.09 (g/ha)	Pyraclostrobin (g/ha)	Compound: Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
0	9		1
0	4.5		0
0	2.25		0
9	9	1:1	83	97
4.5	4.5	1:1	93	93
2.25	2.25	1:1	32	45
2.25	4.5	1:2	87	45

Table B5-44 - Activity (% of untreated) against Phakopsora pachvrhizi

Compound X.09 (g/ha)	Prothioconazole (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
9	0		97
4.5	0		81
2.25	0		64
0	90		94
0	45		80
0	22.5		47
9	90	1:10	96	100
4.5	45	1:10	100	96
2.25	22.5	1:10	90	81
4.5	90	1:20	94	99

Table B5-45 - Activity {% of untreated) against Phakopsora pachvrhizi

Compound X.09 (g/ha)	Difenoconazole (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
9	0		97
4.5	0		81
2.25	0		64
0	90		24
0	45		10

242

Compound X.09 (g/ha)	Difenoconazole (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
0	22.5		3
9	90	1:10	98	98
4.5	45	1:10	97	83
2.25	22.5	1:10	77	65
4.5	90	1:20	96	86

Table B5-46 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.09 (g/ha)	Cyproconazole (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
9	0		97
4.5	0		81
2.25	0		64
0	90		84
0	45		69
0	22.5		15
9	90	1:10	97	100
4.5	45	1:10	96	94
2.25	22.5	1:10	94	70
4.5	90	1:20	99	97

Table B5-47 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.09 (g/ha)	Benzovindiflupyr (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
9	0		95
4.5	0		82
2.25	0		25
0	9		99
0	4.5		80
0	2.25		34
9	9	1:1	99	100

243

Compound X.09 (g/ha)	Benzovindiflupyr (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.5	4.5	1:1	97	96
2.25	2.25	1:1	73	50
4.5	9	1:2	97	100

Table B5-48 - AcÎivitv (% of untreated) against Phakopsora pachyrhizi

Compound X.09 (g/ha)	Fluxapyroxad (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
9	0		95
4.5	0		82
2.25	0		25
0	9		66
0	4.5		7
0	2.25		8
9	9	1:1	98	98
4.5	4.5	1:1	88	83
2.25	2.25	1:1	55	31
4.5	9	1:2	78	94

Table B5-49 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.09 (g/ha)	Isoflucypram (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
9	0		95
4.5	0		82
2,25	0		25
0	9		0
0	4.5		1
0	2.25		2
9	9	1:1	96	95
4.5	4.5	1:1	89	82
2.25	2.25	1:1	36	26

244

Compound X.09 (g/ha)	Isoflucypram (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.5	9	1:2	88	82

Table B5-50 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.01 (g/ha)	Quantis™ (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.5	0		64
2.25	0		31
0	900		0
0	450		0
4.5	900	1:200	81	64
2.25	450	1:200	65	31

Table B5-51 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.08 (g/ha)	Quantis™ (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.5	0		10
2.25	0		1
0	900		0
0	450		0
4.5	900	1:200	26	10
2.25	450	1:200	0	1

Table B5-52 - Activity (% of untreated) against Phakopsora pachyrhizi

Compound X.09 (g/ha)	Quantis™ (g/ha)	Compound : Mixing partner	Observed Activity (%)	COLBY Expected Activity (%)
4.5	0		95
2.25	0		34
0	900		0
0	450		0
4.5	900	1:200	93	95

245

Compound X,09 (g/ha)	Quantis™ (g/ha)	Compound : Mixing partner	Observed Activîty (%)	COLBY Expected Activîty (%)
2,25	450	1:200	71	34

Table B5-53 - Activitv (% of untreated) against Phakopsora pachyrhizi

Compound X.06 (g/ha)	Fenpropidin (g/ha)	Compound : Mixing partner	Observed Activîty (%)	COLBY Expected Activîty (%)
4.5	0		55
2.25	0		38
0	450		77
0	225		72
4.5	450	1:100	97	90
2,25	225	1:100	95	83

Table B5-54 - Activitv (% of untreated) against Phakopsora pachyrhizi

Compound X.06 (g/ha)	Trinexapac-ethyl (g/ha)	Compound : Mixing partner	Observed Activîty (%)	COLBY Expected Activîty (%)
4.5	0		80
2.25	0		7
0	45		0
0	22.5		0
4.5	45	1:10	91	80
2.25	22.5	1:10	70	7

Table B5-55 - Activitv (% of untreated) against Phakopsora pachyrhizi

Compound X.06 (g/ha)	Glyphosate (g/ha)	Compound : Mixing partner	Observed Activîty (%)	COLBY Expected Activîty (%)
4,50	0		21
2,25	0		1
0	90		0
0	45		1
4,50	90	1:20	65	21

246

Compound X.06 (g/ha)	Glyphosate (g/ha)	Compound : Mixing partner	Observed Açtivity (%)	COLBY Expected Açtivity (%)
2.25	45	1:20	9	3

Table B5-56 - Açtivity (% of untreated) against Phakopsora pachyrhizi

Compound X.06 (g/ha)	Mefentrifluconazole (g/ha)	Compound : Mixing partner	Observed Açtivity (%)	COLBY Expected Açtivity (%)
4.50	0		94
2.25	0		71
0	45		20
0	22.5		1
4.50	45	1:10	97	95
2.25	22.5	1:10	92	71

Table B5-57 - Açtivity (% of untreated) against Phakopsora pachyrhizi

Compound X.06 (g/ha)	Pydiflumetofen (g/ha)	Compound : Mixing partner	Observed Açtivity (%)	COLBY Expected Açtivity (%)
4.50	0		94
2.25	0		71
0	45		74
0	22.5		28
4.50	45	1:10	95	98
2.25	22.5	1:10	95	79

Claims

1. A fungicidal composition comprising a mixture of components (A) and (B) as active ingrédients,

CLAIMS:

5 wherein component (A) is a compound of formula (I):

wherein

X is CH or N;

R¹ is methyl;

R² is hydrogen;

R³ is hydrogen;

R⁴ is selected from the group consistîng of hydrogen, chloro, bromo, iodo, methyl, ethyl, n-propyl, /so-propyl, n-butyl, /so-butyl, sec-butyl, trifluoromethyl, trifluoroethyl, /'so-propyloxy, n-propyloxy, cyclopropyl and cyclobutyl;

20 R⁵ is selected from the group consistîng of hydrogen, halogen, methyl and trifluoromethyl;

and wherein R⁴ and R⁵ are not both hydrogen;

or an agronomically acceptable sait thereof;

25 or an N-oxide thereof and

30 component (B) is a compound selected from the group consistîng of;

bixafen, sulfur, copper hydroxide, triclopyricarb, acibenzolar-S-methyi, copper oxychloride, cyproconazole, difenoconazole, epoxicon-azole, flutrîafol, hexaconazoie, ipconazole,

248 metconazole, paclobutrazole, prothioconazole, prochloraz, propiconazole, pyrisoxazole, tebucon-azole, fenpropidin, fenpropimorph, spiroxamine, cyprodînil, fludioxonil, metalaxyl, metalaxyl-M (mefenoxam), carbendazim, penthiopyrad, azoxystrobin, dimoxystrobin, fenaminstrobin, flûtenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, mancozeb, folpet, chlorothalonil, fluazinam, fluxapyroxad, fenhexamid, fos-etyl-aluminium, pyribencarb, tricyclazole, mandipropamid, flubeneteram, isopyrazam, sedaxane, benzovindiflupyr, pydiflumetofen, isoflucypram, isotîanil, dipymetitrone, fluindapyr, coumethoxystrobin (jiaxiangjunzhi), Ivbenmixianan, mandestrobin, oxathiapiprolin, pyraziflumid, inpyrfluxam, mefentrifluconazole, ipfentrifluconazole, aminopyrifen, (Z,2E)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyiminoN,3-dimethyl-pent-3-enamide, florylpicoxamid, fenpicoxamid, ipfiufenoquin, quinofumelin, benzothiostrobin, fluopyram, pyrapropoyne, 2-(difluoromethyl)-N-(3-ethyl-1,1-dimethyl-indan-4yl)pyridine-3-carboxamide, 4-[[6-[2-(2,4-difluorophenyl)-1,1-difiuoro-2-hydroxy-3-(1,2,4-triazol-1yl)propyl]-3-pyridyl]oxy]benzonitrile, metyltetraprole, fluoxapiprolin, enoxastrobin, 4-[[6-[2-(2,4d ifluoropheny 1)-1,1 -difluoro-2-hydroxy-3-(54hioxo-4H-1,2,4-triazol-1 -y l)propyl]-3pyridyl]oxy]benzonitrile, trinexapac, trinexapac-ethyl, counoxystrobin, N^h-[5-bromo-2-methyl-6[(1S)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-fonmamidine, N’-[5-bromo-2methyl-6-[(1 R)-1-methyl·2-propoxy-ethoxy]-3-pyridyl]-N-ethy^-N-methyl·formamidίne, N’-[5bromo-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethy1-N-methyl-formamidine, N'-[5chloro-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methy1-formamidine, N’-[5bromo-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-isopropyl-N-methyl-formamidine, N'[5-bromo-2-methyl-6-(2-propoxypropoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidine, N-isopropylN’-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenyl-ethyl)phenyl]-N-methylformamidine, N’-[4-(1-cyclopropyl-2,2,2-trifluoro-1-hydroxy-ethyl)-5-methoxy-2-methyl-phenyl]-Nisopropyl-N-methyl-forma midine, N-ethyl-N’-[5-methoxy-2-methyl-4-[2-trifluoromethyl)oxetan-2yl]phenyl]-N-methyi-formamidine, N-ethyl-N’-[5-methoxy-2-methyl-4-[2trifuoro methy l)tetrahydrofuran-2-yl]phenyl]-N-methyl-formamidine, N-(2-fluorophenyl)-4-[5(trifluoromethyl)-l ,2,4-oxadiazol-3-yl]benzamide, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5(trifluoromethyl)-l ,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-((4-[5(trîfluoromethyl)-l ,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, [(1S,2S)-1-methyl-2-(otolyl)propyi] (2S)-2-[(4-methoxy-3-propanoyioxy-pyridine-2-carbonyl)amino]propanoate, 1methoxy-3-methyl-1-[[4-[5-(trifluoro methyl)-1,2,4-oxadîazol-3-yl]phenyl] methyl] urea, 1,3dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] methy l]urea, N-[[4-[5-(trifiuoromethyl)-1,2,4oxadiazol-S-yllphenyllmethyllpropanamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, 5,5~dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol3-yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyljmethyl]-1,2,4-triazol-3-amine, 2-[6-(4-chiorophenoxy)-2-(trifluoromethyl)-320877

249 pyridyll-1 -(1,2,4-triazol-1-yi)propan-2-ol, 2-[6-(4-bromophenoxy)-2-(trifluorornethyl)-3-pyridyl]-1(1,2,4-tnazol-1-yl)propan-2-ol, 3-[2-(1-chlorocyclopropyl)-3-(2-nuorophenyl)-2-hydroxypropyl]imidazole-4-carbonitrile, 3-[2-(1-chlorocyclopropyl)-3-(3-chloro-2-fluoro-phenyl)-2hydroxy-propyl]imidazole-4-carbonitrile, (4-phenoxyphenyl)methyl 2-amino-6-methyl-pyridine-3carboxylate, N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yi]benzenecarbothioamide; Nmethyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide; (Z,2E)-5-[1-(2,4dichlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide, (5-methyl-2pyridyl)-E4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone, (3-methylisoxazol-5-yl)-[4[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone, ethyl 1-[[5-[5-(trifluoromethyl)-1,2,4oxadiazol·3-yl]-2-thienyl]methyllpyΓazole-4-carboxylate, 2,2-difluoro-N-methyl-2-[4-[5(trifluoromethyf)-1,2,4-oxadiazol-3-yl]phenyl]acetamide, N-[(Z)-methoxyiminomethyl]-4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-y!]benzamide, N-[N-methoxy-C-methyl-carbonîmidoyl]-4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-[3-(4-chlorophenyl)-4,5-dihydroisoxazol-5yl]-5-methyl-1,2,4-oxadiazole-3-carboxamide, 2-(difluoromethyl)-N-(1,1-dimethyl-3-propyl’indan4-yl)pyridine-3-carboxamide, [(1 S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dîmethyl-butyl] (2S)-2[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]propanoate, [(1 S,2S)-2-(4-fluoro-2-methylphenyl)-1,3-dimethyl-biJty!] (2S)-2-[(3-(acetoxymethoxy)-4-methoxy-pyridine-2carbonyi]amino]propanoate, cfs-jasmone, potassium phosphonate, calcium phosphonate, glyphosate (including the diammonium, isopropylammonium and potassium salts thereof), 2,4-D (including the choline sait and 2-ethylhexyl ester thereof), dicamba (including the aluminium, aminopropyl, bis-aminopropylmethyi, choline, dichloroprop, diglycolamine, dimethylamine, dîmethylammonium, potassium and sodium salts thereof), glufosinate (including the ammonium sait thereof), thiamethoxam, cyclobutrifluram, isocycloseram, spiropidion, abamectin, emamectin, cyantraniliprole, chlorantraniliprole, diafenthiuron, brofianilide, 2-chloro-N-cyc)opropyl-5-(1-{2,6dichloro-4-[1,2,2,2-tetrafiuoro-1-(trifluoromethyl)ethyl]phenyl}-1H-pyrazol-4-y!)-Nmethylnicotinamide and fluxametamide.

2. A fungicidal composition according claim 1, wherein component (A) is a compound selected from:

methyi (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate (compound X.01), methyi (Z)-3-methoxy-2-[2-methyl-5-(3-sec-butylpyrazol-1-yl)phenoxy]prop-2-enoate (compound X.02), methyi (Z)-2-[5-(3-isopropoxypyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.03), methyi (Z)-2-[5-(3-cyclobutylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.04), methyi (Z)-2-[5-(3-isobutylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate,

250 (compound X.05), methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.06), methyl (Z)-2-[5-(3-cyclopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.07), methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trif1uoromethyi)pyrazol-1-yl]phenoxy]prop-2-enoate (compound X.08), methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazo!-2-yl)phenoxy]prop-2-enoate (compound X.09), methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate (compound X.10), methyl (Z)-2-[5-(4-cyclopropyltriazol-2-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.11), or methyl (Z)-2-[5-(4-isopropyltriazol-2-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.12);

or an agronomîcally acceptable sait thereof;

or an N-oxide thereof.

3, A fungicidal composition according to claim 1 or claim 2, wherein component (A) is:

methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate (compound X.01), methyl (Z)-2-[5-(3-isopropylpyrazot-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.06), methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate (compound X.08), methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate (compound X.09), methyl (Z)-3-mettioxy-2-[2-methyl-5-[4-(trifluoromethyl)tr!azol-2-yl]phenoxy]prop-2-enoate (compound X.10), or methyl (Z)-2-[5-(4-isopropyltriazol-2-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate (compound X.12);

or an agronomîcally acceptable sait thereof;

251 or an N-oxide thereof.

4. A fungicidal composition according to any one of daims 1 to 3, wherein component (A) is;

methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate (compound X.01), or methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazoM-yl]phenoxy]prop-2-enoate (compound X.08);

or an agronomically acceptable sait thereof;

or an N-oxide thereof.

5. A fungicidal composition according to any one of daims 1 to 4, wherein component (B) îs a compound selected from the group consisting of bixafen, tridopyricarb, cyproconazole, difenoconazole, epoxicon-azole, flutriafol, hexaconazole, ipconazole, metconazole, prothioconazole, propiconazole, tebucon-azole, azoxystrobïn, dimoxystrobin, fenaminstrobin, flufenoxystrobin, fluoxastrobin, metomi-nostrobin, trifloxystrobin, orysastrobln, picoxystrobin, pyraclostrobîn, pyrametostrobin, pyraoxystrobin, mancozeb, chlorothaionil, fluxapyroxad, pyribencarb, benzovindiflupyr, isoflucypram, coumethoxystrobin (jiaxiangjunzhi), mandestrobin, mefentrifluconazole, ipfentrifluconazole, benzothiostrobin, metyltetraprole, enoxastrobin, coumoxystrobin, [(1S,2S)-1-methyl-2-(o-tolyl)propyl] (2S)-2-[(4-methoxy-3-propanoyloxypyridine-2-carbonyl)amino]propanoate, 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1(1,2,4-triazol-1-yl)propan-2-ol, 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4triazol-1-yl)propan-2-ol, 3-(2-(1 -ch lorocyclopropy 1)-3-(2-fl uorophen y l)-2-hydroxy- propyl]imidazoie-4-carbonitrî!e and 3-[2-(1-chlorocyclopropyl)-3-(3-chloro-2-fluoro-phenyl)-2hydroxy-propyl]imidazole-4-carbonîtrile,

6. A fungicidal composition according to any one of daims 1 to 5, wherein component (B) is a compound selected from the group consisting of cyproconazole, difenoconazole, hexaconazole, prothioconazole, propiconazole, azoxystrobïn, trifloxystrobin, picoxystrobin, pyraclostrobîn mancozeb, chlorothaionil, fluxapyroxad, benzovindiflupyr, isoflucypram and metyltetraprole.

7. A fungicidal composition according to to any one of daims 1 to 6, wherein the weight ratio of component (A) to component (B) is from 100:1 to 1:100.

8. A fungicidal composition according to to any one of daims 1 to 7, wherein the weight ratio of component (A) to component (B) is from 20:1 to 1:40.

252

9. A fungicidal composition according to to any one of claims 1 to 8, wherein the weight ratio of component (A) to component (B) is from 12:1 to 1:25.

10. A fungicidal composition according to to any one of claims 1 to 9, wherein the weight ratio of component (A) to component (B) is from 5:1 and 1:15.

11. A fungicidal composition according to to any one of claims 1 to 10, wherein the weight ratio of component (A) to component (B) is from 2:1 to 1:5.

12. A fungicidal composition according to any of claims 1 to 11, wherein the composition comprises one or more further pesticides selected from the group consisting of:

a fungicide, selected from etridiazole, fluazinam, benzovindiflupyr, pydiflumetofen, benalaxyl, benalaxyl-M (kiralaxyl), furalaxyl, metalaxyl, metalaxyl-M (mefenoxam), dodicin, N'-(2,5D imethyl-4-ph enoxy-phe nyl)-N-ethyî-N-methyl-forma mid ine, N'-[4- (4,5-Dichlora-thiazol-2-yloxy)2,5-dimethyl·phenyl]-N-ethyl·N-methyl-fomnamidίne, N'-[4-[[3-[(4-chlorophenyl)methyl]-1,2,4thiadiazol-S-ylloxyl-Z.S-dimethyl-phenyO-N-ethyi-N-methyl-formamidine, ethirimol, 3'-chloro-2meth oxy-N-[(3RS)-tetra hydro-2-oxofuran-3-yl]acet-2',6'-xyl idide (clozy lacon), cy prod in il, mepanipyrim, pyrimethanil, dithianon, aureofungin, blasticidin-S, biphenyl, chloroneb, dicloran, hexachlorobenzene, quintozene, tecnazene, (TCNB), tolclofos-methyl, metrafenone, 2,6-dichloro-N-(4-trifluoromethylbenzyt)-benzamide_] fluopicolîde (flupicolide), tioxymid, flusulfamide, benomyl, carbendazim, carbendazim chlorhydrate, chlorfenazole, fuberidazole, thiabendazole, thiophanate-methyl, benthiavalicarb, chlobenthiazone, probenazole, acibenzolar, bethoxazin, pyriofenone (IKF-309), acibenzolar-S-methyl, pyribencarb (KIF-7767), butylamine, 3-iodo-2-propinyl n-butylcarbamate (IPBC), iodocarb (isopropanyl butylcarbamate), isopropanyl butylcarbamate (iodocarb), picarbutrazox, polycarbamate, propamocarb, tolprocarb, 3-(difluoromethyl)-N-(7-fluoro-1,1,3,3-tetramethyl-indan-4-yl)-1-methyl-pyrazole-4carboxamide diclocymet, N-[(5-chloro-2-isoρroρyl-ρhenyl)methyl]-N-cyclopropyl·3(difluoromethyl)-5-fluoro-1’methyl-pyrazole-4-carboxamide N-cyclopropyl-3-(difluoromethyl)-5fIuoro-N~[(2-isopropylphenyl)methyl]-1-methyl-pyrazole-4-carboxamide carpropamid, chlorothalonil, flumorph, oxine-copper, cymoxanil, phenamacril, cyazofamid, flutianil, thicyofen, chlozolinate, iprodione, procymidone, vinclozolin, bupirimate, dinocton, dinopenton, dinobuton, dinocap, meptyldinocap, diphenylamine, phosdiphen, 2,Q-dimethyl-[1,4]dithiino[2,3c:5,6-c'Jdipyrrole-1,3,5,7(2H,6H)-tetraone, azithiram, etem, ferbam, mancozeb, maneb, metam, metiram (polyram), metiram-zinc, nabam, propineb, thiram, vapam (metam sodium), zineb, ziram, dithioether, isoprothiolane, ethaboxam, fosetyl, fosetyl-aluminium (fosetyl-al), methyl bromide, methyl iodide, methyl isothiocyanate, cyclafuramid, fenfuram, validamycin, streptomycin, (2RS)-2-bromo-2-(bromomethyl)glutaronitrile (bromothalonil), dodine, doguadtne, guazatine, iminoctadine, iminoctadine triacetate, 2,4-D, 2,4-DB, kasugamycin, dimefhirimol,

253 fenhexamid, hymexazole, hydroxyisoxazofe imazalil, imazalif sulphate, oxpoconazole, pefurazoate, prochloraz, triflumizole, fenamidone, Bordeaux mixture, calcium polysulfïde, copper acetate, copper carbonate, copper hydroxide, copper naphthenate, copper oleate, copper oxychloride, copper oxyquinolate, copper silicate, copper sulphate, copper tallate, cuprous oxide, sulphur, carbaryl, phthalide (fthalide), dingjunezuo (Jun Si Qi), oxathiapiprolin, fluoroimide, mandipropamid, KSF-1002, benzamorf, dimethomorph, fenpropimorph, tridemorph, dodemorph, diethofencarb, fentin acetate, fentin hydroxide, carboxin, oxycarboxin, drazoxolon, famoxadone, m-phenylphenol, p-phenylphenol, tribromophenol (TBP), 2-[2-[(7,8difluûro-2-methyl-3-quinolyl)oxyj-6-fluoro-phenyl]propan-2~ol 2-[2-fluoro-6-[(8-fluoro-2-methyl-3quinolyl)oxy]phenyl]piOpan-2-ol, cyfiufenamid, ofurace, oxadixyl, flutolanil, mepronil, isofetamid, fenpiclonil, fludioxonil, pencycuron, edifenphos, iprobenfos, pyrazophos, phosphores acids, tecloftalam, captafol, captan, ditalimfos, triforine, fenpropidin, piperalin, osthol, 1-methylcyclopropene, 4-CPA, chlormequat, clofencet, dichlorprop, dimethipin, endothal, ethephon, flumetraiin, forchlorfenuron, gibberellic acid, gibberellins, hymexazol, maleic hydrazide, mepiquat, naphthalene acetamide, paclobutrazol, prohexadione, prohexadione-cafcium, thidiazuron, tribufos (tributy! phosphorotrithioate), trînexapac, uniconazole, α-naphthalene acetic acid, polyoxin D (polyoxrim), BLAD, chitosan, fenoxanîl, folpet, 3-(difluoromethyl)-N-methoxy-1-methyl-N-[1-methyl-2-(2,4,6trichlorophenyl)ethy!]pyrazole-4-carboxamide, bixafen, fluxapyroxad, furametpyr, isopyrazam, penfiufen, penthiopyrad, sedaxane, fenpyrazamine, diclomezine, pyrifenox, boscalid, fluopyram, diflumetorim, fenarimol, 5-fluoro-2-(p-tolylmethoxy)pyrimidin-4-amine ferimzone, dimetachlone (dimethaclone), pyroquilon, proquinazid, ethoxyquin, quinoxyfen, 4,4,5-trifluoro3,3-dimethyl-1-(3-quinolyl)isoquinoline 4,4-difluoro-3,3-dimethyl-1-(3-quinolyl)isoquinoline 5fluoro-3,3,4,4-tetramethyi-1-(3-quinolyl)isoquinoline 9-fluoro-2,2-dimethyl-5-(3-quinolyl)-3H-1,4benzoxazepine, tebufloquin, oxolinic acid, chinomethionate (oxythioquinox, quinoxymethionate), spiroxamine, (E)-N-methyi-2- [2- (2, 5-dimethyîphenoxymethyl) phenyl]-2-methoxyiminoacetamide, (mandestrobin), azoxystrobin, coumoxystrobin, dimoxystrobin, enestroburin, pyriotrobin, fenamistrobin, flufenoxystrobin, fluoxastrobin, kresoxim-methyl, mandestrobin, metaminostrobin, metominostrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, triclopyricarb, trifloxystrobin, amisulbrom, dichlofiuanid, tolylfluanid, but-3-ynyl N-[6-[[(Z)-[(1-methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethylJ-2pyridyl]carbamate, dazomet, isotianil, tiadinil, thifluzamide, benthiazole (TCMTB), siithiofam, zoxamide, anilazine, tricyclazole, (.+-.)-cis-1-(4-chlorophenyl)-2-(1H-1,2,4-Îriazol-1-yl)cycloheptanol (huanjunzuo), 1-(5-bromo-2-pyridy 1)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1,2,4triazol-1-yl)propan-2-ol 2-(1-tert-butyl)-1-(2-chlorophenyl)-3-(1,2,4-triazol-1-yl)-propan-2-ol (TCDP), (N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl· formamidine), azaconazole, bitertanoi (biloxazol), bromuconazole, climbazole, cyproconazole, difenoconazole, dimetconazole, diniconazole, diniconazole-M, epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myctobutanil, penconazole, propiconazole, prothioconazole,

254 mefentrifluconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triazoxide, triticonazole, 2-[[(1R,5S)-5-[(4-fluorophenyl)methyl]-1-hydraxy-2,2-dimethylcyclopentyl]methyl]-4H-1,2,4-triazole-3-thione 2-[[3-(2-chloropheny 1)-2-(2,4difluorophenyi)oxiran-2-yl]methyl]-4H-1,2,4-triazo!e-3-thione, ametoctradin (imidium), iprovalicarb, valifenalate, 2-benzyl-4-chlorophenol (Chlorophene), allyl alcohol, azafenidin, benzalkonium chloride, chloropicrin, cresol, daracide, dichtorophen (dichlorophene), difenzoquat, dipyrithione, N-(2-p-chlorobenzoylethyl)-hexaminium chloride, NNF-0721, octhilinone, oxasulfuron, a plant extract comprising tea tree oil Melaleuca altemifolîa (Timorex Gold™), a biostimulant comprising organic carbon, nutrients and amino acids (Quantis™), propamidine and propionic acid; or an insecticide selected from abamectin, acephate, acetamiprid, amidoflumet (S-1955), avermectin, azadirachtin, azinphos-methyl, bifenthrin, bifenazate, broflanilide, buprofezin, carbofuran, cartap, chlorantraniliprole (DPX-E2Y45), chlorfenapyr, chlorfluazuron, chiorpyrîfos, chlorpyrifos-methyl, chromafenozide, clothianidin, cyflumetofen, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, cypermethrin, cyromazine, deitamethrin, diafenthiuron, diazinon, dieldrin, diflubenzuron, dimefluthrin, dimethoate, dinotefuran, diofenolan, emamectin, endosuîfan, esfenvalerate, ethiprole, fenothiocarb, fenoxycarb, fénpropathrin, fenvalerate, fipronil, flonicamid, flubendiamide, flucythrinate, tau-fluvalinate, flufenerim (UR-50701), flufenoxuron, fonophos, halofenozide, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, isofenphos, lufenuron, malathion, metaflumizone, metaldehyde, methamidophos, methidathion, methomyl, methoprene, methoxychlor, metofluthrin, monocrotophos, methoxyfenozide, nitenpyram, nithiazine, novaluron, noviflumuron (XDE-007), oxamyl, parathion, parathion-methyl, permethrin, phorate, phosalone, phosmet, phosphamidon, pirimicarb, profenofos, profluthrin, pymetrozine, pyrafluprole, pyrethrin, pyridalyl, pyrifluquinazon, pyriproîe, pyriproxyfen, rotenone, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen (BSN 2060), spirotetramat, sulprofos, tebufenozide, teflubenzuron, tefluthrin, terbufos, tetrachlorvinphos, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tralomethrin, triazamate, trichlorfon and triflumuron; or a bactéricide selected from streptomycin; or an acaricide selected from amitraz, chinomethionat, chlorobenzilate, cyenopyrafen, cyhexatin, dicofol, dienochlor, etoxazole, fenazaquin, fenbutatin oxide, fénpropathrin, fenpyroximate, hexythiazox, propargite, pyridaben and tebufenpyrad; or a biological agent selected from Bacüfus thuringiensis, Bacilius thuringiensis delta endotoxin, baculovirus, and entomopathogenic bacteria, virus and fungi,

13. A fungicidal composition according to any one of claims 1 to 12, wherein the composition further comprises an agriculturally acceptable carrier and, optionally, a surfactant and/or formulation adjuvants.

14. A method of controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi, on useful plants or on propagation material thereof, which comprises applying to the useful

15.

255 plants, the locus thereof or propagation material thereof a fungicidal composition as defined in any one of claims 1 to 12.

A method according to claim 14, wherein the composition components (A) and (B) are applied in a sequential manner.